The 2004 Surgeon General’s report, The Health Consequences of Smoking: A Report of the Surgeon General (U.S. Department of Health and Human Services [USDHHS] 2004), concluded that the evidence is sufficient to infer a causal relationship between smoking and cancers of the lung, larynx, oral cavity, pharynx, esophagus, pancreas, bladder, kidney, cervix, and stomach, and acute myeloid leukemia. In addition, the report found that evidence suggests a causal relationship between smoking and colorectal and liver cancers. This chapter examines the mechanisms by which cigarette smoking induces cancer. Literature citations for this section’s discussion appear in subsequent sections of this chapter, as appropriate. A schematic overview of the pertinent mechanisms discussed in this chapter is presented in Figure 5.1. The figure depicts the major established pathways of cancer causation by cigarette smoking: (1) the exposure to carcinogens (cancer-causing substances), (2) the formation of covalent bonds between the carcinogens and DNA (DNA adduct formation), and (3) the resulting accumulation of permanent somatic mutations in critical genes (genes appear in italics). Somatic mutations lead to clonal outgrowth and, through accumulation of additional mutations, to development of cancer.

Figure 5.1. Link between cigarette smoking and cancer through carcinogens in tobacco smoke.

Figure 5.1

Link between cigarette smoking and cancer through carcinogens in tobacco smoke.

Each puff of each cigarette contains a mixture of thousands of compounds, including more than 60 well-established carcinogens. The carcinogens in cigarette smoke belong to multiple chemical classes, including polycyclic aromatic hydrocarbons (PAHs), N-nitrosamines, aromatic amines, aldehydes, volatile organic hydrocarbons, and metals. In addition to these well-established carcinogens, others have been less thoroughly investigated. These include alkylated PAHs, oxidants, free radicals, and ethylating agents. Considerable evidence indicates that in human cancers caused by cigarette smoking, PAHs, N-nitrosamines, aromatic amines, and certain volatile organic agents play a major role. Extensive data in the literature demonstrate the uptake of these carcinogens by smokers. The data confirm the expected presence of metabolites of these substances in the urine of smokers at higher levels than those in nonsmokers.

Most carcinogens in cigarette smoke require a metabolic activation process, generally catalyzed by cyto-chrome P-450 enzymes (P-450s), to convert the carcinogens to forms that can covalently bind to DNA and form DNA adducts. P-450s 1A1 and 1B1, which are inducible by cigarette smoke through interactions with the aryl hydrocarbon receptor, are particularly important in the metabolic activation of PAHs. The inducibility of these P-450s may be a critical aspect of cancer susceptibility in smokers. P-450s 1A2, 2A6, 2A13, and 2E1 are also important in the activation of cigarette smoke carcinogens. Competing with the activation process is metabolic detoxification, which excretes carcinogen metabolites in generally harmless forms and is catalyzed by a variety of enzymes, including glutathione-S-transferases (GSTs), uridine-5′-disphosphate-glucuronosyltransferases (UGTs), epoxide hydrolases, and sulfatases. The balance between metabolic activation and detoxification of carcinogens varies among persons and likely affects cancer susceptibility. Persons with a higher activation and lower detoxifica-tion capacity are at the highest risk for smoking-related cancers. This finding is supported by considerable evidence from molecular epidemiologic studies of the polymorphisms (variants) in these enzymes.

The metabolic activation of carcinogens results in the formation of DNA adducts, which are absolutely central to the carcinogenic process. However, some carcinogens can directly form DNA adducts without metabolic activation. Since the mid-1980s, extensive studies have examined the presence of DNA adducts in human tissues. Studies that used nonspecific methods, such as 32P-postlabeling and immunoassays, to measure adducts concluded that adduct levels in the lung and in other tissues are higher in smokers than in nonsmokers. Some epidemiologic data link higher adduct levels with a higher probability of developing cancer.

There are ample cellular repair systems that can remove DNA adducts and maintain a normal DNA structure. These systems include direct repair of DNA bases by alkyltransferases, the excision of DNA damage by base and nucleotide excision repair, mismatch repair, and double-strand break repair. If repair enzymes are overwhelmed by DNA damage or for other reasons cannot function efficiently, DNA adducts may persist and increase the likelihood of developing somatic mutations. Inherited polymorphic variants in some DNA repair enzymes are also associated with decreased DNA repair activity and a potentially higher probability of developing cancer.

Persistent DNA adducts can cause miscoding (e.g., insertion of the wrong base) during replication of DNA when DNA polymerase enzymes process the adducts incorrectly. Considerable specificity exists in the relationship between specific DNA adducts caused by carcinogens in cigarette smoke and the types of observed somatic mutations; for example, an O6-methylguanine adduct causes G→A transitions. These types of mutations are frequently observed in the KRAS oncogene in lung cancer and in the TP53 gene in a variety of cancers induced by cigarette smoke. The KRAS and TP53 mutations observed in lung cancer in smokers appear to reflect DNA damage caused by metabolically activated PAHs. However, a number of other carcinogens or toxicants, such as N-nitrosamines and aldehydes, as well as oxidative damage, are also likely to be involved. Animal studies have firmly established the cancer-causing role of mutations in these genes.

Gene mutations can cause the loss of normal functions in control of cellular growth, ultimately resulting in cellular proliferation and cancer. Studies have strongly linked chromosome damage in cells throughout the aerodigestive tract to exposure to cigarette smoke. The protective process of programmed cell death (apoptosis) can counterbalance these mutational events by removing cells with DNA damage. The balance between mechanisms leading to apoptosis and those suppressing apoptosis has a major impact on tumor growth. In addition, researchers have observed numerous cytogenetic changes in lung cancer.

The central track of Figure 5.1 that proceeds through genetic damage is clearly established as a major pathway by which carcinogens in cigarette smoke can cause cancer. However, the top and bottom tracks of Figure 5.1 indicate that other pathways also contribute to carcinogenesis. Nicotine and tobacco-specific nitrosamines bind to nicotinic receptors and other cellular receptors. This binding then leads to the activation of protein kinase B (AKT, also known as PKB), protein kinase A (PKA), and other key biologic pathways for cytogenetic changes. Cigarette smoke activates EGFR and COX-2, both known to be important in cell proliferation and transformation. Furthermore, the occurrence of cocarcinogens and tumor promoters in cigarette smoke is well established. Although these compounds are not carcinogenic, they clearly enhance the carcinogenicity of cigarette smoke carcinogens through mechanisms that usually lead to stimulation of cell proliferation. The reversibility of cancer risk after smoking cessation supports the role of tumor promoters and other epigenetic factors in tobacco carcinogenesis. However, the specifics of these effects have not been fully elucidated. An important epigenetic pathway is the enzymatic hypermethylation of promoter regions of genes, which can result in gene silencing. If this occurs in tumor-suppressor genes, the result can be unregulated cellular proliferation.

Carcinogen Exposure, Metabolism, and DNA Adducts

Carcinogens in Cigarette Smoke

Carcinogens in cigarette smoke that were evaluated by the International Agency for Research on Cancer (IARC 2004) are listed in Table 5.1. All are carcinogenic in laboratory animals, and 15 are rated as carcinogenic in humans (group 1 carcinogens). Similar evaluations have been published by the USDHHS (2005). The total exposure of smokers to these compounds is approximately 1.4 to 2.2 milligrams (mg) per cigarette (Table 5.1). This estimate is based on machine measurements and may underestimate actual exposure. Some of the strongest of these carcinogens are PAHs, N-nitrosamines, and aromatic amines, which occur in the lowest amounts, and some of the weaker carcinogens, such as acetaldehyde and isoprene, occur in the highest amounts. Thus, a simple addition of the amounts of carcinogenic agents could be misleading. For other carcinogens in cigarette smoke that IARC has not evaluated (e.g., broad spectra of PAHs and aromatic amines), data on frequency of occurrence, levels, and carcinogenic activities are incomplete (IARC 1986).

Table 5.1. IARC evaluations of carcinogens in mainstream cigarette smoke.

Table 5.1

IARC evaluations of carcinogens in mainstream cigarette smoke.

PAHs are incomplete combustion products first identified as carcinogenic constituents of coal tar (Phillips 1983). These products occur as mixtures in tar, soot, broiled foods, automobile engine exhaust, and other materials generated by incomplete combustion (IARC 1983). Generally, PAHs are carcinogens that act locally. Some PAHs, such as benzo[a]pyrene (B[a]P), have powerful carcinogenic activity. Studies have typically evaluated PAH carcinogenicity by application to mouse skin, but PAHs also induce tumors of the lung, trachea, and mammary gland, depending on the route of administration and the animal model used (Dipple et al. 1984).

Heterocyclic compounds include analogs of PAHs containing nitrogen, as well as simpler compounds such as furan, which is a liver carcinogen. N-nitrosamines are a large class of carcinogens with demonstrated activity in at least 30 animal species (Preussmann and Stewart 1984). They are potent and systemic carcinogens that affect different tissues depending on their structure. Two of the most important N-nitrosamines in cigarette smoke are the tobacco-specific 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and N’-nitrosonornicotine (NNN) (Hecht and Hoffmann 1988). NNK caused lung tumors in all species tested, and activity in rats was particularly high. Studies using animal models have demonstrated that NNK also induces tumors of the pancreas, nasal cavity, and liver. In addition, NNN produces esophageal and nasal tumors in rats and respiratory tract tumors in mice and hamsters (Hecht 1998).

Aromatic amines in cigarette smoke are combustion products that include the well-known human bladder carcinogens 2-naphthylamine and 4-aminobiphenyl (4-ABP), which were first characterized as human carcinogens attributable to industrial exposures in the dye industry (Luch 2005). Heterocyclic aromatic amines are also combustion products and are best known for their occurrence in broiled foods (Sugimura 1995), but they also occur in cigarette smoke.

Aldehydes such as formaldehyde and acetaldehyde occur widely in the human environment and are endogenous metabolites found in human blood (IARC 1995c, 1999; Gao et al. 2002). The phenolic compounds cat-echol and caffeic acid are common dietary constituents. High doses of catechol cause glandular stomach tumors when administered in the diet. Catechol can also act as a cocarcinogen, enhancing the activity of carcinogens such as B[a]P (IARC 1999). Dietary caffeic acid caused renal cell tumors in female mice (IARC 1993). The volatile hydrocarbons include 1,3-butadiene, a powerful multiorgan carcinogen in mice that was shown to have weaker activity in rats, and benzene, a known human leukemogen (IARC 1982, 1999). 1,3-butadiene and benzene are arguably the two most prevalent potent carcinogens in cigarette smoke, on the basis of toxicologic criteria (Fowles and Dybing 2003).

Other carcinogenic organic compounds in cigarette smoke include the human carcinogens vinyl chloride in low amounts and ethylene oxide in substantial quantities (IARC 1979). Ethylene oxide is associated with malignancies of the lymphatic and hematopoietic systems in both humans and laboratory animals (IARC 1994). Diverse metals such as the human carcinogen cadmium are also present in cigarette smoke, as is the radioisotope polonium 210, which is carcinogenic to humans.

Cigarette smoke also contains oxidants such as nitric oxide (about 600 micrograms [μg] per cigarette) and related species (Hecht 1999). Free radicals have been detected by electron spin resonance and spin trapping (Hecht 1999). Researchers postulate that the major species of free radicals are a quinone-hydroquinone complex. Other compounds may also be involved in the oxidative damage produced by cigarette smoke. In addition, several studies demonstrate the presence in cigarette smoke of an uncharacterized ethylating agent, which ethylates both DNA and hemoglobin (Hb) (Carmella et al. 2002a; Singh et al. 2005).

In summary, cigarette smoke contains diverse carcinogens. PAH, N-nitrosamines, aromatic amines, 1,3-butadiene, benzene, aldehydes, and ethylene oxide are probably the most important carcinogens because of their carcinogenic potency and levels in cigarette smoke.

Biomarkers of Carcinogens in Smokers

Measurements of carcinogens or their metabolites in urine, blood, and breath can provide convenient and reliable quantitative information on human exposure to carcinogens. The information provided by these measurements, which are biomarkers of exposure, is critical to objective evaluation of carcinogen doses in smokers.

Urinary Biomarkers

Urinary biomarkers are the most widely applied biomarkers of carcinogen exposure in smokers (Hecht 2002b). Urine is relatively simple to obtain in large quantities, and obtaining study participants’ consent and specimens for testing is almost never a difficulty. Carcinogens in cigarette smoke and/or their metabolites are frequently present in substantial quantities in urine. Therefore, reliable quantitation is generally feasible. This section provides an overview of some of the urinary biomarkers most commonly used to estimate carcinogen doses in smokers. The chemical structures of all compounds discussed in this section are illustrated in Figure 5.2.

Figure 5.2. Chemical structures of biomarkers of carcinogen exposure.

Figure 5.2

Chemical structures of biomarkers of carcinogen exposure. Note: 1-HOP = 1-hydroxypyrene; DHBMA = dihydroxybutylmercapturic acid; iso-NNAC = 4-(methylnitrosamino)-4-(3-pyridyl)butyric acid; MHBMA = monohydroxybutenylmercapturic acid; NAB = N’-nitrosoanabasine; (more...)

Polycyclic Aromatic Hydrocarbons

Phenanthrene metabolites. Phenanthrene is the simplest PAH with a bay region (the region of a molecule between positions 4 and 5), a feature closely associated with the carcinogenic activity of PAHs (Figure 5.2). Phenanthrene, however, is inactive as a carcinogen (LaVoie and Rice 1988). Concentrations of phenanthrene in mainstream smoke range from 85 to 620 nanograms (ng) per cigarette (IARC 1986). Studies have quantified the phenanthrene metabolites phenanthrols, phenanthrene dihydrodiols, and r-1,t-2,3,c-4-tetrahydroxy-1,2,3,4-tetrahydrophenanthrene (trans, anti-PheT) in human urine (Hecht 2002b). Levels of phenanthrols in human urine differed between smokers and nonsmokers in some studies but not in others (reviewed in Carmella et al. 2004a). There are sources of phenanthrene exposure other than cigarette smoke, and all people have phenanthrene metabolites in their urine. This finding is well documented in environmental and occupational settings with high exposures to PAH (Grimmer et al. 1993, 1997; Angerer et al. 1997). One metabolite of phenanthrene, trans, anti-PheT, results from the diol epoxide metabolic activation pathway common to many carcinogenic PAHs. This metabolite is a promising new biomarker for PAH uptake and metabolic activation and can be readily quantified by gas chromatography (GC)-negative ion chemical ionization–mass spectrometry (MS) (Hecht et al. 2003). Levels of trans, anti-PheT are higher in smokers than in nonsmokers (Hecht et al. 2003).

1-hydroxypyrene. Pyrene is a noncarcinogenic component in all PAH mixtures; levels in mainstream cigarette smoke were 50 to 270 ng per cigarette (IARC 1986). The major metabolite of pyrene is 1-hydroxypyrene (1-HOP) glucuronide, which can be measured in urine (Jongeneelen et al. 1985). To quantify 1-HOP in urine, enzymatic hydrolysis is used to release 1-HOP, which is then enriched by reverse-phase chromatography and quan-tified by high-performance liquid chromatography (HPLC) with fluorescence detection. Studies have described variations of this method (Carmella et al. 2004b). Hundreds of studies of occupational and environmental PAH exposure have measured 1-HOP as a surrogate marker for total PAH exposure. In reviews of the data on the effects of smoking (Jongeneelen 1994, 2001; Van Rooij et al. 1994; Levin 1995; Heudorf and Angerer 2001; Hecht 2002b), most of the studies noted that 1-HOP levels in the urine of smokers were about twice as high as those in the urine of non-smokers, although some studies have reported greater differences. Levels of 1-HOP may be influenced by genetic polymorphisms in carcinogen-metabolizing enzymes (Alexandrie et al. 2000; Nerurkar et al. 2000; Nan et al. 2001; van Delft et al. 2001).

Other metabolites of polycyclic aromatic hydrocarbons. Studies examining urine biomarkers have measured phenolic metabolites of naphthalene and a variety of PAHs, which show promise as urinary biomarkers of PAH uptake from cigarette smoke (Hecht 2002b; Smith et al. 2002a,b; Serdar et al. 2003). Studies have quantified B[a]P metabolites in urine, but the levels are generally low, limiting their routine application in large studies (Hecht 2002b).

Aromatic Amines and Heterocyclic Aromatic Amines

Researchers have quantified aromatic amines, but not their metabolites, in human urine. In one study, levels of 2-toluidine excreted by smokers were 6.3 ± 3.7 (standard deviation [SD]) μg/24 hours and levels excreted by nonsmokers were 4.1 ± 3.2 (SD) μg/24 hours. The difference was not significant (El-Bayoumy et al. 1986). Another investigation reported urine levels of 2-toluidine that were higher in smokers than in nonsmokers (Riffelmann et al. 1995). There appear to be significant sources of human uptake of 2-toluidine in addition to cigarette smoke. Although these sources are not fully characterized, diet is one likely source. Amounts of 4-ABP excreted by smokers (78.6 ± 85.2 [SD] ng/24 hours) were similar to those excreted by nonsmokers (68.1 ± 91.5 ng/24 hours), and amounts of 2-naphthylamine excreted by smokers (84.5 ± 102.7 ng/24 hours) were similar to those excreted by nonsmokers (120.8 ± 279.2 ng/24 hours) (Grimmer et al. 2000). In another study, Hb adducts appeared to be better biomarkers of exposure to aromatic amines from tobacco smoke than were urinary levels of metabolites (Skipper and Tannenbaum 1990).

Researchers have measured urinary biomarkers of heterocyclic aromatic amines mainly in studies of dietary exposure. Little information is available on the contributions of cigarette smoke to urinary levels of heterocyclic aromatic amines (Hecht 2002b).


4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol and its glucuronides. In rodents and humans, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) and its glucuronides are quantitatively significant metabolites of NNK (Hecht 1998). Both NNAL and NNK are pulmonary carcinogens with particularly strong activity in rats; NNAL also induces pancreatic tumors (Hecht 1998). Glucuronidation of NNAL at the pyridine nitrogen gives NNAL-N-glucuronide, and conjugation at the carbinol oxygen yields NNAL-O-glucuronide. Both NNAL-N-glucuronide and NNAL-O-glucuronide exist as a mixture of two diastereomers, and each diastereomer is a mixture of E- and Z-rotamers (Upadhyaya et al. 2001). The NNAL-N-glucuronide and NNAL-O-glucuronide isomers are collectively referred to as NNAL glucuronides. (R)-NNAL-O-glucuronide does not induce tumors in mice (Upadhyaya et al. 1999). The (S) isomer has not been tested, but glucuronidation generally deactivates a carcinogenic metabolite in any event.

NNAL and NNAL glucuronides can be readily determined in urine by using GC with nitrosamine-selective detection (Carmella et al. 1993, 1995; Hecht et al. 1999) and by MS methods (Carmella et al. 1993, 1999; Parsons et al. 1998; Lackmann et al. 1999; Hecht et al. 2001; Byrd and Ogden 2003). Typical levels are about 1 nanomole (nmol) of NNAL in 24 hours and 2.2 nmol of NNAL glucuronides in 24 hours, with no detection of unchanged NNK. NNAL and NNAL glucuronides are absolutely specific to exposure to tobacco and have not been detected in the urine of nontobacco users unless they were exposed to secondhand smoke. Because NNAL is not present in cigarette smoke, the origin of NNAL and NNAL glucuronides found in urine is the metabolism of NNK. Most investigations demonstrate a correlation between NNAL plus NNAL glucuronides and cotinine in urine. This finding indicates that NNAL and NNAL glucuronides are a biomarker of uptake of the lung carcinogen NNK and that cotinine is a biomarker of nicotine uptake. Ratios of NNAL glucuronides to NNAL vary at least 10-fold in smokers. This ratio could be a potential indicator of cancer risk, because NNAL glucuronides are detoxification products, whereas NNAL is carcinogenic (Carmella et al. 1995; Richie et al. 1997). In human urine, (S)-NNAL-O-glucuronide is the predominant diastereomer of NNAL-O-glucuronide, and the level of (S)-NNAL is slightly higher than that of (R)-NNAL (Carmella et al. 1999). (S)-NNAL is the more tumorigenic enantiomer of NNAL in the A/J mouse lung (Upadhyaya et al. 1999). NNAL and NNAL glucuronides are released slowly from the human body only after smoking cessation. This finding has been linked to a particularly strong retention of (S)-NNAL, possibly at a receptor site (Hecht et al. 1999; Zimmerman et al. 2004). Recent studies indicate that levels of NNAL plus NNAL-glucuronides are not only biomarkers of NNK exposure but also are biomarkers of risk for lung cancer in smokers (Church et al. 2009; Yuan et al. 2009)

N’-nitrosonornicotine, N’-nitrosoanatabine, N’-nitrosoanabasine, and their pyridine-N-glucuronides. Researchers developed a method to analyze NNN, N’-nitrosoanatabine (NATB), N’-nitrosoanabasine (NAB), and their pyridine N-glucuronides (e.g., NNN-N-glucuronide) in human urine. NATB and NAB are tobacco-specific nitrosamines that like NNN and NNK are formed by the nitrosation of tobacco alkaloids (Hecht and Hoffmann 1988). Studies show that NATB is not carcinogenic but that NAB is a weak esophageal carcinogen in rats (Hecht 1998). Mean levels of total NNN, NATB, and NAB in the urine of 14 smokers were 0.18 ± 0.22 SD, 0.19 ± 0.20, and 0.040 ± 0.039 picomoles/mg of creatinine, respectively. These compounds have not been detected in the urine of nonsmokers with no exposure to secondhand smoke.

Nitrosamino acids. Researchers have used the N-nitrosoproline (NPRO) test to compare endogenous nitrosation in smokers and nonsmokers (Bartsch et al. 1989). The results of clinical studies indicate that the frequency of endogenous formation of NPRO is higher in smokers than in nonsmokers and that it may be enhanced by thiocyanate catalysis (Bartsch et al. 1989; Tsuda and Kurashima 1991; Tricker 1997). However, some population-based studies document similar levels of NPRO in smokers and nonsmokers, because this precursor biomarker for nitrosamine formation is primarily from dietary sources (Tricker 1997).

The major nitrosamino acids present in human urine are N-nitrososarcosine, N-nitrosothiazolidine 4-carboxylic acid (NTCA), and trans- and cis-isomers of N-nitroso-2-methylthiazolidine 4-carboxylicacid (NMTCA) (Bartsch et al. 1989; Tsuda and Kurashima 1991). NTCA and NMTCA are formed by reactions of formaldehyde or acetaldehyde with cysteine, followed by nitrosation. Some studies demonstrate increased levels of urinary NTCA and NMTCA in smokers (Tsuda and Kurashima 1991). Although some studies show a correlation between total nitrosamino acids and urinary nicotine plus cotinine among smokers (Malaveille et al. 1989), other studies show mixed results (Tricker 1997). Collectively, the available data support the concept that nitrosamines can be formed endogenously in smokers under some conditions.

Studies suggest that 4-(methylnitrosamino)-4-(3-pyridyl)butyric acid is a potential monitor of endogenous nitrosation of nicotine (Djordjevic et al. 1991). However, researchers could not find any evidence for its formation after oral administration of nicotine or cotinine to persons abstaining from smoking (Tricker et al. 1993).

1,3-butadiene. The major urinary metabolites of 1,3-butadiene are monohydroxybutenyl-mercapturic acids (MHBMAs) and dihydroxybutyl-mercapturic acid (DHBMA). Levels of MHBMA were 86.4 ± 14.0 (SD) μg/24 hours in smokers and 12.5 ± 1.0 μg/24 hours in nonsmokers—a significant difference (Urban et al. 2003). Corresponding levels of DHBMA were 644 ± 90 (SD) μg/24 hours in smokers and 459 ± 72 μg/24 hours in nonsmokers, which were not significantly different (Urban et al. 2003). DHBMA does not appear to be specific to exposure to 1,3-butadiene and is probably not a useful biomarker. Hb adducts have also proven useful as markers of long-term exposure to 1,3-butadiene. The long half-lives of these adducts result in an average measurement that is more time weighted than that for some other metabolites (e.g., urinary meta-bolites) (Swenberg et al. 2001; Boysen et al. 2007).

Benzene. One path of benzene metabolism proceeds by ring oxidation, ultimately by ring cleavage to trans,trans-muconaldehyde, and finally to trans,trans-muconic acid (tt-MA), a metabolite widely used as a bio-marker of benzene uptake (Scherer et al. 1998). Most studies have found significantly elevated levels of tt-MA in the urine of smokers (Scherer et al. 1998; Cocco et al. 2003; Lee et al. 2005). Levels of tt-MA were 1.4 to 4.8 times higher in smokers than in nonsmokers, and the additional amount of tt-MA excreted by smokers ranged from 0.022 to 0.20 mg/gram of creatinine (Scherer et al. 1998). However, sorbic acid, a food constituent that can be transformed metabolically into tt-MA, can contribute to urinary levels of tt-MA and thereby decrease its specificity as a biomarker for benzene uptake (Scherer et al. 1998; Pezzagno et al. 1999).

S-phenylmercapturic acid (S-PMA) is formed by the metabolism of the glutathione conjugate of benzene oxide and has the potential to be specific for benzene uptake (Stommel et al. 1989; van Sittert et al. 1993; Boogaard and van Sittert 1995, 1996; Qu et al. 2000). In one study, S-PMA levels were significantly higher in smokers (1.71 micromoles [μmol]/mole of creatinine) than those in nonsmokers (0.94 μmol/mole of creatinine), whereas tt-MA levels were not significantly different (Boogaard and van Sittert 1996). Researchers believe that S-PMA and tt-MA are the most sensitive biomarkers for low levels of exposure to benzene (Qu et al. 2000, 2003).

Phenol, hydroquinone, catechol, and 1,2,4-tri-hydroxybenzene are also urinary metabolites of benzene. Studies relating urinary levels of these metabolites to occupational exposure to benzene have mixed results, because background levels of the metabolites are high (Inoue et al. 1988, 1989; Ong et al. 1995, 1996; Qu et al. 2000). Urinary catechol levels did not differ significantly between smokers and nonsmokers (Carmella et al. 1982), and diet has been shown to be a major source of urinary catechol (Carmella et al. 1982).

Products of oxidative damage. The presence of free radicals and oxidants in cigarette smoke can lead to oxidative DNA damage and the subsequent formation of products such as 8-oxodeoxyguanosine, thymine glycol, thymidine glycol, and 5-hydroxymethyluracil. Repair of these modified DNA constituents ultimately leads to their excretion in urine. Researchers have frequently quantified 8-oxodeoxyguanosine in urine of smokers and nonsmokers (Loft and Poulsen 1998; Prieme et al. 1998; Renner et al. 2000). Cigarette smoking usually results in levels of 8-oxodeoxyguanosine in urine that modestly increase to 16 to 50 percent higher than those in nonsmokers, but studies have also reported negative results (Nia et al. 2001; Harman et al. 2003; Mukherjee et al. 2004). Smoking cessation caused a 21-percent decrease in the excretion of 8-oxodeoxyguanosine (Prieme et al. 1998). Longitudinal studies have not shown convincing increases in urinary 8-oxodeoxyguanosine that were attributable to smoking, and a complex pattern of factors may affect background levels of this biomarker in urine (Kasai et al. 2001; Pilger et al. 2001; Mukherjee et al. 2004). Studies on the effects of smoking on urinary levels of 5-hydroxymethyluracil or 5-hydroxymethyldeoxyuridine have obtained mixed results (Pourcelot et al. 1999; Harman et al. 2003). One study showed a correlation between smoking and urinary excretion of 3,N4-ethenodeoxycytidine, which may result from endogenous lipid peroxidation (Chen et al. 2004a). Studies have also detected 1,N6-ethenodeoxyadenosine in human urine, but no differences were observed between levels in smokers and those in nonsmokers (Hillestrøm et al. 2004).

Products of alkylating agents. The reaction of alkylating agents with DNA forms alkyladenines, alkylguanines, and other products (Singer and Grunberger 1983). Alkylation at the 3-position of deoxyadenosine or at the 7-position of deoxyguanosine results in products with an unstable glycosidic bond. These products are readily removed from DNA, either spontaneously or by glycosylases, which results in the urinary excretion of 3-alkyladenines and 7-alkylguanines. Studies have more extensively investigated 3-alkyladenines as biomarkers of exposure to alkylating agents, because researchers expected the background levels of 3-alkyladenines in urine to be lower than those of 7-alkylguanines. However, substantial amounts of 3-methyladenine occur in the diet (Prevost et al. 1993; Fay et al. 1997). Nevertheless, two controlled studies demonstrated an increase in the urinary excretion of 3-methyladenine among smokers (Kopplin et al. 1995; Prevost and Shuker 1996). Another study found lower background levels of 3-ethyladenine than those of 3-methyladenine (Prevost et al. 1993). Two studies demonstrated convincing increases in urinary levels of 3-ethyladenine in smokers, indicating the presence in cigarette smoke of an unidentified ethylating agent (Kopplin et al. 1995; Prevost and Shuker 1996). There was no effect from smoking on urinary levels of 3-(2-hydroxyethyl)adenine (Prevost and Shuker 1996). A population-based study found higher levels of both 3-methyladenine and 7-methylguanine in smokers than in nonsmokers, and a second study found no difference in the 3-methyladenine levels (Shuker et al. 1991; Stillwell et al. 1991).

Metals. Studies of urinary cadmium have most consistently demonstrated differences between smokers and nonsmokers. Large studies in Germany and the United States showed increases in urinary cadmium levels with age and smoking (IARC 2004). These results were consistent with those of other studies.

Breath and Blood Biomarkers

Benzene, 1,3-butadiene, and a variety of volatile organic compounds including xylenes, styrene, isoprene, 2,5-dimethylfuran, ethane, and octane were measured in expired air; levels were generally higher in smokers than in nonsmokers (Gordon et al. 2002; Perbellini et al. 2003; IARC 2004). Levels of benzene and 1,3-butadiene in the breath of smokers were 360 and 522 μg/cubic meter (m3), respectively (Gordon et al. 2002). In another study, mean benzene levels ranged from 58.1 to 81.3 μg/m3, depending on the cigarette brand (IARC 2004).

Studies have quantified volatile organic compounds, including benzene and styrene, in the blood of smokers; levels were generally higher than those in the blood of nonsmokers. Benzene levels in blood were significantly associated with the number of cigarettes smoked (IARC 2004). Cadmium levels were also higher in the blood of smokers. Measurements of NNAL in blood demonstrated a mean level of 42 femtomoles/milliliter of plasma in smokers; NNAL was not detected in nonsmokers (Carmella et al. 2005). Cigarette smoke induces oxidative damage as determined by elevated blood protein carbonyls (Reznick et al. 1992) and blood protein-bound glutathione (Muscat et al. 2004). F2-isoprostane levels, which are biomarkers of oxidative damage, were higher in the plasma of smokers than in the plasma of nonsmokers and decreased with vitamin C treatments (Morrow et al. 1995; Dietrich et al. 2002). Hb adducts and DNA adducts in white blood cells are discussed in the next section.


Quantitative analysis of carcinogens or their metabolites in urine, breath, and blood provides a convenient and reliable method of comparing carcinogen exposure among smokers and between smokers and nonsmokers. The most extensive measurements have been made in urine. Urinary biomarkers of several major types of carcinogens in cigarette smoke are reliable indicators of exposure. These biomarkers include trans, anti-PheT and 1-HOP for PAH; total NNAL (NNAL plus NNAL glucuronides) for NNK; MHBMA for 1,3-butadiene; and tt-MA and S-PMA for benzene. The measurements provide good estimates of minimum doses of relevant carcinogens in smokers and allow comparisons with those in nonsmokers. The total carcinogen dose is generally difficult to calculate because the extent of conversion of a given carcinogen to the measured metabolite is usually unknown and can vary widely among individuals. Nevertheless, the results of these studies are illuminating. They show, for example, that levels of metabolites of benzene (about 1,100 nmol/24 hours of tt-MA and 8 nmol/24 hours of S-PMA) and 1,3-butadiene (about 340 nmol/24 hours of MHBMA) exceed levels of other biomarkers (e.g., about 3 nmol/24 hours of NNAL plus NNAL glucuronides and 2 nmol/24 hours of 1-HOP). These results are consistent with the levels of benzene and 1,3-butadiene in cigarette smoke, which were higher than those of NNK and PAH.

However, metabolites of benzene and a metabolite of 1,3-butadiene (DHBMA) are also found in nonsmokers in considerable quantities. Comparisons of smokers and nonsmokers demonstrate that total NNAL is the most discriminatory carcinogen biomarker because the only source of the parent carcinogen NNK is tobacco products. Total NNAL is not detected in nonsmokers unless they have been exposed to secondhand tobacco smoke. Therefore, this biomarker is particularly useful for comparing carcinogen uptake in smokers who, for example, use different tobacco products, because the measurements are not confounded by other exposures such as diet, occupation, or the general environment.

Metabolic Activation and Detoxification of Carcinogens

Most of the carcinogens listed in Table 5.1 require metabolic activation to become intermediate agents, generally electrophiles, which react with nucleophilic sites in DNA to form DNA adducts. All PAHs, heterocyclic compounds, N-nitrosamines, aromatic amines, and heterocyclic aromatic amines in cigarette smoke require metabolic activation. Other compounds in Table 5.1 that require metabolic activation are 1,3-butadiene, isoprene, benzene, nitromethane, 2-nitropropane, nitrobenzene, acrylamide, vinyl chloride, and urethane. Detoxification reactions in most cases compete with metabolic activation and also affect the disposition of compounds that do not require metabolic activation, such as ethylene oxide.

An overview of the metabolism of six carcinogens in tobacco smoke that are implicated in the formation of DNA adducts identified in human tissues is presented in Figure 5.3. The six carcinogens are B[a]P, NNK, N-nitrosodimethylamine (NDMA), NNN, ethylene oxide, and 4-ABP.

Figure 5.3. Metabolism of six carcinogens in tobacco smoke that produce DNA adducts identified in the lungs of smokers.

Figure 5.3

Metabolism of six carcinogens in tobacco smoke that produce DNA adducts identified in the lungs of smokers. Source: Adapted from Cooper et al. 1983; Preussmann and Stewart 1984; Kadlubar and Beland 1985; International Agency for Research on Cancer 1994; (more...)

The major metabolic activation pathway of B[a]P that results in DNA adducts identified in human tissues is the conversion to the highly mutagenic B[a]P-7,8-diol-9,10-epoxides (BPDEs). The formation of BPDE occurs in three steps: the metabolism of B[a]P to B[a] P-7,8-epoxide; hydration of B[a]P-7,8-epoxide to give the dihydrodiol B[a]P-7,8-diol; and further epoxidation to produce BPDE. One of the four enantiomers is strongly carcinogenic and reacts with DNA to form adducts at N2 of deoxyguanosine (BPDE-N2-deoxyguanosine) (Cooper et al. 1983; IARC 1983; Thakker et al. 1985). This adduct was also observed in animals treated with B[a]P.

Two other proposed metabolic activation pathways of B[a]P exist, but the evidence for their involvement in DNA adduct formation in laboratory animals and humans is not as strong as that for BPDE. One pathway involves the conversion of B[a]P-7,8-diol to the corresponding catechol metabolite catalyzed by dihydrodiol dehydrogenase. The catechol can undergo redox cycling to produce a qui-none reactive with DNA, and the redox cycling process can produce oxidative damage to DNA (Penning et al. 1999; Yu et al. 2002). Another metabolic activation process occurs when one electron oxidation of B[a]P produces unstable depurinating DNA adducts that can lead to apurinic sites and miscoding (Casale et al. 2001). A common mechanism of metabolic activation for a number of PAHs is the formation of diol epoxides in which the epoxide ring is in the bay region of the PAH molecule, similar to that in BPDE (Conney 1982; Thakker et al. 1985; Baird and Ralston 1997). Competing with B[a]P metabolic activation processes are detoxification pathways leading to (1) phenols through direct hydroxylation or rearrangement of initially formed epoxides, (2) dihydrodiols through hydration of epoxides catalyzed by epoxide hydrolase, and (3) formation of glutathione, glucuronide, and sulfate conjugates. Researchers have also observed the formation of quinone metabolites from initial hydroxylation at the 6-position, followed by further oxidation (Cooper et al. 1983).

Metabolic activation of NDMA occurs by α-hydroxylation and leads to an unstable α-hydroxymethyl metabolite. This compound spontaneously loses formaldehyde and forms methanediazohydroxide, the same intermediate agent produced in the α-methylene hydroxylation of NNK. Researchers also observed the consequent formation of methyl DNA adducts such as 7-methylguanine, O6-methylguanine, and O4-methylthymidine. Denitrosation produces nitrite and methylamine and is a detoxification pathway (Preussmann and Stewart 1984; Hecht and Samet 2007). The metabolism of NNK and NDMA forms aldehydes, whose roles in carcinogenesis are unclear, but studies show that formaldehyde reacts with DNA and protein to form cross-links and other products (Chaw et al. 1980; Beland et al. 1984; Hecht and Samet 2007).

α-hydroxylation of NNN adjacent to the pyridine ring produces the same intermediate agent formed by methyl hydroxylation of NNK, which leads to pyridyloxobutyl (POB)-DNA adducts (Hecht 1998). α-hydroxylation distal from the pyridine ring also produces a reactive diazohydroxide, but its reactions with DNA have not been fully characterized. The acetate esters of the α-hydroxy-NNN metabolites are mutagenic (Hecht 1998; Hecht and Samet 2007). β-hydroxylation of NNN, a minor pathway, and pyridine-N-oxidation are detoxification reactions. NNN is also detoxified by denitrosation and oxidation to produce norcotinine, and by glucuronidation of the pyridine ring (Hecht 1998; Stepanov and Hecht 2005; Hecht and Samet 2007).

Ethylene oxide reacts directly with DNA to form 7-(2-hydroxyethyl)guanine and other adducts (IARC 1994; Hecht and Samet 2007). Competing detoxification pathways involve glutathione conjugation and excretion of mercapturic acids (IARC 1994).

4-ABP is metabolically activated by N-hydroxylation (Kadlubar and Beland 1985; Hecht and Samet 2007). Conjugation of the resulting hydroxylamine with acetate or other groups, such as sulfate, ultimately produces nitrenium ions, which react with DNA and form adducts mainly at C-8 of guanine. Other aromatic amines, as well as heterocyclic aromatic amines, are predominantly activated metabolically in similar ways. Acetylation of 4-ABP can be a detoxification pathway if it is not followed by N-hydroxylation. Ring hydroxylation and conjugation of the phenols result in detoxification.

Two other important carcinogens from cigarette smoke that require metabolic activation are benzene and 1,3-butadiene. DNA adducts of these compounds have not been detected in human samples. However, there is considerable information on their conversion to intermediate agents that react with DNA.

Benzene is metabolized to benzene epoxide, which is in equilibrium with its 7-member ring tautomer oxepin (Scherer et al. 2001; Hecht and Samet 2007). Researchers have observed the reaction of benzene epoxide with DNA to produce 7-phenylguanine. Further metabolism of benzene epoxide-oxepin can occur in a variety of ways. One way is nonenzymatic rearrangement to phenol, which can be further hydroxylated to hydroquinone, catechol, and 1,2,4-trihydroxybenzene. These metabolites can then be conjugated as glucuronides or sulfates. Hydroquinone can be further oxidized to benzoquinone, which can bind to DNA, or hydration catalyzed by epoxide hydrolase can produce benzene dihydrodiol, which can then be converted to catechol or tt-MA. Another possibility involves conjugation with glutathione that ultimately produces S-PMA. Other pathways of benzene metabolism result in the formation of biphenyl and benzene dioxetane, which can also lead to tt-MA (Scherer et al. 2001; Hecht and Samet 2007). Studies have detected nitrobenzene, nitro-biphenyl, and nitrophenol isomers in the bone marrow of mice treated with benzene; these isomers presumably formed from reactions of benzene with endogenously generated nitric oxide (Chen et al. 2004b; Hecht and Samet 2007).

1,3-butadiene is metabolically activated by epoxidation to give a monoepoxide that can be further metabolized to a diepoxide and a dihydrodiol epoxide (van Sittert et al. 2000; Hecht and Samet 2007), which all form DNA adducts. The dihydrodiol epoxide also produces cross-links in DNA and may be the most important of these intermediate agents (Park and Tretyakova 2004; Hecht and Samet 2007). The epoxides can be hydrated to dihydrodiols and conjugated by reactions with glutathione. 1,3-butadiene metabolism can also lead to epoxidation and formation of N-terminal Hb adducts, providing a longer-term, “time-weighted” measurement of exposure (Swenberg et al. 2001).

Although details remain to be determined, the major pathways of metabolic activation and detoxification of some of the principal carcinogens in cigarette smoke are well established. Reactive intermediate agents that are critical in forming DNA adducts include diol epoxides of PAH, diazonium ions generated by α-hydroxylation of nitrosamines, nitrenium ions formed from esters of N-hydroxylated aromatic amines, and epoxides such as ethylene oxide. Glutathione and glucuronide conjugation play major roles in the detoxification of carcinogens in cigarette smoke.

Enzymology of Carcinogen Metabolism


A number of enzyme families are important in both the activation and detoxification of carcinogens in cigarette smoke, including P-450s, GSTs, UGTs, N-acetyl-transferases (NATs), epoxide hydrolases, and sulfotransferases. The importance of each enzyme to the activation or detoxification of a particular carcinogen depends on characteristics of both the carcinogen (size, polarity, and lipophilicity) and the enzyme (structure, tissue distribution, and regulation of expression). The large number of carcinogens in cigarette smoke and the wide variety of enzymes involved in metabolizing these carcinogens preclude a comprehensive discussion of current understanding of the contribution of each enzyme to every pathway. Therefore, the goals of this presentation are to introduce the families of enzymes involved and to highlight some of the activation and detoxification reactions for specific enzymes and carcinogens.

Cytochrome P-450 Enzymes

P-450s, encoded by CYP genes, are microsomal enzymes that catalyze the oxidation of myriad chemicals, including many of the carcinogens in cigarette smoke. Sequencing the human genome has identified 57 CYP genes, about 15 of which are considered important in the metabolism of xenobiotics (Nelson 2003; Guengerich 2004). Among the P-450s encoded by these genes, a reasonable argument can be made for the role of six (1A1, 1B1, 1A2, 2A6, 2A13, and 2E1) as important catalysts for the metabolic activation of carcinogens in cigarette smoke. PAHs are metabolized by P-450s 1A1 and 1B1 (Shimada and Fujii-Kuriyama 2004), aromatic amines by P-450 1A2 (Kim and Guengerich 2005), and N-nitrosamines by P-450s 2A6, 2A13, and 2E1 (Yoo et al. 1988; Guengerich et al. 1991; Yamazaki et al. 1992; Jalas et al. 2005; Wong et al. 2005a). P-450 2E1 also catalyzes the epoxidation of benzene and 1,3-butadiene (Guengerich et al. 1991; Bolt et al. 2003).

P-450s 1A1 and 1B1 are expressed in a wide range of extrahepatic tissues and catalyze both the activation and detoxification reactions of PAH metabolism (Shimada and Fujii-Kuriyama 2004). In addition, both enzymes are inducible by the PAHs in cigarette smoke (Nebert et al. 2004). Induction of these two enzymes is generally mediated by the aryl hydrocarbon receptor, but differences may exist in the mode of induction for each enzyme. Historically, researchers believed that P-450 1A1 was the predominant P-450 catalyst for the metabolism of PAHs, particularly in the lung. However, the discovery of P-450 1B1 (Sutter et al. 1994) clarified the equal or more predominant role P-450 1B1 may play in the activation of PAHs compared with that of P-450 1A1 (Shimada et al. 1996). Studies show that P-450 1B1, which is heterologously expressed, activates the proximate carcinogen of many PAHs and that in several cases, P-450 1B1 was more efficient than P-450 1A1 (Shimada et al. 1996). For example, (+)-B[a]P-7,8-diol was activated to a genotoxic species to a greater extent by P-450 1B1 than by P-450 1A1 (Shimada et al. 1996). In addition, the ratio of the maximum velocity (Vmax) of an enzyme-catalyzed reaction to the concentration of a substrate that leads to half-maximal velocity (Km) for the formation of B[a]P-7,8-diol was 3.5-fold greater for P-450 1B1 than for P-450 1A1 (Shimada et al. 1999). (The Vmax to Km ratio measures an enzyme’s efficiency.) In contrast, P-450 1A1 was a better catalyst of B[a]P 3-hydroxylation, which is a detoxification pathway (Shimada et al. 1997). Taken together, these data indicate that P-450 1B1 activity, but not P-450 1A1 activity, may contribute to individual susceptibility to B[a]P-induced carcinogenesis. However, cigarette smoke has many different PAH carcinogens, and either P-450 1B1 or 1A1 individually or together may be important in their metabolic activation.

As noted previously (see “Cytochrome P-450 Enzymes” earlier in this chapter), both P-450 1A1 and 1B1 are inducible by PAHs. Studies have reported that levels of messenger RNA (mRNA) and protein of both P-450s were higher in the lungs of smokers than in the lungs of lifetime nonsmokers (Willey et al. 1997; Kim et al. 2004a; Port et al. 2004). The levels of P-450 1A1 and 1B1 proteins were correlated in lung microsomes from all participants who smoked. However, the absolute amount of P-450 1A1 in each person was, on average, more than 10-fold greater than the amount of P-450 1B1 (Kim et al. 2004a). Despite the ability of P-450 1B1 to more efficiently mediate the activation of some PAHs, the higher P-450 1A1 levels may result in each enzyme contributing similarly to the total metabolism of PAHs. An equally important factor in determining the role of these P-450s in the activation of PAHs in cigarette smoke is the variability in the induction of P-450s across individuals. Researchers do not know whether the responsible mechanism is common to both P-450s 1A1 and 1B1.

Studies have characterized P-450 1A2 as the best catalyst for aromatic amine N-oxidation, which is the first step in the activation of these bladder carcinogens (Butler et al. 1989; Landi et al. 1999; Kim and Guengerich 2005). P-450 1A2 is both constitutively expressed and inducible in the liver. The induction of P-450 1A2 is mediated by the aryl hydrocarbon receptor, and hepatic levels vary more than 60-fold from person to person (Nebert et al. 2004). Cigarette smoking induces the levels of this enzyme in the liver. Researchers have also reported that P-450s 1A1 and 1B1 metabolically activate a number of aromatic amines, including 4-ABP, and may play a role in extrahepatic metabolism (Shimada et al. 1996).

Although hepatic P-450 2A6 catalyzes the metabolic activation of NNK (Yamazaki et al. 1992; Jalas et al. 2005), P-450 2A6 is not a particularly efficient catalyst. The extra-hepatic P-450 2A13 might be a more important catalyst of the activation of this carcinogen (Jalas et al. 2005). P-450 2A13 is expressed in the lung (Su et al. 2000) and catalyzes the α-hydroxylation of NNK significantly more efficiently than does P-450 2A6. P-450 2A13 is an excellent catalyst of NNK α-hydroxylation, with a low Km and a high Vmax.P-450 2A13 is the sole catalyst of NNK α-hydroxylation in human fetal nasal tissue and is considered equally important in the lung (Wong et al. 2005b). P-450 2E1 has also catalyzed the activation of both NNN and NNK (Yamazaki et al. 1992). However, the catalytic efficiencies of these reactions are poor (Hecht 1998; Jalas et al. 2005). Studies have identified P-450 2E1 as the best catalyst of NDMA metabolism (Yoo et al. 1988; Guengerich et al. 1991) and as an excellent catalyst of the epoxidation and activation of benzene and 1,3-butadiene (Guengerich et al. 1991; Bolt et al. 2003).

Epoxide Hydrolases

Several carcinogens of tobacco smoke, including PAH, 1,3-butadiene, and benzene, are metabolized to epoxides. These epoxide metabolites are substrates for MEH (also known as EPHX1), an enzyme that catalyzes their hydrolysis (Wood et al. 1976; Snyder et al. 1993; Krause and Elfarra 1997; Fretland and Omiecinski 2000). In mammals, at least five epoxide hydrolases were identified. However, four of these predominantly or exclusively catalyze the hydrolysis of endogenous substrates (Fretland and Omiecinski 2000). The fifth, MEH, plays a role in both the detoxification and activation of xenobiotics. Specifically, MEH is involved in the formation of the reactive diol epoxide metabolites of PAHs, and its activity is therefore critical to the carcinogenicity of these compounds (Conney 1982). For example, MEH catalyzes the hydrolysis of B[a]P-7,8-epoxide to B[a]P-7,8-diol, which is then oxidized to the ultimate carcinogen BPDE (Levin et al. 1976; Gautier et al. 1996). The importance of this enzyme to PAH carcinogenicity is supported by the observation that MEH-null mice are highly resistant to carcinogenesis induced by 7,12-dimethylbenz[a]anthracene (Miyata et al. 1999).

In contrast to its role in the activation of PAHs, MEH detoxifies the epoxides of 1,3-butadiene (Krause and Elfarra 1997; Wickliffe et al. 2003). Studies have reported that several polymorphisms in MEH result in an increased sensitivity to the genotoxic effects of 1,3-butadiene (Abdel-Rahman et al. 2003, 2005). Benzene oxide is also a substrate for MEH (Snyder et al. 1993). However, male mice deficient in MEH are not susceptible to toxic effects induced by benzene (Bauer et al. 2003). The role of benzene oxide in carcinogenesis is unclear.


Another mechanism that may detoxify carcinogenic epoxides is conjugation with glutathione. This reaction can be catalyzed by cytosolic GSTs (Sheehan et al. 2001; Hayes et al. 2005), which are dimeric. Seven classes (alpha, mu, pi, sigma, theta, omega, and zeta) exist in mammalian species (Sheehan et al. 2001), and at least 16 GST subunits exist in humans. However, only four homodimeric enzymes to date have been characterized as catalysts of glutathione conjugation of tobacco smoke carcinogens (Cheng et al. 1995; Norppa et al. 1995; Wiencke et al. 1995; Jernstrom et al. 1996; Sundberg et al. 1998, 2002; Landi 2000; Verdina et al. 2001; Fustinoni et al. 2002; Sørensen et al. 2004a; Hayes et al. 2005). These enzymes are members of four GST classes: alpha (GSTA1-1), mu (GSTM1-1), pi (GSTP1-1), and theta (GSTT1-1). The protein levels of each GST vary significantly from person to person, as well as across tissues within an individual (Rowe et al. 1997; Sherratt et al. 1997; Mulder et al. 1999). Researchers have identified several polymorphisms in the genes encoding these subunits (Hayes et al. 2005). Of particular note with regard to cancer risk in smokers are the *NULL alleles for GSTM1 and GSTT1, which have decreased detoxification capacity and elevated DNA damage. GSTA1, GSTM1, and GSTT1 are expressed in the liver of persons who are not homozygous for either null phenotype; little GSTP1 is present in the liver (Rowe et al. 1997; Sherratt et al. 1997; Mulder et al. 1999). In contrast, the lung expresses higher levels of GSTP1 than those expressed by the other three subunits (Rowe et al. 1997; Sherratt et al. 1997).

GSTA1-1, GSTM1-1, and GSTP1-1 each catalyze the glutathione conjugation of a number of PAH diol epoxides (Jernstrom et al. 1996; Sundberg et al. 1998, 2002). However, the efficiencies and stereoselectivity of each of these enzymes vary with the diol epoxide substrate. For example, GSTM1-1 is a more efficient catalyst of glutathione conjugation of (+)-anti-BPDE than is either GSTA1-1 or GSTP1-1 (Sundberg et al. 1997). The GSTA1-1 and GSTP1-1 enzymes have overall Kcat/Km values for catalytic rate or turnover number that are about 3-fold lower than the value for GSTM1-1, but GSTM1-1 is almost 30-fold better as a catalyst for the conjugation of (-)-anti-BPDE (Sundberg et al. 1997). The contribution of each GST enzyme to the detoxification of PAH diol epoxides varies with the substrate and across different tissues on the basis of their expression levels. In lung tissue from smokers, levels of (+)-anti-BPDE–DNA adducts were dependent on the GSTM1 genotype (Alexandrov et al. 2002). Persons with the GSTM1 null genotype had significantly higher adduct levels than did those with the GST wild-type genotype. These data support the importance of GSTM1-1 activity in BPDE detoxification in the lung, but they do not exclude a role for GSTA1-1 and GSTP1-1 in the detoxification of this or other PAHs.

GSTM1-1 and GSTT1-1 enzymes play a key role in the conjugation of two 1,3-butadiene epoxide metabolites: 3,4-epoxybutene (EB) and diepoxybutane (DEB) (Norppa et al. 1995; Wiencke et al. 1995; Thier et al. 1996; Bernardini et al. 1998; Landi 2000; Fustinoni et al. 2002; Schlade-Bartusiak et al. 2004). The direct measurement of either GSTM1-1 or GSTT1-1 activity with these epoxide substrates has not been reported. However, several studies of sister chromatid exchange (SCE) in human lymphocyte cultures from persons with the GSTT1 null genotype support the role of GSTT1-1 in the detoxification of DEB (Norppa et al. 1995; Wiencke et al. 1995; Bernardini et al. 1998; Landi 2000; Schlade-Bartusiak et al. 2004). In conflict with these data, one study reports the increased mutagenicity of DEB in Salmonella typhimurium TA1535 expressing GSTT1-1, suggesting that the conjugation of this diepoxide is an activation pathway (Thier et al. 1996). The role of both GSTM1-1 and GSTT1-1 in the detoxification of EB is supported by a higher induction of SCE by EB in lymphocyte cultures from persons with either the GSTM1-1 or the GSTT1-1 null genotype (Uusküla et al. 1995; Bernardini et al. 1998). Although GSTs play a role in the metabolism of 1,3-butadiene, it remains unclear whether polymorphisms in GSTs modulate the carcinogenic effects of 1,3-butadiene in humans (Fustinoni et al. 2002).

One major excreted metabolite of benzene is S-PMA, which is formed from the glutathione conjugate of benzene oxide (Snyder and Hedli 1996). This glutathione conjugate may be generated both enzymatically and non-enzymatically, and it is not clear which pathway predominates. However, a number of studies on benzene exposure and toxicity have suggested a role for either GSTM1-1 or GSTT1-1 in the conjugation of benzene oxide (Hsieh et al. 1999; Verdina et al. 2001; Wan et al. 2002; Kim et al. 2004b). Researchers have not directly measured which enzyme is the better catalyst of glutathione conjugation of benzene oxide. The in vivo role of GSTT1-1 in benzene oxide detoxification is supported by a report that S-PMA levels excreted by persons exposed to benzene who carried the wild-type GSTT1* allele were higher than those of persons homozygous for the GSTT1* NULL allele (Sørensen et al. 2004b).

Ethylene oxide is also detoxified by glutathione conjugation (Brown et al. 1996). Although studies have not directly evaluated the role of specific human GSTs, evidence supports the role of GSTT1-1 as a catalyst of this reaction (Hallier et al. 1993; Fennell et al. 2000). On exposure to ethylene oxide, lymphocytes from persons with the GSTT1-1* NULL allele had higher levels of SCE than did those from persons with the wild-type allele (Hallier et al. 1993). In addition, levels of 2-hydroxyethylvaline Hb adducts were higher in smokers than in nonsmokers, because of exposure to ethylene and ethylene oxide in cigarette smoke, and were higher in smokers with the GSTT1* NULL allele than in those with the wild-type allele (Fennell et al. 2000).


Conjugation with glucuronic acid is an important metabolic pathway for a number of carcinogens in tobacco smoke (Bock 1991; Hecht 2002a; Nagar and Remmel 2006). (Conjugation is the addition of a polar moiety to a metabolite to facilitate excretion.) The microsomal enzymes, UGTs, catalyze these conjugation reactions. Researchers have identified 18 human UGTs that are members of two families (UGT1 and UGT2) (Tukey and Strassburg 2000; Burchell 2003; Nagar and Remmel 2006). The UGT1A proteins are encoded by a single gene cluster, and expression of the nine members of this subfamily occurs through exon sharing. Exon 1 is unique for each UGT1A, whereas exon 2 to exon 5 are shared by all UGT1As (Tukey and Strassburg 2000). Thus, all UGT1A proteins are identical in the 245 amino acids of the carboxyl terminus encoded by exon 2 to exon 5 (Tukey and Strassburg 2000; Finel et al. 2005). In contrast, proteins from the UGT2 family are all unique gene products (Riedy et al. 2000; Tukey and Strassburg 2000). The expression of UGTs is tissue specific, and there are large differences in expression among tissues (Gregory et al. 2000, 2004; Tukey and Strassburg 2000; Wells et al. 2004). For example, UGTs 1A1, 1A3, 1A4, 1A6, and 1A9 are highly expressed in the liver; UGTs 1A7, 1A8, and 1A10 are mainly expressed in extrahepatic tissues (Tukey and Strassburg 2000; Gregory et al. 2004; Wells et al. 2004).

Aromatic amines and their N-hydroxy metabolites are glucuronidated to facilitate excretion (Bock 1991; Tukey and Strassburg 2000; Zenser et al. 2002). Glucuronidation is a detoxification reaction. Therefore, variations in the expression and catalytic efficiency of the enzymes that catalyze this reaction may influence the carcinogenicity of particular aromatic amines. In general, researchers have suggested that members of the UGT1A family contribute to the glucuronidation of these carcinogens (Orzechowski et al. 1994; Green and Tephly 1998; Tukey and Strassburg 2000; Zenser et al. 2002). However, UGT2B7 also catalyzes their glucuronidation (Zenser et al. 2002). In most cases, data support UGT1A9 as the best catalyst. For the tobacco smoke carcinogen 4-ABP, the relative catalytic efficiency of N-glucuronidation is UGT1A9>UGT1A4>UGT1A7>UGT 2B7>UGT1A6, but the catalytic efficiency of all these proteins is approximately equal to that of UGT1A1 (Zenser et al. 2002).

The phenol and diol metabolites of PAHs are primarily eliminated as glucuronide conjugates. Researchers have studied the role of specific UGTs in the metabolism of B[a]P (Bock 1991; Guillemette et al. 2000; Fang et al. 2002; Dellinger et al. 2006). Studies with UGT1A-deficient rats have implicated UGT1A enzymes in the detoxification of B[a]P (Wells et al. 2004). The glucuronidation of B[a]P-7,8-diol and 3-hydroxy-, 7-hydroxy-, and 9-hydroxy-B[a]P by heterologously expressed human UGTs has been characterized for a number of UGT1A and UGT2B enzymes (Fang et al. 2002; Dellinger et al. 2006). Among the phenols, UGT1A10 was the most efficient UGT1A catalyst of glucuronidation. UGTs 2B7, 2B15, and 2B17 all catalyzed conjugation of the three B[a]P phenols. However, the Km of the reaction for UGT2B enzymes was 2- to 250-fold higher than that for UGT1A10 (Dellinger et al. 2006). For the carcinogenic (-)-B[a]P-7,8-diol, UGT1A10 was a better catalyst of glucuronidation than was UGT1A9, and UGT2B7 did not catalyze detectable levels of glucuronidation (Fang et al. 2002), but UGT2B7 did catalyze the glucuronidation of (+)-B[a]P-7,8-diol.

In smokers, glucuronidation also plays an important role in the excretion of the NNK metabolite NNAL (Carmella et al. 2002b; Hecht 2002a). Both O-linked and N-linked NNAL glucuronide conjugates are formed (Carmella et al. 2002b). In addition, the direct detoxification of the hydroxymethyl metabolite of NNK occurs by glucuronidation in rats (Murphy et al. 1995). However, the contribution of this pathway to NNK detoxification in smokers has not been identified. In vitro studies with fibroblasts both from UGT1A-deficient and control rats have confirmed a role for UGT1A enzymes in the protection of these cells from NNK-induced micronuclei formation (Kim and Wells 1996). Human UGT1A9, UGT2B7, and UGT2B17 catalyze NNAL-O-glucuronidation, with UGT2B17 being the most active, and UGT1A4 catalyzes NNAL-N-glucuronidation (Ren et al. 2000; Wiener et al. 2004b; Lazarus et al. 2005). The rate of NNAL O- and N-glucuronidation by human liver microsomes varies significantly among persons; researchers have suggested that polymorphisms in UGT2B7 and UGT1A4 contribute to this variability (Wiener et al. 2004a).

Glucuronidation may also contribute to the detoxification of benzene (Bock 1991). In hepatocytes from rats treated with 3-methylcholanthrene to induce UGTs, phenol glucuronidation increases compared with sulfation. Glucuronide conjugates are more stable than the corresponding sulfates, and researchers have suggested the glucuronidation of phenol as a detoxification pathway (Bock 1991). However, to date, the role of glucuronidation in benzene-induced carcinogenesis has not been characterized and is poorly understood.


NATs are cytosolic enzymes that catalyze the transfer of the acetyl group from acetylcoenzyme A to an acceptor molecule (Hein et al. 2000b). This transfer occurs through an enzyme intermediate in which cysteine 68 is acetylated and then deacetylated during the course of the reaction. Humans express two unique enzymes, NAT1 and NAT2, which catalyze both N- and O-acetylation reactions. Researchers have recognized the polymorphic nature of NAT2 for more than 40 years and, more recently, have identified more than 35 alleles (Hein et al. 2000b; Hein 2002). NAT1 is less well studied but is also polymorphic, and more than 25 alleles have been identified (Hein 2002; University of Louisville School of Medicine 2006). Researchers suggest that polymorphisms in both NAT1 and NAT2 influence the activation and detoxification of carcinogenic aromatic amines in tobacco smoke (Hein 2002).

The N-acetylation of aromatic amines, such as 4-ABP, is a detoxification reaction (Hein 2002). In contrast, O-acetylation of the N-hydroxy metabolites of arylamines generated by P-450 (e.g., N-hydroxy-4-ABP) is an activation reaction leading to DNA adduct formation (Hein et al. 1993, 1995; Hein 2002). NAT1 and NAT2 both catalyze each of these reactions (Hein et al. 1993). However, NAT2 is generally considered the more important catalyst of detoxification, and NAT1 is the more important catalyst of activation (Badawi et al. 1995; Hein 2002). This assumption is based on differences in the catalytic efficiency of the enzymes and their tissue distribution in humans as well as on studies with animal models (Hein et al. 1993; Hein 2002).

Studies with recombinant human NAT1 and NAT2 have described differences in the N-acetylation of 4-ABP. The apparent affinity of 4-ABP for NAT2 is significantly greater than that for NAT1, and ratios of NAT1 activity to NAT2 activity and clearance calculations support a greater role for NAT2 than for NAT1 in the N-acetylation of arylamines (Hein et al. 1993). The characterization of NAT1 as the key catalyst of the O-acetylation (i.e., activation) of aromatic amines is more speculative and is primarily driven by the tissue distribution of NAT1 (see the discussion below). No data in the literature report differences between the efficiencies of NAT1- and NAT2-catalyzed O-acetylation of aromatic amines. However, more recent studies that engineered S. typhimurium strains to over-express either NAT1 or NAT2 reported that NAT1, but not NAT2, catalyzed the genotoxic activation of N-hydroxy-4-ABP (Oda 2004). These data provide support for NAT1 as an important catalyst in the activation of this aromatic amine.

The organ and tissue distribution of NAT1 and NAT2 differ markedly (Dupret and Rodrigues-Lima 2005). The NAT2 protein is mainly expressed in the gut and liver; the NAT1 protein is expressed in the liver and a number of other tissues, including the colon and bladder. Researchers believe that aromatic amines in tobacco smoke contribute to smoking-related bladder cancer. Therefore, the potential activation of these compounds in the bladder is important in understanding the etiology of bladder cancer. Researchers have detected NAT1 activity, but not NAT2 activity, in samples of bladder tissue from smokers (Badwawi et al. 1995). In addition, DNA adduct levels measured by 32P-postlabeling correlated with NAT1 activity. These data are thus consistent with a role for NAT1 in the activation of arylamines in tobacco smoke.

Epidemiologic studies that demonstrate a modest increase in risk of bladder cancer in persons phenotypically and genotypically identified as having slow acetylation catalyzed by NAT2 further support the role of NAT2 in the detoxification of aromatic amines (Green et al. 2000; Hein et al. 2000a; Gu et al. 2005) (see “Molecular Epidemiology of Polymorphisms in Carcinogen-Metabolizing Genes” later in this chapter). A number of the NAT2 variant alleles identified in persons with slow acetylation were expressed heterologously and demonstrated a decrease in activity for both the N-acetylation of 4-ABP and O-acetylation of N-hydroxy-4-ABP, primarily because of the instability of the variant enzymes (Hein et al. 1995; Zhu et al. 2002). Both activation and detoxification would be diminished in persons expressing variant NAT2 activity, but NAT1 activity would be maintained. Studies that have characterized NAT1 proteins from a number of variants of this gene have also reported a decrease in enzyme activity (Fretland et al. 2002).

DNA Adducts and Biomarkers


Although formation of carcinogen-DNA adducts is a well-characterized phenomenon in laboratory animals, there were no reports of analyses of DNA adducts in smokers before the mid-1980s. In the past 20 years, a large body of literature on DNA adducts in human tissues has emerged with the development of sensitive methods such as HPLC fluorescence, GCMS, liquid chromatography (LC)–MS, electrochemical detection, 32P-postlabeling, and immunoassay. Researchers have applied all of these methods to analyze DNA adducts, producing data on these biomarkers in molecular epidemiologic studies of cancer susceptibility. Thus, a discussion of DNA adducts in human tissues also includes biomarkers of DNA adduct formation in smokers.

Characterized Adducts in the Human Lung

Available data on characterized DNA adducts in human lung tissue, the tissue most extensively investigated to date, are summarized in Table 5.2. The small number of studies reflects several difficulties in this research. First, DNA from human lung tissue is difficult to obtain. The amounts of DNA available from routine procedures, such as bronchoscopy, are generally too small for analysis of specific DNA adducts. Second, the levels of DNA adducts are generally low: between 1 in 10 million and 1 in 100 million normal DNA bases. Analyzing such small amounts of material is challenging. Nevertheless, methods such as those listed previously and in Table 5.2 were successfully applied. However, because of the limitations noted, the number of participants in most of the studies is small.

Table 5.2. DNA adducts in human lung tissue.

Table 5.2

DNA adducts in human lung tissue.

The major DNA adduct of B[a]P observed in laboratory animals is BPDE-N2-deoxyguanosine. Acid hydrolysis of DNA containing this adduct releases B[a]P-7,8,9,10-tetraol, which can be analyzed by HPLC with fluorescence detection (Rojas et al. 1998). Other BPDE-derived DNA adducts may be hydrolyzed simultaneously. This assay has been applied to lung tissue obtained during surgery (Alexandrov et al. 2002; Boysen and Hecht 2003). Compared with nonsmokers, smokers with the GSTM1 null genotype displayed higher levels of BPDE-DNA adducts in lung tissue, although this finding is based on a small number of cases (Rojas et al. 1998, 2004). BPDE-DNA adducts were detectable in 40 percent of the smokers with whole lung analyses (Boysen and Hecht 2003) and in all samples with analyses of bronchial epithelial cells (Rojas et al. 2004). When the adduct localization in genes was determined by in vitro studies, one target was seen to be at mutational hot spots in the P53 tumor-suppressor gene and the KRAS oncogene in cells (Tang et al. 1999; Feng et al. 2002).

Several studies have quantified 7-methyldeoxyguanosine in human lung tissue. The source of this adduct in smokers could be NDMA, NNK, or perhaps other methylating agents. Studies have reported mixed results: some show higher adduct levels in smokers than in nonsmokers (Hecht and Tricker 1999; Lewis et al. 2004). One study examined O6-methyldeoxyguanosine in human lung tissue but was too small to draw conclusions about the effect of smoking (Wilson et al. 1989).

Three small studies provided evidence for ethyl DNA adducts in human lung tissue (Wilson et al. 1989; Blömeke et al. 1996; Godschalk et al. 2002). Levels of both O6-ethyl-deoxyguanosine and O4-ethylthymidine were higher in smokers than in nonsmokers. Although one source of these adducts could be N-nitrosodiethylamine, its level in cigarette smoke is low. As discussed previously, cigarette smoke contains a direct-acting, but chemically uncharacterized, ethylating agent that may be responsible for the presence of these adducts (see “Carcinogens in Cigarette Smoke” earlier in this chapter).

NNK and NNN are metabolically activated to intermediate agents that pyridyloxobutylate DNA. The resulting POB-DNA adducts can be hydrolyzed with acid to yield 4-hydroxy-1-(3-pyridyl)-1-butanone, which can be detected by GCMS. Application of this method demonstrated higher levels of POB-DNA adducts in lung tissue of smokers than in that of nonsmokers in a small study (Foiles et al. 1991). One study detected 7-(2-hydroxyethyl) deoxyguanosine in human lung tissue (Zhao et al. 1999), and ethylene oxide is the likely source of this adduct. Studies have detected 4-ABP–DNA adducts in human lungs but show no clear effect of smoking on adduct levels (Wilson et al. 1989; Lin et al. 1994).

Researchers have quantified 1,N6-ethenodeoxy-adenosine and 3,N4-ethenodeoxycytidine in human lungs by 32P-postlabeling (Godschalk et al. 2002). These adducts may result from lipid peroxidation or from metabolic activation of vinyl chloride or ethyl carbamate. No differences were reported between smokers and nonsmokers. Studies of the oxidative-damage product 8-oxodeoxyguanosine in the human lung obtained mixed results regarding a relationship between detection of this product and smoking status (Asami et al. 1997; Lee et al. 1999a).

In summary, data on the quantitation of specific DNA adducts in the human lung are limited. However, some studies document clear evidence for elevated levels of adducts resulting from exposure to specific carcinogens such as B[a]P, NNK, or NNN. Several methods used in these studies—HPLC fluorescence, GCMS, LC–MS, and 32P-postlabeling with modifications for specific adducts—have the potential for application to molecular epidemiologic studies that relate specific DNA adduct levels to tobacco exposure and cancer risk.

Uncharacterized Adducts in Human Lung Tissue

Studies have extensively applied two main nonspecific methods—32P-postlabeling and immunoassay—to analyze DNA adducts in human lung tissue, as well as in other tissues. Researchers have discussed the advantages and disadvantages of these methods (Kriek et al. 1998; Wild and Pisani 1998; Poirier et al. 2000; Phillips 2002). Major advantages include high sensitivity for analyzing small amounts of DNA, simplicity of analysis, and no need for extremely expensive equipment. Disadvantages include a lack of chemical specificity, particularly in 32P-postlabeling analyses, and difficulty in quantitation. Studies have extensively reviewed the application of these methods to tissues obtained from smokers (Phillips 2002; Wiencke 2002; IARC 2004).

The output of assays using 32P-postlabeling is often a “diagonal radioactive zone” (DRZ), which consists of uncharacterized radioactive components referred to in the literature as hydrophobic or aromatic DNA adducts. In most cases, little if any evidence supports the true chemical characteristics of these adducts. Nevertheless, the intensity of the DRZ is consistently elevated in samples from smokers. Immunoassays have used various methods of detection, including the fluorescent staining of tissue specimens that allows for the location of adducts. Cross-reactivity is a common problem of immunoassays. For example, antibodies raised against protein conjugates of B[a]P–DNA adducts cross-react with adducts generated from other PAHs.

Many studies using 32P-postlabeling methods examined DNA adduct levels in the peripheral lung, bronchial epithelium, or cells obtained by bronchial lavage of smokers. Most of the studies found that adduct levels were higher in smokers compared with nonsmokers (Győrffy et al. 2004; IARC 2004). Investigations that attempted to draw quantitative relationships between the extent of smoking and adduct levels had inconsistent results (IARC 2004).

Adducts in Other Tissues

Numerous studies have evaluated DNA adduct formation in fetuses and in various tissues and fluids of smokers, including samples from the larynx, oral and nasal mucosa, bladder, cervix, breast, pancreas, stomach, placenta, and cardiovascular system, and samples of sputum, sperm, and blood cells. Researchers have comprehensively reviewed these studies (Phillips 2002; Weincke 2002; IARC 2004), most of which used 32P-postlabeling and immunoassay techniques.

Levels of 7-alkyl-deoxyguanosines determined by 32P-postlabeling in laryngeal DNA were higher in smokers than in nonsmokers (Szyfter et al. 1996), and they correlated with the DRZ in these samples. Studies used immunoassay also to detect 4-ABP–DNA adducts in laryngeal tissue (Flamini et al. 1998). Other studies examined the DRZ by 32P-postlabeling (IARC 2004).

Researchers have detected 1,N2-propanodeoxy-guanosine (PdG) adducts derived from acrolein and crotonaldehyde in the DNA of gingival tissue of smokers and nonsmokers; adduct levels were higher in smokers (Nath et al. 1998). Adducts detected by 32P-postlabeling in oral and nasal tissue were also higher in smokers than in non-smokers. Use of immunoassay techniques revealed that levels of BPDE-DNA, 4-ABP–DNA, and malondialdehyde-DNA adducts in human oral mucosal cells of smokers were higher than those for nonsmokers (IARC 2004).

Using 32P-postlabeling, researchers found 4-ABP–DNA (C-8 deoxyguanosine) adducts in exfoliated urothelial cells and bladder biopsy samples (IARC 2004). In studies using antibodies to 4-ABP–DNA, levels detected in biopsy specimens from the bladder of smokers were higher than those for nonsmokers (IARC 2004). Studies using 32P-postlabeling of bladder DNA from smokers and nonsmokers yielded mixed results; some studies showed higher adduct levels in smokers (IARC 2004).

Using GCMS, Melikian and colleagues (1999) documented that BPDE-DNA adducts were higher in cervical epithelial cells of smokers than in those of nonsmokers. An immunohistochemical analysis using antibodies to BPDE-DNA adduct in human cervical cells also showed higher adduct levels in smokers than in nonsmokers (Mancini et al. 1999). 32P-postlabeling consistently showed higher adduct levels in cervical tissues of smokers than in those of nonsmokers (IARC 2004).

The 32P-postlabeling of DNA from breast tissue yields the characteristic DRZ from smokers. Researchers also investigated adduct levels by using antibodies against BPDE-DNA; results were generally mixed with respect to smoking status (IARC 2004). Studies that used 32P-post-labeling to measure adduct levels in pancreatic and stomach tissues reported a correlation with smoking status (IARC 2004).

Some studies indicate the presence of smoking-related DNA adducts in human placenta, but the overall relationship of placental DNA adducts to smoking is weak (IARC 2004). Analyses of sperm DNA also reported mixed results with respect to smoking status (IARC 2004).

Many studies have examined DNA adducts in blood cells (IARC 2004). The common use of blood cells in these studies is obviously related to the ease of clinically obtaining these samples. From this viewpoint, blood cell DNA is advantageous for biomarker studies. A disadvantage of using blood cells is that adduct levels in blood cells are not necessarily directly related to levels of DNA adducts in the tissues in which smoking-related cancers occur. The collective results of the studies are somewhat inconsistent with respect to the effects of smoking on levels of DNA adducts. This inconsistency probably results in part from competing sources of adduct formation such as diet, occupation, and the general environment. Another factor is the lifetime of the blood cells investigated; longer-lived cells appear to provide more consistent results with respect to smoking (IARC 2004). Studies comparing levels of blood cell–DNA adducts in smokers with or without cancer had mixed results (IARC 2004).

A meta-analysis of the relationship of DNA adduct levels in smokers to cancer, determined by 32P-postlabeling, used data from case-control studies of lung cancer (five studies), oral cancer (one study), and bladder cancer (one study). Six studies measured adducts in white blood cells, and one study used normal lung tissue. Among current smokers, adduct levels for case patients were significantly higher than those for control participants (Veglia et al. 2003).

Protein Adducts as Surrogates for DNA Adducts

Researchers have proposed that levels of carcinogen-Hb adducts and carcinogen-albumin adducts be used as surrogates for the measurements of DNA adducts discussed in the preceding section (Osterman-Golkar et al. 1976; Ehrenberg and Osterman-Golkar 1980). Although these proteins are not considered targets for carcinogenesis, all carcinogens that react with DNA are also thought to react with protein to some extent. Advantages of Hb adducts as surrogates include the ready availability of Hb in blood and the long lifetime of the erythrocyte in humans (approximately 120 days), which provides an opportunity for adducts to accumulate. Other researchers have comprehensively reviewed studies on protein adducts in smokers (Phillips 2002; IARC 2004).

The Hb adducts of aromatic amines have emerged as highly informative carcinogen biomarkers. Levels of these adducts are consistently higher in smokers than in nonsmokers, particularly for 3-ABP–Hb and 4-ABP–Hb adducts. Adduct levels decrease with smoking cessation and are related to the number of cigarettes smoked (Maclure et al. 1990; Skipper and Tannenbaum 1990; Castelao et al. 2001). Adducts that form with the amino terminal valine of Hb are also informative. Important examples include adducts derived from ethylene oxide, butadiene, acrylonitrile, and acrylamide (Bergmark 1997; Fennell et al. 2000; Swenberg et al. 2001). Ethylated N-terminal valine of Hb is also higher in smokers than in nonsmokers (Carmella et al. 2002a).


Overwhelming evidence indicates that DNA adduct levels are higher in most tissues of smokers than in corresponding tissues of nonsmokers. This observation provides bedrock support for the major pathway of cancer induction in smokers that proceeds through DNA adduct formation and genetic damage. DNA adducts studied can generally be divided into two classes: nonspecific adducts, which are detected by 32P-postlabeling and immunoassay, and specific adducts, which are detected by structure-specific methods. Studies of nonspecific DNA adducts are far more common than studies of specific DNA adducts, which are still scarce and are limited mainly to human lung tissue. Strong evidence exists for the presence of a variety of specific adducts in the human lung, and in several cases, adduct levels are higher in smokers than in nonsmokers. Measuring levels of Hb adducts by MS provides a simple and perhaps more practical approach for assessing carcinogen exposure of the cell. In several instances, levels of specific adducts are substantially higher in smokers than in nonsmokers. Collectively, the results of these biomarker studies demonstrate the potential for genetic damage in smokers from the persistence of DNA adducts. The propagation of this genetic damage during clonal outgrowth is consistent with the accumulation of multiple genetic changes observed in lung cancer progression.

Molecular Epidemiology of Polymorphisms in Carcinogen-Metabolizing Genes


Genetic polymorphisms may play a role in tobacco-related neoplasms. Researchers have established cigarette smoking as a major cause of lung cancer: more than 85 percent of lung cancers are attributable to smoking (Ries et al. 2004). However, not all smokers develop lung cancer, and lung cancer can arise in lifetime nonsmokers. This variation in disease has stimulated interest in molecular epidemiologic investigations of genetic polymorphisms, including carcinogen-metabolizing enzymes that may lead to variations in susceptibility to the carcinogens in tobacco smoke (Table 5.3). Considerable data exist on genetic polymorphisms in cancers other than lung cancer, but the discussion here focuses only on lung cancer and bladder cancer, two of the most heavily investigated cancers.

Table 5.3. Selected gene polymorphisms evaluated by molecular epidemiology investigations for relationship to lung cancer through variation in susceptibility to carcinogens in tobacco smoke.

Table 5.3

Selected gene polymorphisms evaluated by molecular epidemiology investigations for relationship to lung cancer through variation in susceptibility to carcinogens in tobacco smoke.

Studies have identified polymorphisms in phase I and II enzymes. Phase I enzymes, such as P-450s, generally add an oxygen atom to a carcinogen, and phase II enzymes, such as GSTs or UGTs, modify the carcinogen by making it highly water soluble for more facile excretion. These enzymes are involved in the activation and detoxification of carcinogens and may be associated with a differential ability to process carcinogens. Researchers have hypothesized that the accumulation of active carcinogen metabolites and hence increased DNA adduct formation add to lung cancer risk. Studies of cases with autopsy of cancer-free lung tissue indicate that polymorphisms in CYP1A1 and GSTM1 genes may be associated with higher DNA adduct levels, suggesting that variations in metabolic pathways can play a role in individual response to carcinogen exposure (Kato et al. 1995). Numerous studies have extended this line of analysis to investigate whether this differential ability to metabolize carcinogens leads to differential lung cancer risk. Overall, data from the study of these polymorphisms have generated inconsistent results. These inconsistencies may be explained in part by the combination of a small sample size and variable frequencies of the polymorphic alleles within different ethnic populations. A summary of some of the specific gene polymorphisms investigated is provided in Table 5.3. A recent review summarizes the effects of genetic polymorphisms on lung cancer (Schwartz et al. 2007), and specific examples are discussed here.

CYP1A1 Gene

Researchers hypothesize that interindividual variations in the ability to activate carcinogens such as PAH through the CYP1A1 gene may lead to differential carcinogenic effects. Studies describe at least two variant polymorphisms in the CYP1A1 gene. The first is a T3801C base change in intron 6, which results in a new MSPI restriction site (Kawajiri et al. 1990). (A restriction site is a site in the gene that is cleaved by a specific restriction enzyme.) The second polymorphism is an A2455G base change in exon 7, which results in an Ile to Val amino acid change (Hayashi et al. 1991). Although these polymorphisms appear to be linked, study results are inconsistent, and wide disparities exist among populations.

Studies of Japanese and Chinese populations associate both of the CYP1A1 variant polymorphisms with an increase in lung cancer risk. Nakachi and colleagues (1991) were the first to report an association of the *MSPI polymorphism with lung cancer risk. For patients with lung cancer, the frequency of harboring the homozygous variant genotype was more than two times higher than that for control participants. Among patients with squamous cell carcinoma (SCC), the homozygous variant genotype was associated with an increased risk of developing lung cancer, especially in those with a lower cumulative dose of cigarette smoke. At low levels of exposure to cigarette smoke, the odds ratio (OR) for developing lung cancer among persons with the homozygous variant genotype was 7.31 (95 percent confidence interval [CI], 2.13–25.12). This increased risk was persistent, but of a lesser magnitude, at higher levels of exposure to cigarette smoke (Nakachi et al. 1991). Okada and colleagues (1994) reported similar findings.

Studies have also associated the ILE462VAL polymorphism of CYP1A1 with lung cancer risk in Japanese and Chinese populations. Again, the homozygous variant *VAL/*VAL genotype was associated with lung cancer at lower cumulative doses of cigarette smoke (Nakachi et al. 1993; Yang et al. 2004; Ng et al. 2005). One explanation posited for this relationship with the dose level in smokers has been that the relevant enzyme is saturated at high doses but not at low doses of cigarette smoke (Vineis et al. 1997). The effects of genetic variability and differential enzymatic activity are more apparent at low doses, when saturation has not been reached.

Results have been inconsistent outside Asian populations. Individual studies often lack statistical power to detect an association (Shields and Harris 2000). Also, CYP1A1 polymorphisms are common in Asian populations (30 percent of the population) (Nakachi et al. 1993), but are far less common among Europeans and North Americans (<10 percent of the population) (Warren and Shields 1997). A study of African Americans and Mexican Americans showed a twofold increase in the risk of lung cancer among light smokers with the *MSPI variant genotype (Ishibe et al. 1997). However, a Brazilian study showed an increase in risk with the *ILE/*VAL polymorphism but not with the MSPI polymorphism (Hamada et al. 1995). A more recent study suggested that in Latinos, the *MSPI variant genotype was associated with an overall inverse OR of 0.51 (95 percent CI, 0.32–0.81), which reflected the inverse interaction with smoking (Wrensch et al. 2005). Reports from Finland, Norway, and Sweden show a lack of association between either of the CYP1A1 polymorphisms and lung cancer risk (Tefre et al. 1991; Hirvonen et al. 1992; Alexandrie et al. 2004). A meta-analysis provides little support for this association (Houlston 2000).

Because of the small sample sizes in these studies, Vineis and colleagues (2003) conducted an analysis of pooled data from the International Collaborative Study on Genetic Susceptibility to Environmental Carcinogens, which included raw data from 22 case-control studies totaling 2,451 cases and 3,358 controls. This data set thus comprised approximately one-half of the case-control studies published at that time. Researchers found an association in Whites between the CYP1A1 homozygous *MSPI variant and lung cancer risk after adjustment of values for age and gender (OR = 2.36; 95 percent CI, 1.16–4.81). The association held for both SCC and adenocarcinomas (Vineis et al. 2003). However, this association failed to reach statistical significance among Asians in this analysis. Moreover, studies such as the research conducted by Nakachi and colleagues (1991, 1993) discussed previously in this section were not included, making the Asian data difficult to interpret.

CYP2E1 Gene

The CYP2E1 gene is involved in the metabolic activation of NDMA, as well as several other tobacco smoke carcinogens. Le Marchand and colleagues (1998) performed a population-based, case-control study with 341 lung cancer cases and 456 controls. These researchers found that CYP2E1 polymorphisms were associated with a decrease in risk of lung adenocarcinoma. A Chinese study (Wang et al. 2003c) confirmed this finding. However, the presence of at least one variant CYP1A1 *MSPI allele was associated with an increased risk of SCC, both alone (2.4-fold increase in risk) and in combination with GSTM1 deletion (3.1-fold increase in risk) (Le Marchand et al. 1998). These researchers suggest that the associations between CYP1A1 and CYP2E1 polymorphisms and subsets of lung cancer indicate a specificity of PAHs to induce SCC and of nitrosamines to induce adenocarcinomas.

CYP2A13 Gene

The CYP2A13 gene is expressed primarily in the respiratory tract and participates in the metabolic activation of N-nitrosamines such as NNK. Researchers have identified a polymorphism in CYP2A13 in which a C→T transition leads to an Arg→Cys substitution at position 257. The variant 257CYS protein, the product of this gene, has one-half to one-third the capacity of the 257ARG protein to activate NNK (Su et al. 2000; Zhang et al. 2002). In a study of 724 lung cancer patients and 791 control participants, Wang and colleagues (2003a) demonstrated that the variant CYP2A13 genotype (*C/*T or *T/*T) was associated with a reduced risk for lung cancer, particularly for adenocarcinomas (OR = 0.41; 95 percent CI, 0.23–0.71). The reduction in risk did not reach statistical significance for SCC or other histologies of lung cancer. The reduced risk for adenocarcinomas was apparent only in smokers, and in light smokers rather than in heavy smokers (Wang et al. 2003a). This finding again indicates that genetic polymorphisms may play a greater role when the carcinogen dose is low and does not saturate enzymatic capacity.

GSTM1 Gene

Study reports have noted large variations in enzymatic activity for several GSTs. About 50 percent of the White population is homozygous for a deletion in the GSTM1 gene that leads to null expression (Seidegard et al. 1988). The GSTM1 enzyme is important in detoxifying carcinogens, and numerous studies have investigated the possible association of the GSTM1 null genotype with lung cancer risk.

Some studies have found an association between the GSTM1 null mutation and lung cancer across many populations. In a Japanese population, the GSTM1 null genotype was positively correlated with SCC of the lung but not with adenocarcinomas (Kihara et al. 1993). A similar analysis in a Finnish population also correlated the GSTM1 null genotype with SCC (Hirvonen et al. 1993). Analyses of Scottish (Zhong et al. 1991), Norwegian (Ryberg et al. 1997), and Turkish populations (Pinarbasi et al. 2003) had similar findings. A U.S. study also suggested that the GSTM1 null genotype was associated with a modest elevation in lung cancer risk, which increased among heavy smokers (Nazar-Stewart et al. 2003). However, some studies have not shown a significant association between the GSTM1 null genotype and lung cancer risk for SCC or overall for lung cancer (London et al. 1995; Rebbeck 1997). A meta-analysis of data from 12 case-control studies comprising 1,593 cases and 2,135 controls showed a moderate increase in the risk of lung cancer across all histologies with the GSTM1 null genotype (OR = 1.41; 95 percent CI, 1.23–1.61) (McWilliams et al. 1995). A more recent meta-analysis of 43 studies including more than 18,000 persons showed a smaller but statistically significant OR of 1.17 (95 percent CI, 1.07–1.27) (Benhamou et al. 2002).

Kihara and colleagues (1994) analyzed data on 178 Japanese patients with lung cancer and 201 healthy control participants and found that the GSTM1 null genotype was associated with an overall increase in lung cancer risk (OR = 1.87; 95 percent CI, 1.21–2.87). The strongest association was for SCC (OR = 2.13; 95 percent CI, 1.11–4.07). With stratification by the amount of smoking, the proportion of GSTM1 null genotype increased progressively in the SCC group from 50 percent in light smokers to 72 percent in heavy smokers (Kihara et al. 1994). One study suggested that higher intakes of cruciferous vegetables reduced lung cancer risk among persons with the GSTM1 genotype (highest versus lowest tertile for amount of smoking; OR = 0.61; 95 percent CI, 0.39–0.95) but not among persons with the GSTM1 null genotype (highest versus lowest tertile; OR = 1.15; 95 percent CI, 0.78–1.68) (Wang et al. 2004b). However, several other studies have shown a greater protective effect in persons with the GSTM1 null genotype who consumed cruciferous vegetables (London et al. 2000; Spitz et al. 2000). One hypothesis is that these participants were less able to eliminate protective isothiocyanates by conjugation with glutathione. In a case-control study, Cheng and colleagues (1999) analyzed data from 162 patients with SCC of the head and neck and 315 healthy control participants. They found that 53.1 percent of the case patients and 42.9 percent of the control participants were null for GSTM1 (p <0.05), whereas 32.7 percent of case patients and 17.5 percent of control participants were null for GSTT1 (p <0.001).

Thus, the effect of GSTM1 alone may not be dramatic. However, it appears to be magnified by gene-environment and gene-diet interactions, and the effects were significantly greater as exposure to cigarette smoke increased. In addition, the high frequency of GSTM1 polymorphisms observed across all ethnicities may contribute to the importance of this variant as a risk factor for developing lung cancer (Brennan et al. 2005).

CYP1A1 and GSTM1 in Combination

Studies of the effect of combined CYP1A1 and GSTM1 variant genotypes hypothesized that increased PAH activation and decreased PAH detoxification in tobacco smokers might lead to an increase in lung cancer risk. Numerous studies have explored this association. Perhaps the studies with the strongest support for this association come from Japan, although they are generally limited by small sample sizes.

Combination of the CYP1A1 variant genotype and the GSTM1 null genotype enhanced the risk of smoking-related lung cancers in a Japanese population. Hayashi and colleagues (1992) demonstrated this finding with the *ILE/*VAL polymorphism. These investigators found an increased frequency of the homozygous *VAL/*VAL genotype combined with the GSTM1 null genotype in lung cancer patients compared with control participants (8.5 percent versus 2.2 percent, respectively). Nakachi and colleagues (1991) reported similar results with both the *MSPI and *ILE/*VAL polymorphisms and the GSTM1 null genotype. The case-control study found that for light smokers, either of the two CYP1A1 susceptible genotypes combined synergistically with the deficient GSTM1 genotype to create a high risk for lung cancer (OR = 16; 95 percent CI, 3.76–68.02 for *MSPI, and OR = 41; 95 percent CI, 8.68–193.61 for *ILE/*VAL). Eighty-seven percent of the light smokers who developed lung cancer had at least one of the three homozygous variant genotypes. The investigators suggested that particularly when the cigarette dose is low, CYP1A1 and GSTM1 may be an important determinant of susceptibility to lung cancer (Nakachi et al. 1991).

Kihara and colleagues (1994) also demonstrated a synergistic effect. Persons with these variant genotypes in both CYP1A1 and GSTM1 had a much higher risk of lung cancer than did those with the variant CYP1A1 and wild-type GSTM1 (OR = 21.9; 95 percent CI, 4.68–112.7 versus OR = 3.2; 95 percent CI, 0.37–24.0). Studies in Scandinavian populations (Alexandrie et al. 1994; Anttila et al. 1994), as well as U.S. populations (García-Closas et al. 1997), support an increase in the risk of lung cancer with the combination of variant CYP1A1 and GSTM1 genotypes. Using data from the International Collaborative Study on Genetic Susceptibility to Environmental Carcinogens database, Vineis and colleagues (2004) found a statistically significant effect of the *MSPI variant on lung cancer risk in Whites (OR = 2.6; 95 percent CI, 1.2–5.7) with evidence for an interaction between the MSPI and GSTM1 null genotypes (OR = 2.8; 95 percent CI, 0.9–8.4).

GSTP1 Gene

Studies have reported polymorphisms in the GSTP1 gene family of phase II enzymes with high expression in the lung. One GSTP1 polymorphism includes an A→G base change that leads to an isoleucine→valine substitution, which results in lower enzymatic activity toward 1-chloro-2,4-dinitrobenzene (Watson et al. 1998) but higher activity toward PAH diol epoxides (Sundberg et al. 1998). Several studies showed no statistically significant association between GSTP1 polymorphisms and lung cancer risk (Harris et al. 1998; Katoh et al. 1999; To-Figueras et al. 1999; Nazar-Stewart et al. 2003). However, in the study with the largest sample size of 1,042 cases and 1,161 controls, the GSTP1 homozygous variant genotype was associated with a higher lung cancer risk at any level of exposure to smoke than was the wild-type genotype (Miller et al. 2003).

The combination of the GSTM1 null genotype and the GSTP1 *G/*G genotype may increase lung cancer risk (Ryberg et al. 1997; Kihara et al. 1999; Perera et al. 2002). In a study of 1,694 cases and 1,694 controls, double variants in GSTM1 and GSTP1, as well as in GSTP1 and TP53, were associated with an increase in lung cancer risk among persons aged 55 years or younger (adjusted OR [AOR] = 4.03; 95 percent CI, 1.47–11.1 for the M1-P1 double variant, and AOR = 5.10; 95 percent CI, 1.42–18.30 for the P1-P53 double variant) (Miller et al. 2002). Another study included 350 persons younger than age 50 years with a diagnosis of lung cancer who were identified from the metropolitan Detroit Surveillance, Epidemiology, and End Results program. The study compared these patients with 410 control participants matched by age, race, and gender. The results indicated that African Americans carrying at least one *G allele at the GSTP1 locus were 2.9 times more likely to develop lung cancer than were African Americans without a *G allele (95 percent CI, 1.29–6.20). African Americans with either one or two genotypes that carry risk at the GSTM1 and GSTP1 loci were at higher risk of developing lung cancer than were African Americans who had fully functional GSTM1 and GSTP1 genes (OR = 2.8; 95 percent CI, 1.1–7.2 for GSTM1, and OR = 4.0; 95 percent CI, 1.3–12.2 for GSTP1). No significant single-gene associations were observed between GSTM1, GSTT1, or GSTP1 and early-onset lung cancer in Whites (Cote et al. 2005).

GSTT1 Gene

Previous results have not supported an association of the GSTT1 gene with lung cancer risk (To-Figueras et al. 1997; Malats et al. 2000; Stücker et al. 2002; Ruano-Ravina et al. 2003; Wang et al. 2003b). In a study of Chinese living in Hong Kong, the GSTT1 null genotype was associated with a higher risk of lung cancer than was the functional GSTT1 genotype (AOR = 1.69; 95 percent CI, 1.12–2.56) only in nonsmokers (Chan-Yeung et al. 2004). A study from Denmark also suggested that the GSTT1 null genotype is associated with a higher risk of lung cancer (Sørensen et al. 2004a).

NAT2 Gene

Several widely studied polymorphisms for the NAT2 gene are associated with decreased activity or reduced stability of the enzyme. Phenotypically, these polymorphisms result in slow or fast acetylation. Study results on the association of the NAT2 gene with lung cancer risk are conflicting. Most studies report no overall increase in risk with the genotype for either slow or fast acetylation (Philip et al. 1988; Martinez et al. 1995; Bouchardy et al. 1998; Saarikoski et al. 2000). However, a few studies report an increase in risk with the genotype for either slow acetylation (Oyama et al. 1997; Seow et al. 1999) or fast acetylation (Cascorbi et al. 1996). In the largest study, of 1,115 lung cancer patients and 1,250 control participants, no association between the NAT2 genotype and lung cancer risk was observed. However, the study noted a significant interaction with smoking. Among nonsmokers, the genotype for rapid acetylation decreased lung cancer risk more than did the genotype for slow acetylation. This relationship was reversed among smokers, and persons with the genotype for rapid acetylation had a higher risk. The authors hypothesized that for nonsmokers, the NAT2 protein may provide a means for N-acetylation, thereby detoxifying aromatic amines and protecting a person against cancer. However, cigarette smoke markedly induces CYP oxidation and could increase the production of reactive intermediate agents in smokers. In this setting, NAT2 may instead O-acetylate these metabolites and thereby produce more reactive metabolites, thus augmenting the cancer risk (Zhou et al. 2002b). A study from Denmark confirmed the associations of the NAT2 gene with smoking status (Sørensen et al. 2005). However, a study from Taiwan suggested that the NAT2 genotype for fast acetylation is associated with an increased risk of lung cancer among women who were lifetime nonsmokers (Chiou et al. 2005).

The NAT2 protein plays an important role in the bio-activation and detoxification of the aromatic amines associated with bladder cancer induced by cigarette smoke. In the phenotypic studies, persons with slow acetylation had increased risk of bladder cancer, particularly when they had occupational exposure to arylamines or were cigarette smokers (Green et al. 2000; Johns and Houlston 2000). In the genotype analysis, more than 20 independent studies, many with small sample size have assessed the association of NAT2 polymorphisms with the risk of bladder cancer. A meta-analysis of published case-control studies conducted in the general population (22 studies, 2,496 cases, and 3,340 controls) examined the relationship of acetylation status (phenotype and genotype) to bladder cancer risk. Persons with slow acetylation had a 40-percent increase in risk compared with risk for persons with rapid acetylation (OR = 1.4; 95 percent CI, 1.2–1.6) (Marcus et al. 2000b). However, studies conducted in Asia generated a summary OR of 2.1 (95 percent CI, 1.2–3.8), studies in Europe generated a summary OR of 1.4 (95 percent CI, 1.2–1.6), and studies in the United States generated a summary OR of 0.9 (95 percent CI, 0.7–1.3).

In addition, a case series meta-analysis of data from a case series of 16 studies of bladder cancer, conducted in the general population and involving 1,999 cases, showed a weak interaction between smoking status and NAT2 slow acetylation (OR = 1.3; 95 percent CI, 1.0–1.6). The interaction was stronger when analyses were restricted to studies conducted in Europe (OR = 1.5; 95 percent CI, 1.1–1.9) (Marcus et al. 2000a). In a pooled analysis of data from 1,530 cases and 731 controls from four case-control studies plus two case series conducted in Whites in European countries, a significant association was reported between NAT2 slow acetylation and bladder cancer (OR = 1.42; 95 percent CI, 1.14–1.77) (Vineis et al. 2001). The risk of cancer was elevated in smokers and in persons with occupational exposure to cigarette smoke, and the highest risk was for persons with slow acetylation (Vineis et al. 2001).

In a hospital-based, case-control study of 201 men in northern Italy and a case-control study with 507 White patients with bladder cancer in the United States, findings also suggested that the NAT2 genotype for slow acetylation was associated with an increased risk of bladder cancer, especially with the joint effects of cigarette smoking and occupational exposure to aromatic amines (Hung et al. 2004; Gu et al. 2005). In a case-control study of bladder cancer in females, exclusive use of permanent hair dye was associated with a 2.9-fold increased risk of bladder cancer among persons with the NAT2 genotype and slow acetylation but not in those with the NAT2 genotype and rapid acetylation (Gago-Dominguez et al. 2003). All of these results confirmed that the genotype for NAT2 slow acetylation is a risk factor for bladder cancer through interaction with smoking or occupational exposure. However, several studies that included populations of Chinese (Ma et al. 2004), northern Indians (Mittal et al. 2004), and Poles (Jaskula-Sztul et al. 2001) reported no association between the NAT2 genotype and bladder cancer risk.

Microsomal Epoxide Hydrolase

Like NAT2, MEH can act as both an activator and a detoxifier of carcinogens. As a detoxifier, MEH catalyzes the hydrolysis of highly reactive epoxide intermediate agents to less reactive dihydrodiols that are excretable. As an activator, MEH is involved in further metabolism of PAH epoxides. Several identified polymorphisms include a T→C base change in exon 3 leading to a tyrosine→histidine substitution at residue 113, which is associated with a decrease in enzymatic activity, and an A→G base change in exon 4, leading to a histidine→arginine substitution at residue 139, which leads to an increase in enzymatic activity (Hassett et al. 1994). Several reports of studies have noted an increased risk of lung cancer among persons carrying polymorphisms associated with an increase in enzymatic activity. A study of Mexican Americans and African Americans found a greater risk of lung cancer among young Mexican Americans with the exon 4 polymorphism, but not among those with the exon 3 polymorphism. No association was observed among African Americans (Wu et al. 2001). The homozygous variant genotype at exon 4 confers increased enzymatic activity and was again associated with an increase in lung cancer risk in a study in Texas (Cajas-Salazar et al. 2003). A study from Austria suggested an association between the exon 3 polymorphism of the MEH gene and a significantly decreased risk of lung cancer (Gsur et al. 2003). The combination of exon 3 and exon 4 polymorphisms that conferred high enzymatic activity also significantly increased the risk (Cajas-Salazar et al. 2003; Park et al. 2005). In a Chinese population in Taiwan, high MEH activity, defined by the corresponding combination of exon 3 and exon 4 polymorphisms, was associated with an increased risk for SCC (Lin et al. 2000). In a French population, high MEH activity was similarly associated with lung cancer risk (Benhamou et al. 1998).

A study of 974 White patients with lung cancer and 1,142 control participants found no relationship between MEH polymorphisms and lung cancer risk overall. However, evidence of gene-environment interactions was observed. Low-activity MEH genotypes were a risk factor for lung cancer among nonsmokers (OR = 1.89; 95 percent CI, 1.08–3.28) but were protective among heavy smokers (OR = 0.65; 95 percent CI, 0.42–1.00) (Zhou et al. 2001b). This effect was stronger in SCC than in adenocarcinoma. The researchers hypothesized that this difference may be explained by the dual actions of MEH. In nonsmokers, the presence of low MEH activity may lead to a decreased ability to detoxify environmental pollutants, thus increasing lung cancer risk. In smokers, MEH may participate in activating the PAHs in cigarette smoke. Therefore, low activity is protective for heavy smokers. Similar results were reported in a Slovak study (Habalová et al. 2004).

In a meta-analysis of data from seven published studies that included 2,078 case patients with lung cancer and 3,081 control participants, investigators found no consistent overall association for either the exon 3 or exon 4 polymorphisms with lung cancer risk (Lee et al. 2002c). However, in an analysis of pooled data from eight studies (four published and four unpublished at that time) with 986 case patients and 1,633 control participants, researchers observed a significant decrease in lung cancer risk (OR = 0.70; 95 percent CI, 0.51–0.96) for the exon 3 *HIS/*HIS genotype. The protective effect of the exon 3 polymorphism seems stronger for adenocarcinomas of the lung than for other histologic types. Researchers found no overall association between MEH activity and lung cancer risk and no consistent modification of the carcinogenic effect of smoking according to the MEH polymorphism. However, the risk of lung cancer decreased among lifetime nonsmokers with high MEH activity and among heavy smokers with the exon 3 *HIS/*HIS genotype (Lee et al. 2002c).

Genes in the Pathway for Metabolism of Reactive Oxygen Species

Studies have identified an alanine→valine substitution at codon 16 of manganese superoxide dismutase (SOD), which may be associated with a less efficient enzyme transport into mitochondria. The *VAL/*VAL genotype is associated with risk of lung cancer higher than that for the wild-type genotype (AOR = 1.67; 95 percent CI, 1.27–2.20) (Wang et al. 2001a). Other studies also associate the heterozygous variant genotype with an increased risk of lung cancer (AOR = 1.34; 95 percent CI, 1.05–1.70) (Wang et al. 2001a, 2004c). Studies have identified a G→A polymorphism in the promoter region of myeloperoxidase (MPO) that decreases *A allele transcription. A study of bronchoalveolar lavage fluid and cells from 106 White smokers who had lung cancer showed an association of the variant genotypes with reduced MPO activity in the fluid and reduced levels of smoking-related DNA adducts in bronchoalveolar cells (Van Schooten et al. 2004). The association was stronger in persons having two variant alleles (homozygous variants) than it was in persons having one normal and one variant allele (heterozygous variants).

Findings on lung cancer risk are conflicting. Most studies performed since 1999 suggested that the variant MPO genotypes are associated with a decreased risk of lung cancer (Le Marchand et al. 2000; Dally et al. 2002; Feyler et al. 2002; Kantarci et al. 2002; Lu et al. 2002; Schabath et al. 2002). In contrast, two studies found no association between either the heterozygous or homozygous variant genotypes and lung cancer risk (Xu et al. 2002; Chevrier et al. 2003). Another study suggested that the MPO-G463A polymorphism associated with a novel estrogen-receptor-binding site modifies the association between the SOD ALA16VAL polymorphism and risk of non-small-cell lung cancer (NSCLC) differently by gender. For women carrying MPO variant genotypes, the AOR of the SOD polymorphism (*VAL/*VAL versus *ALA/*ALA) was 3.26 (95 percent CI, 1.55–6.83). No associations were found in men or women who carried the MPO *G/*G wild-type genotype (Liu et al. 2004).


Studies to date suggest a role for genetic polymorphisms in the risk of lung and bladder cancer in smokers and support a possible association between specific genes and smoking status. Investigations continue on the role of multiple genetic variants that occur simultaneously and the interactions between metabolic gene variants and other kinds of heritable variations, such as DNA repair, cell-cycle control, tumor-suppressor genes, and oncogene activity.

DNA Repair and Conversion of Adducts to Mutations

Repair of DNA Adducts


Tobacco products and smoke contain many chemicals that can damage DNA. Multiple repair pathways protect a human cell against the mutagenic and carcinogenic activities of these DNA-damaging agents. Pathways involved in the repair of tobacco-related DNA damage include direct base repair by alkyltransferases, excision of DNA damage by base excision repair (BER), or nucleotide excision repair (NER), mismatch repair (MMR), and double-strand break repair (DSBR). The inadequate removal of DNA damage results in increased rates of mutagenesis and, as a consequence, the increased likelihood of a person developing cancer.

O6-Alkylguanine–DNA Alkyltransferase


O6-alkylguanine adducts are repaired by the repair protein O6-alkylguanine–DNA alkyltransferase (AGT) in a reaction involving transfer of the methyl group from the O6 position of guanine to a cysteinyl residue on the protein (Pegg 2000). This transfer reaction results in an error-proof repair as it regenerates an unmodified guanine residue in DNA. However, the repair protein is inactivated as the alkylated protein undergoes a conformational change (Daniels et al. 2000) and is degraded (Srivenugopal et al. 1996; Xu-Welliver and Pegg 2002). As a consequence of this repair mechanism, the constitutive levels of AGT determine the initial repair capacity of a cell by this mechanism. Overall capacity of the O6-alkylguanine repair is determined by the rate of protein synthesis and the amount of alkylation at the O6 position of guanine.

Substrate Specificity

Mammalian AGT specifically repairs O6-alkylguanine adducts, and it repairs the larger O6-alkylguanine residues more readily than does the bacterial protein. In rodents, AGT repairs O6-methylguanine, O6-butylguanine, and O6-[4-oxo-4-(3-pyridyl)butyl]guanine at comparable rates, whereas human AGT repairs the bulky adducts more slowly (Mijal et al. 2004). This ability of the rodent protein to accommodate such large structural differences likely results from the additional amino acid residue (Gly166) in the binding pocket of the rodent proteins (Loktionova and Pegg 2002). Therefore, the steric constraints of an active AGT site determine whether it can efficiently repair a bulky O6-alkylguanine adduct such as those more commonly resulting from exposure to smoke.

Protecting Against Mutagenicity of Tobacco Carcinogens

Tobacco smoke contains a number of alkylating agents, such as tobacco-specific nitrosamines, which are capable of forming O6-alkylguanine adducts (Wang et al. 1997; Hecht 1998). AGT protects against the mutagenic and carcinogenic properties of alkylating agents.

In vitro studies. Increased expression of AGT protects against the mutagenic effects of O6-alkylguanine (Ellison et al. 1989) and alkylating agents (Kaina et al. 1991; Wu et al. 1992; Ferrezuelo et al. 1998a,b). Consistently, alkylating agents are more toxic and mutagenic when coadministered with AGT inactivators such as O6-benzylguanine or related compounds (Dolan et al. 1990, 1991; Bronstein et al. 1992). The mutagenic activity of O6-methylguanine or O6-[4-oxo-4-(3-pyridyl)butyl]guanine is enhanced when cells are pretreated with O6-benzylguanine (Pauly et al. 1995, 2002). This finding indicated that AGT is important in protecting against the mutagenic activity of these adducts derived from tobacco constituents.

In vivo studies. AGT is depleted in tissues from NNK-treated rats, and AGT levels are depleted in Clara cells (Belinsky et al. 1988). NNK also reduces AGT levels in the lungs and liver of A/J mice (Peterson et al. 2001). Although the liver function recovers to control values within 96 hours after exposure, AGT activity remains depressed in the lung. Consistently, O6-methylguanine is efficiently repaired in the liver of NNK-treated mice, but it persists for at least two weeks in lung DNA (Peterson and Hecht 1991; Peterson et al. 2001). Notably, levels of O6-methylguanine in lung DNA are highly correlated with pulmonary tumorigenic activity in A/J mice (Peterson and Hecht 1991; Peterson et al. 2001). These observations strongly suggest that the inefficient repair of O6-methylguanine, presumably by AGT, is linked to the tumorigenic activity of NNK. This conclusion is supported by the observation from another study that high AGT levels protect against NNK-induced lung tumorigenesis and that NNK is a less potent lung carcinogen in transgenic mice containing the human AGT transgene (Liu et al. 1999).

Base Excision Repair


BER is a major pathway for the repair of small DNA damage, primarily to alkylated and oxidized DNA bases, as well as the repair of apurinic/apyrimidinic (AP) sites and single-stranded breaks (Fortini et al. 2003; Fromme et al. 2004). BER is initiated by a recognition of the damaged DNA by specific DNA glycosylases. Studies have characterized 12 human glycosylases (Table 5.4) (Christmann et al. 2003; Fortini et al. 2003). Each enzyme has different but sometimes overlapping substrate specificities that are subgrouped into type I and type II glycosylases, depending on their mode of action (Christmann et al. 2003). Type I glycosylases catalyze the cleavage of the N-glycosidic bond, leaving an AP site. Type II glycosylases remove the damaged base in a similar manner. They contain 3′-endonuclease activity that cleaves the AP site, which generates a single-strand break with a 3′-terminal deoxyribose phosphate. Spontaneous hydrolysis of a glycosidic bond can also directly generate AP sites. AP sites are substrates for DNA AP endonuclease, which cuts the phosphodiester bond and causes the formation of a strand break with a 5′-terminal deoxyribose phosphate (Barzilay et al. 1995).

Table 5.4. Human DNA glycosylases.

Table 5.4

Human DNA glycosylases.

Once the phosphodiester bond is cleaved, BER can proceed through two pathways: short-patch or long-patch (Figure 5.4). The balance of the two pathways can depend on tissue type (Sancar et al. 2004). In general, short-patch BER dominates when BER is initiated by glycosylases. Long-patch BER is the preferred pathway when BER is initiated with the formation of AP sites through spontaneous hydrolysis or oxidative base loss (Sancar et al. 2004).

Figure 5.4. Mechanism of base excision repair.

Figure 5.4

Mechanism of base excision repair. Source: Adapted from Christmann et al. 2003 with permission from Elsevier, © 2003. Note: 5dRP = 5′-deoxyribose phosphate; AP = apurinic/apyrimidinic; dRPase = DNA deoxyribophosphodiesterase; (more...)

In short-patch BER, DNA polymerase β (polβ) inserts a new nucleotide at the lesion site and catalyzes the release of 5′-terminal deoxyribose phosphates by β-elimination (Matsumoto and Kim 1995; Sobol et al. 1996; Prasad et al. 1998). This step is followed by ligation of the remaining break by the ligase III x-ray repair cross-complementation group 1 (XRCC1) complex (Kubota et al. 1996).

Long-patch BER occurs in oxidized or reduced AP sites, 3′-unsaturated aldehydes, or 3′-phosphates, because these modifications are resistant to β-elimination by polβ. Therefore, this damage is further processed by long-patch repair dependent on the proliferating cell nuclear antigen (PCNA) after the insertion of a nucleotide at the lesion site by polβ (Christmann et al. 2003; Fortini et al. 2003). This mechanism displaces the damaged strand, which is followed by DNA synthesis of an oligonucleotide (up to 10 nucleotides) by polδ or polɛ in concert with PCNA and replication factor C (Stucki et al. 1998). The flap endo-nuclease 1 (FEN1) recognizes and cleaves off the damaged oligonucleotide flap structure (Klungland and Lindahl 1997). Ligase I catalyzes the final ligation step (Prasad et al. 1996; Srivastava et al. 1998).

Substrate Specificity

Tobacco smoke is rich in reactive oxygen species that can oxidize DNA bases. BER is an important pathway for the repair of oxidized DNA bases, such as 8-oxogua-nine and oxidized pyrimidines, and for the repair of single-strand breaks. Tobacco smoke contains N-nitrosamines capable of generating small alkylguanine damage that is repaired by this pathway. The small chemical alterations frequently miscode if they are not repaired by BER. Therefore, this pathway is particularly important in preventing mutagenesis.

Protecting Against Mutagenicity and Carcinogenicity of Tobacco Carcinogens

Single-gene knockouts of glycosylases in mice are well tolerated, with only modest increases in rates of spontaneous mutagenesis (Fortini et al. 2003). This observation likely results from an overlapping specificity of the various glycosylases and repair pathways. However, mutagenicity of methyl methanesulfonate (MMS) in lymphocytes from alkylpurine-DNA-N-glycosylase–null mice was three to four times higher than that in lymphocytes from wild-type control mice (Elder et al. 1998). Most of the mutations were AT→TA transversions. In addition, 8-oxoguanine DNA glycosylase 1 (OGG1) knockout mice that are aging eventually develop lung cancer (Sakumi et al. 2003). However, in another study, knockout of proteins involved in the steps after removal of the base caused the knockout mice to die at a very young age (Fortini et al. 2003).

Imbalances in the proteins involved in this pathway could have negative consequences. Chinese hamster ovary cells that overexpress alkylpurine DNA glycosylase are more sensitive to both the toxic and mutagenic effects of MMS and have higher numbers of mutations at AT base pairs than do normal Chinese hamster ovary cells (Calléja et al. 1999). This result suggests that an enhanced repair of 3-methyladenine leads to an accumulation of unprocessed AP sites that are also mutagenic. Findings in another study indicate that imbalances and/or polymorphisms in the proteins involved in BER may cause an increase in cancer susceptibility (Fortini et al. 2003).

Nucleotide Excision Repair


NER repairs a wide class of helix-distorting lesions that interfere with base pairing, blocking transcription and normal replication (Petit and Sancar 1999; Sancar et al. 2004). NER is the primary repair mechanism for bulky DNA damage caused by chemicals or ultraviolet (UV) radiation or as a result of protein-DNA cross-links (Sancar et al. 2004). Two NER pathways exist (Figure 5.5): global genomic NER (GGR), which surveys the whole genome for DNA damage, and transcription-coupled repair (TCR), which primarily repairs damage that interferes with transcription. Both pathways involve recognition of DNA damage and excision of the damaged DNA, followed by the synthesis and ligation of new DNA.

Figure 5.5. Mechanism of nucleotide excision repair: (A) global genomic repair; (B) transcription-coupled repair.

Figure 5.5

Mechanism of nucleotide excision repair: (A) global genomic repair; (B) transcription-coupled repair. Source: Adapted from Christmann et al. 2003 with permission from Elsevier, © 2003. Note: CSA = Cockayne syndrome complementation group A; CSB (more...)

Global genomic nucleotide excision repair. Researchers think that GGR is largely transcription independent, occurring throughout the genome because no gene or strand preference for this repair pathway exists (Hanawalt et al. 2003). Proteins involved in this pathway are presented in Table 5.5. The initial step involves recognition of DNA damage (Figure 5.5). The complex of repair factors in the xeroderma pigmentosum group C (XPC) and the homologous recombinational repair group 23B (HR23B) can directly recognize some DNA damage (Hey et al. 2002). However, in some cases, DNA-binding protein is required to enhance the DNA distortion before the recruitment of XPC-HR23B (Tan and Chu 2002; Hanawalt et al. 2003). Repair factors XPA and replication protein A are then recruited to the complex to verify that the alteration in the DNA structure results from a lesion, as opposed to a natural variation in DNA structure (Hanawalt et al. 2003).

Table 5.5. Factors involved in nucleotide excision repair activity in humans.

Table 5.5

Factors involved in nucleotide excision repair activity in humans.

The DNA is then unwound at the site of the lesion. This step occurs on recruitment of the basal transcription initiation factor IIH (TFIIH) multiprotein complex (Christmann et al. 2003). This complex is likely involved in a further verification of damage and detection of the damaged strand. The helicase subunits of TFIIH, XPB, and XPD then unwind the DNA around the lesion.

Once the DNA has unwound, the lesion is excised at defined sites on either side of the damage (Evans et al. 1997). The 3′-incision is catalyzed by XPG (Habraken et al. 1994; O’Donovan et al. 1994), and the 5′-incision is catalyzed by the excision repair cross-complementation group 1 (ERCC1) XPF complex (Sijbers et al. 1996). The resulting DNA gap is filled in by the PCNA-dependent polymerases: polδ and polɛ (Aboussekhra et al. 1995; Araújo et al. 2000). The final ligation is performed by DNA ligase I and associated proteins (Aboussekhra et al. 1995; Mu et al. 1995; Araújo et al. 2000). Findings from in vivo studies suggest that the NER machinery is assembled in a stepwise manner from the individual components at the lesion site. After the repair of a DNA lesion, the entire complex is believed by researchers to disassemble (Houtsmuller et al. 1999; Hoeijmakers 2001).

GGR appears to be inducible in humans (Hanawalt et al. 2003). The proteins that recognize DNA damage in GGR are maintained at low levels under normal physiological conditions. However, as a result of genomic stress, the efficiency of GGR is increased through the activation of the P53 tumor-suppressor gene (Hanawalt et al. 2003). Consequently, the levels of XPC and XPE increase. Repair of PAH adducts depends on the presence of the P53 protein (Hanawalt et al. 2003). These adducts are not repaired in human fibroblasts that lack a functional P53 protein or other gene product (Lloyd and Hanawalt 2000, 2002; Wani et al. 2000).

Transcription-coupled repair. TCR occurs when DNA damage blocks elongating RNA polymerases (Tornaletti and Hanawalt 1999). The transcription-coupled, repair-specific factors belong to two Cockayne syndrome complementation groups (A and B) and are involved in the displacement of the stalled polymerase (Christmann et al. 2003). At this point, TFIIH is recruited to the lesion, and the subsequent steps in TCR proceed in a manner apparently similar to the steps for GGR. Because of the mechanism of DNA damage recognition, TCR is specific to a DNA strand.

Substrate Specificity

The substrate specificity of NER ranges from small to large distortions in DNA structure. The bulky DNA damage generated by PAHs and aromatic amines in tobacco smoke is repaired primarily by NER (Friedberg 2001). The finding that human NER repairs 8-oxoguanine in vitro more efficiently than thymine dimers or thymine glycol (Reardon et al. 1997) suggests that this pathway may be important for the repair of this mutagenic adduct. In addition, human NER repairs O6-methylguanine and N6-methyladenine, as well as A:G and G:G mismatches (Huang et al. 1994).

Protecting Against Mutagenicity and Carcinogenicity of Tobacco Carcinogens

Consistent with the primary role of NER in the repair of bulky DNA damage from PAHs and aromatic amines, cells deficient in NER are more susceptible to the mutagenic and toxic effects of PAHs (Quan et al. 1994, 1995; Lloyd and Hanawalt 2000, 2002; Wani et al. 2000).

Mismatch Repair


MMR corrects replication errors (base-base or insertion-deletion mismatches) resulting from DNA polymerase errors. This repair pathway is also involved in the repair of alkylation DNA damage, such as repair of O6-methylguanine (Duckett et al. 1996), cisplatin-derived 1,2-intrastrand cross-links (Duckett et al. 1996), and adducts derived from B[a]P (Wu et al. 1999), 2-aminofluo-rene, and N-acetyl-2-aminofluorene (Li et al. 1996). This pathway can also repair 8-oxoguanine (Colussi et al. 2002).

An overview of MMR is displayed in Figure 5.6. Recognition of DNA damage occurs primarily by the mutSα complex (Christmann et al. 2003). This complex is composed of the mutS homologous proteins MSH2 (Fishel et al. 1993; Leach et al. 1993) and MSH6 (Palombo et al. 1995). Once the heterodimer is bound to the mismatch, it undergoes an adenosine-triphosphate (ATP)-dependent conformational change (Stojic et al. 2004). This complex is involved in determining which strand is the newly synthesized DNA (Christmann et al. 2003). A second heterodimer (mutLα) composed of mutL homologs MLH1 and PMS2 then binds to the mutSα-DNA complex in another ATP-dependent step (Nicolaides et al. 1994; Papadopoulos et al. 1994; Li and Modrich 1995; Stojic et al. 2004). Exonuclease I then excises the DNA strand containing the mispaired base (Genschel et al. 2002), followed by the resynthesis of new DNA by polδ (Longley et al. 1997).

Figure 5.6. Mechanism of mismatch repair.

Figure 5.6

Mechanism of mismatch repair. Source: Adapted from Christmann et al. 2003 with permission from Elsevier, © 2003. Note: For two steps dependent on adenosine triphosphatase (ATPase), see text. C = cytosine; G = guanine; HMLH1 = human mutL homolog (more...)

MSH2 can also complex with MSH3 to form mutSβ (Acharya et al. 1996; Palombo et al. 1996). The substrate specificity of this alternate complex is different from that of mutSα (Christmann et al. 2003). The mutSα complex recognizes base-base mismatches, as well as insertion-deletion mismatches (Umar et al. 1994), whereas mutSβ binds only to insertion-deletion mismatches (Palombo et al. 1996; Genschel et al. 1998).

Protecting Against Mutagenicity and Carcinogenicity of Tobacco Carcinogens

Persistent adducts that escape repair by AGT, BER, or NER may be processed by MMR. Because MMR occurs after DNA replication (Stojic et al. 2004), this is the last opportunity for DNA damage repair before cell division. Consequently, a defective MMR results in an increase in mutagenesis (Schofield and Hsieh 2003). The overall effect of a defective MMR is the likelihood that cells with persistent DNA damage survive with a miscoded DNA. This combination results in a higher cancer risk.

The role of MMR in the toxicity and mutagenicity of alkylating agents is well documented for methylating agents (Karran 2001; Stojic et al. 2004). Cells lacking functional MMR are more resistant to the toxic effects of methylating agents (Koi et al. 1994; Risinger et al. 1995; Umar et al. 1997; de Wind et al. 1999; Karran 2001; Stojic et al. 2004). However, these cells are sensitive to the mutagenic effects of these compounds (Umar et al. 1997; Zhu et al. 1998). These effects are linked to the ineffective MMR of O6-methylguanine. As a result, a defective MMR is associated with increases in mutagenesis and carcinogenesis mediated by O6-methylguanine (Hickman and Samson 1999; Pauly and Moschel 2001). Similar effects were reported for ethylating agents (Claij et al. 2003).

Double-Strand Break Repair


Two pathways exist for DSBRs: homologous recombination and nonhomologous end-joining. Homologous recombination occurs during DNA replication in the S and G2 phases, whereas nonhomologous end-joining occurs during G0 and G1 phases. Homologous recombination uses the sister chromatid as the template for aligning the breaks in the proper orientation and is consequently error free (Hoeijmakers 2001). However, nonhomologous end-joining does not require sequence homology between the two breaks to ligate them and is therefore prone to errors (Hoeijmakers 2001).

Homologous Recombination

The meiotic recombination 11 (MRE11)-RAD50-NBS1 protein complex initiates DSBR by catalyzing the degradation of the DNA in the 5′ to 3′ direction, generating 3′ single-stranded DNA (Figure 5.7). This single-stranded DNA is protected from degradation by a heptameric ring complex of RAD52 proteins (Stasiak et al. 2000). Replication factor A facilitates the assembly of a RAD51 nucleoprotein filament, which consists of RAD51B, RAD51C, and RAD51D, as well as XRCC2 and XRCC3 (Christmann et al. 2003). RAD51 is able to exchange the single strand with the same sequence from the sister chromatid DNA. This double-stranded copy is then used as a template to correctly repair with DNA synthesis machinery. The resulting Holliday structures are subsequently resolved to generate the repaired DNA (Constantinou et al. 2001).

Figure 5.7. Proposed mechanism of homologous recombination.

Figure 5.7

Proposed mechanism of homologous recombination. Source: Adapted from Christmann et al. 2003 with permission from Elsevier, © 2003. Note: MRE11 = meiotic recombination 11; RAD = S. cerevisiae DNA damage recognition and repair protein; RPA = replication (more...)

Nonhomologous End-Joining

Nonhomologous end-joining merely links the ends of a DSB together in the absence of a template (Figure 5.8). The break is initially recognized by a heterodimer consisting of the proteins KU70 (Reeves and Sthoeger 1989) and KU80 (Jeggo et al. 1992). This binding protects the DNA from digestion and associates it with the protein kinase catalytic subunit DNA-PKcs, which is dependent on DNA. This complex, in turn, activates XRCC4-ligase IV, which connects the broken DNA pieces together once the MRE11-RAD50-NBS1 complex has processed the break (Maser et al. 1997; Nelms et al. 1998). Researchers think that FEN1 and Artemis also play a role in the processing of DSBs (Christmann et al. 2003).

Figure 5.8. Proposed mechanism of nonhomologous end-joining.

Figure 5.8

Proposed mechanism of nonhomologous end-joining. Source: Adapted from Christmann et al. 2003 with permission from Elsevier, © 2003. Note: FEN1 = flap endonuclease 1; MRE11 = meiotic recombination 11; PKcs = protein kinase catalytic subunit; XRCC4 (more...)

Protecting Against Mutagenicity and Carcinogenicity of Tobacco Carcinogens

Scientists think that DSBs trigger large chromosomal aberrations such as chromosomal breaks and exchanges (Pfeiffer et al. 2000). Studies link an increase in chromosomal aberrations to tobacco exposure (DeMarini 2004). These aberrations are more common in pulmonary lung tumors from smokers than in those from nonsmokers (Sanchez-Cespedes et al. 2001). DSBs are also important in triggering cell death (Rich et al. 2000; Lips and Kaina 2001).

Molecular Epidemiology of DNA Repair

Studies support the substantial interindividual variations in DNA repair capacity (DRC). Researchers hypothesize that common variants in the genes that regulate these protein expressions may modulate repair and influence susceptibility to tobacco carcinogenesis. Two complementary approaches to studying DNA repair as a risk factor for tobacco carcinogenesis are applying functional assays and genotyping variants in gene pathways for DNA repair. Table 5.6 summarizes some relevant genes and their variants in pathways involved in repairing tobacco-induced DNA damage.

Table 5.6. Select candidate genes and polymorphisms implicated in repair of tobacco-induced DNA damage.

Table 5.6

Select candidate genes and polymorphisms implicated in repair of tobacco-induced DNA damage.

Functional Assays of DNA Damage and Repair to Tobacco Carcinogens

Berwick and Vineis (2000) extensively reviewed the types of functional assays. The review included assays that use a chemical or physical mutagen challenge such as mutagen sensitivity, single-cell microgel electrophoresis (comet assay), and assays of induced adducts and unscheduled DNA synthesis. The review also included the host-cell reactivation (HCR) assay, which measures cellular ability to remove adducts from plasmids transfected into lymphocyte cultures in vitro by the expression of damaged reporter genes.

Host-Cell Reactivation Assay

The HCR assay measures the expression level of damaged reporter genes, which are involved in reactivation of the host cell. The assay uses undamaged host lymphocytes, is fast, and objectively measures intrinsic cellular repair (Athas et al. 1991). In the assay, lymphocytes are transfected with a damaged, nonreplicating recombinant plasmid harboring a chloramphenicol acet-yltransferase (CAT) reporter gene (PCMVCAT). To study tobacco-related cancers, the mutagen challenge is B[a]P (Gelboin 1980). Experimental conditions produce at least one BPDE-DNA adduct per plasmid, completely blocking transcription of the PCMVCAT gene without inducing conformational changes in the DNA. This finding is important because conformational change of the plasmid could reduce the transfection rate. Because even a single unrepaired DNA adduct can effectively block PCMVCAT transcription (Koch et al. 1993), any measurable PCMV-CAT activity reflects the ability of the transfected cells to remove BPDE-induced adducts from the plasmids (Athas et al. 1991).

Both lymphocytes and skin fibroblasts from patients with basal cell carcinoma, but not with XP, were found to have lower excision repair rates than those from persons without cancer (Wei et al. 1993). Consequently, the repair capacity of lymphocytes may reflect the overall repair capacity of a person. Spitz and colleagues (2003) showed that case patients with lung cancer had a significantly lower DRC than did control participants and that case patients aged 63 years or younger and lifetime nonsmokers had a lower DRC than that of matched control participants. DRC appears to be highest among case patients and control participants who were current smokers than among those who were former smokers and lifetime nonsmokers. Heavy smokers among both case patients and control participants tended to have more proficient DRC than did light smokers. This finding indicated that cigarette smoking may stimulate DRC in response to the DNA damage caused by carcinogens in tobacco. Such an adaptation would be consistent with a baseline DRC that can be mobilized on an increased demand for repair (Eller et al. 1997; Cheng et al. 1998). This adaptation of DRC to smoking, if it exists, appears to be long term rather than transient, because the effect was still present in former smokers but was not stronger in those who had smoked in the 24 hours before the blood sample was drawn (Wei et al. 2000). The finding that long-term heavy smokers with lung cancer had an efficient DRC may also indicate that heavy exposure overwhelms even relatively resistant phenotypes.

Luciferase Host-Cell Reactivation Assay

Researchers have modified the HCR assay by replacing CAT with luciferase (LUC). The cell-extraction procedure is far more simplified for the LUC assay. A luminometer measures LUC optical density, and the laboratory procedures are shorter. The results for the DRC phenotype from the independent CAT and LUC assays in parallel are highly correlated, with a correlation coefficient of 0.65 (p <0.0001) (Qiao et al. 2002a). This finding suggests that these two assays are comparable.

8-Oxoguanine DNA Glycosylase Activity Assay

The OGG test is another functional repair assay that measures the specific activity of the enzyme 8-oxoguanine DNA N-glycosylase in protein extracts prepared from peripheral blood mononuclear cells (Paz-Elizur et al. 2003). The OGG1 enzyme removes 8-oxoguanine from DNA and leaves behind an abasic site that is rapidly cleaved by the AP lyase of OGG1. OGG activity (in units per μg of protein extract) is the amount of fragment cleaved by 1 μg of extract in one hour under standard reaction conditions (Paz-Elizur et al. 2003). In a pilot case-control study of NSCLC, the mean value of OGG activity in the case patients was significantly lower than that in the control participants and was independent of tumor histology, gender, and smoking status (Paz-Elizur et al. 2003). In addition, OGG activity in protein extracts from peripheral blood mononuclear cells correlated well with that from lung tissue in the same patients (p = 0.003).

Mutagen Sensitivity Assays

Researchers use cytogenetic assays extensively to measure human exposure and response to genotoxic agents. These assays are based on the unproven hypothesis that the extent of genetic damage in the lymphocytes may reflect critical events in carcinogenesis in the affected tissues. The assays can only indirectly indicate DRC from the cellular damage that remains after mutagenic exposure and recovery and therefore probably reflect nonspecific impairment of the DNA repair machinery (Berwick and Vineis 2000).

Hsu and colleagues (1989) developed the in vitro mutagen challenge assay to demonstrate interindividual differences in susceptibility to carcinogenic agents. This assay counts the frequency of bleomycin-induced breaks in short-term lymphocyte cultures, as a measure of cancer susceptibility. Bleomycin is a clastogenic agent that mimics the effects of radiation by generating free oxygen radicals capable of producing DNA single-strand breaks and DSBs after forming a complex with DNA, ferrous ions, and oxygen that releases oxygen radicals (Burger et al. 1981). Most of the breaks are repaired by BER. Repair is rapid, with a half-life of only a few minutes (López-Larraza et al. 1990).

Mutagen sensitivity is an independent risk factor for lung cancer that has a dose-response relationship with the number of induced chromosomal breaks (Spitz et al. 1995, 2003; Strom et al. 1995; Wu et al. 1995, 1998a; Zheng et al. 2003). The risks associated with mutagen sensitivity, stratified by smoking status, are elevated in all smoking strata but are highest in current smokers and in the heaviest smokers. For studying tobacco-related cancers, a more appropriate mutagen to trigger DNA damage is BPDE; BPDE-induced sensitivity is a risk factor for lung cancer (Wei et al. 1996; Wu et al. 1998a,b).

Comet Assay

The comet assay (single-cell microgel electrophoresis) is applicable to any cell line or tissue from which a single-cell suspension can be obtained (Ross et al. 1995). Singh and associates (1988) have described the methods in detail. For this assay, a cell culture is mixed with agarose gel and attached to a microscope slide. The cells are lysed by submerging the slides in freshly prepared lysis buffer to remove all cellular proteins. To allow for DNA denaturation, unwinding, and expression of the alkali-labile sites, the slides are then placed in an alkali buffer (pH = 12.0). To separate the damaged DNA from the intact nuclei, a constant electric current is applied, and the slides are neutralized, fixed, and stored in the dark at room temperature until ready for analysis. During electrophoresis, damaged DNA migrates from the nucleus toward the anode as a result of the constant electric current, which forms the typical “comet” cell. A predetermined number of cells are manually selected, and comet cells are automatically quantified with appropriate imaging software.

Case patients with lung and bladder cancer had significantly higher levels of induced DNA damage after exposure to both BPDE and γ-radiation, which were assessed by the mean “tail moment” in lymphocytes. (The tail moment is the product of lymphocyte tail length and the fraction of the total DNA in the tail.) Higher levels of DNA damage were positively associated with increased risk of bladder and lung cancer (Schabath et al. 2003; Wu et al. 2005). Schmezer and colleagues (2001) showed that case patients with lung cancer were significantly more sensitive to bleomycin and had a reduced DRC (68 percent in case patients and 81 percent in control participants [p <0.001]). Rajee-Behbahani and colleagues (2001) reported a similar DRC finding of 67 percent in 160 case patients with lung cancer and 79.3 percent in 180 control participants. When the data from the cases and controls were considered together, only 18 percent of the case patients were below the median level of sensitivity to bleo-mycin for all control participants, and 82 percent were in the hypersensitive range.

Mohrenweiser and Jones (1998) have pointed out several lines of evidence documenting that differences in DRC reflect genetic differences. DRC in lymphocyte subpopulations from an individual exhibited similar repair capacities. Furthermore, intraindividual variations in repair capacity among subpopulations of lymphocytes are significantly smaller than are interindividual variations (Crompton and Ozsahin 1997). The phenotype of reduced repair capacity in the NER pathway is independent of the phenotype for DSBR (Wu et al. 1998a).

Researchers have performed extensive resequencing of DNA repair genes to identify variations that may be associated with a reduced function of their encoded proteins rather than an absence of function. Such polymorphisms could explain interindividual differences in DRC (Spitz et al. 2001; Qiao et al. 2002b; Wu et al. 2003). Although the variant alleles are likely to be associated with only a modest cancer risk, because they exist at a polymorphic frequency, the attributable risks can become substantial. As Berwick and Vineis (2000) noted, studies that compare genetic polymorphisms with results of functional assays will likely be the most valuable type of investigations to clarify the role of a defect in DRC with the development of cancer.

Polymorphisms in O6-Alkylguanine–DNA Alkyltransferase

The ability of a cell to withstand alkyl damage is related to the number of AGT molecules in the cell and the rate of de novo synthesis of AGT. AGT levels differed among persons, and protein levels in the liver, colon, and peripheral blood varied 4-, 10-, and 20-fold, respectively (Myrnes et al. 1983; Strauss et al. 1989; Povey et al. 2000). Environmental and genetic factors, but not age, affect expression levels of AGT (Margison et al. 2003). AGT levels are higher in normal lung, colorectal, and placental tissues from smokers than in those from nonsmokers, although these findings are controversial (Slupphaug et al. 1992; Drin et al. 1994; Povey et al. 2000). Exposure to AGT inhibitory aldehydes, such as formaldehyde from occupational exposure, can deplete AGT activity (Hayes et al. 1997). Expression of AGT is higher in NSCLC tumor tissues from smokers than in those from nonsmokers (Mattern et al. 1998). However, small-scale studies examining AGT activity in peripheral lymphocytes have not observed significant differences between smokers and nonsmokers (Vähäkangas et al. 1991; Oesch and Klein 1992; Hall et al. 1993) or between case patients with cancer and control participants (Boffetta et al. 2002). It is not clear how well AGT activity in lymphocytes predicts levels in lung tissue.

The AGT gene contains multiple polymorphisms in the 5′ upstream region, which comprises the promoter and enhancer regions, as well as exon 1 (Egyházi et al. 2002; Krzesniak et al. 2004). These genetic variations may account for some of the interindividual variations in expression levels. Eight allelic variants in this region occur at a frequency of at least 0.01. One-half of these variants have a prevalence of 0.1 to 0.6, and this finding suggests a contribution to the variability in AGT expression within populations (Krzesniak et al. 2004). The prevalence of the best-studied enhancer polymorphism, C1099T, is 0.09 to 0.12 and is associated with an increase in promoter- enhancer activity in the LUC assay (Krzesniak et al. 2004). However, heterozygotes for this enhancer polymorphism do not appear to be at a markedly lower risk of developing lung cancer (OR = 0.82; 95 percent CI, 0.41–1.67) (Krzesniak et al. 2004). None of the other enhancer-promoter polymorphisms have been examined for their relationship with AGT or cancer risk.

Mutations at or near the cysteine acceptor site can affect AGT activity (Crone et al. 1994). Two polymorphisms have been identified in this region of the protein: codon 143 *ILE/*VAL and codon 160 *GLY/*ARG. The variant isoform codon 160 *GLY/*ARG has exhibited activity to repair bulky alkylated DNA adducts that is significantly less than that of the GLY wild-type phenotype (Edara et al. 1996; Mijal et al. 2004). The estimated prevalence of the 143 variant is 0.07 in Whites, 0.03 in African Americans (Kaur et al. 2000), and as high as 0.24 in Swedish populations (Ma et al. 2003). The codon 160 variant allele is likely a mutant, because it was found at a frequency less than 0.01 (Kaur et al. 2000). These researchers reported a marginally significant increase in the risk of lung cancer associated with the codon 143 *ILE/*VAL genotype (OR = 2.1; 95 percent CI, 1.01–4.7), and no interaction of genotype and smoking dose was seen. More recently, Cohet and colleagues (2004) reported an OR of 2.05 (95 percent CI, 1.03–4.07) for lung cancer among lifetime carriers of the codon 143 and 160 variant alleles who were nonsmokers. The authors suggested that the strongest risk was associated with exposure to secondhand tobacco smoke.

Polymorphisms in the Pathway for Repair of Base Excision

Cross-Complementation Group 1 for Excision Repair

The XRCC1 gene encodes a protein that functions in BER and involves the excision of the damaged region, followed by repair synthesis that uses the opposite strand as the template. The XRCC1 protein forms scaffolding with DNA ligase III, polβ, and poly (adenosine diphosphate–ribose) polymerase (PARP) to rejoin DNA strand breaks and repair gaps left during BER. Of the estimated 17 variants, 1 is a polymorphism at the XRCC1 28152 site (G→A transition) of codon 399 in exon 10 that results in a nonconservative amino acid substitution of arginine for glutamine. Goode and colleagues (2002) extensively reviewed the conflicting results for lung cancer studies. For example, Divine and colleagues (2001) reported a more than twofold risk for lung adenocarcinoma associated with the *GLN/*GLN genotype. Zhou and colleagues (2003) found an association that was largely restricted to nonsmokers and light smokers. Some studies failed to find any association between the *GLN/*GLN genotype and lung cancer risk (Butkiewicz et al. 2001; Ratnasinghe et al. 2001; Popanda et al. 2004; Zhang et al. 2005b). However, Matullo and colleagues (2001a) did find an association for bladder cancer. David-Beabes and London (2001) reported a decreased risk of lung cancer for both African American and White patients. Other studies also report conflicting findings regarding an increased risk associated with the exon 10 *ARG/*ARG genotype (Lee et al. 2001; Stern et al. 2001).

Another polymorphism at the XRCC1 26304 site (C→T transversion) of codon 194 in exon 6 results in a nonconservative amino acid substitution of arginine. Most studies suggest a reduced risk of cancer associated with the 399*ARG variant allele (Goode et al. 2002). Studies of lung, bladder, head and neck, and gastric cancers all showed inverse associations with the variant allele; some studies included evidence of an interaction with smoking (Sturgis et al. 1999; David-Beabes and London 2001; Ratnasinghe et al. 2001; Stern et al. 2001). Two studies noted no association for esophageal and lung cancers (Butkiewicz et al. 2001; Lee et al. 2001).

A few earlier studies evaluated the functional significance of these polymorphisms. Lunn and colleagues (1999) noted that persons with the 399*GLN allele were at a significantly higher risk (OR = 2.4) for exhibiting detectable aflatoxin B1 adducts and a higher frequency of the glycophorin A variant than were carriers of the 399*ARG/*ARG allele. This study also reported a dose-response relationship between smoking status and presence of the polymorphism for detecting the adducts and the glycophorin A variant (Lunn et al. 1999). However, no significant effects were noted for other XRCC1 polymorphisms. Duell and colleagues (2000) found elevated SCE frequencies and polyphenol DNA adducts with 399*GLN/*GLN homozygous genotypes. Abdel-Rahman and El-Zein (2000) noted that persons carrying the *GLN allele had significantly higher numbers of SCEs in response to NNK treatment than did *ARG/*ARG genotype carriers. No differences were detected in persons with the codon 194 genotype.

Matullo and colleagues (2001b) found higher DNA adduct levels among lifetime nonsmokers who were healthy and were homozygous for the 399*GLN allele than among those with the wild-type genotype (15.6 versus 6.78, p = 0.007). Wang and colleagues (2003a) showed that persons with the variant 194*TRP allele had fewer bleomycin- and BPDE-induced breaks per cell than did those with the wild-type genotype. The XRCC1 codon 399 is within the BRCT domain (amino acids 301 to 402) that interacts with PARP and is in many proteins with activity involving response to DNA damage and cell-cycle checkpoints. This region also has homology with yeast RAD4 repair-related genes. Because the role of XRCC1 in BER brings together DNA polβ, DNA ligase III, and PARP at the site of DNA damage, repair activity of the exon 10 variant may be altered. The codon 194 polymorphism is in the linker region of the XRCC1 N-terminal domain separating the helix 3 and polβ involved in binding a single- nucleotide gap DNA substrate (Marintchev et al. 1999). Therefore, this polymorphism is less likely to cause a significant change in repair function.

OGG1 Gene

The product of the OGG1 gene catalyzes the excision of a modified base, 8-oxoguanine, which may be formed by exposure to reactive oxygen species. The reduced ability to excise 8-oxoguanine may lead to an accumulation of oxidation-induced mutations. Studies have identified several polymorphisms at the OGG1 locus. The most frequently studied polymorphism is a common C→G transversion in exon 7 that results in an amino acid alteration at codon 326 (Ser→Cys). The HOGG1 protein encoded by the wild-type 326*SER allele exhibited substantially higher DNA repair activity than did the 326*CYS variant in an in vitro Escherichia coli complementation activity assay (Kohno et al. 1998).

Researchers have observed fairly consistent increased risks of OGG1 polymorphisms (Goode et al. 2002). The largest study was a U.S.-population-based, multiethnic study of lung cancer that identified a significantly increased risk associated with the *CYS/*CYS genotype (*CYS/*CYS versus *SER/*SER; OR = 2.1; 95 percent CI, 1.2–3.7) (Le Marchand et al. 2002). A small, hospital-based study of lung cancer in Japan supported these results (Sugimura et al. 1999). Findings in a third study of lung cancer that also suggested an increased risk had similar findings for comparison of the two homozygote groups (OR = 2.2; 95 percent CI, 0.4–11.8) (Wikman et al. 2000). Analyses of esophageal cancer also showed an increased risk associated with the *CYS/*CYS genotype (OR = 1.9; 95 percent CI, 1.3–2.6) (Xing et al. 2001). However, overall findings regarding an interaction with smoking were inconsistent.

Polymorphisms in the Pathway for Nucleotide Excision Repair

Xeroderma Pigmentosum A

XPA is an essential DNA-binding protein in the NER pathway that aids in correctly positioning the repair machinery around the damaged areas and in maintaining contact with core repair factors during the repair process. XPA interacts with other proteins, such as replication protein A, TFIIH, and XRCC1/XPF (Volker et al. 2001). Studies have identified an A→G transversion variant in the 5′ noncoding region (Butkiewicz et al. 2000). Researchers investigating this polymorphism in lung cancer reported similar results in two studies. Wu and colleagues (2003) reported that the presence of one or two copies of the *G allele instead of the *A allele was associated with a reduced lung cancer risk for all ethnic groups. Furthermore, control participants with one or two copies of the *G allele demonstrated more efficient DRC, as measured by the HCR assay, than did control participants with the homozygous A genotype. In a study in Korea, Park and colleagues (2002) reported that the *G/*G genotype was also associated with a significantly decreased lung cancer risk when the combined *A/*A and *A/*G genotype was used as the reference group. Butkiewicz and colleagues (2004) reported similarly increased risks that had borderline statistical significance for the *A/*A genotype in all participants and for SCC and adenocarcinomas. For heavy smokers, the risk estimate was 2.52 (95 percent CI, 1.2–5.4). Popanda and colleagues (2004) reported a nonsignificant risk of 1.53 for the *A/*A genotype compared with the *G/*G genotype. Thus, all studies confirm the protective effect of the *G/*G genotype and the enhanced risk for the *A/*A genotype.

Xeroderma Pigmentosum C

XPC is the step-limiting factor in NER. Researchers have found two single nucleotide polymorphisms (SNPs) in the coding region. ALA499VAL is a single *C/*T nucleotide polymorphism that codes for an amino acid substitution (Ala/Val) at codon 499. Another SNP, LYS939GLN, is a single *A/*C nucleotide polymorphism that codes for an amino acid substitution (Lys/Gln) at codon 939. This variant allele is associated with an increased risk of bladder cancer (Sanyal et al. 2004). There is also a bi-allelic poly AT insertion/deletion polymorphism (PAT) in intron 9 of XPC. The *PAT allele has been associated with risk of head and neck cancer (Shen et al. 2001).

Cross-Complementation Group 1 for Excision Repair

The XRCC1 gene codes for a 5′ incision subunit of the NER complex (Mohrenweiser et al. 1989). The XRCC1 and XPF proteins form a stable complex in vivo and in vitro (de Laat et al. 1999). Although studies have reported no defect in the human XRCC1 gene, cells from XRCC1-deficient mice have an increase in genomic instability and a repair-deficient phenotype (Melton et al. 1998). Five known polymorphisms of the XRCC1 gene do not cause an amino acid change and are validated in the SNP500Can-cer Database of the National Cancer Institute. However, researchers think that a polymorphism with A→C transversion at nucleotide 8092 in the 3′ untranslated region affects mRNA stability (Shen et al. 1998). Studies have implicated the XRCC1 polymorphism in the risk of adult-onset glioma (Chen et al. 2000) but not in head and neck cancer (Sturgis et al. 2002). Zhou and colleagues (2005) found no overall effect on lung cancer risk, but they did find a lower lung cancer risk in heavy smokers and a significantly higher risk in lifetime nonsmokers (OR = 2.11; 95 percent CI, 1.03–4.31).

Xeroderma Pigmentosum Complementation Group D

XPD (XRCC2) is one of the seven genetic complementation groups that encode for proteins in the NER pathway. The XPD protein has a role in both NER and basal transcription. XPD functions as an evolutionary conserved ATP-dependent helicase within the multisub-unit transcription repair factor complex TFIIH. Of the three polymorphisms identified in XPD, two are in exons and the third is silent. The G→A transition in exon 10 at codon 312 results in an amino acid change (Asp→Asn). The transition A→C at codon 751 in exon 23 produces a Lys→Gln change. The amino acid substitution Lys751 Gln in exon 23 does not reside in a known helicase/adenosine triphosphatase domain, but it is an amino acid residue identical in human, mouse, hamster, and fish XPD. This finding suggests a functional relevance for such a highly evolutionary conserved sequence (Shen et al. 1998). Goode and colleagues (2002) extensively reviewed numerous reports from case-control studies of lung cancer that have conflicting results. The largest study included 1,092 lung cancer case patients and 1,240 control participants who were spouses or friends (Zhou et al. 2002a). The overall AOR was 1.47 (95 percent CI, 1.1–2.0) for the ASP312ASN polymorphism (*ASN/*ASN versus *ASP/*ASP), but there was no association for the LYS-751GLN polymorphism (*GLN/*GLN versus *LYS/*LYS). Analyses of the interactions between genes and smoking revealed that the adjusted ORs for each of the two polymorphisms decreased significantly as pack-years1 increased. The interaction between the ASP312ASN polymorphism and smoking status was stronger than that between the LYS751GLN polymorphism and smoking. The researchers concluded that cumulative cigarette smoking modified the association between XPD polymorphisms and lung cancer risk. Spitz and colleagues (2001) reported AORs for the variant LYS751GLN and ASP312ASN genotypes of 1.36 and 1.51, respectively, although neither estimate was statistically significant. For persons homozygous for the variant genotype at either locus, the AOR was 1.84 (95 percent CI, 1.11–3.04; p = 0.018 for trend).

A recent review and meta-analysis of nine international case-control studies that included 2,886 lung cancer cases and 3,085 controls for codon 312 (LYS751GLN) and 3,374 lung cancer cases and 3,880 controls for codon 751 (ASP312ASN) did not demonstrate significant associations with either variant genotype (Benhamou and Sarasin 2005). However, for U.S. studies alone, both variants were associated with a significantly increased risk for lung cancer (ORs = 1.43 and 1.25, respectively). Hu and colleagues (2004) conducted another meta-analysis. The combined case-control studies reported a 21-percent higher risk for the 751*C/*C genotype (OR = 1.21; 95 percent CI, 1.02–1.43) and a 27-percent higher risk for the XPD 312*A/*A genotype (OR = 1.27; 95 percent CI, 1.04–1.56) among cases than among controls. Among studies of persons of Asian versus White descent, only the studies of Whites found a significantly higher risk for the XPD 751*C/*C genotype (OR = 1.23; 95 percent CI, 1.03–1.47). For the XPD 312*A/*A genotype, the risk among Whites compared with other races had borderline statistical significance (OR = 1.22; 95 percent CI, 0.99–1.49) among cases compared with controls. TFIIH transcriptional activity may be tolerant to amino acid changes in the XPD protein, and mutations may destroy or alter the repair function without affecting transcriptional activity. As Lunn and colleagues (2000) suggested, the effects of the *LYS allele may differ in different repair pathways, as assessed by different repair assays. The overall effect of conservative mutations in XPD may be subtle, because they do not alter XPB and XPD helicase activity, and multiple alterations might be needed before any effect is noted.

XPF/ERCC1 Gene Complex

ERCC1 forms a complex with XPF when it makes a dual incision at the single-strand to double-strand transition at the 5′ end of the damaged DNA strand (Shen et al. 1998). This complex is required to repair interstrand cross-links. A T→C transition at codon 662 results in a serine→proline substitution. Fan and colleagues (1999) reported six SNPs, five in coding regions. Three of the SNPs resulted in nonconserved amino acid differences.

XPG/ERCC5 Gene Complex

This complex shows homology with yeast RAD2 and carries out incision at the 3′ end of the lesion in the DNA strand (Harada et al. 1995; Hyytinen et al. 1999). Only two of the seven validated SNPs appear with significant frequency. In one polymorphism, a single nucleotide substitution (G→C) causes an amino acid change (His1104Asp) at codon 1104. In the other polymorphism, a C→G substitution produces an amino acid change from cysteine to serine at codon 529. Sanyal and colleagues (2004) showed that the variant *C/*C genotype was significantly less frequent in cases of bladder cancer than in controls. Jeon and colleagues (2003) reported similar findings for 310 lung cancer cases, in which the frequency of the variant genotype was less than that for the other two genotypes combined (AOR = 0.54; 95 percent CI, 0.37–0.80). This protective effect was attenuated in heavy smokers. Jeon and colleagues (2003) pointed out that because this SNP is in the C-terminus, it might alter binding to other proteins in the incision complex, thereby affecting DRC.

RAD23B Gene

The RAD23B gene is an evolutionary, well-conserved gene with 10 exons. The protein complexes with XPC to bind to different types of lesions and recruit the necessary factors for NER. Of the six validated SNPs, four are seen with considerable frequency. One of the most frequently observed polymorphisms is a substitution (C→T) resulting in an amino acid change at codon 249 (Ala249Val).

Genotype-Phenotype Correlations

Amino acid differences, especially at conserved sites in these enzymes, could result in changes in repair proficiency. The next logical step is the challenging task of evaluating the functional relevance of these polymorphisms. A variety of factors that modulate the path from genotype to phenotype include protein-protein interaction, posttranslational modification, gene silencing, epigenetic regulation, and environmental factors. Furthermore, proteins involved in DNA repair pathways are often multifunctional, resulting in a variety of phenotypes.

Both of the common genotypes *LYS/*LYS 751 and 312 *ASP/*ASP XPD were associated with a DRC more efficient than that for heterozygotes and with a significantly higher DRC than that for the homozygote mutants (Spitz et al. 2001). These results were confirmed in a different study population with a different mutagen challenge: a UV exposure of 800 joules per square meter that like BPDE invoked NER (Qiao et al. 2002b). Additional validation came from a correlative study that used the comet assay to assess DNA damage and repair (Schabath et al. 2003). These data are consistent with some of the published small-scale studies of these types of genotype-phenotype correlations. Hou and colleagues (2002) noted a significant increase in DNA adduct levels, as measured by 32P-postlabeling, with an increased number of variant alleles in exon 10 (p = 0.02) and exon 23 (p = 0.001). In addition, persons with the combined exon 10 *A/*A and exon 23 *C/*C genotype showed significantly higher levels of adducts than those for persons carrying any of the other genotypes (p = 0.02). Lunn and colleagues (2000) reported that possessing the common XPD genotype, *LYS/*LYS 751, was associated with an increased risk of suboptimal DRC, which was reflected in the number of x-ray–induced lymphocyte chromatid aberrations. No association with the *ASN312 allele was found.

However, Møller and colleagues (1998) reported no relationship between the LYS751GLN polymorphism and DRC, as measured by HCR or comet assay in 80 participants, including 20 healthy persons. Another study with a small sample of 76 healthy persons found no association between either SCE frequencies or the presence of DNA adducts by LYS751GLN genotype (Duell et al. 2000).

For a complex disease such as cancer, multiple genes—each with a small effect—probably act independently or interact with other genes to influence the disease phenotype. Although these data suggest that the polymorphisms have a functional relevance, biochemical and biologic characterizations of the variants are needed to validate these findings.

Polymorphisms in the Pathway for Double-Strand Break Repair

The XRCC3 gene encodes a protein that acts in the pathway for DSB/homologous recombination repair (DSB/REC repair) and repairs chromosomal damage such as breaks, translocations, and deletions. XRCC3 is a protein related to RAD51, which is a critical component of DSB/REC. Shen and colleagues (1998) identified a C→T substitution in exon 7 at position 18067 of XRCC3, a polymorphism that results in a threonine→methionine amino acid substitution at codon 241. David-Beabes and colleagues (2001) found no significant association between the XRCC3241 polymorphism and lung cancer. This finding was consistent with a smaller study of NSCLC that also found no association after adjustments for age and smoking (Butkiewicz et al. 2001). Wang and colleagues (2003c) reported an elevated but not statistically significant risk of lung cancer associated with polymorphisms of the XRCC3 *T allele in African Americans and Mexican Americans, which was evident largely in heavy smokers. Other studies have associated this XRCC3 polymorphism with an increased risk for melanoma skin cancer (Winsey et al. 2000) and bladder carcinoma (Matullo et al. 2001a). The THR241MET genetic variant may also contribute to increases in DNA adducts and bladder cancer risk (Stern et al. 2002).


The association between common variants in DNA repair genes and the risk for tobacco-induced cancers is the focus of considerable interest, but the results to date are inconsistent. Complementary functional studies are likely to be valuable in addressing these inconsistencies. Molecular epidemiologists now have better access to high-throughput genotyping platforms and an enhanced ability to focus on analyses based on pathways. Haplotype analyses also increase the power to detect relevant associations. In addition, computational algorithms such as PolyPhen and Scale-Invariant Feature Transform correlate with risk estimates, and new analytic tools are being developed.

Conversion of DNA Adducts to Mutations

DNA replication plays a major role in inducing point mutations—substitutions of one base pair for another and small mutations due to insertion or deletion of bases. DNA adducts per se are not mutations and can be removed by various DNA repair mechanisms in cells (Friedberg et al. 1995). When repair is not completed before a replication complex encounters the DNA adducts or other lesions, various events are induced, which are sensed by cell-cycle checkpoint mechanisms that halt cell-cycle progression (Sancar et al. 2004). When the lesion is a strand break, replication causes a DSB that is repaired by homologous recombination or by the erroneous nonhomologous end-joining mechanism. When the lesion is an interstrand cross-link, the stall of a replication complex triggers the unhooking of the cross-link by endonucleolytic incisions on both sides of the cross-link in one strand. When the lesion is a modified base or the loss of a base, a DNA polymerase often inserts a nucleotide, either correctly or incorrectly, opposite the lesion and extends the DNA strand beyond the site. The modification of a template nucleotide generally impairs its ability to serve as a template in efficiency and fidelity. Therefore, DNA synthesis slows down or is blocked at the site of the adducted template.

Translesion DNA synthesis occurs when a DNA polymerase succeeds in DNA synthesis over the modified template. The synthesis reaction sometimes results in the insertion of an incorrect nucleotide opposite a lesion. This insertion leads to base-substitution mutations, the skipping of the lesion nucleotide template, or the realignment of a growing primer strand on the template strand at the adducted region, which produces frameshift mutations. This step results in the introduction of mutations, and the subsequent replication of the mutated strand establishes the mutation in the genome. This section describes the mechanism of mutation induction by translesion DNA synthesis.

Molecular Analysis of Conversion to Mutations

The strategy for studying the conversion of adducts to mutations is to incorporate a chemically characterized DNA adduct or lesion into a specific sequence (Basu and Essigmann 1988). A DNA adduct can be incorporated into an oligonucleotide sequence by total chemical synthesis. However, a modified oligonucleotide may be prepared by direct reaction with a mutagen, followed by HPLC and/or gel electrophoresis purification. The modified oligonucleotide is then used as a substrate for in vitro and in vivo studies of translesion DNA synthesis, repair, and structure. This experimental approach generally demonstrates a clear relationship between cause and effect. The advantage of this approach is the ability to analyze in detail events in translesion synthesis such as (1) quantification of the effects of blocking DNA synthesis, (2) miscoding frequency, and (3) miscoding specificity.

In vitro studies of translesion synthesis that use purified DNA polymerases complement the in vivo studies. As described in the following section, cells have various types of DNA polymerases and some of them are responsible for translesion synthesis. Therefore, the characterization of in vitro translesion synthesis could help to identify the polymerase responsible for translesion synthesis in cells. In vitro studies can be divided into two phases: insertion and extension steps. The insertion step determines which nucleotide is most efficiently inserted opposite a lesion by a given polymerase. The extension step determines which nucleotide terminus is most efficiently extended opposite a lesion. These experiments characterize the efficiency and fidelity of translesion synthesis by a given polymerase. The results of the in vitro experiments may be reflected in translesion synthesis in cells if the polymerase is involved in the synthesis. The involvement of a candidate polymerase is examined by studying translesion synthesis in a host cell lacking the polymerase of interest. Finally, the involvement is confirmed by a complementation experiment in mutant cells that express the exogenous gene for the polymerase of interest. Thus, translesion synthesis across a given DNA lesion is studied in detail. One limitation of this site-specific experiment is the inability to study the effects on chromosomal aberrations. In addition, the results may not apply to other sequence contexts. Nevertheless, this approach has provided a tremendous amount of information on the mechanism of DNA adduct conversion to mutations.

Translesion Synthesis in Mammalian Cells

DNA polymerases are key players in mutation induction. They introduce mutations during replication and determine the types of mutations generated. Great progress has been made in DNA polymerase studies in the last several years. Many novel DNA polymerases were discovered in prokaryotes and eukaryotes (Hübscher et al. 2002). These DNA polymerases play important roles in various aspects of DNA metabolism. The Y family polymerases (Ohmori et al. 2001) include eukaryotic polη, polκ, and polτ, as well as REV1 and E. coli polIV and polV. In addition, polζ is a member of the B family. Researchers think these Y family polymerases are specialized for translesion synthesis (Prakash and Prakash 2002). These discoveries have led to the general idea that these polymerases are responsible for overcoming the blocking effects of DNA adducts and constitute an important mechanism for tolerating unrepaired DNA lesions.

The role of the polη polymerase is most clearly understood. This polymerase is coded by the XPV gene, which is defective in persons with XP variant cells (Johnson et al. 1999; Masutani et al. 1999). Although these cells possess NER capability, they carry a predisposition to skin cancer on exposure to sunlight. The discovery that polη is able to bypass the cis-syn thymine-thymine dimer efficiently and accurately (Masutani et al. 1999) indicates that this polymerase plays a very important role in protection from the deleterious effects of unrepaired UV photoproducts. In its absence, the unrepaired lesions are bypassed by one or more other polymerases in an error-prone manner leading to skin cancer (Gibbs et al. 1998, 2000). X-ray crystallographic studies reveal that Y family polymerases have loose catalytic pockets enabling them to accommodate unusual base pairs (Trincao et al. 2001). This structural feature could explain the low fidelity of DNA synthesis on a normal DNA template.

In vitro experiments on translesion synthesis using purified polymerases reveal that each polymerase catalyzes bypass synthesis across various lesions with a different efficiency and fidelity (Table 5.7). The current model of the mechanism for mammalian translesion synthesis is illustrated in Figure 5.9. When a replicative DNA polymerase is inhibited by a lesion, translesion synthesis can be completed by the action of one polymerase or by the cooperation of two polymerases (Prakash and Prakash 2002). Among these polymerases, polζ is unique because it has low ability to insert a nucleotide opposite a lesion but is efficient at extending from unmatched terminal pairs (Johnson et al. 2000). Therefore, researchers think that this polymerase plays a role mainly in extending from a terminus opposite a lesion where another polymerase has inserted a nucleotide and the further extension is blocked.

Table 5.7. Translesion-specialized DNA polymerases (pol) and activities on various DNA lesions.

Table 5.7

Translesion-specialized DNA polymerases (pol) and activities on various DNA lesions.

Figure 5.9. Model of mechanism for mammalian translesion synthesis.

Figure 5.9

Model of mechanism for mammalian translesion synthesis. Note: Replicative polymerase δ encounters DNA lesion (open circle) in template, progression of DNA synthesis is blocked, and δ temporarily disengages. Y family polymerases (η, (more...)

Factors in Outcome of Translesion Synthesis

Many studies reveal that the efficiency and fidelity of translesion synthesis depend on the host (Moriya et al. 1994, 1996). Some DNA adducts miscode in one host (human cells) but not in another (E. coli), and the reverse also occurs (Moriya et al. 1994; Pandya and Moriya 1996). This finding underscores the importance of evaluating translesion events in the appropriate host: human cells. The discrepancy most likely reflects the difference in the activity of the translesion polymerases involved.

Sequence context also plays an important role in determining the outcome of translesion synthesis. Generally, a DNA adduct in iterated sequences, such as monotonous repeats (e.g., GGGGG) and dinucleotide repeats (e.g., GCGCGC), tends to cause frameshift mutations because these sequences misalign easily (Benamira et al. 1992). However, the same adduct induces base-substitution mutations in a different sequence context (Moriya et al. 1994). Sequence context influences base-substitution events (Moriya et al. 1996; Page et al. 1998) and trans-lesion efficiency (Latham et al. 1993) (see “Benzo[a] pyrene-7,8-Diol-9,10-Epoxide-N2-Deoxyguanosine stereo-isomers” later in this chapter).

Thus, translesion events are determined by the interplay between a DNA adduct, its sequence environment, and the DNA polymerase involved. This finding underscores the importance of conducting experiments with use of a proper sequence context and host.

Conversion of Cigarette-Smoke-Induced DNA Adducts to Mutations

Conversion of DNA adducts induced by cigarette smoke to mutations is summarized in Table 5.8. The discussion that follows provides additional details.

Table 5.8. Mutational specificity of selected DNA adducts derived from tobacco smoke.

Table 5.8

Mutational specificity of selected DNA adducts derived from tobacco smoke.


O6-POB-deoxyguanosine is formed by a pyridyloxo-butylating metabolite of the tobacco-specific N-nitrosamines NNK and NNN and is removed by AGT. Therefore, in the presence of this repair enzyme, the adduct induced only a moderate miscoding frequency. The resulting mutations were G→A transitions. In the absence of AGT, the miscoding frequency markedly increased to more than 90 percent (Pauly et al. 2002). The results were similar in E. coli and human cells. These results indicate that the frequency of miscoding for this adduct is high. The DNA polymerase involved almost exclusively inserts deoxythy-midine monophosphate opposite the adduct, leading to G→A transitions. Thus, repair by the alkyltransferase is extremely critical to the avoidance of mutation induction by this adduct. The biologic characteristics of this adduct are similar to those of O6-methyldeoxyguanosine (Pauly and Moschel 2001). The DNA polymerase that catalyzes the translesion synthesis and the bypass efficiency of this synthesis remain to be determined.

O6-Methyldeoxyguanosine and O4-Methylthymidine

The O6-methyldeoxyguanosine and O4-methyl-thymidine adducts induce mutations by stable pairing to thymidine (Dosanjh et al. 1993) and deoxyguanosine (Toorchen and Topal 1983), respectively. Accordingly, their miscoding potentials are high (Dosanjh et al. 1991; Pauly and Moschel 2001) and are similar to those of O6-POB-deoxyguanosine. MMR acts on base pairs containing O6-methyldeoxyguanosine after replication (Branch et al. 1993) and leads to cell death as a result of a futile MMR. Therefore, MMR mutants are more resistant to methylating agents (Branch et al. 1993) and are more prone to mutation after exposure to these agents (Pauly and Moschel 2001).


8-oxodeoxyguanosine is a representative adduct formed by oxidative damage to DNA, and researchers have extensively studied its mutagenic properties and repair mechanisms (Grollman and Moriya 1993). The miscoding property of this adduct derives from its propensity to assume a syn conformation and to pair easily with deoxy-adenosine (anti), which leads to G→T transversions. To avoid this mutation induction, cells have developed an elaborate postreplication BER mechanism that specifically removes misinserted deoxyadenosine by the action of the DNA glycosylase, adenine-DNA-glycosylase (Parker and Eshleman 2003). Subsequently, when deoxycytidine monophosphat) is inserted opposite the adduct, 8-oxo-deoxyguanosine is removed by another BER initiated by OGG1, and a G:C pair is restored.

This adduct is also formed in the nucleotide pool. When 8-oxodeoxyguanosine-triphosphate is inserted opposite a deoxyadenosine template, the misinsertion leads to an A→C transition. To avoid this event, the cellular enzyme MTH1 converts 8-oxodeoxyguanosine triphosphate to 8-oxodeoxyguanosine monophosphate, which is no longer a substrate for DNA synthesis. Thus, cells have developed several layers of defense mechanisms against 8-oxodeoxyguanosine. Therefore, the apparent frequency of mutation induction by this adduct is low in normal cells. However, when MYH is inactivated, the frequency of G→T transversions increases drastically (Moriya and Grollman 1993; Hashimoto and Moriya, unpublished data) and mutations in this gene lead to a high incidence of spontaneous human colon cancer (Al-Tassan et al. 2002).


Various unsaturated α,β-aldehydes, such as acrolein and crotonaldehyde, produce the DNA adduct PdG. Ac-rolein produces two positional isomers: 8-(γ-) and 6-(α-) xy hydroxyl PdG. When positioned in double-stranded DNA, the α adduct is more genotoxic than the γ adduct. The α adduct has significantly more blocking effects, and the γ adduct, but not the α adduct, miscodes with G→T transversions at a frequency of approximately 10 percent (Yang et al. 2002). Most of the miscoding events were induced by polη (Yang et al. 2003). Structural studies reveal that the exocyclic ring of the γ adduct, but not the α adduct, opens in a manner similar to that of the malondialdehyde-induced deoxyguanosine adduct (Mao et al. 1999) when paired to deoxycytidine (de los Santos et al. 2001). This finding may account for the weaker blocking effect and the lack of miscoding, because the ring-opened γ adduct pairs nicely to deoxycytidine with the Watson-Crick type of (anti-anti) conformation. When the γ adduct is inserted in single-stranded DNA and replicates in mammalian cells, the resulting structure miscodes by inducing G→T transversions (Kanuri et al. 2002). In addition, the ring-opened deoxyguanosine adduct forms inter-strand G-G cross-links in the sequence 5′CpG (Kozekov et al. 2003), which may also contribute to the genotoxicity of acrolein.

Exocyclic Etheno Adducts

Although the etheno adduct 1,N6-ethenodeoxy-adenosine miscodes efficiently in simian kidney cells, it does not miscode in E. coli (Pandya and Moriya 1996). This finding emphasizes the importance of the host. The finding is probably attributable to the difference in the fidelity of the DNA polymerase involved in translesion synthesis. The etheno adduct 3,N4-ethenodeoxycytidine miscodes efficiently in both hosts (Moriya et al. 1994).

Apurinic/Apyrimidinic Sites

AP sites are generated by the cleavage of a glycosidic bond between a base and a sugar in DNA for various reasons such as (1) the action of a DNA glycosylase and (2) modifications to a base that destabilize the glycosidic bond. These sites do not convey any coding information. Deoxyadenosine is often inserted opposite these sites in E. coli (Lawrence et al. 1990), which is known as “the A rule” (Strauss 1991). However, this rule does not appear to be applicable in mammalian cells: various bases are inserted opposite these sites in those cells (Cabral Neto et al. 1994; Gibbs and Lawrence 1995).

Benzo[a]pyrene-7,8-Diol-9,10-Epoxide-N2-Deoxyguanosine Stereoisomers

Studies have extensively characterized the genotoxicity of different stereoisomers of BPDE-N2-deoxyguanosine (Moriya et al. 1996; Fernandes et al. 1998). A prominent feature is that both the surrounding DNA sequence and the host markedly influence miscoding frequency (Moriya et al. 1996; Fernandes et al. 1998; Page et al. 1998) and miscoding specificity (Kozack et al. 2000). The major adduct, (+)-BPDE-N2-deoxyguanosine, induces mainly G→T and G→A transversions in 5′-TGC and 5′-AGA sequence contexts, respectively, which researchers hypothesize is attributable to differences in adduct conformations in different sequence contexts (Kozack et al. 2000). The deoxyadenosine adduct (BPDE-N6-deoxyadenosine) also miscodes with A→T transversions (Page et al. 1999).


The adduct 4-ABP-C8-deoxyguanosine barely miscodes in E. coli by inducing G→C transversions (Verghis et al. 1997). Because researchers observed G→T, G→A, and G→C mutations in an experiment that used a randomly modified single-strand DNA (Verghis et al. 1997), the possibilities of the effects from the sequence context and the involvement of other deoxyguanosine adducts, such as those at N2, remain to be explored. Furthermore, it appears that a 4-ABP-deoxyadenosine adduct induces A→T transversions (Lasko et al. 1988; Hatcher and Swaminathan 1995).

Assessment of Genotoxicity of DNA Adducts

Genotoxic properties of a DNA lesion can be characterized by using chemically defined substrates. The genotoxicity of a DNA lesion is determined by factors such as the efficiency and fidelity of translesion synthesis and repair. For point mutations, however, the “genotoxic potency” of a DNA adduct can be determined by assessing the bypass efficiency and the miscoding potency. According to this formula, a DNA lesion that is easily bypassed with a high frequency of miscoding events is defined as a highly genotoxic DNA adduct. Furthermore, when the genotoxicity of a DNA lesion is assessed, the information on its abundance in the genome, which reflects the balance between formation and removal, should also be considered. Therefore, conceptually, the total genotoxicity of a DNA adduct could be estimated by determining its genotoxic potency and its abundance in DNA.

According to these criteria, the genotoxicity of the 8-oxodeoxyguanosine adduct, which is a unique case, would be high because it exists in high levels in genomic DNA and is easily bypassed by a DNA polymerase with a high miscoding frequency. However, the apparent genotoxicity is low because of the postreplication repair that is catalyzed by MYH. Therefore, when the postreplication repair is inactivated, this adduct can become a significant genotoxic adduct (Al-Tassan et al. 2002).

Data for the genotoxic effects of DNA lesions derived from tobacco smoke are scarce, and a systematic study is needed. Together with information on the abundance of each lesion, the genotoxicity of tobacco-related DNA adducts might be ranked by using site-specific modified plasmids, introducing them with the use of host cells, and subsequently recovering them for sequence analysis.

Gene Mutations in Tobacco-Induced Cancer

Chromosome Instability and Loss

Lung Cancer

The detection of numerous cytogenetic changes provided the first link to the molecular pathogenesis of lung cancer. Mapping chromosomal sites for rearrangement, breakpoints, and losses revealed both common and distinct changes in both SCLC and NSCLC. In SCLC, breakpoints are commonly seen in chromosomes 1, 3, 5, and 17, although researchers have observed losses of the short arm (p) of chromosomes 3 and 17 and of the long arm (q) of chromosome 5 (Balsara and Testa 2002). Subsequent studies using comparative genomic hybridization showed that deletions on chromosomes 3p, 4q, 5q, 10q, 13q, and 17p were common in SCLC (Petersen et al. 1997). In NSCLC, multiple numeric and structural changes were seen across many chromosomes. The most frequent sites (60 to 80 percent) for chromosome loss were found on chromosomes 3p, 6q, 8p, 9p, 9q, 17p, 18q, 19p, 21q, and 22q (Balsara and Testa 2002). Some of the most common sites for chromosome loss included 3p, 9p, 13q, and 17p. These sites were also detected in nonmalignant bronchial epithelium of current and former smokers and were absent in lifetime nonsmokers (Mao et al. 1997; Witsuba et al. 1997). These findings strongly link tobacco exposure to the development of chromosome damage throughout the aerodigestive tract.

Identification of Tumor-Suppressor Genes

The commonality for specific regions in the genome to lose alleles suggested the presence of tumor-suppressor genes within these loci. The RB gene was the first tumor-suppressor gene linked to lung cancer (Harbour et al. 1988). A loss of function of this gene through either deletion or point mutation occurs in 90 percent of SCLCs, whereas few NSCLCs harbor changes in this tumor-suppressor gene (Table 5.9) (Shimizu et al. 1994). The most frequently inactivated tumor-suppressor gene in lung cancer is TP53. TP53 mutations are found in 70 percent of SCLCs, 65 percent of SCCs, and 33 percent of adenocarcinomas (Greenblatt et al. 1994). (For discussion of specific mutations and their potential relationship to carcinogens in cigarette smoke, see “Relationship of TP53 Mutations to Smoking and Carcinogens” later in this chapter.)

Table 5.9. Frequency of mutation or deletion of tumor-suppressor genes in lung cancer.

Table 5.9

Frequency of mutation or deletion of tumor-suppressor genes in lung cancer.

A frequent deletion within chromosome 3p14 led to the identification of the FHIT gene (Zabarovsky et al. 2002). The most common fragile site of the human genome FRA3B maps in the FHIT gene and may contribute to the susceptibility of this locus to gene rearrangement induced by carcinogens in cigarette smoke. Researchers have observed a loss of the FHIT protein in 50 percent of lung cancers, but somatic mutations are uncommon in the FHIT gene. The epigenetic inactivation by methylation of the 5′CpG island located in the promoter region of FHIT represents another mechanism for inactivating this gene in lung cancer (see “Gene Promoter Hypermethylation in Cancer Induced by Tobacco Smoke” later in this chapter).

The importance of the inactivation of tumor-suppressor genes FHIT, RB, and TP53 in lung cancer is evident from their functions. The binding of hypophosphorylated RB to cyclin-dependent kinase (CDK) 4 or 6 blocks transit of the RB protein through the G1/S boundary of the cell cycle. Inactivating mutations result in the loss of a functional hypophosphorylated protein associated with a shortening of the G1 phase of the cell cycle and the enhancement of cell proliferation, a hallmark of the cancer cell (Nevins 1992). The TP53 gene is central to several critical processes needed to control the response of the cell to exogenous stress from exposure to cigarette smoke. This gene functions as a transcription factor within several pathways and as a sensor of DNA damage (Robles et al. 2002). Thus, the TP53 gene has an important role in cell-cycle checkpoints, DNA repair, apoptosis, and senescence. A loss of TP53 function is also an early event in the genesis of SCC that occurs in bronchial dysplasia (Sozzi et al. 1992; Bennett et al. 1993). Studies have also detected TP53 mutations in peripheral lung tissue from patients with lung cancer, a finding that supports a role for this gene in the early development of adenocarcinomas (Hussain et al. 2001). The FHIT gene induces apoptosis mediated by CASPASE-8 and independent of mitochondrial mediators and inhibits cell growth through interactions with the SRC protein kinase (Pekarsky et al. 2004; Roz et al. 2004). A loss of function of the FHIT, RB, and TP53, genes leads to the immortalization of bronchial epithelial cells, a key step in neoplastic transformation (Reddel et al. 1988) (see “Signal Transduction” later in this chapter).

Tumor-Suppressor Genes Inactivated in Lung Cancer

The search for tumor-suppressor genes inactivated through the two-hit mechanism of the loss of one allele and the mutation of the remaining allele has not recently identified any genes with a frequency of inactivation approaching that seen for the RB and TP53 genes. The discussion that follows describes the involvement of several genes and their functions in subsets of lung cancer (Table 5.9). The mitotic checkpoint gene CHFR, which functions in early prophase to regulate chromosome condensation, was mutated in 3 of 53 lung carcinomas (Mariatos et al. 2003). Studies found three somatic mutations in the proapoptotic gene CASPASE-8 in 2 of 30 lung tumors (Hosomi et al. 2003). MYO18B is a candidate tumor-suppressor gene at chromosome 22q12. Of 46 primary NSCLCs, 6 contained somatic mutations within this gene. Restoring MYO18B function in cell lines inhibited anchorage-independent growth, thus supporting its function as a tumor-suppressor gene in lung cancer (Nishioka et al. 2002).

The PTEN gene is located on chromosome 10. Its gene product is phosphatidylinositol 3′-phosphatase, a protein tyrosine phosphatase that uses the phosphoinositide second messenger, phosphatidylinositol 3,4,5-triphosphate (PIP3), as a physiological substrate (Maehama et al. 2001). Researchers have identified point mutations of the PTEN gene in cell lines from 3 of 35 SCLCs and 3 of 18 NSCLCs; there were two homozygous deletions in primary SCLCs (Forgacs et al. 1998). Mutations that impair PTEN function result in a marked increase in PIP3 levels and in the constitutive activation of AKT survival, thus signaling pathways that in turn promote hyperplasia and tumor formation. Thus, although it is not common in lung cancer, a PTEN mutation or deletion profoundly affects an important signaling pathway in the cell.

Two additional genes with poorly characterized functions and localized to chromosome 3p are altered in lung cancer through deletion or mutation. A specific ATG→AGG mutation in codon 50 of the ARP gene was seen in 8 of 20 lung cancers. In addition, researchers observed either exon deletion or intron insertion in the DLC1 gene in 11 of 30 NSCLCs (Zabarovsky et al. 2002). Frequent deletion involving the short arm of chromosome 19 occurs in lung adenocarcinomas (Sanchez-Cespedes et al. 2001). One gene mapped to this chromosome region is STK11, in which germline mutations are causal for Peutz-Jeghers syndrome. This syndrome is characterized by a series of anomalies and increased risk for gastrointestinal and extraintestinal malignancies (Giardiello et al. 1987). Inactivating mutations and/or deletion of the LKB1/STK11 protein were described in about one-third of primary adenocarcinomas (Sanchez-Cespedes et al. 2002; Ji et al. 2007), and these abnormalities were closely associated with mutation of the KRAS oncogene in the same tumors (Ji et al. 2007; Matsumoto et al. 2007). The STK11 gene may function as a growth-inhibiting gene that is activated through phosphorylation by the ATM gene, which senses DNA damage (Sapkota et al. 2002), and acts through pathways dependent or independent of the P53 protein to suppress invasion and metastasis (Karuman et al. 2001; Upadhyay et al. 2006; Ji et al. 2007). In addition to inactivating by mutation, epigenetic silencing by promoter hypermethylation has emerged as a major mechanism for inactivating many genes in lung cancer, some of which are described here (e.g., MYO18B). (For a detailed discussion, see “Gene Promoter Hypermethylation in Cancer Induced by Tobacco Smoke” later in this chapter.)

Activation of Oncogenes in Lung Cancer

Oncogenes encode proteins that influence cell cycling and promote cancer. They are usually “gain-of-function” mutations of normal genes. Researchers see KRAS gene mutations in approximately 30 to 40 percent of adenocarcinomas but rarely in SCCs, SCLCs, or lung tumors from nonsmokers (Slebos et al. 1990; Westra et al. 1996; Ahrendt et al. 2003). Mutations are localized to codons 12, 13, and 61. More than 85 percent occur within codon 12. Nearly 70 percent of the mutations are G→T transversions within codon 12 that change a glycine codon (GGT) to valine (GTT) or cysteine (TGT). Mouse lung tumors induced by B[a]P and other PAHs show exclusively G→T transversions in codon 12 of the Kras gene. These findings support the hypothesis that activation of this oncogene in lung tumors results from DNA damage leading to base mispairing of these deoxyguanosines. In vitro studies have demonstrated that DNA adducts formed from the metabolism of B[a]P, NNK, and reactive oxygen species can all lead to G→T transversions (Table 5.8) (You et al. 1989; Belinsky et al. 1992). Thus, the activation of carcinogens in tobacco smoke and the pulmonary inflammation that ensues from exposure to particulate matter together can lead to activation of the KRAS oncogene. Studies detected KRAS gene mutations in 39 percent of atypical alveolar hyperplasia, a putative precursor to adenocarcinoma (Slebos et al. 1996). A similarity in the percentage of precursor lesions and tumors containing KRAS mutations supports the importance of this gene in tumor progression in a subset of adenocarcinomas.

The sequence of events leading to activation of the RAS signal transduction pathway is well characterized (Lechner and Fugaro 2000). When the RAS protein is activated through mutations in codon 12, 13, or 61, it binds irreversibly to guanosine triphosphate (GTP) in the cell, which initiates a cascade of protein activations, beginning with v-rafmurine leukemia viral oncogene 1 (RAF-1), that transmits a signal from the cell membrane to the nuclear transcription machinery. Ultimately, these signals culminate in the activation of transcription factors including MYC, FOS, and JUN, which in turn influence many cellular activities such as transcription, translation, cytoskeletal organization, and cell-cell interactions. This signal remains active until GTPase (guanosine triphosphatase) dephosphorylates GTP to guanosine diphosphate. Thus, a RAS oncogene mutation leads to the disruption of many cellular pathways and provides a strong oncogenic signal for neoplastic transformation (see “Signal Transduction” later in this chapter).

The MYC family of genes (C-MYC, N-MYC, and L-MYC) plays a prominent role in the growth of the developing and mature adult lung. Extensive studies have evaluated the expression and amplification of these genes in NSCLC and SCLC (Jänne and Johnson 2000). Most lung cancers express one or more of the MYC family of genes, whereas gene amplification is seen in a minority of primary tumors (Table 5.10). Gene rearrangements involving different exons are associated with amplification detected in cell lines but are uncommon in primary tumors (Kinzler et al. 1986; Mäkelä et al. 1991; Sekido et al. 1992). Mechanisms responsible for the increased expression of the MYC genes in the absence of gene amplification are not well understood. Increased expression could occur through increased activity in the RAS signaling pathway through either KRAS oncogene mutations or effects on the activity of genes in this pathway, such as the activity of mitogen-activated protein kinase (MAPK) (Jull et al. 2001).

Table 5.10. Frequency of gene amplification and increased expression of genes in lung cancer.

Table 5.10

Frequency of gene amplification and increased expression of genes in lung cancer.

Increased gene expression is common in lung cancer but often is not associated with gene amplification. Two genes studied extensively are EGFR and NEU (HER-2/NEU [ERBB2]). EGFR is the receptor for the epidermal growth factor and the HER-2/NEU protein, and the binding of these growth factors to this receptor is associated with increased DNA synthesis, cell proliferation, and differentiation. An increased expression of the EGFR gene was not seen in SCLCs but occurred in 34 to 62 percent of NSCLCs (Hirsch et al. 2003b; Suzuki et al. 2005). In addition, an increased expression of this gene was more common in SCC than in adenocarcinoma—82 versus 44 percent (Hirsch et al. 2003b). In contrast, gene amplification was detected in 9 to 25 percent of tumors (Hirsch et al. 2003b; Suzuki et al. 2005). Expression of the HER-2/NEU gene was seen in 23 to 58 percent of NSCLCs and in 0 to 7 percent of SCLCs (Shi et al. 1992; Junker et al. 2005; Pelosi et al. 2005). Similar to EGFR, HER-2/NEU was more commonly expressed in SCC than in adenocarcinoma, and gene amplification was rare in all tumors (<5 percent).

Observation of EGFR expression in 34 to 62 percent of NSCLCs led to the development of small molecule inhibitors of the tyrosine kinase domain of the wild-type EGFR protein (Fukuoka et al. 2003; Herbst and Bunn 2003; Lynch et al. 2004; Amann et al. 2005; Baselga and Arteaga 2005). The clinical response of approximately 10 percent of European patients and 30 percent of patients from Japan to treatment with the EGFR inhibitors gefitinib or erlotinib led to a search for the mechanism responsible (Kris et al. 2003; Pérez-Soler et al. 2004). The outcome of these studies was the identification of somatic mutations in the tyrosine kinase domain of the EGFR gene in most patients who had demonstrated a clinical response to the drugs (Lynch et al. 2004; Amann et al. 2005). In addition, recent studies suggest that the EGFR copy number and KRAS mutation may also be involved in determining a response to gefitinib and erlotinib. Subsequent studies have sequenced the EGFR gene in thousands of NSCLCs from patients in Asia, Europe, and the United States. These studies found that most mutations were due to either a deletion involving exon 19 or a missense mutation in exon 21. In addition, mutations were two to three times more likely in women than in men and three to five times more likely in nonsmokers than in current or former smokers (Johnson and Jänne 2005). Finally, the prevalence of mutations was 10 percent in tumors of patients from Europe and the United States compared with 30 percent in tumors from persons of Asian background residing in Japan and Taiwan.

The BRAF gene encodes a RAS-regulated kinase that can mediate cell growth. BRAF mutations were found in 5 of 179 NSCLCs and are almost exclusively confined to adenocarcinomas (Brose et al. 2002; Naoki et al. 2002). Although the mutation is relatively uncommon in lung cancer, its location in either exon 11 or exon 15 altered the phosphorylation of BRAF by AKT (Guan et al. 2000). The disruption of AKT-induced BRAF inhibition could contribute to malignant transformation.

Oncogene Activation, Tumor-Suppressor Gene Inactivation, and Lung Cancer Survival

Researchers have studied the prognostic impact of commonly altered genes in lung cancer. The effect of an activated KRAS oncogene on survival was assessed in 69 patients, including 48 with stage I adenocarcinoma that was completely resected (Slebos et al. 1990). Twelve of 19 patients with a KRAS mutation died within the follow-up period (median, 47 months) compared with 22 of 50 patients with a tumor negative for the KRAS oncogene. This significant difference in survival was observed even though patients with a KRAS mutation had a less advanced disease than those with no mutation. All seven patients with stage III disease were negative for mutations. Rosell and colleagues (1993) conducted a similar study of largely stage I resected adenocarcinomas that again revealed a reduced survival rate independent of lymph node status for patients whose tumor contained a mutated KRAS gene. In contrast, a larger study of 127 adenocarcinomas found no difference in survival by KRAS mutation status (Keohavong et al. 1996). Overall, data are conflicting with respect to KRAS mutations as prognostic factors and further research is needed (Aviel-Ronen et al. 2006).

Studies have examined the effect of TP53 gene mutations on prognosis in both early- and late-stage lung cancers. After four years of follow-up, the hazard ratio for 106 patients with stage I resected NSCLC with a TP53 mutation was 2.8 for death, compared with patients who had a wild-type gene (Ahrendt et al. 2003). Four years after surgery, 78 percent of patients with no TP53 mutation and 52 percent with a TP53 mutation were alive. A previous study by Tomizawa and colleagues (1999) found a similar survival benefit for patients with stage I NSCLC and no TP53 mutations, which also confer a poor clinical outcome for those with advanced NSCLC. Independent of chemotherapy or supportive care, median survival duration for patients with stage III or IV NSCLC with or without a TP53 mutation was 17 versus 39 weeks, respectively (Murakami et al. 2000). Recently, a study of 420 patients with primary head and neck cancer (Poeta et al. 2007) showed that disruptive TP53 mutations in tumor DNA are associated with reduced survival after surgical treatment of SCC of the head and neck (hazard ratio, 1.7; 95 percent CI, 1.2–2.4; p = 0.003).

Together, it is apparent that the inactivation of the TP53 tumor-suppressor gene and the activation of the KRAS oncogene in NSCLCs and other tumors are correlated with exposure to cigarette smoke and contribute to a phenotype that reduces survival in both early and advanced stages of the disease.

Relationship of TP53 Mutations to Smoking and Carcinogens

TP53 Mutations in Smoking-Associated Lung Cancers

TP53 gene mutations are found in approximately 40 percent of human lung cancers; TP53 is the most commonly mutated tumor-suppressor gene in lung cancer (see “Identification of Tumor-Suppressor Genes” earlier in this chapter). These mutations are generally more common in smokers than in nonsmokers (Greenblatt et al. 1994; Hernandez-Boussard and Hainaut 1998; Pfeifer et al. 2002). One study shows that the relative risk of having a TP53 mutation in lung cancer was up to 13 times higher in lifetime heavy smokers than in lifetime nonsmokers (Le Calvez et al. 2005). G→T transversions are commonly observed in smoking-associated lung cancers (Greenblatt et al. 1994; Hainaut and Hollstein 2000; Hainaut and Pfeifer 2001). The frequency of G→T transversions in lung cancers from smokers is higher than that for lung cancers and most other cancers in nonsmokers (Greenblatt et al. 1994; Husgafvel-Pursiainen and Kannio 1996; Hernandez-Boussard and Hainaut 1998; Bennett et al. 1999; Hainaut and Pfeifer 2001). Mutational patterns for lung cancers from smokers and nonsmokers are shown in Figure 5.10. The difference between 28.9 percent G→T transversion mutations in “designated smokers” (i.e., smoking status indicated in literature) and 13.4 percent G→T mutations in nonsmokers has high statistical significance (p < 0.001, χ2 test). The frequency of G→T transversions is higher in lung cancer tumors than in other tumors, except for liver cancers associated with geographic areas with evidence of food contamination from aflatoxins (Greenblatt et al. 1994).

Figure 5.10. Patterns of TP53 gene mutations and percentage of G→T transversion mutations in human lung cancers.

Figure 5.10

Patterns of TP53 gene mutations and percentage of G→T transversion mutations in human lung cancers. Source: Data are from the R9 version (July 2004) of the International Agency for Research on Cancer TP53 mutation database (IARC 2006). Note: Cell (more...)

In most internal cancers not strongly linked to smoking, such as breast, brain, and colorectal, the frequency of G→T mutations is 8 to 10 percent (Figure 5.10). Nonsmokers have a higher percentage of G→A transitions (42.5 percent) than do smokers (27.9 percent), a difference that is also statistically significant. Figure 5.10 includes categories of both designated smokers and “all lung cancer cases minus nonsmokers.” This category is based on the knowledge that, overall, 90 percent of these lung cancers occur in smokers (Proctor 2001). The proportion of G→T transversions, as well as the overall mutation pattern for all persons with lung cancers, except nonsmokers, is similar to observations of researchers for designated smokers (Figure 5.10). The difference in G→T transversions in smokers versus nonsmokers may be attributable to bias in the database used, which pools data from studies that differ in aims, size, and methods for ascertaining smoking status. However, in a more recent study of a series of 21 mutations that was designed to address this possibility, TP53 gene mutations were found in 27.5 percent of current smokers, 15.8 percent of former smokers, and 4.8 percent of lifetime nonsmokers (Le Calvez et al. 2005). These observations suggest that the difference in G→T transversions in smokers versus nonsmokers may be larger than that indicated in the database, perhaps due to the misclassification in the database of long-term former smokers as nonsmokers.

To address the issue of whether the major histologic types of lung cancer show differences in TP53 mutational patterns, researchers analyzed the IARC TP53 mutation database separately for these tumors (Figure 5.11). The frequencies of G→T transversions in the TP53 database were 31.4 percent in adenocarcinomas, 27.1 percent in SCCs, 27.5 percent in SCLCs, and 34.7 percent in large-cell carcinomas. Furthermore, the global mutation patterns were similar in the two main histologic types: adenocarcinoma and SCC. Thus, the different types of lung cancer in smokers all show an excess of G→T transversions compared with cancers unrelated to exposure to tobacco smoke.

Figure 5.11. Patterns of TP53 gene mutations and percentage of G→T transversion mutations in different histologic types of lung cancer.

Figure 5.11

Patterns of TP53 gene mutations and percentage of G→T transversion mutations in different histologic types of lung cancer. Source: Data are from the R9 version (July 2004) of the International Agency for Research on Cancer TP53 mutation database (more...)

TP53 mutations do not occur at random along the coding sequence. They are typically clustered at mutation “hot spots,” which are within the DNA binding domain of the TP53 protein and span codons 120 to 300. Figure 5.12 shows the concordance of codon distribution of G→T transversions (upper panel) along the TP53 gene in lung cancer with the distribution of adducts in this gene in bronchial epithelial cells treated with BPDE. Hot spots of G→T mutations in cancers of the brain, breast, and colon differ from those in lung cancers (Pfeifer et al. 2002). The codons containing mutation hot spots are important because they may allow determination of which carcinogen caused the mutation. However, hot spot codons may exist solely as a consequence of phenotypic selection in tumors. To address this issue, studies have compared the mutational events in different types of cancers at a number of common hot spot codons. The major lung cancer mutation hot spots at codons 158, 245, 248, and 273 are commonly G→T transversions in lung cancer but are generally other mutation types (almost exclusively G→A) in other internal tumors not associated with smoking (Pfeifer et al. 2002).

Figure 5.12. Concordance between codon distribution of G→T transversions along TP53 gene in lung cancers (top) and distribution of adducts of benzo[a]pyrene-7,8-diol-9,10-epoxide (BPDE)–DNA adducts in bronchial epithelial cells (bottom).

Figure 5.12

Concordance between codon distribution of G→T transversions along TP53 gene in lung cancers (top) and distribution of adducts of benzo[a]pyrene-7,8-diol-9,10-epoxide (BPDE)–DNA adducts in bronchial epithelial cells (bottom). Source: Adduct (more...)

G→T Transversions in Lung Cancer

The major product of the diol epoxide BPDE reaction with DNA is BPDE-N2-deoxyguanosine, which induces mainly G→T transversions, depending on the sequence context, after a DNA polymerase carries out error-prone translesion synthesis past this adduct (Eisenstadt et al. 1982; Chen et al. 1990; Ruggeri et al. 1993; Yoon et al. 2001) (see “Conversion of DNA Adducts to Mutations” earlier in this chapter). Using the UvrABC incision method in combination with a ligation-mediated polymerase chain reaction (LMPCR), scientists mapped the distribution of BPDE and other PAH diol epoxide adducts at the nucleotide level along exons of the TP53 gene in normal human bronchial epithelial cells treated with diol epoxide (Denissenko et al. 1996; Smith et al. 2000). Frequent adduct formation occurred at guanine positions in codons 156, 157, 158, 245, 248, and 273. These positions of preferential formation of PAH adducts are major mutational hot spots in human lung cancers (Figure 5.12). The only exception is codon 156, where G→T substitution commonly results in a phenotypically silent mutation and is therefore not selected during tumorigenesis.

Researchers analyzed the distribution of BPDE-N2-deoxyguanosine within TP53 exons by using stable isotope labeling LC-electrospray ionization tandem MS (Tretyakova et al. 2002; Matter et al. 2004). In this approach, specific guanine nucleobases within TP53 gene sequences were labeled with 15N so the BPDE adducts originating from these positions could be distinguished from the lesions formed at other sites. Researchers observed an excellent agreement with the data from the UvrABC-LMPCR method (Denissenko et al. 1996). All four diastereomers of BPDE-N2-deoxyguanosine were formed preferentially at the frequently mutated TP53 codons 157, 158, 245, 248, and 273. The contributions of individual diastereomers to the total adducts at a given site varied but were highest (70.8 to 92.9 percent) for (+)-trans-BPDE-N2-deoxyguanosine (Matter et al. 2004).

A mechanistic basis for the selectivity of formation of diol epoxide–DNA adducts in the TP53 gene is the enhancement of adduct formation by 5-methylcytosine bases present at CpG dinucleotide sequences (Denissenko et al. 1997; Chen et al. 1998; Weisenberger and Romano 1999; Tretyakova et al. 2002; Matter et al. 2004). All CpG sequences in TP53 coding exon 5 through exon 9 were completely methylated in all of the tissues examined, including the lung (Tornaletti and Pfeifer 1995). In the TP53 gene of lung cancers, the five major G→T mutational hot spots at codons 157, 158, 245, 248, and 273 (Figure 5.12) consisted of methylated CpGs (Yoon et al. 2001). Methylation at CpG sites may increase the binding of planar carcinogenic compounds at the intercalation step through the hydrophobic effect of the methyl group that can stabilize intercalated adduct conformations (Zhang et al. 2005a). However, the precise mechanism by which cytosine methylation at CpG sites enhances carcinogen binding and mutagenesis still needs to be determined. In contrast, the presence of 5′-neighboring 5-methylcytosine inhibited formation of guanine adducts by NNK metabolites (Rajesh et al. 2005).

Studies show that the preferential formation of BPDE adducts at methylated CpG sites is reflected in the strongly enhanced mutagenesis at CpG sequences after cells were treated with BPDE. This finding was demonstrated with three different mutated reporter genes, including two chromosomal genes with methylated CpG sequences (Yoon et al. 2001).

Methylated CpG sites are preferentially modified by several carcinogens, including aromatic amines and aflatoxins (Chen et al. 1998). However, the exact range of compounds that target methylated CpGs is not known. In one study, researchers did not observe a preferential mutagenesis at methylated CpGs by the aromatic amine 4-ABP (Besaratinia et al. 2002). G→T transversions resulting from 8-oxodeoxyguanosine are not specifically targeted to methylated CpG sequences (Lee et al. 2002a). A more recent study demonstrated that the DNA adduction profile of acrolein in the P53 gene was similar to that of BPDE and other PAH diol epoxides, indicating that this α,β-unsaturated aldehyde reacts at methylated CpG sites and, because of its high concentration in cigarette smoke compared with that of PAHs, could contribute to the TP53 mutations observed in lung tumors from smokers (Feng et al. 2006).

Hussain and colleagues (2001) have shown that exposing bronchial epithelial cells to BPDE produces G→T transversions in the TP53 gene at lung cancer hot spot codons 157, 248, and 249. Nontumorous lung tissues from smokers with lung cancer carried a high TP53 mutational load at these codons, even when another TP53 mutation was present in the tumor itself. DeMarini and colleagues (2001) studied TP53 and KRAS mutations in lung tumors from Chinese women who were nonsmokers and whose tumors were associated with exposure to smoky coal containing high levels of PAHs and probably other compounds such as acrolein. The tumors showed a high percentage of mutations that were G→T transversions in the KRAS oncogene (86 percent) or the TP53 gene (76 percent). In the TP53 gene, the mutations clustered at the CpG-rich codons 153 through 158 and at codons 249 and 273.

The site specificity of mutagenesis by PAH diol epoxides implies that targeted adduct formation, in addition to phenotypic selection, is responsible for shaping the TP53 mutational spectrum in lung tumors. According to the IARC TP53 mutation database, more than 80 percent of G→T transversions in lung cancers are targeted to guanines on the nontranscribed DNA strand. This observation suggests that a preferential repair of DNA lesions occurs on the transcribed strand. DNA repair experiments analyzing BPDE adducts in the TP53 gene showed that the nontranscribed strand is repaired more slowly than is the transcribed strand (Denissenko et al. 1998). These findings support the proposal that both the initial DNA adduct levels and a bias in repair of DNA strands may contribute to the mutational spectrum of the human TP53 gene in lung cancer.

TP53 Gene Mutations in Other Smoking-Associated Cancers

Of four cancer types analyzed, only SCC of the larynx showed a strong similarity with lung cancers. Prevalence of G→T transversions was high (25.9 percent), and many occurred at PAH-target codons 157 and 245. A gradient in the upper respiratory tract reflects the prevalence of TP53 G→T transversions in cancers of smokers. This prevalence ranges from low in the oral cavity, to intermediate in the larynx, and high in various histologic types of lung cancers. The gradient may reflect the existence of an underlying, parallel gradient in the extent of exposure of respiratory tract cells to carcinogens in tobacco smoke. In oral cancers, studies show that the TP53 mutation load is proportional to the extent of smoking, with an almost fourfold increase in the prevalence of mutations among heavy smokers compared with nonsmokers (Brennan et al. 1995). In one study of oral and esophageal SCC, however, the frequency of G→T transversions is only slightly higher (16.5 and 19.6 percent, respectively) than those in cancers not strongly related to exposure to tobacco smoke (e.g., breast, colorectal, and brain cancers). The patterns of mutations in both oral and esophageal SCC are similar, perhaps reflecting the importance of common risk factors, such as the combined use of tobacco and alcohol, infections by human papilloma virus (Gillison and Shah 2003), and various lifestyle behaviors such as tobacco chewing or consuming scalding hot beverages, as well as similar histology in oral and esophageal tissues. In contrast, the mutation pattern is different in esophageal adenocarcinomas, with a high prevalence of G→T transversions at CpG sites (Figure 5.13) and a type of mutation that could be associated with the overproduction of reactive nitrogen species due to inflammation (Ambs et al. 1999).

Figure 5.13. Patterns of TP53 gene mutations and percentage of G→T transversions in smoking-associated cancers other than lung cancer.

Figure 5.13

Patterns of TP53 gene mutations and percentage of G→T transversions in smoking-associated cancers other than lung cancer. Source: Data are from R9 version (July 2004) of International Agency for Research on Cancer TP53 mutation database (IARC (more...)

For bladder cancer, the mutation pattern shows an unusually high prevalence of G→A transitions at non-CpG sites. These mutations are not distributed at random, and bladder-specific mutation hot spots can be seen at codons 280 and 285, according to the IARC TP53 database. Both codons occur within the same primary sequence context (5′AGAG), which raises the possibility that this sequence may be a preferential target site for a carcinogen involved in bladder carcinogenesis. However, aromatic amines, a potent class of bladder carcinogens in tobacco smoke, produce mainly G→T mutations (Besaratinia et al. 2002).

Limitations to the Study of TP53 Mutations and Smoking-Induced Cancer

Although the study of mutations in the TP53 gene provides potentially useful leads for understanding mechanisms of tobacco carcinogenesis, this approach also has limitations. As already mentioned, various carcinogen-DNA adducts can produce G→T transversions and even similar spectra of mutations. In addition, most of this research is not population based, and the studies may be biased with respect to the stage of lung cancer represented. Finally, lack of a mutation in the TP53 gene does not necessarily mean that the tumor is not related to smoking, because other uncharacterized changes could have occurred.

Loss of Mechanisms for Growth Control

Signal Transduction


Normally, cell signaling is very tightly regulated and begins with the transduction of the signal through a membrane receptor. The signal is conveyed through a series of intracellular proteins, and the result is the regulation of cellular processes including proliferation and apoptosis. In lung cancer cells, the processes governing these events are frequently deregulated by DNA-damaging mutations induced by cigarette smoke or other alterations in the molecules of numerous signaling pathways. The balance between mechanisms leading to apoptosis (proapoptotic) and those suppressing apoptosis (antiapoptotic) or suppressing increased proliferation will have a major impact on lung tumor growth. Identifying and targeting signaling pathways that lead to therapeutic resistance could help to neutralize a patient’s resistance to standard therapies.


Apoptosis was first described in 1972 (Kerr et al. 1972). The term “apoptosis” is from the Greek word for “falling off.” Apoptosis is a natural process that consists of a well-orchestrated cascade of distinct biologic and histologic events (Kerr et al. 1972). These events are critical for eliminating injured or genomically unstable cells while minimizing damage to surrounding normal cells (Martin 2002). The induction of apoptosis prevents the malignant growth of cancer cells (Rich et al. 2000). The deregulation of the mechanisms governing apoptosis is a distinctive characteristic of most cancer cells (Hanahan and Weinberg 2000).

Apoptosis is characterized by morphologic features including membrane blebbing, cell shrinking, and chromosomal condensation. Apoptosis is generally believed to occur through two “effector” mechanisms: extrinsic (death receptor mediated) and intrinsic (mitochondrial mediated) (Hengartner 2000). The extrinsic pathway is regulated by binding a “death receptor molecule” to the cancer cell’s membrane receptor (i.e., death receptor). The intrinsic pathway is mediated by rendering the mitochondrial membrane permeable, a phenomenon directly influenced by the ratio of the interaction of proapoptotic and antiapoptotic proteins. In general, researchers believe that the inactivation of apoptosis through the intrinsic pathway is the primary mechanism through which DNA-damaging agents from tobacco smoke act to enhance the survival of lung cancer cells, which is the focus of this section.

Key Apoptotic Regulators

One or more pathways may lead to apoptosis. Stress signals stimulate a pathway that activates proteins to respond to DNA damage. These proteins subsequently phosphorylate, activate, and stabilize the P53 protein. The activated P53 protein drives the transcription of genes associated with cell-cycle arrest, DNA repair, and apoptosis. These genes include the BCL-2 family of proteins, which consists of both proapoptotic and antiapoptotic members. The BCL-2 family of proteins interacts with the outer mitochondrial membrane to regulate the release of cytochrome c, which results in the activation of aspartyl and cysteine proteases (caspases) (Igney and Krammer 2002). The caspases are crucial executioners of apoptosis (Meier et al. 2000; Reed 2000). Once stimulated, the caspases activate endonucleases that subsequently cleave the DNA of the targeted cell into nucleosome-sized fragments, which is a common characteristic of apoptosis.

A multitude of signaling molecules mediate the mechanisms that govern apoptosis. An imbalance in proapoptotic and antiapoptotic signaling events contributes to the development and progression of lung cancer. The mechanisms for the deregulation of apoptosis can be categorized into (1) the decrease of signaling associated directly with the induction of apoptosis and (2) the increase of signaling leading to the suppression of apoptosis. This decrease may include mutations induced by cigarette smoke or other smoke-related mechanisms that activate oncogenes or inactivate tumor-suppressor proteins or other proapoptotic proteins. The increase may include mutations induced by cigarette smoke, certain kinases, other antiapoptotic proteins or transcription factors, or overexpression or constitutive activation of growth factors. The end result of this deregulation usually includes a profound resistance to apoptosis.

Regulation of Tumor Suppressors and Proapoptotic Proteins

Decrease of important proapoptotic proteins of the BCL-2 family and tumor suppressors such as the P53 and RB proteins is a characteristic in many types of cancers, including lung cancer. This decrease provides lung cancer cells with a strong ability to resist apoptosis, which leads to a distinct advantage for cell survival (Figure 5.14).

Figure 5.14. Tobacco-associated suppression of proapoptotic proteins and tumor-suppressor proteins.

Figure 5.14

Tobacco-associated suppression of proapoptotic proteins and tumor-suppressor proteins. Note: Tobacco-associated suppression of proapoptotic proteins and tumor-suppressor proteins increases cell proliferation and resistance to apoptosis. Two major signaling (more...)

BCL-2 Family Proteins

In normal cells, stresses initiate apoptosis through the mitochrondrial or intrinsic pathway, and the BCL-2 family proteins are important mediators of the apoptotic response. These proteins are characterized by the presence of one to four conserved BCL-2 homology (BH) domains. The BCL-2 family can be divided into antiapoptotic members: BCL-2, BCL-XL, and myeloid cell leukemia-1. The proapoptotic BCL-2 proteins are subdivided into two groups: the multidomain BAX subfamily (BAK, BAX, and BOK) and the BH3-only proteins (BAD, BID, and BIM) (Korsmeyer 1995; Hale et al. 1996; Adams and Cory 1998; Huang and Strasser 2000; Cory et al. 2003). The BCL-2 family of proteins appears to directly influence the permeability of the mitochondrial membrane to regulate apoptosis.

The interaction of BAX with the mitochrondrial membrane causes the release of cytochrome c into the cytosol, where it binds to apoptotic-releasing factor 1. The binding of cytochrome c and apoptotic-releasing factor 1 results in the activation of cysteine-aspartic acid protease-9 (CASPASE-9), which is required to form the “apoptosome” complex that initiates apoptosis. The apoptotic response is critically dependent on the ratio of the expression of proapoptotic and antiapoptotic BCL-2 members (Zha et al. 1997; Korsmeyer 1999; Kroemer 1999; Reed 1999; Huang and Strasser 2000; Lutz 2000; Cheng et al. 2001; Ruvolo et al. 2001). A lack of BAX (Zhang et al. 2000a; Schmitt and Lowe 2002) or an increase of BCL-2 or BCL-XL (Schott et al. 1995; Walczak et al. 2000; Chipuk et al. 2001) suppresses apoptosis, whereas a decrease of BCL-XL or BCL-2 enhances apoptosis (Hayward et al. 2003). Dimers containing BAX and BCL-2 inactivate BAX and therefore inhibit apoptosis. In addition, phosphorylation of the BAD protein results in its inactivation, because only the nonphosphorylated form of BAD can antagonize the antiapoptotic BCL-2 or BCL-XL at the mitochondrial membrane (Hermeking 2003).

Nicotine suppresses the death of lung cancer cells by phosphorylation mediated by the extracellular signal-regulated kinase (ERK) of BCL-2 (Heusch and Maneckjee 1998; Mai et al. 2003). Conversely, NNK inactivates BAD through β-adrenergic receptors and protein kinase C (PKC), which promotes survival of NSCLC cells (Lahn et al. 2004; Jin et al. 2005). Nicotine also stimulates cell survival through the phosphorylation and inhibition of BAD activated by β-adrenergic-receptor–mediated AKT-, PKA-, and/or ERK-dependent pathways (Jin et al. 2004a). These studies show that BCL-2 family members are critical effectors of signaling pathways that promote cancer cell survival in response to components of cigarette smoke—in these cases, through direct receptor binding rather than DNA damage.

P53 Protein

The P53 pathway is clearly involved in cellular life or death. The P53 tumor-suppressor protein can induce the expression of BAX and additional proapoptotic members of the BCL-2 family (Miyashita and Reed 1995; Yin et al. 1997; Oda et al. 2000a,b; Nakano and Vousden 2001). In addition to having direct effects on BCL-2 family proteins, the P53 protein also increases activity of the APAF1 gene (Robles et al. 2001), which as indicated earlier, is a member of the apoptosome complex and is critical for the activation of CASPASE-9 to initiate apoptosis (Soengas et al. 1999) (see “BCL-2 Family Proteins” earlier in this chapter). Although it is primarily a nuclear protein, P53 may function outside the nucleus by translocating to the mitochondria, where it interacts directly with antiapoptotic proteins such as BCL-2 and BCL-XL to induce apoptosis (Mihara et al. 2003). The aberrant inactivation of P53 leads to a deregulation of cell-cycle control and a suppression of many crucial proapoptotic pathways (Ford and Hanawalt 1995; Wang et al. 1995a,b; Offer et al. 1999; Vogelstein et al. 2000; Zhou et al. 2001a). The loss of P53 function markedly decreases the sensitivity of lung cancer cells to apoptosis induced by exposure to tobacco smoke or other stresses (Lowe et al. 1994).

Retinoblastoma Protein

Inactivation of the RB protein results in the release and activation of the transcription factor E2F (Flemington et al. 1993; Helin et al. 1993). Some E2F family members induce expression of the genes important in apoptosis, such as the P14ARF gene (DeGregori et al. 1997; Bates et al. 1998). The P14ARF protein is a negative regulator of murine double minute 2 (MDM2), a P53 binding protein. The inhibition of MDM2 leads to elevated P53 levels and apoptosis. The E2F protein can also activate proapoptotic BCL-2 family members and caspases (Nahle et al. 2002; Hershko and Ginsberg 2004).

Regulation of Antiapoptotic Proteins and Effects

Studies document that many genes and signaling proteins are overexpressed or display gain-of-function mutations in lung cancers. These include the EGFR gene, signal transduction and activator of transcription, PKC, RAS/MAPK, phosphatidylinositol-3 kinase (PI-3K)/AKT, PTEN, nuclear factor-kappa B (NF-κB), and COX (Figure 5.15).

Figure 5.15. Protein-signaling pathways deregulated in lung cancer.

Figure 5.15

Protein-signaling pathways deregulated in lung cancer. Note: Many protein-signaling pathways deregulated in lung cancer represent a dense interactive network with a range of potential survival-enhancing effects. Tobacco- or cigarette smoke-associated (more...)

Epidermal Growth Factor Receptor

Exposure of oral cells to cigarette smoke caused an increase in EGFR tyrosine kinase activity (Moraitis et al. 2005). Signaling through EGFR can lead to survival signals that suppress dependent (downstream) apoptotic pathways or stimulate cell proliferation. Some evidence suggests that EGFR signaling can influence the levels and activities of antiapoptotic BCL-2 family members (Kari et al. 2003). The EGFR gene is overexpressed and thus constitutively activated in lung cancer cells (Sridhar et al. 2003) and bronchial preneoplastic lesions (Rusch et al. 1995; Kurie et al. 1996; Piyathilake et al. 2002). In addition, a truncated form of the EGFR protein (EGFRvIII) is constitutively active in NSCLC cells (Okamoto et al. 2003). The expression of this mutant form of EGFR is associated with an increase in cell transformation and with the constitutive activation of important downstream signaling pathways for survival, including the PI-3K/AKT pathway (Antonyak et al. 1998; Moscatello et al. 1998; Tang et al. 2000).

RAS/Mitogen-Activated Protein Kinase

Activation of the RAS pathway sends a strong anti-apoptotic signal, and the constitutive activation of RAS can transform normal cells. Oncogenic RAS protein has a primary role in the development of lung cancer (Johnson et al. 2001a). RAS activates several pathways, including RAF/mitogen-activated protein kinase kinase (MEK)/ERK, PKC, PI-3K/AKT, and NF-κB (Kauffmann-Zeh et al. 1997; Kennedy et al. 1997; Peeper et al. 1997; Baldwin 2001). These pathways are commonly deregulated by RAS in lung cancers (Adjei 2001a,b). RAF/MEK/ERK pathway activation can lead to changes in downstream gene expression through the activation of activator protein-1 (AP-1). AP-1 is a well-characterized transcription factor composed of homodimers and/or heterodimers of the JUN and FOS gene families (Angel and Karin 1991). AP-1 regulates the transcription of various genes. Many stimuli, including tumor promoters, mediate AP-1 binding to the DNA of genes that govern cellular processes such as inflammation, proliferation, and apoptosis (Angel and Karin 1991).

Phosphatidylinositol-3 Kinase, Phosphatidylinositol 3′-Phosphatase, and Protein Kinase B

PI-3K consists of a family of heterodimeric complexes, each composed of a p110 catalytic subunit and a regulatory subunit that exists primarily as a p85 form (Tolias et al. 1995; Vanhaesebroeck et al. 1997; Wymann and Pirola 1998). This family of proteins is involved in the regulation of proliferation, viability, adhesion, and motility migration in numerous cell types (Carpenter and Cantley 1996; Khwaja 1999; Rameh and Cantley 1999; Blume-Jensen and Hunter 2001; Roymans and Slegers 2001). Cell survival and oncogenic transformation require PI-3K activation (Datta et al. 1999; Stambolic et al. 1999). PI-3K–dependent kinases include 3-phosphoinositide–dependent protein kinase-1 (PDK1) and AKT (PKB). The PI-3K pathway can also be activated by the EGFR protein and by an activated RAS protein (Rodriguez-Viciana et al. 1997). One of the first steps in PI-3K signaling is the activation of PDK1, which phosphorylates and activates AKT (Coffer et al. 1998; Belham et al. 1999). AKT phosphorylates and inactivates several proapoptotic proteins, including BAD and CASPASE-9. Other targets of AKT important in the regulation of apoptosis include glycogen-synthase-kinase-3 (Pap and Cooper 1998), the Forkhead transcription factor FKHRL1 (Brunet et al. 1999), and the mammalian target of rapamycin/p70S6 kinase (McCormick 2004). Furthermore, AKT inactivates P53 by phosphorylating MDM2, which increases the ability of MDM2 to bind to and promote P53 degradation (Ogawara et al. 2002). AKT also suppresses apoptosis by activating NF-κB through AKT phosphorylation of I kappa-B kinase alpha (Ozes et al. 1999; Romashkova and Makarov 1999).

Most NSCLC cells display an increase in PI-3K activity that results in highly active AKT and other downstream mediators (Moore et al. 1998; Brognard et al. 2001). AKT is important in the survival of lung cancer cells and is constitutively activated in most NSCLC cell lines to promote the survival of NSCLC cells under stressful conditions (Brognard et al. 2001). Studies have also found AKT expression in SCLC tumor samples (Lee et al. 2002b; Mukohara et al. 2003), SCLC cell lines (Moore et al. 1998), SCLC tumors (Blackhall et al. 2003), mouse tumors induced by tobacco carcinogens (West et al. 2003), and human bronchial dysplastic lesions (Tsao et al. 2003). (For additional details on AKT activation by components of cigarette smoke through receptor interactions, see “Activation of Cytoplasmic Kinase by Tobacco Smoke” later in this chapter.)

Nuclear Factor-Kappa B

NF-κB is a rapidly induced transcription factor responsive to stress that functions to intensify the transcription of a variety of genes, including those encoding cytokines, growth factors, and acute response proteins (Baldwin 1996). Nicotinic activation of nicotinic acetylcholine receptors (nAChRs) stimulates NF-κB activity downstream of ERK and AKT, which promotes tumor growth and angiogenesis through the vascular endothelial growth factor (VEGF) in vivo (Heeschen et al. 2001, 2002). Moreover, NF-κB activation by exposure to cigarette smoke in lung cancer cells induces the expression of COX-2 (Anto et al. 2002; Shishodia and Aggarwal 2004). Recent results suggest that nicotine, but not NNK, activates NF-κB– dependent survival of lung cancer cells in addition to their proliferation. These studies illustrate that the activation of NF-κB by nicotine or by cigarette smoke in its entirety through receptor binding can promote tumorigenesis in the lung through many mechanisms, including increased levels of VEGF and COX-2.


COX-1 and COX-2 were shown to catalyze synthesis of prostaglandins from arachidonic acid. Researchers observed that COX-1 was constitutively expressed in most tissues, whereas COX-2 was inducible and found at elevated levels in various cancers (Koki et al. 2002; Dannenberg and Subbaramaiah 2003; Dubinett et al. 2003). In lung cancers, researchers have found COX-2 expression at most stages of tumor progression (Hida et al. 1998; Huang et al. 1998; Wolff et al. 1998; Hosomi et al. 2000; Anderson et al. 2002; Fang et al. 2003). Others reported high levels of COX-2 in NSCLC and premalignant lesions, but COX-2 expression is less consistent in SCLC (Wolff et al. 1998; Hosomi et al. 2000). Studies show that NNK induces a high expression of COX-2 in rats (El-Bayoumy et al. 1999). Levels of COX-2 mRNA are about four times higher in the oral mucosa of smokers than in that of lifetime non-smokers (Moraitis et al. 2005). Researchers believe that at least one role of COX-2 in cancer is associated with cell resistance to apoptosis and an increase in metastatic potential (Gupta and Dubois 2001). The supporting evidence shows that COX-2 overexpression coincides with an increased BCL-2 expression (Tsujii and DuBois 1995) and an increased stabilization of the antiapoptotic protein survivin (Li et al. 1998a; Krysan et al. 2004). Lung cancer cells that were induced to express COX-2 demonstrated an increase in survival time (Lin et al. 2001b), and COX-2 inhibitors stimulated apoptosis in lung carcinoma cells (Hida et al. 2000; Yao et al. 2000; Chang and Weng 2001).


Apoptosis is commonly suppressed in lung cancer, which correlates with increases in cancer cell survival and proliferation. Deregulation of the many pathways for growth control (Figure 5.15) in lung cancer is attributable partly to interactions of carcinogens in cigarette smoke with the KRAS oncogene, the P53 tumor-suppressor gene, and other genes. These pathways represent a dense interactive network with a range of potential effects on cell survival. Mechanisms associated with cigarette smoke that increase resistance to apoptosis include activation of antiapoptotic proteins and/or suppression of proapoptotic and tumor-suppressor proteins.

Cigarette Smoke and Activation of Cell-Surface Receptors in Cancer

Airway Epithelial Cells

Nicotinic Acetylcholine Receptors

Neuronal nAChRs are large membrane-associated proteins that are the first line of contact between cells and components of cigarette smoke such as nicotine and NNK. These proteins were originally described as receptors for acetylcholine (ACh). Their function in the brain has been studied in detail because of their ability to mediate the addictive effects of nicotine. Each receptor is made up of five subunits arranged in a barrel-like structure, creating a pore that allows calcium to enter the cell in response to ligand binding. Nine alpha subunits (α2 through α10) and three beta subunits (β2 through β4) combine with each other to form heteropentamers (combinations of α2 through α6 with β2 through β4) or homopentamers (α7 through α10). Each nAChR consists of 5 subunits, and researchers have identified at least 12 subunits; thus, many functional nAChRs exist. Different ligands, including nicotine, NNK, and ACh, have varying affinities for different nAChRs. Despite this complexity, the primary receptors that mediate the addictive effects of nicotine are α4β2 nAChRs, whereas α7 nAChRs are high-affinity receptors for NNK (Lindstrom 1997, 2003). Moreover, the discovery that mutations in the α4 nAChR subunit lower the threshold for addiction raises the possibility that genetic variations in these receptors could increase susceptibility to nicotine dependence and exposure to carcinogens through smoking (Tapper et al. 2004).

Although nAChRs were originally thought to be limited to neuronal cells, studies have identified functional nAChRs in tissues outside the nervous system. This finding raises the possibility that these receptors may mediate some of the systemic effects of smoking. In lung tissues, researchers have discovered nAChRs in human bronchial epithelial cells, vascular endothelial cells, pulmonary neuroendocrine cells, neuroepithelial bodies, NSCLC cells, and SCLC cells (Tarroni et al. 1992; Maneckjee and Minna 1994; Macklin et al. 1998; Maus et al. 1998; Schuller and Orloff 1998; Wang et al. 2001b; Fu et al. 2003; Schuller et al. 2003; Song et al. 2003a,b; Tsurutani et al. 2005).

The stimulation of nAChRs by components of cigarette smoke has biologic effects on cells that are important for the initiation, progression, and maintenance of cancer. The activation of nAChRs in lung epithelial cells by nicotine or NNK promotes the survival and proliferation of human mesothelioma and lung cancer cells (Maneckjee and Minna 1994; Schuller and Orloff 1998; West et al. 2002; Schuller et al. 2003; Trombino et al. 2004; Tsurutani et al. 2005). In normal cells, nicotine can stimulate properties consistent with cell transformation and the early stages of cancer formation, such as increased cell proliferation, decreased cellular dependence on the extracellular matrix for survival, and decreased contact inhibition, which is the natural process of arresting cell growth when two or more cells come in contact with each other (West et al. 2003). Furthermore, nicotine stimulation of endothelial nAChRs promotes angiogenesis, another property of cancer (Heeschen et al. 2001, 2002; Zhu et al. 2003). Thus, the induced activation of nAChRs in lung tissues by components of cigarette smoke can promote processes required for development of cancer.

In addition to stimulating nAChRs directly, components of cigarette smoke can indirectly stimulate nAChRs by promoting the growth of tobacco-related cancers that express and secrete ACh, the endogenous ligand for these receptors. SCLC and NSCLC cells synthesize, transport, and release ACh in vitro, which stimulates proliferation of cancer cells through the autocrine activation of nAChRs (Song et al. 2003a; Proskocil et al. 2004). This finding suggests that there are many mechanisms for activation of nAChRs in lung cancer and further emphasizes the importance of these receptors in the biology of tobacco-related cancer.

β-Adrenergic Receptors

The β-adrenergic receptors are neuronal receptors that may play a role in mediating effects of cigarette smoke related to signal transduction. NNK is structurally similar to epinephrine, the endogenous ligand for the β-adrenergic receptor, suggesting that in addition to binding nAChRs, NNK may bind to these receptors. Once bound to β-adrenergic receptors, NNK can stimulate the release of arachidonic acid (Schuller et al. 1999; Weddle et al. 2001). The enzyme COX-2 converts arachidonic acid to prostaglandin E2, which mediates inflammation and promotes cell survival and proliferation in cancer. This finding is important because cell lines from human lung cancer overexpress the β-adrenergic receptor (Schuller et al. 2001), and several studies suggest that the presence or expression of arachidonic acid is a risk factor for pulmonary adenocarcinomas (Alavanja et al. 1993, 2001). Thus, these studies indicate that the β-adrenergic receptor may be an important mediator of signal transduction pathways associated with exposure to cigarette smoke.

Other Receptors

The ERBB family is another group of EGFRs that indirectly mediate signal transduction associated with cigarette smoke. The four types of ERBB receptors are EGFR (HER-1), HER-2, HER-3, and HER-4. These receptors act in pairs to stimulate downstream signaling pathways that mediate the survival and proliferation of both normal cells and cancer cells. Ligands that bind to ERBB family members include the epidermal growth factor TGFα and amphiregulin. In addition, receptors can be activated in the absence of a ligand through overexpression of the receptors themselves. Both of these mechanisms play a role in activation of these receptors mediated by cigarette smoke.

The hypothesis that ERBB receptors mediate the effects of cigarette smoke on airway epithelial cells emerged from correlative clinical data and mechanisms defined in vitro. Clinical data include many reports of EGFR and HER-2 overexpression in lung cancer (Hendler and Ozanne 1984; Cerny et al. 1986; Veale et al. 1987; Hirsch et al. 2003a; Tan et al. 2003). In addition, some studies have shown that EGFR overexpression and activation in human lung cancers correlate with shorter survival times, suggesting that they play an important role in development of cancer (Kern et al. 1990; Kanematsu et al. 2003; Selvaggi et al. 2004).

Clinical data also support the hypothesis that ERBB expression and activation change with exposure to cigarette smoke or its components. Studies have demonstrated the overexpression of EGFR and ERBB3 in the bronchial epithelium of smokers (Yoneda 1994; O’Donnell et al. 2004). Results of mechanistic in vitro studies, such as the demonstration that NNK-induced transformation of lung epithelial cells is associated with an increase in EGFR expression, support these observations (Lonardo et al. 2002). Moreover, exposure to nicotine alone can increase the expression of EGFR in cervical cancer cell lines (Mathur et al. 2000). Studies also demonstrate that exposure to tobacco smoke increases the activity of EGFR, and metabolites of B[a]P induce activation of EGFR and downstream signaling pathways that promote proliferation (Burdick et al. 2003; Moraitis et al. 2005). These studies support the idea that components of cigarette smoke modulate the expression and activation of the ERBB family of receptors.

In addition to increasing the expression of ERBB family members, components of tobacco smoke stimulate cells to produce ligands that activate the receptors. In clinical specimens, studies have described the coexpression of EGFR and its ligand TGFα in human NSCLC. In one study, both EGFR and TGFα were expressed in 38 percent of the cases of NSCLC examined (Rusch et al. 1993). In a second study, 72 percent of SCCs and 34 percent of adenocarcinomas expressed both EGFR and TGFα (Hsieh et al. 2000). This finding may be clinically important because a retrospective analysis showed that the coexpression of EGFR and TGFα is an indicator of a poor prognosis (Tateishi et al. 1990). These studies suggest that the stimulation of ERBB ligands induced by cigarette smoke may be an important mechanism of signal transduction.

Consistent with the clinical data, in vitro studies show that condensate from cigarette smoke stimulates the release of amphiregulin and TGFα from the cell membrane, which leads to the autocrine activation of EGFR and cell proliferation (Richter et al. 2002; Lemjabbar et al. 2003; Moraitis et al. 2005). Several studies demonstrate that cigarette smoke condensate activates matrix metalloproteinases (MMPs), which are enzymes on the extracellular surface of cells that cleave these ligands from the extracellular matrix. Support for these in vitro observations comes from the demonstration that MMP activity is higher in lung tissues from smokers than in those from nonsmokers (Kang et al. 2003; Kangavari et al. 2004).

In addition to stimulating downstream kinases, EGFR activation by cigarette smoke may provide a mechanistic link to the increased inflammation characteristic of smokers by increasing COX-2 activity (see “Activation of Cytoplasmic Kinase by Tobacco Smoke” later in this chapter). In vitro data suggest that autocrine activation of EGFR, by the expression of the TGFα and AREG genes induced by tobacco smoke, stimulates COX-2 expression (Moraitis et al. 2005). Cigarette smoke also increases COX-2 expression by lung fibroblasts in vitro, and B[a]P increases COX-2 expression by oral epithelial cells (Kelley et al. 1997; Martey et al. 2004). Thus, many in vitro studies demonstrate that EGFR activation by components of cigarette smoke can contribute to inflammation through the increased expression and activation of COX-2.

Clinical data support the validity of these in vitro observations. For example, studies document increased levels of COX-2 in the oral mucosa of smokers (Moraitis et al. 2005) and in urothelial tissues from smokers with bladder cancer (Badawi et al. 2002). Moreover, COX-2 is expressed only in neoplastic epithelial cells, not in normal bronchial epithelial cells (Hastürk et al. 2002). COX-2 overexpression in lung cancer is associated with tumor angiogenesis and survival and proliferation of tumor cells (Riedl et al. 2004) and with a poor prognosis in NSCLC (Achiwa et al. 1999; Yuan et al. 2005). Thus, the stimulation of EGFR that leads to COX-2 activity by exposure to cigarette smoke is another mechanism mediated by a growth factor receptor to promote cell survival and proliferation in carcinogenesis.

Activation of Cytoplasmic Kinase by Tobacco Smoke

Activation of cell-surface receptors by components of tobacco smoke stimulates downstream kinases that mediate cancer cell survival, proliferation, and resistance to chemotherapy. The best-described kinases activated by smoking are AKT, ERK, PKC, and PKA. All of these kinases can be activated by cigarette smoke components through nAChRs, but ERBB family members also mediate AKT and ERK activation by cigarette smoke components. In addition, β-adrenergic receptor activation by cigarette smoke components can activate PKA and PKC. Thus, these proteins can be activated by tobacco smoke components through multiple receptor-mediated mechanisms, suggesting that the proteins are important mediators of smoking-induced signal transduction.

Protein Kinase B

The serine/threonine kinase AKT may be the critical effector of signaling induced by cigarette smoke, because AKT is stimulated in response to the activation of nAChRs, β-adrenergic receptors, and the ERBB family of receptors. Moreover, AKT controls many cellular processes that promote cell survival, proliferation, and the resistance of cancer cells to chemotherapy. Clinical data also suggest that AKT activation indicates a poor prognosis in many tobacco-related cancers. Thus, activation of this kinase by components of tobacco smoke can affect many cellular processes important for the initiation, growth, and progression of tumors.

AKT might be important for the initiation as well as the maintenance of tobacco-related cancers. Nicotine and NNK cause rapid AKT activation through different nAChRs (West et al. 2003; Tsurutani et al. 2005). B[a]P metabolites activate AKT in breast epithelial cells, although the cellular receptor responsible for the effect has not been identified (Burdick et al. 2003). Furthermore, nicotine-induced AKT activation in normal human bronchial cells or in small airway epithelial cells promotes cell survival, proliferation, and anchorage-independent growth, all of which are properties of transformed cells (West et al. 2003). These studies are important because they suggest that AKT activation by tobacco smoke components may precede the formation of DNA mutations that cause cancer. Thus, AKT activation could serve as a biochemical gatekeeper for lung carcinogenesis by promoting the survival of cells that would normally die from DNA damage.

In addition to promoting AKT-dependent growth and survival of normal epithelial cells, tobacco smoke components have similar effects on cells throughout the phenotypic spectrum of transformation. In a mouse model of NNK-induced lung tumorigenesis, an increase in AKT activation was associated with an increase in the progression of NNK-induced lung lesions (West et al. 2004b). In human lung cancer cells, nicotine or NNK activated the AKT pathway and stimulated AKT-dependent proliferation through nAChRs (Tsurutani et al. 2005). Moreover, these researchers showed that nicotinic activation of AKT increased survival of lung cancer cells after treatment with chemotherapeutic agents or radiation (Tsurutani et al. 2005). The fact that tobacco smoke components activate AKT and promote the survival of cancer cells is important, and it is supported by the finding that cancer patients who continue to smoke during chemotherapy have a worse prognosis than those who stop smoking (Johnston-Early et al. 1980; Browman et al. 1993; Videtic et al. 2003).

Clinical data and preclinical models support the hypothesis that AKT activation is an early event in carcinogenesis. AKT is activated in preneoplastic lung lesions induced by exposure to NNK (West et al. 2004a) and in dysplastic lung lesions from smokers (Massion et al. 2004). In addition, AKT activation is associated with poor survival in patients with tobacco-related cancers, including lung cancer and pancreatic cancer (David et al. 2004; Hirami et al. 2004; Yamamoto et al. 2004; Tsurutani et al. 2005). Together, these clinical studies support the idea that AKT plays an important role in the formation and maintenance of tobacco-related cancers.

Extracellular Signal-Regulated Kinases

In addition to AKT, ERK may play an important role in smoking-related cancers because it can be activated in response to components of tobacco smoke through both nAChR and ERBB receptors. In normal cells, ERK is activated in response to many extracellular signals and stimulates cell proliferation. In SCLC and pulmonary neuroendocrine cells, NNK-induced activation of nAChR leads to the activation of RAF-1 and its downstream effector ERK (Jull et al. 2001; Schuller et al. 2003). In addition, B[a]P metabolites activate ERK (Burdick et al. 2003), and nicotine activates ERK and promotes cell survival (Heusch and Maneckjee 1998). Thus, like AKT, ERK can be activated as an acute response to tobacco smoke components. Because ERK and AKT can promote cell survival and proliferation, early activation of both kinases may contribute to the initiation, promotion, and progression of cancer.

Researchers have also described ERK activation in tobacco-related cancers, thus validating the mechanisms defined in vitro. ERK activation is associated with poor survival in SCLC, which occurs almost exclusively in smokers (Blackhall et al. 2003). The overexpression of C-MYC, an oncogene activated by ERK, has been described in lung cancer and promotes proliferation as well as resistance to cell death (Zajac-Kaye 2001). Thus, tobacco smoke components stimulate ERK, which promotes cell proliferation and contributes to the poor prognosis of lung cancer patients with this biochemical alteration.

Protein Kinase C

The PKC kinases also mediate cellular responses to exposure to tobacco smoke. Several isoforms of PKC can promote cell survival, most notably PKCα. Nicotine- and NNK-induced activation of PKCα through the β-adrenergic receptor promotes the survival of lung cancer cells (Schuller et al. 2003). In addition, nicotinic activation of nAChRs activates PKC in human bronchial epithelial cells, as well as in lung cancer cells (Maneckjee and Minna 1994; Carlisle et al. 2004). In SCLC, NNK-induced activation of nAChRs causes PKC activation associated with cell proliferation (Jull et al. 2001). Another PKC isoform, PKCδ, seems to act atypically in NSCLC cells. Activation of PKCδ in NSCLC promotes cell survival and resistance to chemotherapeutic agents (Clark et al. 2003), and nicotine can prevent chemotherapy from inhibiting PKC (Heusch and Maneckjee 1998). Like AKT, nicotinic activation of PKC has ramifications for smokers by contributing to chemotherapeutic resistance. This finding is consistent with the finding that patients with lung cancer who continue to smoke during chemotherapy have a worse prognosis than those who stop smoking.

A clinical study also demonstrates the importance of PKC in tobacco-related cancers. Lahn and colleagues (2004) found that PKCα is overexpressed in a subset of NSCLC. Collectively, the results suggest that the activation of prosurvival PKC isoforms by cigarette smoke is an important mechanism of cell proliferation mediated by nAChRs and β-adrenergic receptors in carcinogenesis.

Protein Kinase A

Another cytoplasmic kinase activated by components of tobacco smoke is PKA. Under normal physiological conditions, PKA is stimulated through the production of cyclic adenosine monophosphate by activated G protein–coupled receptors. Nicotinic activation of PKA occurs through both nAChRs and β-adrenergic receptors (Dajas-Bailador et al. 2002; Jin et al. 2004a). The primary effect of nAChR-mediated PKA activation was an increase in cell proliferation. Nicotinic activation of PKA through β-adrenergic receptors, however, promoted cell survival. Although the data on PKA are limited, they suggest that PKA might be an important mediator of signal transduction, mediating cell survival and proliferation in response to activation by nAChRs and β-adrenergic receptors.

Downstream Targets of Signaling Cascades Mediated by Tobacco Smoke

Activation of cell-surface receptors induced by components of tobacco smoke and the subsequent activation of cytoplasmic kinases stimulate other proteins that dictate cellular responses, such as cell survival and proliferation. Although activated kinases have many downstream targets, the two most studied are the transcription factor NF-κB and proteins in the BCL-2 family. Activation of these proteins by tobacco smoke components through signaling cascades promotes processes involved in initiation, progression, and maintenance of cancers (see “Signal Transduction” earlier in this chapter).

Gene Promoter Hypermethylation in Cancer Induced by Tobacco Smoke

Alternative to Mutation

Gene promoter hypermethylation is an epigenetic change of a gene involving extensive methylation at the 5′ position of C in CpG islands within the promoter region and often extending into exon 1 of regulatory genes (Jones and Baylin 2002; Herman and Baylin 2003). “Epigenetic” refers to alteration in gene expression resulting from changes other than DNA sequence. The end result of this process can be loss of gene transcription and therefore the silencing of gene function.

Inactivation of the P16 Gene in Lung Cancer

One region on chromosome 9p contains the CDKN2A (P16) tumor-suppressor gene (Kamb et al. 1994; Merlo et al. 1994). Mutations within the P16 coding sequence are uncommon in lung cancer (Kamb et al. 1994). In contrast, this gene is inactivated by hypermeth-ylation at prevalences up to 60 percent and 70 percent in adenocarcinomas and SCC of the lung, respectively (Merlo et al. 1995; Belinsky et al. 1998; Kim et al. 2001; Zöchbaur-Müller et al. 2001; Divine et al. 2005). This discovery of inactivation of a tumor-suppressor gene by hypermethylation in lung cancer and identification of such inactivation of the P16 gene launched an area of research to uncover other genes inactivated by this mechanism. The targeting of P16 for inactivation is likely attributable to the critical function of this gene in the cell, which is to inhibit CDKs that bind cyclin D1 and phosphorylate the RB gene product (Lukas et al. 1995; Weinberg 1995). This regulation is lost if either the P16 or the RB gene is inactivated. The reciprocal relationship between RB alterations in SCLC and P16 alterations in NSCLC supports the premise that dysfunction within the RB pathway is a major target in research on the genesis of lung cancer (Swafford et al. 1997).

Critical Pathways Inactivated in Non-Small-Cell and Small-Cell Lung Cancer

More than 50 genes are inactivated by gene promoter hypermethylation in lung cancer, and new genes are still being identified through genomewide screening approaches (Suzuki et al. 2002; Palmisano et al. 2003). The pathways and genes involved are summarized in Table 5.11.

Table 5.11. Pathways altered through gene silencing by promoter methylation.

Table 5.11

Pathways altered through gene silencing by promoter methylation.

Of particular importance is the DNA repair gene AGT, which protects cells from the carcinogenic effects of alkylating agents by removing adducts from the O6 position of deoxyguanosine (see “Repair of DNA Adducts” earlier in this chapter). Failure to repair this DNA adduct could lead to mutations in genes such as KRAS and TP53. AGT is inactivated by gene promoter methylation in 24 to 48 percent of adenocarcinomas (Esteller et al. 1999; Zöchbaur-Müller et al. 2001; Pulling et al. 2003). SCLC studies conducted for methylation of this gene are limited. Studies have reported an association between AGT promoter hypermethylation and a G→A transition mutation at CpG sites within the TP53 gene in NSCLC (Wolf et al. 2001). In contrast, no association was found between AGT gene methylation and a transition mutation in codon 12 of the KRAS gene from adenocarcinomas (Pulling et al. 2003).

The RAS superfamily of GTP-binding proteins plays an important role in signal transduction pathways that control cell proliferation, differentiation, and death (Campbell et al. 1998; Downward 2001) (see “Activation of Oncogenes in Lung Cancer” earlier in this chapter). Researchers identified a new family of genes that encode RAS-binding proteins. One of these genes, RASSF1A, is located at chromosome 3p21 and inactivated in 30 percent of NSCLCs and in 100 percent of SCLCs (Dammann et al. 2000; Burbee et al. 2001). Attempts to determine the function of this gene are continuing (Agathanggelou et al. 2003). RASSF1A protein forms a heterodimer with NORE1A, which allows it to bind with the proapoptotic protein MST1 (Khokhlatchev et al. 2002). Binding RAS to this complex may mediate RAS-dependent apoptosis. NORE1A is also silenced by methylation in NSCLC but not in SCLC (Hesson et al. 2003). Therefore, silencing either RASSF1A or NORE1A could effectively block apoptosis mediated by RAS activation. Two other RASSF family members appear to be involved in lung cancer development. Studies show that RASSF2 binds directly to the KRAS gene in a GTP-dependent manner and appears to promote both cell-cycle arrest and apoptosis through this interaction (Vos et al. 2003). The expression of this gene is markedly reduced in some lung cancer cell lines, thus suggesting silencing by gene promoter hypermethylation. There is support for this mechanism of inactivation in studies on colon cancer that document hypermethylation of this gene in 70 percent of tumors (Hesson et al. 2005). A third member of this gene family, RASSF4, shares 25 percent homology with RASSF1A and 40 percent with RASSF2 and is methylated in approximately 20 percent of NSCLCs and SCLCs (Eckfeld et al. 2004). Thus, the loss of function among members of the RASSF gene family is important to the development of lung cancer.

Gene Silencing in Lung Cancer

The most extensively studied gene with respect to timing of methylation in NSCLC is P16. Examination of biopsy specimens from premalignant lesions obtained from people without SCLC or from different airways or at different bronchial generations revealed a progressive increase in the prevalence of P16 methylation as the disease developed. The frequency of P16 methylation was 17 percent in basal cell hyperplasia, and the frequency increased incrementally over the histologic stages to 60 percent in SCCs (Belinsky et al. 1998). Further studies examined bronchial epithelial cells obtained by bronchos-copy from cancer-free smokers and found that inactivation of the P16 gene is likely one of the earliest events in lung cancer (Belinsky et al. 2002). Researchers detected P16 methylation in specimens from 25 of 137 biopsy procedures (18 percent) classified as histologically normal, metaplasia, or mild dysplasia. In contrast, no P16 methylation was found in biopsy specimens obtained from lifetime nonsmokers. Researchers used an animal model to determine the timing of P16 methylation in adenocarcinomas. In rats, 94 percent of adenocarcinomas induced by NNK were hypermethylated at the P16 promoter; this change was frequently detected in precursor lesions to the tumors: adenomas and hyperplastic lesions (Belinsky et al. 1998).

Inactivation of the AGT gene appears to be a later event in lung cancer than is the inactivation of P16. Only 3 of 40 biopsy specimens (8 percent) from heavy smokers with histologies including normal, hyperplasia, metaplasia, and dysplasia showed methylation of the AGT gene (Pulling et al. 2003). In addition, the prevalence of AGT methylation increased between stage I adenocarcinoma and stages II to IV. Finally, of the 137 bronchial biopsy specimens studied, 3 percent of the DAPK gene and none of the RASSF1A genes showed methylation, which suggests that the silencing of these genes likely occurs after P16 inactivation in SCC (Pulling et al. 2003). In contrast, the inactivation of DAPK by methylation in alveolar hyperplasias in a murine model of lung adenocarcinomas suggests a role for this gene in the early development of adenocarcinomas (Pulling et al. 2004).

Gene Promoter Hypermethylation, Prognosis, and Clinical Risk Factors

Numerous studies have evaluated relationships between gene promoter methylation and established clinical risk factors such as smoking dose and tumor stage. In addition, researchers have examined in detail the effect of gene-specific methylation on the survival of patients with a diagnosis of early-stage lung cancer. Results from investigations of the most commonly studied genes in lung cancer are highlighted here.

P16 methylation was significantly associated with pack-years of smoking and with an independent risk factor that predicts a shorter survival for patients who had resection of a stage I adenocarcinoma (Kim et al. 2001). Several other studies also support P16 methylation as a prognostic factor for survival of patients who had resection of a stage I adenocarcinoma (Suzuki et al. 2002; Wang et al. 2004a). In contrast, RASSF1A methylation in stage III NSCLC was a stronger predictor of poor survival than was P16 methylation (Wang et al. 2004a). These two genes may differ in that the silencing of P16 is an early event involved in initiation of tumorigenesis, whereas RASSF1A methylation is a later event more likely involved in progression of tumorigenesis. Thus, the methylation of RASSF1A may lead to a more aggressive tumor phenotype. This hypothesis is supported by the more frequent involvement of RASSF1A methylation in tumors with a vascular invasion, pleural involvement, and a poorly differentiated histology (Tomizawa et al. 2002). Persons who started smoking before 19 years of age were 4.2 times more likely to have methylation of the RASSF1A gene than were those who started smoking after 19 years of age (Kim et al. 2003). This research also suggests that for patients with stage I or stage II NSCLC at diagnosis, methylation of this gene is associated with a poorer prognosis (Kim et al. 2003).

Other Tobacco-Related Cancers

In addition to the studies on lung cancer described here, other studies have shown association of cigarette smoking with gene promoter hypermethylation in other tobacco-related cancers, such as the head and neck and bladder. Aberrant promoter methylation is common in head and neck cancer and has been detected by using saliva samples (Rosas et al. 2001). Promoter methylation of the P16, DAPK, E-CADHERIN, and RASSF1A genes was associated with smoking and commonly found in head and neck cancer (Hasegawa et al. 2002). P16 promoter hypermethylation and the loss of P16 protein expression were detected in head and neck SCC; loss of expression correlated significantly with a history of alcohol consumption or tobacco use (Ai et al. 2003). The prevalence of P15 methylation in the healthy epithelium of patients with head and neck SCC who had long-term smoking and drinking behaviors was significantly higher than that in nonsmokers (Wong et al. 2003). Another study suggested that P15 gene methylation could be induced by chronic smoking and drinking and could play a role in the early stages of head and neck SCC (Chang et al. 2004). Cigarette smoking was also associated with an increased risk of promoter methylation of the P16 gene in bladder cancer (Marsit et al. 2006).

Molecular Epidemiology of Cell-Cycle Control and Tobacco-Induced Cancer


Cell-cycle checkpoints delay cell-cycle progression, thereby affording adequate time for DNA repair to occur. Such checkpoint signaling also activates pathways leading to apoptosis if the damage cannot be repaired. The introduction of new techniques of profiling gene expression has enabled researchers to comprehensively evaluate activity of proteins in regulating the cell cycle (Singhal et al. 2003). A hallmark of the neoplastic cell is the ability to disrupt the tightly regulated cell-cycle control and enable the cell to bypass checkpoints, especially at the G1/S and G2/M boundaries (Hanahan and Weinberg 2000). Persons with defects in cell-cycle checkpoints (acquired or inherited) could therefore exhibit chromosome damage, genomic instability, and increased susceptibility to tobacco carcinogenesis.

In vitro studies show an association between exposure to tobacco carcinogens and the disruption of cell-cycle control (Khan et al. 1999). Furthermore, Jin and colleagues (2004b) provide data showing that NNK promotes cell survival and proliferation through phosphorylation of the proteins BCL-2 and C-MYC. Studies implicate tobacco carcinogens in genetic alterations in the P16-RB and P14ARF-P53 pathways, mainly through the formation of DNA adducts. Variations in cell-cycle checkpoints might also be attributed to functional polymorphisms in cell-cycle control genes. The SNP500Cancer Database reports that 27 genes related to the cell cycle are polymorphic, and these include genes that control checkpoints for both the G1/S and G2 phases of the cell cycle. However, only a few genes, including CCND1, TP53, P21, and P73, have been studied in tobacco-related cancers.

CCND1 Gene

The CCND1 gene, together with CDK4, P16, and the tumor-suppressor gene RB, comprise a linked system governing the passage of the cell through the cell cycle (Betticher et al. 1997). A common finding in a variety of cancers is the amplification or overexpression of CCND1, which contributes to tumor initiation, progression, and outcome, such as death. A G→A polymorphism at codon 242 in the conserved splice donor region of exon 4 increases alternate splicing (Betticher et al. 1995). The alternate transcript appears to encode for a protein- missing sequence involved in protein turnover, and therefore, the encoded protein may have a longer half-life. This extended half-life, in turn, would facilitate passage of damaged cells through the checkpoint for the G1/S phase and promote proliferation rather than apoptosis. Researchers have studied the association between the CCND1 genotype and cancer risk in several tobacco-related cancers. Qiuling and colleagues (2003) reported that the CCND1 *A/*A genotype was associated with a significantly increased risk of lung cancer (OR = 1.87; 95 percent CI, 1.01–3.45) compared with that for the *G/*G genotype. The risk was even higher in young persons and men. A similar finding was reported in cancer of the head and neck (Zheng et al. 2001). These investigators demonstrated that carriers of the *A/*A genotype, on average, had diagnoses of cancer 3.5 years earlier than did carriers of the*G/*G genotype. Wang and colleagues (2002) reported that the *A/*A genotype was associated with a significantly higher risk of transitional cell carcinoma of the bladder than that for the *A/*G plus *G/*G genotypes (OR = 1.76; 95 percent CI, 1.09–2.84). However, neither Cortessis and colleagues (2003) nor Yu and colleagues (2003) reported significant associations with either bladder cancer or esophageal SCC, respectively. Spitz and colleagues (2005) demonstrated an increased risk for lung cancer associated with this polymorphism. The risk estimate was 1.35 (95 percent CI, 1.05–1.73) for the *A/*A and *A/*G genotypes compared with the *G/*G genotypes.

P21 Protein

Cell-cycle inhibitor protein P21 (WAF1/CIP1) acts as a checkpoint regulator for the G1/S and G2/M phases. Marwick and colleagues (2002) showed a significant increase in P21 mRNA expression in alveolar epithelial cells after exposure to condensate from cigarette smoke and concluded that oxidative stress induced by cigarette smoke modulates the expression of P21.

Three studies of lung cancer have examined the association of cancer risk with a polymorphism of P21 at codon 31 (SER31ARG), but the findings were inconsistent. Själander and colleagues (1996) reported an increased frequency of the variant allele (*ARG) among patients with lung cancer (p <0.004). Two other studies failed to replicate this finding (Shih et al. 2000; Su et al. 2003). However, Chen and colleagues (2002) reported that the variant allele (*ARG) was associated with increased risk of bladder cancer.

TP53 Gene

Studies have reported 14 polymorphisms in the TP53 gene, 3 of which have been widely studied: a G→C polymorphism at codon 72 (proline/arginine), a 16bp insertion in intron 3, and a G→A transition in intron 6. Polymorphisms in codons 21, 36, and 213 are silent. The polymorphism in codon 47 involves a rare allele with a frequency less than 5 percent. The codon 72 polymorphism on exon 4 produces variant proteins with an arginine (CGC) or proline (CCC) at the site. Thomas and colleagues (1999) reported differences between the two variants in their ability to interact with basic elements of the transcriptional machinery and to induce apoptosis. Weston and colleagues (1992) reported an increased frequency of the proline allele in lung adenocarcinoma, which was consistent with findings in a Japanese study of lung cancer (Kawajiri et al. 1993). Jin and colleagues (1995) reported significantly higher risks for the *PRO/*PRO genotype among patients with lung cancer who were younger than 55 years of age and among patients reporting fewer than 30 pack-years of smoking. In a study of NSCLC, Nelson and coworkers (2005) found that mutation on the *PRO allele was associated with a significantly worse outcome than that for patients with no mutation or with mutation on the *ARG allele.

Mutations in intron sequences may initiate aberrant pre-mRNA splicing that results in a defective protein (Hillebrandt et al. 1997) or that may influence mutations in the coding region. Either result would increase the likelihood of a deleterious phenotype (Malkinson and You 1994). Biroš and colleagues (2001) reported a higher percentage of the intron 6 variant allele in patients with lung cancer than in control participants. However, Birgander and colleagues (1995) found no association of the allele with lung cancer. Several studies estimated the pairwise haplotype frequencies for the polymorphisms in exon 4 and introns 3 and 6. The researchers proposed that the P53 haplotypes were associated with a higher risk for lung cancer (Birgander et al. 1995; Biroš et al. 2001). In one study of 635 pairs of lung cancer patients and control participants, variant alleles of TP53 exon 4, introns 3 and 6, and their variant haplotypes were associated with an increased risk of lung cancer (Wu et al. 2002). In a meta-analysis of TP53 polymorphisms and lung cancer risk that included data from 16 case-control studies, Matakidou and colleagues (2003) concluded that persons with the P53 exon 4 *PRO/*PRO genotype had a 1.18-fold increase in lung cancer risk (OR = 1.18; 95 percent CI, 0.99–1.41). Other researchers have observed a similar association with polymorphisms of P53 introns 3 and 6. However, evidence of these associations has not been consistent (Wang et al. 1999; Mabrouk et al. 2003).

P73 Gene

The P73 gene activates the promoters of several genes that are responsive to the TP53 gene and participate in cell-cycle control, DNA repair, and apoptosis and inhibit cell growth in a P53-like manner by inducing apoptosis or cell-cycle arrest in the G1 phase (Nomoto et al. 1998; Cai et al. 2000). Loss of heterozygosity at the P73 locus is relatively common. Studies have identified an estimated 17 polymorphisms. Two common SNPs at positions 4 (G→A) and 14 (C→T) in the uncoding region of exon 2 of the P73 gene are in complete linkage disequilibrium and may affect P73 function by altering the efficiency of translation initiation (Kaghad et al. 1997).

Studies have reported the role of the P73 G4C14→A4T14 polymorphism in the risk of smoking-related cancer (Ryan et al. 2001; Hamajima et al. 2002; Hiraki et al. 2003; Huang et al. 2003). In NSCLC, the most significant effect observed was among male smokers (OR = 1.87; 95 percent CI, 1.25–2.80) with SCLC, suggesting that this P73 polymorphism may have an impact on the repair of tobacco-associated DNA damage. A study of 1,054 patients with lung cancer and 1,139 control participants found a dose-response relationship between the frequency of heterozygous or homozygous variant alleles and risk of lung cancer (trend test, p <0.001). ORs were 1.32 (95 percent CI, 1.10–1.59) for the frequency of heterozygous alleles and 1.54 (95 percent CI, 1.05–2.26) for the frequency of homozygous alleles (Li et al. 2004b). The risk of lung cancer was more pronounced in persons younger than 50 years of age, men, light smokers, and patients with SCLC. The variant genotypes were also associated with an increased risk for SCCs of the head and neck that was statistically significant (OR = 1.33) and an even higher risk among current smokers (OR = 1.77) (Li et al. 2004a).

Other Aspects

Carcinogenic Effects of Whole Mixture and Fractions of Tobacco Smoke

Researchers have conducted inhalation studies of cigarette smoke in hamsters, rats, mice, rabbits, dogs, and nonhuman primates. The model systems used in these studies had various problems, including the inability of any study to accurately duplicate human smoking behaviors. Nevertheless, comprehensive reviews of these studies have found a large amount of useful information (IARC 1986, 2004; Coggins 1998; Witschi 2000). Researchers observed the most consistent results on cancer induction in Syrian golden hamsters; whole cigarette smoke and its particulate phase induced malignant tumors and other lesions in the larynx. Tumors were not induced by the gas phase of cigarette smoke.

Findings of studies that induced malignant tumors by inhalation of cigarette smoke and its particulate phase are consistent with those in the substantial amount of literature demonstrating that condensate from cigarette smoke, which lacks volatile constituents of the gas phase, causes benign and malignant tumors when applied to mouse skin and rabbit ears or instilled in rat lungs by intrapulmonary administration (Hoffmann et al. 1978; IARC 1986, 2004). Collectively, these results clearly show that major carcinogenic fractions of cigarette smoke reside in the particulate phase.

Extensive fractionation studies were conducted with cigarette smoke condensate (Hoffmann et al. 1978). Bioassays of the resulting fractions applied to the skin of mice demonstrated that the neutral portion of the condensate has carcinogenic activity and the acidic portion has tumor-promoting and cocarcinogenic activity. The recombined neutral and acidic portions accounted for about 80 percent of the carcinogenic activity of the condensate. Subfractionation of the neutral portion revealed that certain PAHs were the major tumor initiators in this fraction. However, these PAHs alone, in the levels at which they occur, were insufficient to induce tumors. Moreover, when these PAHs were added to the condensate, the tumor yield was higher than with the condensate alone. These results indicate that the combination of PAHs acting as tumor initiators, together with cocarcinogens in the condensate, accounted for the tumorigenicity of the condensate on mouse skin. Researchers identified catechol and alkyl catechols as major cocarcinogens in the condensate, and the weakly acidic portion of the condensate demonstrated tumor-promoting activity (Van Duuren and Gold-schmidt 1976; Hecht et al. 1981). Other cocarcinogens in cigarette smoke include undecane, pyrene, fluoranthene, and B[a]P (Van Duuren and Goldschmidt 1976). The identity of tumor promoters in cigarette smoke is largely unknown, although simple phenols may contribute weakly (Hecht et al. 1975). Researchers have also observed tumor-promoting activity of cigarette smoke in inhalation experiments with hamsters (IARC 1986). PAH-enriched fractions of cigarette smoke condensate instilled in the rat lung also resulted in tumor formation (IARC 1986).

These results clearly demonstrate the carcinogenic, tumor-promoting, and cocarcinogenic activity of the particulate phase of cigarette smoke. However, some data indicate that constituents of the gas phase also contribute to tumor induction. Early studies in Snell’s mice demonstrated an increase in pulmonary adenocarcinomas in animals exposed to the gas phase alone (IARC 2004). In an exposure model using 89 percent sidestream smoke and 11 percent mainstream smoke, increased multiplicity of lung adenomas was consistently observed in A/J mice exposed to the smoke for five months, followed by a four-month resting period. Tumor response in this model was clearly attributable to the gas phase, because filtration had no effect on multiplicity of lung adenomas (Witschi 2000; IARC 2004). The results of these studies indicate that a volatile carcinogen in cigarette smoke—possibly 1,3-butadiene—produced a tumorigenic response in the A/J mouse lung.

Two other studies not included in the reviews previously cited here demonstrate convincingly that cigarette smoke administered to rats or mice by whole-body exposure for extended periods induces benign and malignant tumors of the respiratory tract (Mauderly et al. 2004; Hutt et al. 2005). When male and female F-344 rats were exposed to smoke from 1R3 research cigarettes or to clean air for six hours per day, five days per week for up to 30 months, the exposure significantly increased the incidence of nonneoplastic and neoplastic proliferative lung lesions in females. The combined incidence of bronchoalveolar adenomas and carcinomas was 14 percent in the high-exposure group (250 mg of particulates per m3 of air), 6 percent in the low-exposure group (100 mg/m3), and none in the controls. Mutations in codon 12 of the KRAS gene occurred in 4 of 23 tumors. Both males and females had significant increases in neoplasia of the nasal cavity (Mauderly et al. 2004). Female B6C3F1 mice were exposed to smoke for 6 hours per day, 5 days per week, for 925 days (250 mg/m3) or were sham exposed. The incidence of lung adenoma (28 percent) and lung adenocarcinoma (20 percent) in the mice exposed to smoke were significant (Hutt et al. 2005).

Synergistic Interactions in Tobacco Carcinogenesis


There is persuasive epidemiologic evidence that alcohol consumption and smoking synergistically increase the risk for cancers of the oral cavity, pharynx, larynx, and esophagus (IARC 2004). No single mechanism clearly explains these observations, but several have been proposed and there is reasonable support for some. The most consistent body of evidence relates to the effects of alcohol on the distribution of carcinogenic nitrosamines. Swann and colleagues (1984) demonstrated that alcohol could inhibit the hepatic metabolism and clearance of NDMA, a carcinogen in tobacco smoke. This inhibition occurs because ethanol competitively inhibits hepatic cytochrome P-450 2E1, the main hepatic enzyme responsible for metabolism of NDMA. Consequently, more NDMA reaches extrahepatic tissues where it can be metabolically activated and has the potential to cause cancer. Anderson and coworkers (1992 (1996) demonstrated that coad-ministration of ethanol and NDMA to A/J mice resulted in an incidence of lung tumors higher than that in mice treated with NDMA alone and that this increase was a consequence of inhibition of hepatic metabolism and not of tumor promotion. Furthermore, administration of ethanol to patas monkeys before they received NDMA resulted in a 14.6-fold increase in O6-methylguanine in esophageal DNA and other extrahepatic tissues (Anderson et al. 1996).

Another potential mechanism also involves the effects of ethanol on P-450 2E1, but as an inducer of this enzyme. Chronic ethanol consumption is known to induce production of hepatic P-450 2E1, and researchers hypothesized that this induction could lead to increased metabolic activation of carcinogens in tobacco smoke (McCoy et al. 1979). Some N-nitrosamines in tobacco smoke—NDMA, N-nitrosodiethylamine, and N-nitrosopyrrolidine—are all substrates for P-450 2E1. McCoy and colleagues (1981) demonstrated that chronic ethanol consumption in hamsters increased the metabolism of N-nitrosopyrrolidine in hepatic and target tissue (e.g., trachea), as well as the carcinogenicity of this nitrosamine, which increases the occurrence of tumors in the nasal cavity and trachea. The carcinogenicity of N-nitrosodiethylamine in the rat esophagus was also increased by simultaneous administration of ethanol (Gibel 1967). Overall, however, the effects of ethanol consumption on N-nitrosamine carcinogenesis have been mixed, and they appear to depend on the N-nitrosamine studied and the protocol used. For example, long-term ethanol consumption had no effect on the carcinogenicity of NNN in the hamster and only modest or no effect in the rat (McCoy et al. 1981; Trushin et al. 1984).

Other mechanisms for the enhancing effect of alcohol consumption on tobacco carcinogenesis have been discussed (Pöschl and Seitz 2004). Persons who abuse alcohol generally have nutritional deficiencies, which could exacerbate the effects of smoking. They commonly have folate deficiency that could contribute to an inhibition of transmethylation, which is important in gene regulation. Zinc deficiency is known to result in enhanced carcinogenesis in the rat esophagus (Fong et al. 2001). Reduced serum and hepatic levels of vitamin A in persons with long-term alcohol abuse may affect carcinogenesis. Alcohol could also act as a solvent, increasing absorption of tobacco carcinogens (Squier et al. 1986).


Smoking and exposure to asbestos interact synergistically to increase the risk for lung cancer (IARC 2004). The mechanism for this synergy is unknown. Researchers have investigated a number of possibilities, however, and these have been summarized (Nelson and Kelsey 2002). It has been proposed that asbestos fibers serve as a vehicle to deliver tobacco carcinogens to the cell nucleus. Surfactant phospholipids may help to solubilize carcinogenic PAH, increasing their concentrations in the lung epithelium. Studies have also demonstrated that asbestos fibers can induce chromosomal aberrations and extensive deletions, potentially adding to the DNA damage produced by carcinogens in tobacco smoke. Furthermore, asbestos may cause oxidative damage that could be related to in-flammation and cell death related to pulmonary fibrosis associated with exposure to asbestos. It seems likely that asbestos fibers could cause proliferation that may increase the probability of mutations attributable to DNA damage by tobacco smoke carcinogens.

Carcinogens as Causes of Specific Cancers

Data from carcinogenicity studies, product analyses, and findings from studies using biochemistry and molecular biology support a significant role for certain carcinogens in tobacco-induced cancer (Table 5.12).

Table 5.12. Carcinogens and tobacco-induced cancers.

Table 5.12

Carcinogens and tobacco-induced cancers.

Considerable evidence favors PAHs and NNK as major factors in development of lung cancer. PAHs are strong carcinogens acting locally; thus, fractions of tobacco smoke enriched in these compounds are carcinogenic (Hoffmann et al. 1978; Deutsch-Wenzel et al. 1983; IARC 1983) (see “Carcinogens in Cigarette Smoke” earlier in this chapter). Researchers have detected PAH-DNA adducts in human lungs, and the spectrum of mutations in the TP53 gene isolated from lung tumors was similar to the pattern of DNA damage produced in vitro by PAH diol epoxide metabolites and in cell cultures by B[a]P (Pfeifer et al. 2002; Phillips 2002; Boysen and Hecht 2003; Liu et al. 2005) (see “DNA Adducts and Biomarkers” earlier in this chapter).

NNK is a strong systemic carcinogen in lungs of rodents that induces lung tumors independent of the route of administration (Hecht 1998). NNK was found to be particularly potent in the rat. Significant incidence of lung tumors was induced by total doses as low as 6 mg/kilogram (kg) of body weight or by 1.8 mg/kg as part of a dose-response trend. These doses are comparable to an estimated NNK dose of 1.1 mg/kg in persons who have smoked for 40 years (Hecht 1998). DNA adducts derived from NNK or from the related tobacco-specific nitrosamine, NNN, are present in lung tissue from smokers, and metabolites of NNK are found in the urine of smokers (Hecht 2002b). Epidemiologic data indicate that a systemic carcinogen causes lung cancer in cigar smokers who do not inhale the smoke; this finding is consistent with the tumorigenic properties of NNK (Boffetta et al. 1999; Shapiro et al. 2000).

The changing histology of lung cancer is also consistent with the role of NNK: adenocarcinoma has now overtaken SCC as the most common lung cancer type. This nitrosamine in tobacco smoke produces primarily adenocarcinomas in rodents. However, this outcome has also been attributed to differing inhalation patterns of current cigarette smokers (Travis et al. 1995; Hecht 1998). As nitrate concentrations in tobacco increased from 1959 to 1997, NNK concentrations in mainstream smoke increased and those of B[a]P decreased. Researchers attributed these changes to tobacco blends with higher levels of air-cured tobacco, the use of reconstituted tobacco, and other factors (Hoffmann et al. 2001). Other compounds that could be involved in lung cancer include 1,3-butadiene, isoprene, ethylene oxide, ethyl carbamate, aldehydes, benzene, metals, and oxidants, but the collective evidence for each of these substances is not as strong as the evidence for PAHs and NNK (Hecht 1999).

The particulate phase of cigarette smoke causes tumors of the larynx in hamsters, which could be attributed to PAHs (IARC 1986). TP53 gene mutations identified in tumors of the human larynx support a role for PAHs in the development of this cancer (Pfeifer et al. 2002). N-nitrosamines, as well as acetaldehyde and formaldehyde, induce nasal tumors in rodents and are likely candidates for causing nasal tumors associated with smoking (Preussmann and Stewart 1984; IARC 1995c, 1999). On the basis of animal studies, PAH, NNK, and NNN are the most likely causes of oral cancer in smokers (Hoffmann and Hecht 1990). N-nitrosamines are the most effective esophageal carcinogens known. NNN causes tumors of the esophagus in rats and is the most prevalent N-nitrosamine carcinogen in cigarette smoke (Hecht and Hoffmann 1989; Lijinsky 1992).

NNK and several other N-nitrosamines and furan in cigarette smoke are effective hepatocarcinogens in rats (Preussmann and Stewart 1984; IARC 1995b). NNK and its major metabolite NNAL are the only known pancreatic carcinogens in tobacco products. Biochemical data from studies of human tissue provide some support for the role of these carcinogens in smoking-related pancreatic cancer, although the studies did not detect DNA adducts (Rivenson et al. 1988; Prokopczyk et al. 2002, 2005). Biochemical studies demonstrate that both NNK and PAHs can reach the cervix in humans and are metabolically activated in these tissues (Melikian et al. 1999; Prokopczyk et al. 2001). Researchers have detected DNA adducts derived from B[a]P and other hydrophobic compounds in cervical tissue from smokers (Melikian et al. 1999; Phillips 2002). Therefore, in combination with the human papilloma virus, these compounds may contribute to development of cervical cancer in smokers (IARC 1995a). 4-ABP and 2-naphthylamine are known human bladder carcinogens, and considerable data from human studies support the role of aromatic amines as the major cause of bladder cancer in smokers (IARC 1974; Skipper and Tannenbaum 1990; Skipper et al. 1994; Landi et al. 1996; Probst-Hensch et al. 2000; Castelao et al. 2001). The most probable cause of leukemia in smokers is exposure to benzene, which occurs in large quantities in cigarette smoke and is a known cause of acute myelogenous leukemia in humans (IARC 1982).

Cigarette smoke causes oxidative damage probably because it contains free radicals, such as nitric oxide, and contains mixtures of hydroquinones, semiquinones, and quinones that can induce reduction and oxidation (redox cycling) (Pryor et al. 1998; Hecht 1999). Smokers have lower levels of ascorbic acid in plasma and, sometimes, higher levels of oxidized DNA bases in white blood cells than do nonsmokers. However, the role of oxidative damage as a cause of specific tobacco-induced cancers remains unclear (Hecht 1999).

Tobacco Carcinogens, Immune System, and Cancer

Cigarette smoke alters a range of immunological functions including innate and adaptive immune responses (Sopori 2002). These effects, acting as tumor- promoting or cocarcinogenic stimuli, could affect tobacco-related carcinogenesis. Cigarette smoking increases the number of alveolar macrophages in the lung, possibly leading to higher levels of oxygen radicals and MPO activity, which are hypothesized to be important in tumor promotion. Investigators examined the effects of smoking on the function of natural killer (NK) cells—a lymphoid cell type involved in surveillance of tumor growth (Lu et al. 2007). They obtained strong evidence that suppression of NK cell activation was related to increased lung metastases in mice exposed to cigarette smoke. Other studies demonstrated that nicotine is immunosuppressive and thus might be responsible for some of the effects of cigarette smoke (Sopori 2002).

Epidemiology of Family History and Lung Cancer

Studies of familial aggregation of lung cancer provide indirect evidence supporting the possibility of an inherited component to tobacco carcinogenesis. A number of published studies showed that significantly more lung cancers were reported in first-degree relatives of pro-bands with lung cancer than were reported in first-degree relatives of healthy control participants. Assuming that the family structure does not differ between cases and controls, this pattern could be explained by shared genes among the family members, shared smoking patterns, or a combination of both factors. By incorporating smoking histories of the probands and the first-degree relatives into a study of familial aggregation, researchers can begin to assess the level of familial risk of cancer while adjusting for tobacco use. However, few studies of familial aggregation incorporate history of involuntary exposure of family members to tobacco smoke. Estimates of the overall proportion of patients with lung cancer who have family history of lung cancer in a first-degree relative range from 6 (Li and Hemminki 2004) to 16 percent (Sellers et al. 1992).

Forty years ago, Tokuhata and Lilienfeld (1963) observed that the number of deaths from lung cancer was higher among relatives of lung cancer case patients than it was among relatives of control participants. These researchers also reported a fourfold excess of lung cancer mortality in nonsmoking relatives of 270 lung cancer pro-bands. The effect among relatives who smoked was less pronounced (twofold). These findings suggest that the risk was not solely attributable to shared smoking patterns in the relatives. Other studies have since demonstrated a familial component of risk for lung cancer. The ORs associated with family history ranged from 1.3 to 7.2 (Ooi et al. 1986; Samet et al. 1986; Wu et al. 1988, 1996; Osann 1991; Shaw et al. 1991; Schwartz et al. 1996; Mayne et al. 1999). For example, in a comparison of 336 lung cancer pro-bands with relatives of control spouses, Ooi and colleagues (1986) reported an association between a family history of lung cancer and a threefold excess risk (OR = 3.09; 95 percent CI, 1.9–5.0). Shaw and associates (1991) found an OR of 2.8 (95 percent CI, 1.2–6.6) for risk of lung cancer among two or more relatives of case patients. Brownson and colleagues (1997) reported a trend for increasing risk associated with the number of first-degree relatives with lung cancer. The risk was more than twofold for persons with five affected family members.

One approach that evaluates familial aggregation while controlling for the impact of smoking focused on lifetime nonsmokers. Wu and colleagues (2004) evaluated 216 lung cancer probands who were female non-smokers and reported that family history of lung cancer was associated with a 5.7-fold (OR = 5.7; 95 percent CI, 1.9–16.9) increase in lung cancer risk. Wu and colleagues (1988) noted, after adjustment for exposure to secondhand smoke, a 30-percent increase in risk that was not statistically significant for history of cancers of the respiratory tract. This association was especially evident in mothers and sisters. The risk was also slightly elevated for lung cancer (OR = 1.3; 95 percent CI, 1.0–1.6). Mayne and colleagues (1999) also focused on familial risk in a population-based, case-control study of 437 lifetime nonsmokers and former smokers who had lung cancer and 437 matched control participants. The investigators observed increased risk of cancers of the aerodigestive tract among parents of case patients (OR = 2.78; 95 percent CI, 1.30–5.95) and increased risk of lung cancer among siblings and offspring of case patients (OR = 4.14; 95 percent CI, 0.88–19.46; p = 0.07). They also reported approximately twofold increases in risk of breast cancer among mothers (OR = 2.52; 95 percent CI, 1.21–5.24) and sisters (OR = 2.07; 95 percent CI, 0.99–4.31) of lung cancer patients who were nonsmokers. On the other hand, Kreuzer and colleagues (2002) reported no evidence of familial risk in 234 lung cancer probands who were female nonsmokers.

Other investigators have reported familial aggregation of lung cancer among relatives of case patients who were nonsmokers with early-onset of lung cancer (at ≤60 years of age). Schwartz and colleagues (1996) noted that family members of these case patients (aged 40 to 59 years) had a sixfold increase in risk of lung cancer after adjustments for the age, gender, and race of each relative. In a subsequent study involving 118 population-based pro-bands, Schwartz and colleagues (1999) also showed that family members of case patients younger than 40 years of age who had lung cancer were at increased risk for other cancers. Kreuzer and colleagues (1998) concluded that lung cancer in a first-degree relative was associated with a 2.6-fold increase in risk of lung cancer among young case patients younger than 46 years of age. Elevated risk was not detected in older case patients. A study in Germany of 945 lung cancer cases and 983 controls reported increased risk of lung cancer among first-degree relatives (RR = 1.7; 95 percent CI, 1.1–2.5) and a 4.75-fold increase in risk among relatives of probands younger than 50 years of age who had a diagnosis of lung cancer (Bromen et al. 2000). Radzikowska and colleagues (2001) also noted stronger evidence from a study in Poland for aggregation of cancers among 757 patients with lung cancer who were younger than 50 years of age.

On the other hand, Etzel and colleagues (2003) observed the familial aggregation of lung cancer and smoking-related cancers in late-onset lung cancers in persons older than 55 years of age, but not in early-onset lung cancers. An advantage of this study was the ability to adjust for the smoking status of the relatives. The study noted an excess of cancer among relatives of probands who were current smokers but not among relatives of lifetime nonsmokers. More recently, Li and Hemminki (2004) evaluated familial risks by using data from the Swedish Family Cancer Database and demonstrated that the his-tologic type of lung cancer in relatives was generally random. These researchers also estimated that 25 percent of familial lung cancers were diagnosed before 50 years of age, which represented about 1.6 percent of all lung cancers before 68 years of age.

However, a cohort study of lung cancer mortality among male twins showed no role for genetic predisposition (Braun et al. 1994). Li and colleagues (1998b) used a parametric likelihood approach and adjustment for shared covariates to study familial association in the age at onset that they hypothesized to be attributable to genetic factors. The analysis indicated that a history of smoking, exposure to secondhand smoke, and chronic obstructive airway disease were all associated with lung cancer risk. After adjustments were made for these factors, there was little evidence of familial aggregation.

In a recent series with high-risk multiplex families, Bailey-Wilson and colleagues (2004) mapped a major susceptibility locus of lung cancer through a genome-wide linkage analysis to chromosome 6q23–25 near the PARKIN gene, which carries predisposition for a significantly increased hereditary risk of lung cancer. A study of this locus also indicated presence of gene-environment interaction, and even light smoking by carriers of this gene significantly increased the risk for lung cancer compared with that among heavy smokers. Carriers who did not smoke had much lower risk, comparable to risk for noncarriers. This finding indicated existence of a sensitive group of persons for whom any amount of smoking is deleterious.

Studies have also presented evidence of Mendelian inheritance in lung cancer. Sellers and colleagues (1990) found that the pattern of occurrence of lung cancer was compatible with the Mendelian codominant inheritance of a rare and major autosomal gene. However, a similar study of families with lung cancer probands who did not smoke revealed no evidence for a major gene model and reported that an environmental model best explained the segregation pattern in the data (Yang et al. 1997). Gauderman and Morrison (2000) determined that when the same data were analyzed but missing data for smoking behaviors were produced from modeling techniques, a single autosomal dominant locus provided a slightly better fit than the codominant model suggested by Sellers and colleagues (1990). In addition to possible etiologic heterogeneity, the inconsistency of these findings may be partly due to the insufficient power for the statistical analysis of limited sample sizes. A reanalysis by Yang and colleagues (1999) found evidence of a major gene with the Mendelian codominant model in the families of probands of nonsmokers younger than 60 years of age. This analysis rejected both the codominant and environmental models and suggested that multiple genetic and/or environmental factors contribute to the age at onset of lung cancer. Therefore, researchers need more complex genetic models for the distribution of age at onset.

Xu and colleagues (2005) completed a segregation analysis on 14,378 persons from 1,561 case families with aggregation of lung cancer. In their modeling, these researchers adjusted for the effects of smoking, gender, and age. This work provided evidence for a model involving multiple gene loci and interactions that contribute to the age at onset of lung cancer.

One caveat that applies to all of these studies is the validity of data on family history, an issue indirectly addressed in an evaluation of family histories of cancer in participants in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (Pinsky et al. 2003). The data showed that in the ratios of reported-to-expected rates of cancer in family members, there were important differences in rates of reporting family history of cancer according to the gender, race, ethnicity, and age of the respondents. These differences were mostly due to underreporting with respect to these covariates. Ziogas and Anton-Culver (2003) found that family histories of cancer reported by probands were more accurate for first-degree relatives and that probands referred through clinics had lower false-positive rates for reporting of family history than did population-based probands. Bondy and colleagues (1994) evaluated the accuracy of cancer diagnosis reported by probands among family members by comparing reported cancer information with documentation available through medical records and death certificates. The study noted high levels of accuracy for cancers of first-degree relatives, as evidenced by agreement between reporting by probands and information in records. Thus, these findings of familial aggregation suggest a role for the inherited susceptibility of lung cancer beyond that associated with familial clustering of smoking behaviors, taking into account family size and structure.

A genomewide association study in 2008 identified a region of strong linkage disequilibrium on the long arm of chromosome 15 as a susceptibility locus for lung cancer (Amos et al. 2008). Studies replicating this association have focused attention on the most likely candidate genes in this region, CHRNA3 and CHRNA5, which encode subunits of the nAChR (Hung et al. 2008). Le Marchand and colleagues (2008) found that carriers of the lung-cancer-associated variants in these genes extract more nicotine and are thus exposed to a higher internal dose of carcinogenic nicotine-derived nitrosamines. SNPs in the same region have also been associated with nicotine dependence and smoking intensity (Caporaso et al. 2009).

Evidence Summary

Although cigarette smoke contains diverse carcinogens, PAH, N-nitrosamines, aromatic amines, 1,3-butadiene, benzene, aldehydes, and ethylene oxide are among the most important carcinogens because of their carcinogenic potency and levels in cigarette smoke. Moreover, the major pathways of metabolic activation and detoxification of some of the principal carcinogens in cigarette smoke are well established. Reactive intermediate agents critical in forming DNA adducts include diol epoxides of PAH, diazonium ions generated by α-hydroxylation of nitrosamines, nitrenium ions formed from esters of N-hydroxylated aromatic amines, and epoxides such as ethylene oxide. Glutathione and glucuronide conjugation play major roles in detoxification of carcinogens in cigarette smoke.

Familial predisposition and genetic polymorphisms may play a role in tobacco-related neoplasms. Researchers have established cigarette smoking as a major cause of lung cancer; more than 85 percent of lung cancers are attributable to smoking. However, not all smokers develop lung cancer, and lung cancer can arise in lifetime non-smokers. This variation in disease has stimulated interest in molecular epidemiology of genetic polymorphisms, including genes that regulate the cell cycle and genes for carcinogen-metabolizing enzymes that may lead to variations in susceptibility to the carcinogens in tobacco smoke. Studies to date suggest a role for these genetic polymorphisms in the risk of lung and bladder cancer in smokers, and they support the possibility of interactions between genes and smoking status.

Quantitative analysis of carcinogens or their metabolites in urine, breath, and blood provides a convenient and reliable method of comparing exposure to carcinogens among smokers and between smokers and non-smokers. Urinary biomarkers of several major types of carcinogens in cigarette smoke are reliable indicators of exposure, and the measurements provide good estimates of minimum doses of relevant carcinogens in smokers and allow comparisons with nonsmokers. The total carcinogen dose is generally difficult to calculate because the extent of conversion of a given carcinogen to the measured metabolite is usually unknown. However, relative carcinogen levels in cigarettes generally correlate with metabolite levels in urine. Comparisons of smokers and nonsmokers demonstrate that total NNAL is the most discriminatory biomarker in that tobacco products are the only source of the parent carcinogen NNK.

Evidence is overwhelming that DNA adduct levels are higher in most tissues of smokers than in corresponding tissues of nonsmokers. This observation provides bedrock support for the major pathway of cancer induction in smokers that proceeds through formation of DNA adducts and genetic damage. Studies of specific adducts are still scarce and are limited mainly to human lung tissue. Strong evidence supports the presence of a variety of specific adducts in the human lung, and in several studies, adduct levels are higher in smokers than in nonsmokers. Collectively, the results of these biomarker studies clearly demonstrate the potential for genetic damage in smokers from the persistence of DNA adducts.

Adducts lead to mutations that drive the process of tumor formation and progression through additional genetic alterations. Chromosomal losses are more common in tumors from smokers. Furthermore, inactivating mutations of the TP53 tumor-suppressor gene and activating mutations of the KRAS oncogene in NSCLCs and other tumors are correlated with exposure to cigarette smoke, and they contribute to a phenotype that reduces survival time in both early and advanced stages of the disease. Different types of lung cancer in smokers all show an excess of G→T transversions compared with cancers that are not related to exposure to tobacco smoke. The site specificity of mutagenesis by PAH diol epoxides implies that targeted adduct formation, in addition to phenotypic selection, is responsible for shaping the TP53 mutational spectrum in lung tumors. Propagation of these genetic alterations during clonal outgrowth is consistent with accumulation of multiple genetic changes observed in progression of lung cancer.

Gene promoter hypermethylation is an epigenetic change involving extensive methylation at the 5-position of C in CpG islands within the promoter region and often extending into exon 1 of regulatory genes. The end result of this process can be loss of gene transcription and therefore the silencing of gene function. Promoter methylation of several genes including P16 occurs early in tumor formation. P16 methylation was significantly associated with pack-years of smoking and was an independent risk factor for shorter survival in patients with early resectable adenocarcinomas. Other genes such as RASSF1A may be more frequently methylated in various tumor types from smokers. Methylation of genes, such as AGT promoter hypermethylation, may increase G→A transition mutations at CpG sites within the TP53 gene in NSCLC.

The activation of nAChRs in lung epithelial cells by nicotine or NNK promotes survival and proliferation of cancer cells and also leads to increased angiogenesis. Activation of cell-surface receptors induced by components of tobacco smoke and subsequent activation of cytoplasmic kinases stimulate other proteins that dictate cellular responses, such as cell survival and proliferation. Although activated kinases have many downstream targets, the two most studied are the transcription factor NF-κB and proteins in the BCL-2 family. Activation of key intracellular proteins by tobacco smoke components through signaling cascades promotes processes that are important for initiation, progression, and maintenance of cancer. Apoptosis, the normal mechanism of endogenous cell elimination, is also commonly suppressed in lung cancer by these components. Thus, key genetic and epigenetic events that lead to cancer causation, as well as critical cellular pathways that further growth and development of transformed cells, are directly targeted by components of cigarette smoke individually and in combination as a potent carcinogenic mixture.


  1. The doses of cigarette smoke carcinogens resulting from inhalation of tobacco smoke are reflected in levels of these carcinogens or their metabolites in the urine of smokers. Certain biomarkers are associated with exposure to specific cigarette smoke carcinogens, such as urinary metabolites of the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1- butanone and hemoglobin adducts of aromatic amines.
  2. The metabolic activation of cigarette smoke carcinogens by cytochrome P-450 enzymes has a direct effect on the formation of DNA adducts.
  3. There is consistent evidence that a combination of polymorphisms in the CYP1A1 and GSTM1 genes leads to higher DNA adduct levels in smokers and higher relative risks for lung cancer than in those smokers without this genetic profile.
  4. Carcinogen exposure and resulting DNA damage observed in smokers results directly in the numerous cytogenetic changes present in lung cancer.
  5. Smoking increases the frequency of DNA adducts of cigarette smoke carcinogens such as benzo[a]pyrene and tobacco-specific nitrosamines in the lung and other organs.
  6. Exposure to cigarette smoke carcinogens leads to DNA damage and subsequent mutations in TP53 and KRAS in lung cancer.
  7. There is consistent evidence that smoking leads to the presence of promoter methylation of key tumor suppressor genes such as P16 in lung cancer and other smoking-caused cancers.
  8. There is consistent evidence that smoke constituents such as nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone can activate signal transduction pathways directly through receptor-mediated events, allowing the survival of damaged epithelial cells that would normally die.
  9. There is consistent evidence for an inherited susceptibility of lung cancer with some less common genotypes unrelated to a familial clustering of smoking behaviors.
  10. Smoking cessation remains the only proven strategy for reducing the pathogenic processes leading to cancer in that the specific contribution of many tobacco carcinogens, alone or in combination, to the development of cancer has not been identified.


  1. Abdel-Rahman SZ, Ammenheuser MM, Omiecinski CJ, Wickliffe JK, Rosenblatt JI, Ward JB Jr. Variability in human sensitivity to 1,3-butadiene: influence of polymorphisms in the 5′-flanking region of the microsomal epoxide hydrolase gene (EPHX1). Toxicological Sciences. 2005;85(1):624–31. [PMC free article: PMC4091891] [PubMed: 15716486]
  2. Abdel-Rahman SZ, El-Zein RA. The 399Gln polymorphism in the DNA repair gene XRCC1 modulates the genotoxic response induced in human lymphocytes by the tobacco-specific nitrosamine NNK. Cancer Letters. 2000;159(1):63–71. [PubMed: 10974407]
  3. Abdel-Rahman SZ, El-Zein RA, Ammenheuser MM, Yang Z, Stock TH, Morandi M, Ward JB Jr. Variability in human sensitivity to 1,3-butadiene: influence of the allelic variants of the microsomal epoxide hydrolase gene. Environmental and Molecular Mutagenesis. 2003;41(2):140–6. [PubMed: 12605384]
  4. Aboussekhra A, Biggerstaff M, Shivji MK, Vilpo JA, Moncollin V, Podust VN, Protic M, Hubscher U, Egly JM, Wood RD. Mammalian DNA nucleotide excision repair reconstituted with purified protein components. Cell. 1995;80(6):859–68. [PubMed: 7697716]
  5. Acharya S, Wilson T, Gradia S, Kane MF, Guerrette S, Marsischky GT, Kolodner R, Fishel R. hMSH2 forms specific mispair-binding complexes with hMSH3 and hMSH6. Proceedings of the National Academy of Sciences of the United States of America. 1996;93(24):13629–34. [PMC free article: PMC19374] [PubMed: 8942985]
  6. Achiwa H, Yatabe Y, Hida T, Kuroishi T, Kozaki K, Nakamura S, Ogawa M, Sugiura T, Mitsudomi T, Takahashi T. Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas. Clinical Cancer Research. 1999;5(5):1001–5. [PubMed: 10353732]
  7. Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell survival. Science. 1998;281(5381):1322–6. [PubMed: 9735050]
  8. Adjei AA. Blocking oncogenic Ras signaling for cancer therapy. Journal of the National Cancer Institute. 2001a;93(14):1062–74. [PubMed: 11459867]
  9. Adjei AA. Ras signaling pathway proteins as therapeutic targets. Current Pharmaceutical Design. 2001b;7(16):1581–94. [PubMed: 11562300]
  10. Agathanggelou A, Bièche I, Ahmed-Choudhury J, Nicke B, Dammann R, Baksh S, Gao B, Minna JD, Downward J, Maher ER, et al. Identification of novel gene expression targets for the Ras association domain family 1 (RASSF1A) tumor suppressor gene in non-small cell lung cancer and neuroblastoma. Cancer Research. 2003;63(17):5344–51. [PMC free article: PMC3484890] [PubMed: 14500366]
  11. Ahrendt SA, Hu Y, Buta M, McDermott MP, Benoit N, Yang SC, Wu L, Sidransky D. p53 Mutations and survival in stage I non-small-cell lung cancer: results of a prospective study. Journal of the National Cancer Institute. 2003;95(13):961–70. [PubMed: 12837832]
  12. Ai L, Stephenson KK, Ling W, Zuo C, Mukunyadzi P, Suen JY, Hanna E, Fan CY. The p16 (CDKN2a/INK4a) tumor-suppressor gene in head and neck squamous cell carcinoma: a promoter methylation and protein expression study in 100 cases. Modern Pathology. 2003;16(9):944–50. [PubMed: 13679459]
  13. Alavanja MC, Brown CC, Swanson C, Brownson RC. Saturated fat intake and lung cancer risk among nonsmoking women in Missouri. Journal of the National Cancer Institute. 1993;85(23):1906–16. [PubMed: 8230280]
  14. Alavanja MC, Field RW, Sinha R, Brus CP, Shavers VL, Fisher EL, Curtain J, Lynch CF. Lung cancer risk and red meat consumption among Iowa women. Lung Cancer. 2001;34(1):37–46. [PubMed: 11557111]
  15. Alexandrie A-K, Nyberg F, Warholm M, Rannug A. Influence of CYP1A1, GSTM1, GSTT1, and NQO1 genotypes and cumulative smoking dose on lung cancer risk in a Swedish population. Cancer Epidemiology, Biomarkers & Prevention. 2004;13(6):908–14. [PubMed: 15184245]
  16. Alexandrie A-K, Sundgerg MI, Seidegård J, Tornling G, Rannug A. Genetic susceptibility to lung cancer with special emphasis on CYP1A1 and GSTM1: a study on host factors in relation to age at onset, gender and histological cancer types. Carcinogenesis. 1994;15(9):1785–90. [PubMed: 7923570]
  17. Alexandrie A-K, Warholm M, Carstensen U, Axmon A, Hagmar L, Levin JO, Östman C, Rannug A. CYP1A1 and GSTM1 polymorphisms affect urinary 1-hydroxypyrene levels after PAH exposure. Carcinogenesis. 2000;21(4):669–76. [PubMed: 10753202]
  18. Alexandrov K, Cascorbi I, Rojas M, Bouvier G, Kriek E, Bartsch H. CYP1A1 and GSTM1 genotypes affect benzo[a]pyrene DNA adducts in smokers’ lung: comparison with aromatic/hydrophobic adduct formation. Carcinogenesis. 2002;23(12):1969–77. [PubMed: 12507920]
  19. Al-Tassan N, Chmiel NH, Maynard J, Fleming N, Livingston AL, Williams GT, Hodges AK, Davies DR, David SS, Sampson JR, et al. Inherited variants of MYH associated with somatic G:C→T:A mutations in colorectal tumors. Nature Genetics. 2002;30(2):227–32. [PubMed: 11818965]
  20. Amann J, Kalyankrishna S, Massion PP, Ohm JE, Girard L, Shigematsu H, Peyton M, Juroske D, Huang Y, Stuart Salmon J, et al. Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Research. 2005;65(1):226–35. [PubMed: 15665299]
  21. Ambs S, Bennett WP, Merriam WG, Ogunfusika MO, Oser SM, Harrington AM, Shields PG, Felley-Bosco E, Hussain P, Harris CC. Relationship between p53 mutations and inducible nitric oxide synthase expression in human colorectal cancer. Journal of the National Cancer Institute. 1999;91(1):86–8. [PubMed: 9890175]
  22. Amos CI, Wu X, Broderick P, Gorlov IP, Gu J, Eisen T, Dong Q, Zhang Q, Gu X, Vijayakrishnan J, et al. Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nature Genetics. 2008;40(5):616–22. [PMC free article: PMC2713680] [PubMed: 18385676]
  23. Anderson LM, Carter JP, Logsdon DL, Driver CL, Kovatch RM. Characterization of ethanol’s enhancement of tumorigenesis by N-nitrosodimethylamine in mice. Carcinogenesis. 1992;13(11):2107–11. [PubMed: 1423883]
  24. Anderson LM, Souliotis VL, Chhabra SK, Moskal TJ, Harbaugh SD, Kyrtopoulos SA. N-nitrosodimethyl-amine-derived O6-methylguanosine in DNA of monkey gastrointestinal and urogenital organs and enhancement by ethanol. International Journal of Cancer. 1996;66(1):130–4. [PubMed: 8608956]
  25. Anderson WF, Umar A, Viner JL, Hawk ET. The role of cyclooxygenase inhibitors in cancer prevention. Current Pharmaceutical Design. 2002;8(12):1035–62. [PubMed: 11945150]
  26. Angel P, Karin M. The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochimica et Biophysica Acta. 1991;1072(2–3):129–57. [PubMed: 1751545]
  27. Angerer J, Mannschreck C, Gündel J. Biological monitoring and biochemical effect monitoring of exposure to polycyclic aromatic hydrocarbons. International Archives of Occupational and Environmental Health. 1997;70(6):365–77. [PubMed: 9439982]
  28. Anto RJ, Mukhopadhyay A, Shishodia S, Gairola CG, Aggarwal BB. Cigarette smoke condensate activates nuclear transcription factor-κB through phosphorylation and degradation of IκBα: correlation with induction of cyclooxygenase-2. Carcinogenesis. 2002;23(9):1511–8. [PubMed: 12189195]
  29. Antonyak MA, Moscatello DK, Wong AJ. Constitutive activation of c-Jun N-terminal kinase by a mutant epidermal growth factor receptor. Journal of Biological Chemistry. 1998;273(5):2817–22. [PubMed: 9446590]
  30. Anttila S, Hirvonen A, Husgafvel-Pursiainen K, Karjalainen A, Nurminen T, Vainio H. Combined effect of CYP1A1 inducibility and GSTM1 polymorphism on histologic type of lung cancer. Carcinogenesis. 1994;15(6):1133–5. [PubMed: 8020145]
  31. Araújo SJ, Tirode F, Coin F, Pospiech H, Syväoja JE, Stucki M, Hübscher U, Egly J-M, Wood RD. Nucleotide excision repair of DNA with recombinant human proteins: definition of the minimal set of factors, active forms of TFIIH, and modulation by CAK. Genes & Development. 2000;14(3):349–59. [PMC free article: PMC316364] [PubMed: 10673506]
  32. Asami S, Manabe H, Miyake J, Tsurudome Y, Hirano T, Yamaguchi R, Itoh H, Kasai H. Cigarette smoking induces an increase in oxidative DNA damage, 8-hydroxydeoxyguanosine, in a central site of the human lung. Carcinogenesis. 1997;18(9):1763–6. [PubMed: 9328173]
  33. Aspinwall R, Rothwell DG, Roldan-Arjona T, Anselmino C, Ward CJ, Cheadle JP, Sampson JR, Lindahl T, Harris PC, Hickson ID. Cloning and characterization of a functional human homolog of Escherichia coli endonuclease III. Proceedings of the National Academy of Sciences of the United States of America. 1997;94(1):109–14. [PMC free article: PMC19249] [PubMed: 8990169]
  34. Athas WF, Hedayati MA, Matanoski GM, Farmer ER, Grossman L. Development and field-test validation of an assay for DNA repair in circulating human lymphocytes. Cancer Research. 1991;51(21):5786–93. [PubMed: 1933849]
  35. Aviel-Ronen S, Blackhall FH, Shepherd FA, Tsao MS. K-ras mutations in non-small-cell lung carcinoma: a review. Clinical Lung Cancer. 2006;8(1):30–8. [PubMed: 16870043]
  36. Badawi AF, Habib SL, Mohammed MA, Abadi AA, Michael MS. Influence of cigarette smoking on prostaglandin synthesis and cyclooxygenase-2 gene expression in human urinary bladder cancer. Cancer Investigation. 2002;20(5–6):651–6. [PubMed: 12197220]
  37. Badawi AF, Hirvonen A, Bell DA, Lang NP, Kadlubar FF. Role of aromatic amine acetyltransferases, NAT1 and NAT2, in carcinogen-DNA adduct formation in the human urinary bladder. Cancer Research. 1995;55(22):5230–7. [PubMed: 7585581]
  38. Bailey-Wilson JE, Amos CI, Pinney SM, Petersen GM, de Andrade M, Wiest JS, Fain P, Schwartz AG, You M, Franklin W, et al. A major lung cancer susceptibility locus maps to chromosome 6q23–25. American Journal of Human Genetics. 2004;75(3):460–74. [PMC free article: PMC1182024] [PubMed: 15272417]
  39. Baird WM, Ralston SL. Carcinogenic polycyclic aromatic hydrocarbons. Comprehensive Toxicology: Chemical Carcinogens and Anticarcinogens. Bowden GT, Fischer SM, editors. Vol. 12. New York: Elsevier Science; 1997. pp. 171–200.
  40. Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB. Journal of Clinical Investigation. 2001;107(3):241–6. [PMC free article: PMC199203] [PubMed: 11160144]
  41. Baldwin AS Jr. The NF-κB and IκB proteins: new discoveries and insights. Annual Review of Immunology. 1996;14:649–81. [PubMed: 8717528]
  42. Balsara BR, Testa JR. Chromosomal imbalances in human lung cancer. Oncogene. 2002;21(45):6877–83. [PubMed: 12362270]
  43. Bartsch H, Ohshima H, Pignatelli B, Calmels S. Human exposure to endogenous N-nitroso compounds: quantitative estimates in subjects at high risk for cancer of the oral cavity, oesophagus, stomach and urinary bladder. Cancer Surveys. 1989;8(2):335–62. [PubMed: 2696584]
  44. Barzilay G, Walker LJ, Robson CN, Hickson ID. Site- directed mutagenesis of the human DNA repair enzyme HAP1: identification of residues important for AP endonuclease and RNase H activity. Nucleic Acids Research. 1995;23(9):1544–50. [PMC free article: PMC306895] [PubMed: 7784208]
  45. Baselga J, Arteaga CL. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. Journal of Clinical Oncology. 2005;23(11):2445–59. [PubMed: 15753456]
  46. Basu AK, Essigmann JM. Site-specifically modified oli-godeoxynucleotides as probes for the structural and biological effects of DNA-damaging agents. Chemical Research in Toxicology. 1988;1(1):1–18. [PubMed: 2979705]
  47. Bates S, Phillips AC, Clark PA, Stott F, Peters G, Ludwig RL, Vousden KH. p14ARF links the tumour suppressors RB and p53. Nature. 1998;395(6698):124–5. [PubMed: 9744267]
  48. Bauer AK, Faiola B, Abernethy DJ, Marchan R, Pluta LJ, Wong VA, Gonzalez FJ, Butterworth BE, Borghoff SJ, Everitt JI, et al. Male mice deficient in microsomal epoxide hydrolase are not susceptible to benzene- induced toxicity. Toxicological Sciences. 2003;72(2):201–9. [PubMed: 12655032]
  49. Beland FA, Fullerton NF, Heflich RH. Rapid isolation, hydrolysis and chromatography of formaldehyde-modified DNA. Journal of Chromatography A. 1984;308:121–31. [PubMed: 6746809]
  50. Belham C, Wu S, Avruch J. Intracellular signalling: PDK1 - a kinase at the hub of things. Current Biology. 1999;9(3):R93–R96. [PubMed: 10021376]
  51. Belinsky SA. Gene-promoter hypermethylation as a bio-marker in lung cancer. Nature Reviews Cancer. 2004;4(9):707–17. [PubMed: 15343277]
  52. Belinsky SA, Devereux TR, Foley JF, Maronpot RR, Anderson MW. Role of the alveolar type II cell in the development and progression of pulmonary tumors induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in the A/J mouse. Cancer Research. 1992;52(11):3164–73. [PubMed: 1591728]
  53. Belinsky SA, Dolan ME, White CM, Maronpot RR, Pegg AE, Anderson MW. Cell specific differences in O6-methylguanine-DNA methyltransferase activity and removal of O6-methylguanine in rat pulmonary cells. Carcino-genesis. 1988;9(11):2053–8. [PubMed: 3180342]
  54. Belinsky SA, Nikula KJ, Palmisano WA, Michels R, Saccomanno G, Gabrielson E, Baylin SB, Herman JG. Aberrant methylation of p16INK4a is an early event in lung cancer and a potential biomarker for early diagnosis. Proceedings of the National Academy of Sciences of the United States of America. 1998;95(20):11891–6. [PMC free article: PMC21736] [PubMed: 9751761]
  55. Belinsky SA, Palmisano WA, Gilliland FD, Crooks LA, Divine KK, Winters SA, Grimes MJ, Harms HJ, Tellez CS, Smith TM, et al. Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers. Cancer Research. 2002;62(8):2370–7. [PubMed: 11956099]
  56. Benamira M, Singh U, Marnett LJ. Site-specific frame-shift mutagenesis by a propanodeoxyguanosine adduct positioned in the (CpG)4 hot-spot of Salmonella typhimurium hisD3052 carried on an M13 vector. Journal of Biological Chemistry. 1992;267(31):22392–400. [PubMed: 1429591]
  57. Benhamou S, Lee WJ, Alexandrie A-K, Boffetta P, Bouchardy C, Butkiewicz D, Brockmöller J, Clapper ML, Daly A, Dolzan V, et al. Meta- and pooled analyses of the effects of glutathione-S-transferase M1 polymorphisms and smoking on lung cancer risk. Carcinogenesis. 2002;23(8):1343–50. [PubMed: 12151353]
  58. Benhamou S, Reinikainen M, Bouchardy C, Dayer P, Hirvonen A. Association between lung cancer and microsomal epoxide hydrolase genotypes. Cancer Research. 1998;58(23):5291–3. [PubMed: 9850050]
  59. Benhamou S, Sarasin A. ERCC2/XPD gene polymorphisms and lung cancer: a HuGE review. American Journal of Epidemiology. 2005;161(1):1–14. [PubMed: 15615908]
  60. Bennett WP, Colby TV, Travis WD, Borkowski A, Jones RT, Lane DP, Metcalf RA, Samet JM, Takeshima Y, Gu JR, et al. p53 Protein accumulates frequently in early bronchial neoplasia. Cancer Research. 1993;53(20):4817–22. [PubMed: 8402667]
  61. Bennett WP, Hussain SP, Vahakangas KH, Khan MA, Shields PG, Harris CC. Molecular epidemiology of human cancer risk: gene-environment interactions and p53 mutation spectrum in human lung cancer. Journal of Pathology. 1999;187(1):8–18. [PubMed: 10341702]
  62. Bergmark E. Hemoglobin adducts of acrylamide and acrylonitrile in laboratory workers, smokers and non-smokers. Chemical Research in Toxicology. 1997;10(1):78–84. [PubMed: 9074806]
  63. Bernardini S, Hirvonen A, Pelin K, Norppa H. Induction of sister chromatid exchange by 1,2-epoxy-3-butene in cultured human lymphocytes: influence of GSTT1 genotype. Carcinogenesis. 1998;19(2):377–80. [PubMed: 9498293]
  64. Berwick M, Vineis P. Markers of DNA repair and susceptibility to cancer in humans: an epidemiologic review. Journal of the National Cancer Institute. 2000;92(11):874–97. [PubMed: 10841823]
  65. Besaratinia A, Bates SE, Pfeifer GP. Mutational signature of the proximate bladder carcinogen N-hydroxy-4-acetylaminobiphenyl: inconsistency with the p53 mutational spectrum in bladder cancer. Cancer Research. 2002;62(15):4331–8. [PubMed: 12154037]
  66. Betticher DC, Thatcher N, Altermatt HJ, Hoban P, Ryder WDJ, Heighway J. Alternate splicing produces a novel cyclin D1 transcript. Oncogene. 1995;11(5):1005–11. [PubMed: 7675441]
  67. Betticher DC, White GRM, Vonlanthen S, Liu X, Kappeler A, Altermatt HJ, Thatcher N, Heighway J. G1 control gene status is frequently altered in resectable non-small cell lung cancer. International Journal of Cancer. 1997;74(5):556–62. [PubMed: 9355981]
  68. Birgander R, Själander A, Rannug A, Alexandrie A-K, Sundberg MI, Seidegård J, Tornling G, Beckman G, Beckman L. P53 polymorphisms and haplotypes in lung cancer. Carcinogenesis. 1995;16(9):2233–6. [PubMed: 7554081]
  69. Biroš E, Kalina I, Kohút A, Štubňa J, Šalagovič J. Germ line polymorphisms of the tumor suppressor gene p53 and lung cancer. Lung Cancer. 2001;31(2–3):157–62. [PubMed: 11165394]
  70. Bjørås M, Luna L, Johnsen B, Hoff E, Haug T, Rognes T, Seeberg E. Opposite base-dependent reactions of a human base excision repair enzyme on DNA containing 7,8-dihydro-8-oxoguanine and abasic sites. EMBO Journal. 1997;16(20):6314–22. [PMC free article: PMC1326315] [PubMed: 9321410]
  71. Blackhall FH, Pintilie M, Michael M, Leighl N, Feld R, Tsao M-S, Shepherd FA. Expression and prognostic significance of kit, protein kinase B, and mitogen-activated protein kinase in patients with small cell lung cancer. Clinical Cancer Research. 2003;9(6):2241–7. [PubMed: 12796392]
  72. Blömeke B, Greenblatt MJ, Doan VD, Bowman ED, Murphy SE, Chen CC, Kato S, Shields PG. Distribution of 7-alkyl-2′-deoxyguanosine adduct levels in human lung. Carcinogenesis. 1996;17(4):741–8. [PubMed: 8625485]
  73. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature. 2001;411(6835):355–65. [PubMed: 11357143]
  74. Bock KW. Roles of UDP-glucuronosyltransferases in chemical carcinogenesis. Critical Reviews in Biochemistry and Molecular Biology. 1991;26(2):129–50. [PubMed: 1914494]
  75. Boffetta P, Nyberg F, Mukeria A, Benhamou S, Constantinescu V, Batura-Gabryel H, Brüske-Hohlfeld I, Schmid G, Simonato L, Pelkonen P, et al. O6-alkylguanine-DNA-alkyltransferase activity in peripheral leukocytes, smoking and risk of lung cancer. Cancer Letters. 2002;180(1):33–9. [PubMed: 11911967]
  76. Boffetta P, Pershagen G, Jöckel K-H, Forastiere F, Gaborieau V, Heinrich J, Jahn I, Kreuzer M, Merletti F, Nyberg F, et al. Cigar and pipe smoking and lung cancer risk: a multicenter study from Europe. Journal of the National Cancer Institute. 1999;91(8):697–701. [PubMed: 10218507]
  77. Bolt HM, Roos PH, Thier R. The cytochrome P-450 isoenzyme CYP2E1 in the biological processing of industrial chemicals: consequences for occupational and environmental medicine. International Archives of Occupational and Environmental Health. 2003;76(3):174–85. [PubMed: 12690492]
  78. Bondy ML, Strom SS, Colopy MW, Brown BW, Strong LC. Accuracy of family history of cancer obtained through interviews with relatives of patients with childhood sarcoma. Journal of Clinical Epidemiology. 1994;47(1):89–96. [PubMed: 8283198]
  79. Boogaard PJ, van Sittert NJ. Biological monitoring of exposure to benzene: a comparison between S-phenylmercapturic acid, trans, trans-muconic acid, and phenol. Occupational and Environmental Medicine. 1995;52(9):611–20. [PMC free article: PMC1128315] [PubMed: 7550802]
  80. Boogaard PJ, van Sittert NJ. Suitability of S-phenyl mercapturic acid and trans-trans-muconic acid as bio-markers for exposure to low concentrations of benzene. Environmental Health Perspectives. 1996;104(Suppl 6):1151–7. [PMC free article: PMC1469762] [PubMed: 9118886]
  81. Bouchardy C, Mitrunen K, Wikman H, Husgafvel-Pursiainen K, Dayer P, Benhamou S, Hirvonen A. N-acetyltransferase NAT1 and NAT2 genotypes and lung cancer risk. Pharmacogenetics. 1998;8(4):291–8. [PubMed: 9731715]
  82. Boysen G, Georgieva NI, Upton PB, Walker VE, Swenberg JA. N-terminal globin adducts as biomarkers for formation of butadiene derived epoxides. Chemico-Biological Interactions. 2007;166(1–3):84–92. [PubMed: 17084829]
  83. Boysen G, Hecht SS. Analysis of DNA and protein adducts of benzo[a]pyrene in human tissues using structure-specific methods. Mutation Research. 2003;543(1):17–30. [PubMed: 12510015]
  84. Branch P, Aquilina G, Bignami M, Karran P. Defective mismatch binding and a mutator phenotype in cells tolerant to DNA damage. Nature. 1993;362(6421):652–4. [PubMed: 8464518]
  85. Braun MM, Caporaso NE, Page WF, Hoover RN. Genetic component of lung cancer: cohort study of twins. Lancet. 1994;344(8920):440–3. [PubMed: 7914565]
  86. Brennan JA, Boyle JO, Koch WM, Goodman SN, Hruban RH, Eby YJ, Couch MJ, Forastiere AA, Sidransky D. Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. New England Journal of Medicine. 1995;332(11):712–7. [PubMed: 7854378]
  87. Brennan P, Hsu CC, Moullan N, Szeszenia-Dabrowska N, Lissowska J, Zaridze D, Rudnai P, Fabianova E, Mates D, Bencko V, et al. Effect of cruciferous vegetables on lung cancer in patients stratified by genetic status: a mendelian randomisation approach. Lancet. 2005;366(9496):1558–60. [PubMed: 16257343]
  88. Brognard J, Clark AS, Ni Y, Dennis PA. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Research. 2001;61(10):3986–97. [PubMed: 11358816]
  89. Bromen K, Pohlabeln H, Ingeborg J, Ahrens W, Jöckel K-H. Aggregation of lung cancer in families: results from a population-based case-control study in Germany. American Journal of Epidemiology. 2000;152(6):497–505. [PubMed: 10997539]
  90. Bronstein SM, Hooth MJ, Swenberg JA, Skopek TR. Modulation of ethylnitrosourea-induced toxicity and mutagenicity in human cells by O6-benzylguanine. Cancer Research. 1992;52(14):3851–6. [PubMed: 1617659]
  91. Brose MS, Volpe P, Feldman M, Kumar M, Rishi I, Gerrero R, Einhorn E, Herlyn M, Minna J, Nicholson A, et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Research. 2002;62(23):6997–7000. [PubMed: 12460918]
  92. Browman GP, Wong G, Hodson I, Sathya J, Russell R, McAlpine L, Skingley P, Levine MN. Influence of cigarette smoking on the efficacy of radiation therapy in head and neck cancer. New England Journal of Medicine. 1993;328(3):159–63. [PubMed: 8417381]
  93. Brown CD, Wong BA, Fennell TR. In vivo and in vitro kinetics of ethylene oxide metabolism in rats and mice. Toxicology and Applied Pharmacology. 1996;136(1):8–19. [PubMed: 8560484]
  94. Brownson RC, Alavanja MCR, Caporaso N, Berger E, Chang JC. Family history of cancer and risk of lung cancer in lifetime non-smokers and long-term ex-smokers. International Journal of Epidemiology. 1997;26(2):256–63. [PubMed: 9169159]
  95. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden KC, Blenis J, Greenberg ME. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell. 1999;96(6):857–68. [PubMed: 10102273]
  96. Burbee DG, Forgacs E, Zöchbauer-Müeler S, Shivakumar L, Fong K, Gao B, Randle D, Kondo M, Virmani A, Bader S, et al. Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. Journal of the National Cancer Institute. 2001;93(9):691–9. [PMC free article: PMC4374741] [PubMed: 11333291]
  97. Burchell B. Genetic variation of human UDP-glucuronosyltransferase: implications in disease and drug glucuronidation. American Journal of Pharmacogenomics. 2003;3(1):37–52. [PubMed: 12562215]
  98. Burdick AD, Davis JW II, Liu KJ, Hudson LG, Shi H, Monske ML, Burchiel SW. Benzo(a)pyrene quinones increase cell proliferation, generate reactive oxygen species, and transactivate the epidermal growth factor receptor in breast epithelial cells. Cancer Research. 2003;63(22):7825–33. [PubMed: 14633709]
  99. Burger RM, Peisach J, Horwitz SB. Mechanism of bleomycin action: in vitro studies. Life Sciences. 1981;28(7):715–27. [PubMed: 6164898]
  100. Butkiewicz D, Popanda O, Risch A, Edler L, Dienemann H, Schulz V, Kayser K, Drings P, Bartsch H, Schmezer P. Association between the risk for lung adenocarcinoma and a (–4) G-to-A polymorphism in the XPA gene. Cancer Epidemiology, Biomarkers & Prevention. 2004;13(12):2242–6. [PubMed: 15598786]
  101. Butkiewicz D, Rusin M, Enewold L, Shields PG, Chorazy M, Harris CC. Genetic polymorphisms in DNA repair genes and risk of lung cancer. Carcinogenesis. 2001;22(4):593–7. [PubMed: 11285194]
  102. Butkiewicz D, Rusin M, Harris CC, Chorazy M. Identification of four single nucleotide polymorphisms in DNA repair genes: XPA and XPB (ERCC3) in Polish population. Human Mutation. 2000;15(6):577–8. [PubMed: 10862089]
  103. Butler MA, Iwasaki M, Guengerich FP, Kadlubar FF. Human cytochrome P-450PA (P-450IA2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proceedings of the National Academy of Sciences of the United States of America. 1989;86(20):7696–700. [PMC free article: PMC298137] [PubMed: 2813353]
  104. Byrd GD, Ogden MW. Liquid chromatographic/tandem mass spectrometric method for the determination of the tobacco-specific nitrosamine metabolite NNAL in smokers’ urine. Journal of Mass Spectrometry. 2003;38(1):98–107. [PubMed: 12526011]
  105. Cabral Neto JB, Caseira Cabral RE, Margot A, Le Page F, Sarasin A, Gentil A. Coding properties of a unique apurinic/apyrimidinic site replicated in mammalian cells. Journal of Molecular Biology. 1994;240(5):416–20. [PubMed: 8046747]
  106. Cai YC, Yang G-Y, Nie Y, Wang L-D, Zhao X, Song Y-L, Seril DN, Liao J, Xing EP, Yang CS. Molecular alterations of p73 in human esophageal squamous cell carcinomas: loss of heterozygosity occurs frequently; loss of imprinting and elevation of p73 expression may be related to defective p53. Carcinogenesis. 2000;21(4):683–9. [PubMed: 10753204]
  107. Cajas-Salazar N, Au WW, Zwischenberger JB, Sierra-Torres CH, Salama SA, Alpard SK, Tyring SK. Effect of epoxide hydrolase polymorphisms on chromosome aberrations and risk for lung cancer. Cancer Genetics and Cytogenetics. 2003;145(2):97–102. [PubMed: 12935919]
  108. Calléja F, Jansen JG, Vrieling H, Laval F, van Zeeland AA. Modulation of the toxic and mutagenic effects induced by methyl methanesulfonate in Chinese hamster ovary cells by overexpression of the rat N-alkylpurine-DNA glycosylase. Mutation Research. 1999;425(2):185–94. [PubMed: 10216211]
  109. Campbell SL, Khosravi-Far R, Rossman KL, Clark GJ, Der CJ. Increasing complexity of Ras signaling. Oncogene. 1998;17(11):1395–413. [PubMed: 9779987]
  110. Caporaso N, Gu F, Chatterjee N, Sheng-Chih J, Yu K, Yeager M, Chen C, Jacobs K, Wheeler W, Landi MT, et al. Genome-wide and candidate gene association study of cigarette smoking behaviors. PLoS ONE. 2009;4(2):e4653. [PMC free article: PMC2644817] [PubMed: 19247474] [CrossRef]
  111. Carlisle DL, Hopkins TM, Gaither-Davis A, Silhanek MJ, Luketich JD, Christie NA, Siegfried JM. Nicotine signals through muscle-type and neuronal nicotinic acetylcholine receptors in both human bronchial epithelial cells and airway fibroblasts. Respiratory Research. 2004;5(1):27. [PMC free article: PMC544394] [PubMed: 15588326]
  112. Carmella SG, Akerkar S, Hecht SS. Metabolites of the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in smokers’ urine. Cancer Research. 1993;53(4):721–4. [PubMed: 8428352]
  113. Carmella SG, Akerkar S, Richie JP Jr, Hecht SS. Intraindividual and interindividual differences in metabolites of the tobacco-specific lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in smokers’ urine. Cancer Epidemiology, Bio-markers & Prevention. 1995;4(6):635–42. [PubMed: 8547830]
  114. Carmella SG, Chen M, Villalta PW, Gurney JG, Hatsukami DK, Hecht SS. Ethylation and methylation of hemoglobin in smokers and nonsmokers. Carcinogenesis. 2002a;23(11):1903–10. [PubMed: 12419839]
  115. Carmella SG, Chen M, Yagi H, Jerina DM, Hecht SS. Analysis of phenanthrols in human urine by gas chromatography-mass spectrometry: potential use in carcinogen metabolite phenotyping. Cancer Epidemiology, Biomarkers & Prevention. 2004a;13(12):2167–74. [PubMed: 15598776]
  116. Carmella SG, Han S, Villalta PW, Hecht SS. Analysis of total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol in smokers’ blood. Cancer Epidemiology, Biomarkers & Prevention. 2005;14(11):2669–72. [PubMed: 16284395]
  117. Carmella SG, LaVoie EJ, Hecht SS. Quantitative analysis of catechol and 4-methylcatechol in human urine. Food and Chemical Toxicology. 1982;20(5):587–90. [PubMed: 6890513]
  118. Carmella SG, Le K-A, Hecht SS. Improved method for determination of 1-hydroxypyrene in human urine. Cancer Epidemiology, Biomarkers & Prevention. 2004b;13(7):1261–4. [PubMed: 15247141]
  119. Carmella SG, Le K-A, Upadhyaya P, Hecht SS. Analysis of N- and O-glucuronides of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) in human urine. Chemical Research in Toxicology. 2002b;15(4):545–50. [PubMed: 11952341]
  120. Carmella SG, Ye M, Upadhyaya P, Hecht SS. Stereochemistry of metabolites of a tobacco-specific lung carcinogen in smokers’ urine. Cancer Research. 1999;59(15):3602–5. [PubMed: 10446969]
  121. Carpenter CL, Cantley LC. Phosphoinositide kinases. Current Opinion in Cell Biology. 1996;8(2):153–8. [PubMed: 8791418]
  122. Casale GP, Singhal M, Bhattacharya S, Ramanathan R, Roberts KP, Barbacci DC, Zhao J, Jankowiak R, Gross ML, Cavalieri EL, et al. Detection and quantification of depurinated benzo[a]pyrene-adducted DNA bases in the urine of cigarette smokers and women exposed to household coal smoke. Chemical Research in Toxicology. 2001;14(2):192–201. [PubMed: 11258968]
  123. Cascorbi I, Brockmoller J, Mrozikiewicz PM, Bauer S, Loddenkemper R, Roots I. Homozygous rapid aryl-amine N-acetyltransferase (NAT2) genotype as a susceptibility factor for lung cancer. Cancer Research. 1996;56(17):3961–6. [PubMed: 8752164]
  124. Castelao JE, Yuan J-M, Skipper PL, Tannenbaum SR, Gago-Dominguez M, Crowder JS, Ross RK, Yu MC. Gender- and smoking-related bladder cancer risk. Journal of the National Cancer Institute. 2001;93(7):538–45. [PubMed: 11287448]
  125. Cerny T, Barnes DM, Hasleton P, Barber PV, Healy K, Gullick W, Thatcher N. Expression of epidermal growth factor receptor (EGF-R) in human lung tumours. British Journal of Cancer. 1986;54(2):265–9. [PMC free article: PMC2001525] [PubMed: 3017396]
  126. Chakravarti D, Ibeanu GC, Tano K, Mitra S. Cloning and expression in Escherichia coli of a human cDNA encoding the DNA repair protein N-methylpurine-DNA glycosylase. Journal of Biological Chemistry. 1991;266(24):15710–5. [PubMed: 1874728]
  127. Chang H-C, Weng C-F. Cyclooxygenase-2 level and culture conditions influence NS398-induced apoptosis and caspase activation in lung cancer cells. Oncology Reports. 2001;8(6):1321–5. [PubMed: 11605058]
  128. Chang HW, Ling GS, Wei WI, Yuen AP-W. Smoking and drinking can induce p15 methylation in the upper aerodigestive tract of healthy individuals and patients with head and neck squamous cell carcinoma. Cancer. 2004;101(1):125–32. [PubMed: 15221997]
  129. Chan-Yeung M, Tan-Un KC, Ip MSM, Tsang KWT, Ho SP, Ho JCM, Chan H, Lam WK. Lung cancer susceptibility and polymorphisms of glutathione-S-transferase genes in Hong Kong. Lung Cancer. 2004;45(2):155–60. [PubMed: 15246186]
  130. Chaw YF, Crane LE, Lange P, Shapiro R. Isolation and identification of cross-links from formaldehyde-treated nucleic acids. Biochemistry. 1980;19(24):5525–31. [PubMed: 7459328]
  131. Chen H-JC, Wu C-F, Hong C-L, Chang C-M. Urinary excretion of 3, N4-etheno-2′-deoxycytidine in humans as a biomarker of oxidative stress: association with cigarette smoking. Chemical Research in Toxicology. 2004a;17(7):896–903. [PubMed: 15257614]
  132. Chen JX, Zheng Y, West M, Tang MS. Carcinogens preferentially bind at methylated CpG in the p53 mutational hotspots. Cancer Research. 1998;58(10):2070–5. [PubMed: 9605744]
  133. Chen K-M, El-Bayoumy K, Cunningham J, Aliaga C, Li H, Melikian AA. Detection of nitrated benzene metabolites in bone marrow of B6C3F1 mice treated with benzene. Chemical Research in Toxicology. 2004b;17(3):370–7. [PubMed: 15025507]
  134. Chen P, Wiencke J, Aldape K, Kesler-Diaz A, Miike R, Kelsey K, Lee M, Liu J, Wrensch W. Association of an ERCC1 polymorphism with adult-onset glioma. Cancer Epidemiology, Biomarkers & Prevention. 2000;9(8):843–7. [PubMed: 10952103]
  135. Chen R-H, Maher VM, McCormick JJ. Effect of excision repair by diploid human fibroblasts on the kinds and locations of mutations induced by (±)-7β,8α-dihydroxy-9α,10α-epoxy-7,8,9,10-tetrahydrobenzo[a] pyrene in the coding region of the HPRT gene. Proceedings of the National Academy of Sciences of the United States of America. 1990;87(21):8680–4. [PMC free article: PMC55021] [PubMed: 2122466]
  136. Chen W-C, Wu H-C, Hsu C-D, Chen H-Y, Tsai F-J. p21 Gene codon 31 polymorphism is associated with bladder cancer. Urologic Oncology. 2002;7(2):63–6. [PubMed: 12474524]
  137. Cheng EH, Wei MC, Weiler S, Flavell RA, Mak TW, Lindsten T, Korsmeyer SJ. BCL-2, BCL-XL sequester BH3 domain-only molecules preventing BAX- and BAK- mediated mitochondrial apoptosis. Molecular Cell. 2001;8(3):705–11. [PubMed: 11583631]
  138. Cheng L, Eicher SA, Guo Z, Hong WK, Spitz MR, Wei Q. Reduced DNA repair capacity in head and neck cancer patients. Cancer Epidemiology, Biomarkers & Prevention. 1998;7(6):465–8. [PubMed: 9641488]
  139. Cheng L, Sturgis EM, Eicher SA, Char D, Spitz MR, Wei Q. Glutathione-S-transferase polymorphisms and risk of squamous-cell carcinoma of the head and neck. International Journal of Cancer. 1999;84(3):220–4. [PubMed: 10371337]
  140. Cheng T-J, Christiani DC, Xu X, Wain JC, Wiencke JK, Kelsey KT. Glutathione S-transferase μ genotype, diet, and smoking as determinants of sister chromatid exchange frequency in lymphocytes. Cancer Epidemiology, Biomarkers & Prevention. 1995;4(5):535–42. [PubMed: 7549811]
  141. Chevrier I, Stücker I, Houllier A-M, Cenee S, Beaune P, Laurent-Puig P, Loriot M-A. Myeloperoxidase: new polymorphisms and relation with lung cancer risk. Pharmacogenetics and Genomics. 2003;13(12):729–39. [PubMed: 14646692]
  142. Chiou H-L, Wu M-F, Chien W-P, Cheng Y-W, Wong R-H, Chen C-Y, Lin T-S, Lee H. NAT2 fast acetylator genotype is associated with an increased risk of lung cancer among never-smoking women in Taiwan. Cancer Letters. 2005;223(1):93–101. [PubMed: 15890241]
  143. Chipuk JE, Bhat M, Hsing AY, Ma J, Danielpour D. Bcl-xL blocks transforming growth factor-β1-induced apoptosis by inhibiting cytochrome c release and not by directly antagonizing Apaf-1-dependent caspase activation in prostate epithelial cells. Journal of Biological Chemistry. 2001;276(28):26614–21. [PubMed: 11320089]
  144. Christmann M, Tomicic MT, Roos WP, Kaina B. Mechanisms of human DNA repair: an update. Toxicology. 2003;193(1–2):3–34. [PubMed: 14599765]
  145. Church TR, Anderson KE, Caporaso NE, Geisser MS, Le CT, Zhang Y, Benoit AR, Carmella SG, Hecht SS. A prospectively measured serum biomarker for a tobacco-specific carcinogen and lung cancer in smokers. Cancer Epidemiology, Biomarkers & Prevention. 2009;18(1):260–6. [PMC free article: PMC3513324] [PubMed: 19124507]
  146. Claij N, van der Wal WA, Dekker M, Jansen L, te Riele H. DNA mismatch repair deficiency stimulates N-ethyl-N-nitrosourea-induced mutagenesis and lymphomagenesis. Cancer Research. 2003;63(9):2062–6. [PubMed: 12727820]
  147. Clark AS, West KA, Blumberg PM, Dennis PA. Altered protein kinase C (PKC) isoforms in non-small cell lung cancer cells: PKCδ promotes cellular survival and chemotherapeutic resistance. Cancer Research. 2003;63(4):780–6. [PubMed: 12591726]
  148. Cocco P, Tocco MG, Ibba A, Scano L, Ennas MG, Flore C, Randaccio FS. trans, trans-Muconic acid excretion in relation to environmental exposure to benzene. International Archives of Occupational and Environmental Health. 2003;76(6):456–60. [PubMed: 12684810]
  149. Coffer PJ, Jin J, Woodgett JR. Protein kinase B (c-Akt): a multifunctional mediator of phosphatidylinositol 3-kinase activation. Biochemical Journal. 1998;335( Pt 1):1–13. [PMC free article: PMC1219745] [PubMed: 9742206]
  150. Coggins CR. A review of chronic inhalation studies with mainstream cigarette smoke in rats and mice. Toxicologic Pathology. 1998;26(3):307–14. [PubMed: 9608635]
  151. Cohet C, Borel S, Nyberg F, Mukeria A, Brüske-Hohlfeld I, Constantinescu V, Benhamou S, Brennan P, Hall J, Boffetta P. Exon 5 polymorphisms in the O6-alkylguanine DNA alkyltransferase gene and lung cancer risk in non–smokers exposed to second-hand smoke. Cancer Epidemiology, Biomarkers & Prevention. 2004;13(2):320–3. [PubMed: 14973087]
  152. Colussi C, Parlanti E, Degan P, Aquilina G, Barnes D, Macpherson P, Karran P, Crescenzi M, Dogliotti E, Bignami M. The mammalian mismatch repair pathway removes DNA 8-oxodGMP incorporated from the oxidized dNTP pool. Current Biology. 2002;12(11):912–8. [PubMed: 12062055]
  153. Conney AH. Induction of microsomal enzymes by foreign chemicals and carcinogenesis by polycyclic aromatic hydrocarbons: G.H.A. Clowes Memorial Lecture. Cancer Research. 1982;42(12):4875–917. [PubMed: 6814745]
  154. Constantinou A, Davies AA, West SC. Branch migration and Holliday junction resolution catalyzed by activities from mammalian cells. Cell. 2001;104(2):259–68. [PubMed: 11207366]
  155. Cooper CS, Grover PL, Sims P. The metabolism and activation of benzo[a]pyrene. Progress in Drug Metabolism. Bridges JW, Chasseaud LF, editors. Vol. 7. New York: John Wiley & Sons; 1983. pp. 295–396.
  156. Cortessis VK, Siegmund K, Xue S, Ross RK, Yu MC. A case-control study of cyclin D1 CCND1 870A → G polymorphism and bladder cancer. Carcinogenesis. 2003;24(10):1645–50. [PubMed: 12896908]
  157. Cory S, Huang DCS, Adams JM. The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene. 2003;22(53):8590–607. [PubMed: 14634621]
  158. Cote ML, Kardia SLR, Wenzlaff AS, Land SJ, Schwartz AG. Combinations of glutathione S-transferase genotypes and risk of early-onset lung cancer in Caucasians and African Americans: a population-based study. Carcinogenesis. 2005;26(4):811–9. [PubMed: 15661806]
  159. Crompton NEA, Ozsahin M. A versatile and rapid assay of radiosensitivity of peripheral blood leukocytes based on DNA and surface-marker assessment of cytotoxicity. Radiation Research. 1997;147(1):55–60. [PubMed: 8989370]
  160. Crone TM, Goodtzova K, Edara S, Pegg AE. Mutations in human O6-alkylguanine-DNA alkyltransferase imparting resistance to O6-benzylguanine. Cancer Research. 1994;54(23):6221–7. [PubMed: 7954470]
  161. Dajas-Bailador FA, Soliakov L, Wonnacott S. Nicotine activates the extracellular signal-regulated kinase 1/2 via the α7 nicotinic acetylcholine receptor and protein kinase A, in SH-SY5Y cells and hippocampal neurones. Journal of Neurochemistry. 2002;80(3):520–30. [PubMed: 11905997]
  162. Dally H, Gassner K, Jäger B, Schmezer P, Spiegelhalder B, Edler L, Drings P, Dienemann H, Schulz V, Kayser K, et al. Myeloperoxidase (MPO) genotype and lung cancer histologic types: the MPO -463 A allele is associated with reduced risk for small cell lung cancer in smokers. International Journal of Cancer. 2002;102(5):530–5. [PubMed: 12432558]
  163. Dammann R, Li C, Yoon J-H, Chin PL, Bates S, Pfeifer GP. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nature Genetics. 2000;25(3):315–9. [PubMed: 10888881]
  164. Daniels DS, Mol CD, Arvai AS, Kanugula S, Pegg AE, Tainer JA. Active and alkylated human AGT structures: a novel zinc site, inhibitor and extrahelical base binding. EMBO Journal. 2000;19(7):1719–30. [PMC free article: PMC310240] [PubMed: 10747039]
  165. Dannenberg AJ, Subbaramaiah K. Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. Cancer Cell. 2003;4(6):431–6. [PubMed: 14706335]
  166. Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts. Genes & Development. 1999;13(22):2905–27. [PubMed: 10579998]
  167. David O, Jett J, LeBeau H, Dy G, Hughes J, Friedman M, Brody AR. Phospho-Akt overexpression in non–small cell lung cancer confers significant stage-independent survival disadvantage. Clinical Cancer Research. 2004;10(20):6865–71. [PubMed: 15501963]
  168. David-Beabes GL, London SJ. Genetic polymorphism of XRCC1 and lung cancer risk among African–Americans and Caucasians. Lung Cancer. 2001;34(3):333–9. [PubMed: 11714530]
  169. David-Beabes GL, Lunn RM, London SJ. No association between the XPD (Lys751Gln) polymorphism or the XRCC3 (Thr241Met) polymorphism and lung cancer risk. Cancer Epidemiology, Biomarkers & Prevention. 2001;10(8):911–2. [PubMed: 11489761]
  170. de Laat WL, Jaspers NGJ, Hoeijmakers JHJ. Molecular mechanism of nucleotide excision repair. Genes & Development. 1999;13(7):768–85. [PubMed: 10197977]
  171. de los Santos C, Zaliznyak T, Johnson F. NMR characterization of a DNA duplex containing the major acrolein-derived deoxyguanosine adduct γ-OH-1, N2-propano-2′-deoxyguanosine. Journal of Biological Chemistry. 2001;276(12):9077–82. [PubMed: 11054428]
  172. de Wind N, Dekker M, Claij N, Jansen L, van Klink Y, Radman M, Riggins G, van der Valk M, van’t Wout K, te Riele H. HNPCC-like cancer predisposition in mice through simultaneous loss of Msh3 and Msh6 mismatch-repair protein functions. Nature Genetics. 1999;23(3):359–62. [PubMed: 10545954]
  173. DeGregori J, Leone G, Miron A, Jakoi L, Nevins JR. Distinct roles for E2F proteins in cell growth control and apoptosis. Proceedings of the National Academy of Sciences of the United States of America. 1997;94(14):7245–50. [PMC free article: PMC23805] [PubMed: 9207076]
  174. Dellinger RW, Fang J-L, Chen G, Weinberg R, Lazarus P. Importance of UDP-glucuronosyltransferase 1A10 (UGT1A10) in the detoxification of polycyclic aromatic hydrocarbons: decreased glucuronidative activity of the UGT1A10139LYS isoform. Drug Metabolism and Disposition. 2006;34(6):943–9. [PubMed: 16510539]
  175. DeMarini DM. Genotoxicity of tobacco smoke and tobacco smoke condensate: a review. Mutation Research. 2004;567(2–3):447–74. [PubMed: 15572290]
  176. DeMarini DM, Landi S, Tian D, Hanley NM, Li X, Hu F, Roop BC, Mass MJ, Keohavong P, Gao W, et al. Lung tumor KRAS and TP53 mutations in nonsmokers reflect exposure to PAH-rich coal combustion emissions. Cancer Research. 2001;61(18):6679–81. [PubMed: 11559534]
  177. Denissenko MF, Chen JX, Tang M, Pfeifer GP. Cytosine methylation determines hot spots of DNA damage in the human P53 gene. Proceedings of the National AcademyofSciencesoftheUnitedStatesofAmerica. 1997;94(8):3893–8. [PMC free article: PMC20538] [PubMed: 9108075]
  178. Denissenko MF, Pao A, Pfeifer GP, Tang M. Slow repair of bulky DNA adducts along the nontranscribed strand of the human p53 gene may explain the strand bias of transversion mutations in cancers. Oncogene. 1998;16(10):1241–7. [PubMed: 9546425]
  179. Denissenko MF, Pao A, Tang M-S, Pfeifer GP. Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in P53. Science. 1996;274(5286):430–2. [PubMed: 8832894]
  180. Deutsch-Wenzel RP, Brune H, Grimmer G, Dettbarn G, Misfeld J. Experimental studies in rat lungs on the carcinogenicity and dose-response relationships of eight frequently occurring environmental polycyclic aromatic hydrocarbons. Journal of the National Cancer Institute. 1983;71(3):539–44. [PubMed: 6577228]
  181. Dietrich M, Block G, Hudes M, Morrow JD, Norkus EP, Traber MG, Cross CE, Packer L. Antioxidant supplementation decreases lipid peroxidation biomarker F2-isoprostanes in plasma of smokers. Cancer Epidemiology, Biomarkers & Prevention. 2002;11(1):7–13. [PubMed: 11815395]
  182. Dipple A, Moschel RC, Bigger CAH. Polynuclear aromatic hydrocarbons. Chemical Carcinogens. ACS Monograph 182. 2nd ed. Searle CE, editor. Vol. 1. Washington: American Chemical Society; 1984. pp. 41–163.
  183. Divine KK, Gilliland FD, Crowell RE, Stidley CA, Bocklage TJ, Cook DL, Belinsky SA. The XRCC1 399 glutamine allele is a risk factor for adenocarcinoma of the lung. Mutation Research. 2001;461(4):273–8. [PubMed: 11104903]
  184. Divine KK, Pulling LC, Marron-Terada PG, Liechty KC, Kang T, Schwartz AG, Bocklage TJ, Coons TA, Gilliland FD, Belinsky SA. Multiplicity of abnormal promoter methylation in lung adenocarcinomas from smokers and never smokers. International Journal of Cancer. 2005;114(3):400–5. [PubMed: 15578700]
  185. Djordjevic MV, Sigountos CW, Brunnemann KD, Hoffmann D. Formation of 4-(methylnitrosamino)-4-(3-pyridyl)butyric acid in vitro and in mainstream cigarette smoke. Journal of Agricultural and Food Chemistry. 1991;39(1):209–13.
  186. Dolan ME, Mitchell RB, Mummert C, Moschel RC, Pegg AE. Effect of O6-benzylguanine analogues on sensitivity of human tumor cells to the cytotoxic effects of alkylating agents. Cancer Research. 1991;51(13):3367–72. [PubMed: 1647266]
  187. Dolan ME, Moschel RC, Pegg AE. Depletion of mammalian O6-alkylguanine-DNA alkyltransferase activity by O6-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents. Proceedings of the National Academy of Sciences of the United States of America. 1990;87(14):5368–72. [PMC free article: PMC54325] [PubMed: 2164681]
  188. Dosanjh MK, Menichini P, Eritja R, Singer B. Both O4-methylthymine and O4-ethylthymine preferentially form alkyl TG pairs that do not block in vitro replication in a defined sequence. Carcinogenesis. 1993;14(9):1915–9. [PubMed: 8403218]
  189. Dosanjh MK, Singer B, Essigmann JM. Comparative mutagenesis of O6-methylguanine and O4-methylthymine in Escherichia coli. Biochemistry. 1991;30(28):7027–33. [PubMed: 2069960]
  190. Downward J. The ins and outs of signalling. Nature. 2001;411(6839):759–62. [PubMed: 11459043]
  191. Drin I, Schoket B, Kostic S, Vincze I. Smoking-related increase in O6-alkylguanine-DNA alkyltransferase activity in human lung tissue. Carcinogenesis. 1994;15(8):1535–9. [PubMed: 8055630]
  192. Dubinett SM, Sharma S, Huang M, Dohadwala M, Pold M, Mao JT. Cyclooxygenase-2 in lung cancer. Progress in Experimental Tumor Research. 2003;37:138–62. [PubMed: 12795053]
  193. Duckett DR, Drummond JT, Murchie AIH, Reardon JT, Sancar A, Lilley DMJ, Modrich P. Human MutSα recognizes damaged DNA base pairs containing O6-methylguanine, O4-methylthymine, or the cis-platin-d(GpG) adduct. Proceedings of the National Academy of Sciences of the United States of America. 1996;93(13):6443–7. [PMC free article: PMC39042] [PubMed: 8692834]
  194. Duell EJ, Wiencke JK, Cheng T-J, Varkonyi A, Zuo ZF, Ashok TDS, Mark EJ, Wain JC, Christiani DC, Kelsey KT. Polymorphisms in the DNA repair genes XRCC1 and ERCC2 and biomarkers of DNA damage in human blood mono-nuclear cells. Carcinogenesis. 2000;21(5):965–71. [PubMed: 10783319]
  195. Dupret J-M, Rodrigues-Lima F. Structure and regulation of the drug-metabolizing enzymes arylamine N-acetyltransferases. Current Medicinal Chemistry. 2005;12(3):311–8. [PubMed: 15723621]
  196. Eckfeld K, Hesson L, Vos MD, Bieche I, Latif F, Clark GJ. RASSF4/AD037 is a potential Ras effector/rumor suppressor of the RASSF family. Cancer Research. 2004;64(23):8688–93. [PubMed: 15574778]
  197. Edara S, Kanugula S, Goodtzova K, Pegg AE. Resistance of the human O6-alkylguanine-DNA alkyltransferase containing arginine at codon 160 to inactivation by O6-benzylguanine. Cancer Research. 1996;56(24):5571–5. [PubMed: 8971155]
  198. Egyházi S, Ma S, Smoczynski K, Hansson J, Platz A, Ring-borg U. Novel O6-methylguanine-DNA methyltrans-ferase SNPs: a frequency comparison of patients with familial melanoma and healthy individuals in Sweden. Human Mutation. 2002;20(5):408–9. [PubMed: 12402349]
  199. Ehrenberg L, Osterman-Golkar S. Alkylation of macromolecules for detecting mutagenic agents. Teratogenesis, Carcinogenesis, and Mutagenesis. 1980;1(1):105–27. [PubMed: 6119796]
  200. Eide I, Zhao C, Kumar R, Hemminki K, Wu K, Swenberg JA. Comparison of 32P-postlabeling and high-resolution GC/MS in quantifying N7-(-hydroxyethyl) guanine adducts. Chemical Research in Toxicology. 1999;12(10):979–84. [PubMed: 10525275]
  201. Eisenstadt E, Warren AJ, Porter J, Atkins D, Miller JH. Carcinogenic epoxides of benzo[a]pyrene and cyclopenta[cd]pyrene induce base substitutions via specific transversions. Proceedings of the National Academy of Sciences of the United States of America. 1982;79(6):1945–9. [PMC free article: PMC346098] [PubMed: 7043469]
  202. El-Bayoumy K, Donahue JM, Hecht SS, Hoffmann D. Identification and quantitative determination of aniline and toluidines in human urine. Cancer Research. 1986;46(12 Pt 1):6064–7. [PubMed: 3779628]
  203. El-Bayoumy K, Iatropoulos M, Amin S, Hoffmann D, Wynder EL. Increased expression of cyclooxygenase-2 in rat lung tumors induced by the tobacco-specific nitro-samine 4-(methylnitrosamino)-4-(3-pyridyl)-1-buta-none: the impact of a high-fat diet. Cancer Research. 1999;59(7):1400–3. [PubMed: 10197601]
  204. Elder RH, Jansen JG, Weeks RJ, Willington MA, Deans B, Watson AJ, Mynett KJ, Bailey JA, Cooper DP, Rafferty JA, et al. Alkylpurine-DNA-N-glycosylase knockout mice show increased susceptibility to induction of mutations by methyl methanesulfonate. Molecular and Cellular Biology. 1998;18(10):5828–37. [PMC free article: PMC109169] [PubMed: 9742100]
  205. Eller MS, Maeda T, Magnoni C, Atwal D, Gilchrest BA. Enhancement of DNA repair in human skin cells by thymidine dinucleotides: evidence for a p53-mediated mammalian SOS response. Proceedings of the National Academy of Sciences of the United States of America. 1997;94(23):12627–32. [PMC free article: PMC25061] [PubMed: 9356500]
  206. Ellison KS, Dogliotti E, Connors TD, Basu AK, Essigmann JM. Site-specific mutagenesis by O6-alkylgua-nines located in the chromosomes of mammalian cells: influence of the mammalian O6-alkylguanine-DNA alkyltransferase. Proceedings of the National Academy of Sciences of the United States of America. 1989;86(22):8620–4. [PMC free article: PMC298339] [PubMed: 2813414]
  207. Esteller M, Hamilton SR, Burger PC, Baylin SB, Herman JG. Inactivation of the DNA repair gene O6-methylgua-nine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Research. 1999;59(4):793–7. [PubMed: 10029064]
  208. Etzel CJ, Amos CI, Spitz MR. Risk for smoking-related cancer among relatives of lung cancer patients. Cancer Research. 2003;63(23):8531–5. [PubMed: 14679021]
  209. Evans E, Moggs JG, Hwang JR, Egly JM, Wood RD. Mechanism of open complex and dual incision formation by human nucleotide excision repair factors. EMBO Journal. 1997;16(21):6559–73. [PMC free article: PMC1170260] [PubMed: 9351836]
  210. Fan F, Liu C, Tavaré S, Arnheim N. Polymorphisms in the human DNA repair gene XPF. Mutation Research. 1999;406(2–4):115–20. [PubMed: 10479728]
  211. Fang HY, Lin T-S, Lin J-P, Wu YC, Chow K-C, Wang L-S. Cyclooxygenase-2 in human non-small cell lung cancer. European Journal of Surgical Oncology. 2003;29(2):171–7. [PubMed: 12633561]
  212. Fang J-L, Beland FA, Doerge DR, Wiener D, Guillemette C, Marques MM, Lazarus P. Characterization of benzo(a) pyrene-trans-7,8-dihydrodiol glucuronidation by human tissue microsomes and overexpressed UDP-glucuronosyltransferase enzymes. Cancer Research. 2002;62(7):1978–86. [PubMed: 11929814]
  213. Fay LB, Leaf CD, Gremaud E, Aeschlimann JM, Steen C, Shuker DE, Turesky RJ. Urinary excretion of 3-methyl-adenine after consumption of fish containing high levels of dimethylamine. Carcinogenesis. 1997;18(5):1039–44. [PubMed: 9163693]
  214. Feng Z, Hu W, Chen JX, Pao A, Li H, Rom W, Hung M-C, Tang M. Preferential DNA damage and poor repair determine ras gene mutational hotspot in human cancer. Journal of the National Cancer Institute. 2002;94(20):1527–36. [PubMed: 12381705]
  215. Feng Z, Hu W, Hu Y, Tang M-S. Acrolein is a major cigarette-related lung cancer agent: preferential biding at p53 mutational hotspots and inhibition of DNA repair. Proceedings of the National Academy of Sciences of the United States of America. 2006;103(42):15404–9. [PMC free article: PMC1592536] [PubMed: 17030796]
  216. Fennell TR, MacNeela JP, Morris RW, Watson M, Thompson CL, Bell DA. Hemoglobin adducts from acrylonitrile and ethylene oxide in cigarette smokers: effects of glutathione S-transferase T1-null and M1-null genotypes. Cancer Epidemiology, Biomarkers & Prevention. 2000;9(7):705–12. [PubMed: 10919741]
  217. Fernandes A, Liu T, Amin S, Geacintov NE, Grollman AP, Moriya M. Mutagenic potential of stereoisomeric bay region (+)- and (–)-cis-anti-benzo[a]pyrene diol epoxide-N2-2′-deoxyguanosine adducts in Escherichia coli and simian kidney cells. Biochemistry. 1998;37(28):10164–72. [PubMed: 9665722]
  218. Ferrezuelo F, Prieto-Álamo M-J, Jurado J, Pueyo C. Influence of DNA repair by (A)BC excinuclease and Ogt alkyltransferase on the distribution of mutations induced by n-propyl-N-nitrosourea in Escherichia coli. Environmental and Molecular Mutagenesis. 1998a;31(1):82–91. [PubMed: 9464319]
  219. Ferrezuelo F, Prieto-Álamo M-J, Jurado J, Pueyo C. Role of DNA repair by (A)BC excinuclease and Ogt alkyl-transferase in the final distribution of LacI−d mutations induced by N-butyl-N-nitrosourea in Esherichia coli. Mutagenesis. 1998b;13(5):507–14. [PubMed: 9800196]
  220. Feyler A, Voho A, Bouchardy C, Kuokkanen K, Dayer P, Hirvonen A, Benhamou S. Point: myeloperoxidase −463G → A polymorphism and lung cancer risk. Cancer Epidemiology, Biomarkers & Prevention. 2002;11(12):1550–4. [PubMed: 12496042]
  221. Finel M, Li X, Gardner-Stephen D, Bratton S, Mackenzie PI, Radominska-Pandya A. Human UDP-glucuronosyl-transferase 1A5: identification, expression, and activity. Journal of Pharmacology and Experimental Therapeutics. 2005;315(3):1143–9. [PubMed: 16120810]
  222. Fishel R, Lescoe MK, Rao MR, Copeland NG, Jenkins NA, Garber J, Kane M, Kolodner R. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell. 1993;7(1):1027–38. [PubMed: 8252616]
  223. Flamini G, Romano G, Curigliano G, Chiominto A, Capelli G, Boninsegna A, Signorelli C, Ventura L, Santella RM, Sgambato A, et al. 4-Aminobiphenyl-DNA adducts in laryngeal tissue and smoking habits: an immunohistochemical study. Carcinogenesis. 1998;19(2):353–7. [PubMed: 9498288]
  224. Flemington EK, Speck SH, Kaelin WG Jr. E2F-1-mediated transactivation is inhibited by complex formation with the retinoblastoma susceptibility gene product. Proceedings of the National Academy of Sciences of the United States of America. 1993;90(15):6914–8. [PMC free article: PMC47045] [PubMed: 8346196]
  225. Foiles PG, Akerkar SA, Carmella SG, Kagan M, Stoner GD, Resau JH, Hecht SS. Mass spectrometric analysis of tobacco-specific nitrosamine-DNA adducts in smokers and nonsmokers. Chemical Research in Toxicology. 1991;4(3):364–8. [PubMed: 1912321]
  226. Fong LYY, Nguyen VT, Farber JL. Esophageal cancer prevention in zinc-deficient rats: rapid induction of apoptosis by replenishing zinc. Journal of the National Cancer Institute. 2001;93(20):1525–33. [PubMed: 11604475]
  227. Ford JM, Hanawalt PC. Li-Fraumeni syndrome fibroblasts homozygous for p53 mutations are deficient in global DNA repair but exhibit normal transcription-coupled repair and enhanced UV resistance. Proceedings of the National Academy of Sciences of the United States of America. 1995;92(19):8876–80. [PMC free article: PMC41070] [PubMed: 7568035]
  228. Forgacs E, Biesterveld EJ, Sekido Y, Fong K, Muneer S, Wistuba II, Milchgrub S, Brezinschek R, Virmani A, Gazdar AF, et al. Mutation analysis of the PTEN/MMAC1 gene in lung cancer. Oncogene. 1998;17(12):1557–65. [PubMed: 9794233]
  229. Fortini P, Pascucci B, Parlanti E, D’Errico M, Simonelli V, Dogliotti E. The base excision repair: mechanisms and its relevance for cancer susceptibility. Biochimie. 2003;85(11):1053–71. [PubMed: 14726013]
  230. Fowles J, Dybing E. Application of toxicological risk assessment principles to the chemical constituents of cigarette smoke. Tobacco Control. 2003;12(4):424–30. [PMC free article: PMC1747794] [PubMed: 14660781]
  231. Fretland AJ, Doll MA, Zhu Y, Smith L, Leff MA, Hein DW. Effect of nucleotide substitutions in N-acetyltransferase-1 on N-acetylation (deactivation) and O-acetylation (activation) of arylamine carcinogens: implications for cancer predisposition. Cancer Detection and Prevention. 2002;26(1):10–4. [PubMed: 12088197]
  232. Fretland AJ, Omiecinski CJ. Epoxide hydrolases: biochemistry and molecular biology. Chemico-Biological Interactions. 2000;129(1–2):41–59. [PubMed: 11154734]
  233. Friedberg EC. How nucleotide excision repair protects against cancer. Nature Reviews Cancer. 2001;1(1):22–33. [PubMed: 11900249]
  234. Friedberg EC, Walker GC, Siede W, editors. DNA Repair and Mutagenesis. Washington: ASM Press; 1995.
  235. Fromme JC, Banerjee A, Verdine GL. DNA glycosylase recognition and catalysis. Current Opinion in Structural Biology. 2004;14(1):43–9. [PubMed: 15102448]
  236. Fu XW, Nurse CA, Farragher SM, Cutz E. Expression of functional nicotinic acetylcholine receptors in neuro-epithelial bodies of neonatal hamster lung. American Journal of Physiology – Lung Cellular and Molecular Physiology. 2003;285(6):L1203–L1212. [PubMed: 12818889]
  237. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard J-Y, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non–small-cell lung cancer. Journal of Clinical Oncology. 2003;21(12):2237–46. [PubMed: 12748244]
  238. Fustinoni S, Soleo L, Warholm M, Begemann P, Rannug A, Neumann H-G, Swenberg JA, Vimercati L, Foà V, Colombi A. Influence of metabolic genotypes on bio-markers of exposure to 1,3-butadiene in humans. Cancer Epidemiology, Biomarkers & Prevention. 2002;11(10):1082–90. [PubMed: 12376511]
  239. Gago-Dominguez M, Bell DA, Watson MA, Yuan J-M, Castelao JE, Hein DW, Chan KK, Coetzee GA, Ross RK, Yu MC. Permanent hair dyes and bladder cancer: risk modification by cytochrome P4501A2 and N-acetyl-transferases 1 and 2. Carcinogenesis. 2003;24(3):483–9. [PubMed: 12663508]
  240. Gao C, Takezaki T, Wu J, Li Z, Wang J, Ding J, Liu Y, Hu X, Xu T, Tajima K, et al. Interaction between cytochrome P-450 2E1 polymorphisms and environmental factors with risk of esophageal and stomach cancers in Chinese. Cancer Epidemiology, Biomarkers & Prevention. 2002;11(1):29–34. [PubMed: 11815398]
  241. García-Closas M, Kelsey KT, Wiencke JK, Xu X, Wain JC, Christiani DC. A case-control study of cytochrome P450 1A1, glutathione S-transferase M1, cigarette smoking and lung cancer susceptibility (Massachusetts, United States). Cancer Causes & Control. 1997;8(4):544–53. [PubMed: 9242469]
  242. Gauderman WJ, Morrison JL. Evidence for age-specific genetic relative risks in lung cancer. American Journal of Epidemiology. 2000;151(1):41–9. [PubMed: 10625172]
  243. Gautier J-C, Urban P, Beaune P, Pompon D. Simulation of human benzo[a]pyrene metabolism deduced from the analysis of individual kinetic steps in recombinant yeast. Chemical Research in Toxicology. 1996;9(2):418–25. [PubMed: 8839044]
  244. Gelboin HV. Benzo[a]pyrene metabolism, activation, and carcinogenesis: role and regulation of mixed function oxidases and related enzymes. Physiological Reviews. 1980;60(4):1107–66. [PubMed: 7001511]
  245. Genschel J, Bazemore LR, Modrich P. Human exonuclease I is required for 5′ and 3′ mismatch repair. Journal of Biological Chemistry. 2002;277(15):13302–11. [PubMed: 11809771]
  246. Genschel J, Littman SJ, Drummond JT, Modrich P. Isolation of MutSβ from human cells and comparison of the mismatch repair specificities of MutSβ and MutSα Journal of Biological Chemistry. 1998;273(31):19895–901. [PubMed: 9677427]
  247. Giardiello FM, Welsh SB, Hamilton SR, Offerhaus GJ, Gittelsohn AM, Booker SV, Krush AJ, Yardley JH, Luk GD. Increased risk of cancer in the Peutz-Jeghers syndrome. New England Journal of Medicine. 1987;316(24):1511–14. [PubMed: 3587280]
  248. Gibbs PEM, Lawrence CW. Novel mutagenic properties of abasic sites in Saccharomyces cerevisiae. Journal of Molecular Biology. 1995;251(2):229–36. [PubMed: 7643399]
  249. Gibbs PEM, McGregor WG, Maher VM, Nisson P, Lawrence CW. A human homolog of the Saccharomyces cerevisiae REV3 gene, which encodes the catalytic subunit of DNA polymerase ζ Proceedings of the National Academy of Sciences of the United States of America. 1998;95(12):6876–80. [PMC free article: PMC22668] [PubMed: 9618506]
  250. Gibbs PEM, Wang X-D, Li Z, McManus TP, McGregor WG, Lawrence CW, Maher VM. The function of the human homolog of Saccharomyces cerevisiae REV1 is required for mutagenesis induced by UV light. Proceedings of the National Academy of Sciences of the United States of America. 2000;97(8):4186–91. [PMC free article: PMC18191] [PubMed: 10760286]
  251. Gibel VW. Experimentelle untersuchung zur synkarzino-genese beim ösophaguskarzinom (Experimental studies on syncarcinogenesis in esophageal carcinoma) [German] Archiv für Geschwulstforschung. 1967;30(3):181–9. [PubMed: 4299442]
  252. Gillison ML, Shah KV. Chapter 9: role of human papillomavirus in nongenital cancers. Journal of the National Cancer Institute Monographs. 2003;(31):57–65. [PubMed: 12807947]
  253. Godschalk R, Nair J, van Schooten FJ, Risch A, Drings P, Kayser K, Dienemann H, Bartsch H. Comparison of multiple DNA adduct types in tumor adjacent human lung tissue: effect of cigarette smoking. Carcinogenesis. 2002;23(12):2081–6. [PubMed: 12507931]
  254. Goode EL, Ulrich CM, Potter JD. Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiology, Biomarkers & Prevention. 2002;11(12):1513–30. [PubMed: 12496039]
  255. Gordon SM, Wallace LA, Brinkman MC, Callahan PJ, Kenny DV. Volatile organic compounds as breath bio-markers for active and passive smoking. Environmental Health Perspectives. 2002;110(7):689–98. [PMC free article: PMC1240915] [PubMed: 12117646]
  256. Green J, Banks E, Berrington A, Darby S, Deo H, Newton R. N-acetyltransferase 2 and bladder cancer: an overview and consideration of the evidence for gene-environment interaction. British Journal of Cancer. 2000;83(3):412–7. [PMC free article: PMC2374558] [PubMed: 10917561]
  257. Green MD, Tephly TR. Glucuronidation of amine substrates by purified and expressed UDP-glucuronosyl-transferase proteins. Drug Metabolism and Disposition. 1998;26(9):860–7. [PubMed: 9733664]
  258. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Research. 1994;54(18):4855–78. [PubMed: 8069852]
  259. Gregory PA, Hansen AJ, Mackenzie PI. Tissue specific differences in the regulation of the UDP glucurono-syltransferase 2B17 gene promoter. Pharmacogenetics. 2000;10(9):809–20. [PubMed: 11191885]
  260. Gregory PA, Lewinsky RH, Gardner-Stephen DA, Mac-kenzie PI. Regulation of UDP glucuronosyltransferases in the gastrointestinal tract. Toxicology and Applied Pharmacology. 2004;199(3):354–63. [PubMed: 15364550]
  261. Grimmer G, Dettbarn G, Jacob J. Biomonitoring of poly-cyclic aromatic hydrocarbons in highly exposed coke plant workers by measurement of urinary phenan-threne and pyrene metabolites (phenols and dihydrodiols). International Archives of Occupational and Environmental Health. 1993;65(3):189–99. [PubMed: 8282417]
  262. Grimmer G, Dettbarn G, Seidel A, Jacob J. Detection of carcinogenic aromatic amines in the urine of nonsmokers. Science of the Total Environment. 2000;247(1):81–90. [PubMed: 10721145]
  263. Grimmer G, Jacob J, Dettbarn G, Naujack KW. Determination of urinary metabolites of polycyclic aromatic hydrocarbons (PAH) for the risk assessment of PAH-exposed workers. International Archives of Occupational and Environmental Health. 1997;69(4):231–9. [PubMed: 9137996]
  264. Grollman AP, Moriya M. Mutagenesis by 8-oxoguanine: an enemy within. Trends in Genetics. 1993;9(7):246–9. [PubMed: 8379000]
  265. Gsur A, Zidek T, Schnattinger K, Feik E, Haidinger G, Hollaus P, Mohn-Staudner A, Armbruster C, Madersbacher S, Schatzl G, et al. Association of microsomal epoxide hydrolase polymorphisms and lung cancer risk. British Journal of Cancer. 2003;89(4):702–6. [PMC free article: PMC2376930] [PubMed: 12915882]
  266. Gu J, Liang D, Wang Y, Lu C, Wu X. Effects of N-acetyl transferase 1 and 2 polymorphisms on bladder cancer risk in Caucasians. Mutation Research. 2005;581(1–2):97–104. [PubMed: 15725609]
  267. Guan K-L, Figueroa C, Brtva TR, Zhu T, Taylor J, Barber TD, Vojtek AB. Negative regulation of the serine/threonine kinase B-Raf by Akt. Journal of Biological Chemistry. 2000;275(35):27354–9. [PubMed: 10869359]
  268. Guengerich FP. Cytochrome P450: what have we learned and what are the future issues? Drug Metabolism Reviews. 2004;36(2):159–97. [PubMed: 15237850]
  269. Guengerich FP, Kim DH, Iwasaki M. Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects. Chemical Research in Toxicology. 1991;4(2):168–79. [PubMed: 1664256]
  270. Guillemette C, Ritter JK, Auyeung DJ, Kessler FK, Housman DE. Structural heterogeneity at the UDP-glucuro-nosyltransferase 1 locus: functional consequences of three novel missense mutations in the human UGT1A7 gene. Pharmacogenetics. 2000;10(7):629–44. [PubMed: 11037804]
  271. Gupta RA, Dubois RN. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nature Reviews Cancer. 2001;1(1):11–21. [PubMed: 11900248]
  272. Györffy E, Anna L, Györi Z, Segesdi J, Minárovits J, Soltész I, Kostič S, Csekeö A, Poirier MC, Schoket B. DNA adducts in tumour, normal peripheral lung and bronchus, and peripheral blood lymphocytes from smoking and non-smoking lung cancer patients: correlations between tissues and detection by 32P-postlabelling and immunoassay. Carcinogenesis. 2004;25(7):1201–9. [PubMed: 15001535]
  273. Habalová V, Šalagovič J, Kalina I, Štubňa J. Combined analysis of polymorphisms in glutathione S-transferase M1 and microsomal epoxide hydrolase in lung cancer patients. Neoplasma. 2004;51(5):352–7. [PubMed: 15640939]
  274. Habraken Y, Sung P, Prakash L, Prakash S. A conserved 5′ to 3′ exonuclease activity in the yeast and human nucleotide excision repair proteins RAD2 and XPG. Journal of Biological Chemistry. 1994;269(16):31342–5. [PubMed: 7989298]
  275. Hainaut P, Hollstein M. p53 and human cancer: the first ten thousand mutations. Advances in Cancer Research. 2000;77:81–137. [PubMed: 10549356]
  276. Hainaut P, Pfeifer GP. Patterns of p53 G → T transversions in lung cancers reflect the primary mutagenic signature of DNA-damage by tobacco smoke. Carcinogenesis. 2001;22(3):367–74. [PubMed: 11238174]
  277. Hale AJ, Smith CA, Sutherland LC, Stoneman VEA, Longthorne VL, Culhane AC, Williams GT. Apoptosis: molecular regulation of cell death. European Journal of Biochemistry. 1996;236(1):1–26. [PubMed: 8617251]
  278. Hall J, Brésil H, Donato F, Wild CP, Loktionova NA, Kazanova OI, Komyakov IP, Lemekhov VG, Likhachev AJ, Montesano R. Alkylation and oxidation-DNA damage repair activity in blood leukocytes of smokers and nonsmokers. International Journal of Cancer. 1993;54(5):728–33. [PubMed: 8325702]
  279. Hallier E, Langhof T, Dannappel D, Leutbecher M, Schroder K, Goergens HW, Muller A, Bolt HM. Polymorphism of glutathione conjugation of methyl bromide, ethylene oxide and dichloromethane in human blood: influence on the induction of sister chromatid exchanges (SCE) in lymphocytes. Archives of Toxicology. 1993;67(3):173–8. [PubMed: 8494496]
  280. Hamada GS, Sugimura H, Suzuki I, Nagura K, Kiyokawa E, Iwase T, Tanaka M, Takahashi T, Watanabe S, Kino J, et al. The heme-binding region polymorphism of cyto-chrome P450IA1 (CypIA1) rather than the Rsal polymorphisms of IIE1 (CypIIE1), is associated with lung cancer in Rio de Janeiro. Cancer Epidemiology, Bio-markers & Prevention. 1995;4(1):63–7. [PubMed: 7534543]
  281. Hamajima N, Matsuo K, Suzuki T, Nakamura T, Matsuura A, Hatooka S, Shinoda M, Kodera Y, Yamamura Y, Hirai T, et al. No associations of p73 G4C14-to-A4T14 at exon 2 and p53 Arg72Pro polymorphisms with the risk of digestive tract cancers in Japanese. Cancer Letters. 2002;181(1):81–5. [PubMed: 12430182]
  282. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57–70. [PubMed: 10647931]
  283. Hanawalt PC, Ford JM, Lloyd DR. Functional characterization of global genomic DNA repair and its implications for cancer. Mutation Research. 2003;544(2–3):107–14. [PubMed: 14644313]
  284. Haracska L, Unk I, Johnson RE, Johansson E, Burgers PMJ, Prakash S, Prakash L. Roles of yeast DNA poly-merase δ and ζ and of Rev1 in the bypass of abasic sites. Genes & Development. 2001;15(8):945–54. [PMC free article: PMC312678] [PubMed: 11316789]
  285. Haracska L, Yu S-L, Johnson RE, Prakash L, Prakash S. Efficient and accurate replication in the presence of 7,8-dihydro-8-oxoguanine by DNA polymerase η Nature Genetics. 2000;25(4):458–61. [PubMed: 10932195]
  286. Harada YN, Matsuda Y, Shiomi N, Shiomi T. Complementary DNA sequence and chromosomal localization of xpg, the mouse counterpart of human repair gene XPG/ERCC5. Genomics. 1995;28(1):59–65. [PubMed: 7590748]
  287. Harbour JW, Lai SL, Whang-Peng J, Gazdar AF, Minna JD, Kaye FJ. Abnormalities in structure and expression of the human retinoblastoma gene in SCLC. Science. 1988;241(4863):353–7. [PMC free article: PMC5480895] [PubMed: 2838909]
  288. Harman SM, Liang L, Tsitouras PD, Gucciardo F, Heward CB, Reaven PD, Ping W, Ahmed A, Cutler RG. Urinary excretion of three nucleic acid oxidation adducts and isoprostane F2α measured by liquid chromatography-mass spectrometry in smokers, ex-smokers, and nonsmokers. Free Radical Biology & Medicine. 2003;35(10):1301–9. [PubMed: 14607529]
  289. Harris MJ, Coggan M, Langton L, Wilson SR, Board PG. Polymorphism of the Pi class glutathione-S-transferase in normal populations and cancer patients. Pharmaco-genetics. 1998;8(1):27–31. [PubMed: 9511178]
  290. Hasegawa M, Nelson HH, Peters E, Ringstrom E, Posner M, Kelsey KT. Patterns of gene promoter methylation in squamous cell cancer of the head and neck. Oncogene. 2002;21(27):4231–6. [PubMed: 12082610]
  291. Hassett C, Aicher L, Sidhu JS, Omiecinski CJ. Human microsomal epoxide hydrolase: genetic polymorphism and functional expression in vitro of amino acid variants. Human Molecular Genetics. 1994;3(3):421–8. [PMC free article: PMC4868095] [PubMed: 7516776]
  292. Hastürk S, Kemp B, Kalapurakal SK, Kurie JM, Hong WK, Lee JS. Expression of cyclooxygenase-1 and cyclooxy-genase-2 in bronchial epithelium and nonsmall cell lung carcinoma. Cancer. 2002;94(4):1023–31. [PubMed: 11920472]
  293. Hatcher JF, Swaminathan S. Detection of deoxyadenosine-4-aminobiphenyl adduct in DNA of human uroepithelial cells treated with N-hydroxy-4-aminobiphenyl following nuclease P1 enrichment and 32P-postlabeling analysis. Carcinogenesis. 1995;16(2):295–301. [PubMed: 7859361]
  294. Haushalter KA, Todd Stukenberg MW, Kirschner MW, Verdine GL. Identification of a new uracil-DNA glycosylase family by expression cloning using synthetic inhibitors. Current Biology. 1999;9(4):174–85. [PubMed: 10074426]
  295. Hayashi S, Watanabe J, Kawajiri K. High susceptibility to lung cancer analyzed in terms of combined genotypes of P4501A1 and μ-class glutathione S-transferase genes. Japanese Journal of Cancer Research. 1992;83(8):866–70. [PMC free article: PMC5918950] [PubMed: 1399823]
  296. Hayashi S, Watanabe J, Nakachi K, Kawajiri K. Genetic linkage of lung cancer-associated MspI polymorphisms with amino acid replacement in the heme binding region of the human cytochrome P450IA1 gene. Journal of Biochemistry. 1991;110(3):407–11. [PubMed: 1722803]
  297. Hayes JD, Flanagan JU, Jowsey IR. Glutathione transferases. Annual Review of Pharmacology and Toxicology. 2005;45:51–88. [PubMed: 15822171]
  298. Hayes RB, Klein S, Suruda A, Schulte P, Boeniger M, Stewart P, Livingston GK, Oesch F. O6-alkylguanine DNA alkyltransferase activity in student embalmers. American Journal of Industrial Medicine. 1997;31(3):361–5. [PubMed: 9055960]
  299. Hayward RL, Macpherson JS, Cummings J, Monia BP, Smyth JF, Jodrell DI. Antisense Bcl-xl down-regulation switches the response to topoisomerase I inhibition from senescence to apoptosis in colorectal cancer cells, enhancing global cytotoxicity. Clinical Cancer Research. 2003;9(7):2856–65. [PubMed: 12855666]
  300. Hazra TK, Izumi T, Boldogh I, Imhoff B, Kow YW, Jaruga P, Dizdaroglu M, Mitra S. Identification and characterization of a human DNA glycosylase for repair of modified bases in oxidatively damaged DNA. Proceedings of the National Academy of Sciences of the United States of America. 2002a;99(6):3523–8. [PMC free article: PMC122556] [PubMed: 11904416]
  301. Hazra TK, Izumi T, Maidt L, Floyd RA, Mitra S. The presence of two distinct 8-oxoguanine repair enzymes in human cells: their potential complementary roles in preventing mutation. Nucleic Acids Research. 1998;26(22):5116–22. [PMC free article: PMC147966] [PubMed: 9801308]
  302. Hazra TK, Kow YW, Hatahet Z, Imhoff B, Boldogh I, Mokkapati SK, Mitra S, Izumi T. Identification and characterization of a novel human DNA glycosylase for repair of cytosine-derived lesions. Journal of Biological Chemistry. 2002b;277(34):30417–20. [PubMed: 12097317]
  303. Hecht SS. Biochemistry, biology, and carcinogenicity of tobacco-specific N-nitrosamines. Chemical Research in Toxicology. 1998;11(6):559–603. [PubMed: 9625726]
  304. Hecht SS. Tobacco smoke carcinogens and lung cancer. Journal of the National Cancer Institute. 1999;91(14):1194–210. [PubMed: 10413421]
  305. Hecht SS. Cigarette smoking and lung cancer: chemical mechanisms and approaches to prevention. Lancet Oncology. 2002a;3(8):461–9. [PubMed: 12147432]
  306. Hecht SS. Human urinary carcinogen metabolites: bio-markers for investigating tobacco and cancer. Carcino-genesis. 2002b;23(6):907–22. [PubMed: 12082012]
  307. Hecht SS. Tobacco carcinogens, their biomarkers and tobacco-induced cancer. Nature Reviews. 2003;3(10):733–44. [PubMed: 14570033]
  308. Hecht SS, Carmella SG, Chen M, Koch JFD, Miller AT, Murphy SE, Jensen JA, Zimmerman CL, Hatsukami DK. Quantitation of urinary metabolites of a tobacco-specific lung carcinogen after smoking cessation. Cancer Research. 1999;59(3):590–6. [PubMed: 9973205]
  309. Hecht SS, Carmella S, Mori H, Hoffmann D. Role of catechol as a major cocarcinogen in the weakly acidic fraction of smoke condensate. Journal of the National Cancer Institute. 1981;66(1):163–9. [PubMed: 6935456]
  310. Hecht SS, Chen M, Yagi H, Jerina DM, Carmella SG. r-1,t-2,3,c-4-Tetrahydroxy-1,2,3,4-tetrahydrophenanthrene in human urine: a potential biomarker for assessing polycyclic aromatic hydrocarbon metabolic activation. Cancer Epidemiology, Biomarkers & Prevention. 2003;12(12):1501–8. [PubMed: 14693744]
  311. Hecht SS, Hoffmann D. Tobacco-specific nitrosamines, an important group of carcinogens in tobacco and tobacco smoke. Carcinogenesis. 1988;9(6):875–84. [PubMed: 3286030]
  312. Hecht SS, Hoffmann D. The relevance of tobacco-specific nitrosamines to human cancer. Cancer Surveys. 1989;8(2):273–94. [PubMed: 2696581]
  313. Hecht SS, Isaacs S, Trushin N. Lung tumor induction in A/J mice by the tobacco smoke carcinogens 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and benzo[a]pyrene: a potentially useful model for evaluation of chemopreventive agents. Carcinogenesis. 1994;15(12):2721–5. [PubMed: 8001227]
  314. Hecht SS, Rivenson A, Braley J, DiBello J, Adams JD, Hoffmann D. Induction of oral cavity tumors in F344 rats by tobacco-specific nitrosamines and snuff. Cancer Research. 1986;46(8):4162–6. [PubMed: 3731083]
  315. Hecht SS, Samet JM. Cigarette smoking. Environmental and Occupational Medicine. 4th ed. Rom WN, Markowitz SB, editors. Philadelphia: Lippincott Williams & Wilkins; 2007. pp. 1521–51.
  316. Hecht SS, Thorne RL, Maronpot RR, Hoffmann D. A study of tobacco carcinogenesis. XIII: tumor-promoting sub-fractions of the weakly acidic fraction. Journal of the National Cancer Institute. 1975;55(6):1329–36. [PubMed: 1547]
  317. Hecht SS, Tricker AR. Nitrosamines derived from nicotine and other tobacco alkaloids. Analytical Determination of Nicotine and Related Compounds and Their Metabolites. Gorrod JW, Jacob P III, editors. New York: Elsevier Science; 1999. pp. 421–88.
  318. Hecht SS, Ye M, Carmella SG, Fredrickson A, Adgate JL, Greaves IA, Church TR, Ryan AD, Mongin SJ, Sexton K. Metabolites of a tobacco-specific lung carcinogen in the urine of elementary school-aged children. Cancer Epidemiology, Biomarkers & Prevention. 2001;10(11):1109–16. [PubMed: 11700257]
  319. Heeschen C, Jang JJ, Weis M, Pathak A, Kaji S, Hu RS, Tsao PS, Johnson FL, Cooke JP. Nicotine stimulates angiogenesis and promotes tumor growth and atherosclerosis. Nature Medicine. 2001;7(7):833–9. [PubMed: 11433349]
  320. Heeschen C, Weis M, Aicher A, Dimmeler S, Cooke JP. A novel angiogenic pathway mediated by non-neuronal nicotinic acetylcholine receptors. Journal of Clinical Investigation. 2002;110(4):527–36. [PMC free article: PMC150415] [PubMed: 12189247]
  321. Hein DW. Molecular genetics and function of NAT1 and NAT2: role in aromatic amine metabolism and carcino-genesis. Mutation Research. 2002:506–507. 65–77. [PubMed: 12351146]
  322. Hein DW, Doll MA, Fretland AJ, Leff MA, Webb SJ, Xiao GH, Devanaboyina U-S, Nangju NA, Feng Y. Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiology, Biomarkers & Prevention. 2000a;9(1):29–42. [PubMed: 10667461]
  323. Hein DW, Doll MA, Rustan TD, Ferguson RJ. Metabolic activation of N-hydroxyarylamines and N-hydroxyaryl-amides by 16 recombinant human NAT2 allozymes: effects of 7 specific NAT2 nucleic acid substitutions. Cancer Research. 1995;55(16):3531–6. [PubMed: 7627960]
  324. Hein DW, Doll MA, Rustan TD, Gray K, Feng Y, Ferguson RJ, Grant DM. Metabolic activation and deactivation of arylamine carcinogens by recombinant human NAT1 and polymorphic NAT2 acetyltransferases. Carcinogenesis. 1993;14(8):1633–8. [PubMed: 8353847]
  325. Hein DW, McQueen CA, Grant DM, Goodfellow GH, Kadlubar FF, Weber WW. Pharmacogenetics of the arylamine N-acetyltransferases: a symposium in honor of Wendell W. Weber. Drug Metabolism and Disposition. 2000b;28(12):1425–32. [PubMed: 11095579]
  326. Helin K, Harlow E, Fattaey A. Inhibition of E2F-1 transactivation by direct binding of the retinoblastoma protein. Molecular and Cellular Biology. 1993;13(10):6501–8. [PMC free article: PMC364709] [PubMed: 8413249]
  327. Hendler FJ, Ozanne BW. Human squamous cell lung cancers express increased epidermal growth factor receptors. Journal of Clinical Investigation. 1984;74(2):647–51. [PMC free article: PMC370518] [PubMed: 6086719]
  328. Hendrich B, Bird A. Identification and characterization of a family of mammalian methyl-CpG binding proteins. Molecular and Cellular Biology. 1998;18(11):6538–47. [PMC free article: PMC109239] [PubMed: 9774669]
  329. Hendrich B, Hardeland U, Ng H-H, Jiricny J, Bird A. The thymine glycosylase MBD4 can bind to the product of deamination at methylated CpG sites. Nature. 1999;401(6777):301–4. [PubMed: 10499592]
  330. Hengartner MO. The biochemistry of apoptosis. Nature. 2000;407(6805):770–6. [PubMed: 11048727]
  331. Herbst RS, Bunn PA Jr. Targeting the epidermal growth factor receptor in non-small cell lung cancer. Clinical Cancer Research. 2003;9(16 Pt 1):5813–24. [PubMed: 14676101]
  332. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. New England Journal of Medicine. 2003;349(21):2042–54. [PubMed: 14627790]
  333. Hermeking H. The 14-3-3 cancer connection. Nature Reviews Cancer. 2003;3(12):931–43. [PubMed: 14737123]
  334. Hernandez-Boussard TM, Hainaut P. A specific spectrum of p53 mutations in lung cancer from smokers: review of mutations compiled in the IARC p53 data-base. Environmental Health Perspectives. 1998;106(7):385–91. [PMC free article: PMC1533115] [PubMed: 9637795]
  335. Hershko T, Ginsberg D. Up-regulation of Bcl-2 homology 3 (BH3)-only proteins by E2F1 mediates apoptosis. Journal of Biological Chemistry. 2004;279(10):8627–34. [PubMed: 14684737]
  336. Hesson L, Dallol A, Minna JD, Maher ER, Latif F. NORE1A, a homologue of RASSF1A tumour suppressor gene is inactivated in human cancers. Oncogene. 2003;22(6):947–54. [PubMed: 12584574]
  337. Hesson LB, Wilson R, Morton D, Adams C, Walker M, Maher ER, Latif F. CpG island promoter hypermethylation of a novel Ras-effector gene RASSF2A is an early event in colon carcinogenesis and correlates inversely with K-ras mutations. Oncogene. 2005;24(24):3987–94. [PubMed: 15806169]
  338. Heudorf U, Angerer J. Urinary monohydroxylated phe-nanthrenes and hydroxypyrene - the effects of smoking habits and changes induced by smoking on monoox-ygenase-mediated metabolism. International Archives of Occupational and Environmental Health. 2001;74(3):177–83. [PubMed: 11355291]
  339. Heusch WL, Maneckjee R. Signalling pathways involved in nicotine regulation of apoptosis of human lung cancer cells. Carcinogenesis. 1998;19(4):551–6. [PubMed: 9600337]
  340. Hey T, Lipps G, Sugasawa K, Iwai S, Hanaoka F, Krauss G. The XPC-HR23B complex displays high affinity and specificity for damaged DNA in a true-equilibrium fluorescence assay. Biochemistry. 2002;41(21):6583–7. [PubMed: 12022861]
  341. Hickman MJ, Samson LD. Role of DNA mismatch repair and p53 in signaling induction of apoptosis by alkylating agents. Proceedings of the National Academy of Sciences of the United States of America. 1999;96(19):10764–9. [PMC free article: PMC17957] [PubMed: 10485900]
  342. Hida T, Kozaki K, Muramatsu H, Masuda A, Shimizu S, Mitsudomi T, Sugiura T, Ogawa M, Takahashi T. Cyclo-oxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines. Clinical Cancer Research. 2000;6(5):2006–11. [PubMed: 10815926]
  343. Hida T, Yatabe Y, Achiwa H, Muramatsu H, Kozaki K, Nakamura S, Ogawa M, Mitsudomi T, Sugiura T, Takahashi T. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Research. 1998;58(17):3761–4. [PubMed: 9731479]
  344. Hilbert TP, Chaung W, Boorstein RJ, Cunningham RP, Teebor GW. Cloning and expression of the cDNA encoding the human homologue of the DNA repair enzyme, Escherichia coli endonuclease III. Journal of Biological Chemistry. 1997;272(10):6733–40. [PubMed: 9045706]
  345. Hillebrandt S, Streffer C, Demidchik EP, Biko J, Reiners C. Polymorphisms in the p53 gene in thyroid tumours and blood samples of children from areas in Belarus. Mutation Research. 1997;381(2):201–7. [PubMed: 9434876]
  346. Hillestrøm PR, Hoberg A-M, Weimann A, Poulsen HE. Quantification of 1,N6-etheno-2′-deoxyadenosine in human urine by column-switching LC/APCI-MS/MS. Free Radical Biology & Medicine. 2004;36(11):1383–92. [PubMed: 15135174]
  347. Hiraki A, Matsuo K, Hamajima N, Ito H, Hatooka S, Suyama M, Mitsudomi T, Tajima K. Different risk relations with smoking for non-small-cell lung cancer: comparison of TP53 and TP73 genotypes. Asian Pacific Journal of Cancer Prevention. 2003;4(2):107–12. [PubMed: 12875622]
  348. Hirami Y, Aoe M, Tsukuda K, Hara F, Otani Y, Koshimune R, Hanabata T, Nagahiro I, Sano Y, Date H, et al. Relation of epidermal growth factor receptor, phosphorylated-Akt, and hypoxia-inducible factor-1α in non-small cell lung cancers. Cancer Letters. 2004;214(2):157–64. [PubMed: 15363541]
  349. Hirsch FR, Scagliotti GV, Langer CJ, Varella-Garcia M, Franklin WA. Epidermal growth factor family of receptors in preneoplasia and lung cancer: perspectives for targeted therapies. Lung Cancer. 2003a;41(Suppl 1):S29–S42. [PubMed: 12867060]
  350. Hirsch FR, Varella-Garcia M, Bunn PA Jr, Di Maria MV, Veve R, Bremmes RM. Epidermal growth factor receptor in non–small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. Journal of Clinical Oncology. 2003b;21(20):3798–807. [PubMed: 12953099]
  351. Hirvonen A, Husgafvel-Pursiainen K, Anttila S, Vainio H. The GSTM1 null genotype as a potential risk modifier for squamous cell carcinoma of the lung. Carcinogenesis. 1993;14(7):1479–81. [PubMed: 8330369]
  352. Hirvonen A, Husgafvel-Pursiainen K, Karjalainen A, Anttila S, Vainio H. Point mutational Msp and Ile-Val polymorphisms closely linked in the CYP1A1 gene: lack of association with susceptibility to lung cancer in a Finnish study population. Cancer Epidemiology, Biomarkers & Prevention. 1992;1(6):485–9. [PubMed: 1284589]
  353. Hoeijmakers JH. Genome maintenance mechanisms for preventing cancer. Nature. 2001;411(6835):366–74. [PubMed: 11357144]
  354. Hoffmann D, Adams JD, Lisk D, Fisenne I, Brunnemann KD. Toxic and carcinogenic agents in dry and moist snuff. Journal of the National Cancer Institute. 1987;79(6):1281–6. [PubMed: 3480379]
  355. Hoffmann D, Djordjevic MV, Fan J, Zang E, Glynn T, Connolly GN. Five leading U.S. commercial brands of moist snuff in 1994: assessment of carcinogenic N-nitrosamines. Journal of the National Cancer Institute. 1995;87(24):1862–9. [PubMed: 7494230]
  356. Hoffmann D, Hecht SS. Advances in tobacco carcinogenesis. Handbook of Experimental Pharmacology. Cooper CS, Grover PL, editors. 94/I. Heidelberg (Germany): Springer-Verlag; 1990. pp. 63–102.
  357. Hoffmann D, Hoffmann I, El Bayoumy K. The less harmful cigarette: a controversial issue. A tribute to Ernst L. Wynder. Chemical Research in Toxicology. 2001;14(7):767–90. [PubMed: 11453723]
  358. Hoffmann D, Schmeltz I, Hecht SS, Wynder EL. Tobacco carcinogenesis. Poly-cyclic Hydrocarbons and Cancer. 1st ed. Gelboin H, Ts’o POP, editors. New York: Academic Press; 1978. pp. 85–117.
  359. Hosomi Y, Gemma A, Hosoya Y, Nara M, Okano T, Takenaka K, Yoshimura A, Koizumi K, Shimizu K, Kudoh S. Somatic mutation of the Caspase-5 gene in human lung cancer. International Journal of Molecular Medicine. 2003;12(4):443–6. [PubMed: 12964016]
  360. Hosomi Y, Yokose T, Hirose Y, Nakajima R, Nagai K, Nishiwaki Y, Ochiai A. Increased cyclooxygenase 2 (COX-2) expression occurs frequently in precursor lesions of human adenocarcinoma of the lung. Lung Cancer. 2000;30(2):73–81. [PubMed: 11086200]
  361. Hou S-M, Fält S, Angelini S, Yang K, Nyberg F, Lambert B, Hemminki K. The XPD variant alleles are associated with increased aromatic DNA adduct level and lung cancer risk. Carcinogenesis. 2002;23(4):599–603. [PubMed: 11960912]
  362. Houlston RS. CYP1A1polymorphismsandlungcancerrisk: a meta-analysis. Pharmacogenetics. 2000;10(2):105–14. [PubMed: 10761998]
  363. Houtsmuller AB, Rademakers S, Nigg AL, Hoogstraten D, Hoeijmakers JHJ, Vermeulen W. Action of DNA repair endonuclease ERCC1/XPF in living cells. Science. 1999;284(5416):958–61. [PubMed: 10320375]
  364. Hsieh ETK, Shepherd FA, Tsao M-S. Co-expression of epidermal growth factor receptor and transforming growth factor-α is independent of ras mutations in lung adenocarcinoma. Lung Cancer. 2000;29(2):151–7. [PubMed: 10963846]
  365. Hsieh L-L, Liou S-H, Chiu L-L, Chen Y-H. Glutathione S-transferase (GST) M1 and GST T1 genotypes and hematopoietic effects of benzene exposure. Archives of Toxicology. 1999;73(2):80–2. [PubMed: 10350187]
  366. Hsu TC, Johnston DA, Cherry LM, Ramkissoon D, Schantz SP, Jessup JM, Winn RJ, Shirley L, Furlong C. Sensitivity to genotoxic effects of bleomycin in humans: possible relationship to environmental carcinogenesis. International Journal of Cancer. 1989;43(3):403–9. [PubMed: 2466800]
  367. Hu Z, Wei Q, Wang X, Shen H. DNA repair gene XPD polymorphism and lung cancer risk: a meta-analysis. Lung Cancer. 2004;46(1):1–10. [PubMed: 15364127]
  368. Huang DCS, Strasser A. BH3-only proteins—essential initiators of apoptotic cell death. Cell. 2000;103(6):839–42. [PubMed: 11136969]
  369. Huang JC, Hsu DS, Kazantsev A, Sancar A. Substrate spectrum of human excinuclease: repair of abasic sites, methylated bases, mismatches, and bulky adducts. Proceedings of the National Academy of Sciences of the United States of America. 1994;91(25):12213–7. [PMC free article: PMC45407] [PubMed: 7991608]
  370. Huang M, Stolina M, Sharma S, Mao JT, Zhu L, Miller PW, Wollman J, Herschman H, Dubinett SM. Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin 12 production. Cancer Research. 1998;58(6):1208–16. [PubMed: 9515807]
  371. Huang X-E, Hamajima N, Katsuda N, Matsuo K, Hirose K, Mizutani M, Iwata H, Miura S, Xiang J, Tokudome S, et al. Association of p53 codon Arg72Pro and p73 G4C14-to-A4T14 at exon 2 genetic polymorphisms with the risk of Japanese breast cancer. Breast Cancer. 2003;10(4):307–11. [PubMed: 14634508]
  372. Hübscher U, Maga G, Spadari S. Eukaryotic DNA polymerases. Annual Review of Biochemistry. 2002;71:133–63. [PubMed: 12045093]
  373. Hung RJ, Boffetta P, Brennan P, Malaveille C, Hautefeuille A, Donato F, Gelatti U, Spaliviero M, Placidi D, Carta A, et al. GST, NAT, SULT1A1, CYP1B1 genetic polymorphisms, interactions with environmental exposures and bladder cancer risk in a high-risk population. International Journal of Cancer. 2004;110(4):598–604. [PubMed: 15122594]
  374. Hung RJ, McKay JD, Gaborieau V, Boffetta P, Hashibe M, Zaridze D, Mukeria A, Szeszenia-Dabrowska N, Lissowska J, Rudnai P, et al. A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature. 2008;452(7187):633–7. [PubMed: 18385738]
  375. Husgafvel-Pursiainen K, Kannio A. Cigarette smoking and p53 mutations in lung cancer and bladder cancer. Environmental Health Perspectives. 1996;104( Suppl 3):553–6. [PMC free article: PMC1469661] [PubMed: 8781382]
  376. Hussain SP, Amstad P, Raja K, Sawyer M, Hofseth L, Shields PG, Hewer A, Phillips DH, Ryberg D, Haugen A, et al. Mutability of p53 hotspot codons to benzo(a) pyrene diol epoxide (BPDE) and the frequency of p53 mutations in nontumorous human lung. Cancer Research. 2001;61(17):6350–5. [PubMed: 11522624]
  377. Hutt JA, Vuillemenot BR, Barr EB, Grimes MJ, Hahn FF, Hobbs CH, March TH, Gigliotti AP, Seilkop SK, Finch GL, et al. Life-span inhalation exposure to mainstream cigarette smoke induces lung cancer in B6C3F1 mice through genetic and epigenetic pathways. Carcinogenesis. 2005;26(11):1999–2009. [PubMed: 15944214]
  378. Hyytinen ER, Frierson HF Jr, Sipe TW, Li CL, Degeorges A, Sikes RA, Chung LW, Dong JT. Loss of heterozygosity and lack of mutations of the XPG/ERCC5 DNA repair gene at 13q33 in prostate cancer. Prostate. 1999;41(3):190–5. [PubMed: 10517877]
  379. Igney FH, Krammer PH. Death and anti-death: tumour resistance to apoptosis. Nature Reviews Cancer. 2002;2(4):277–88. [PubMed: 12001989]
  380. Inoue O, Seiji K, Kasahara M, Nakatsuka H, Watanabe T, Yin SG, Li GL, Cai SX, Jin C, Ikeda M. Determination of catechol and quinol in the urine of workers exposed to benzene. British Journal of Industrial Medicine. 1988;45(7):487–92. [PMC free article: PMC1009634] [PubMed: 3395585]
  381. Inoue O, Seiji K, Nakatsuka H, Watanabe T, Yin S, Li GL, Cai SX, Jin C, Ikeda M. Excretion of 1,2,4-benzenetriol in the urine of workers exposed to benzene. British Journal of Industrial Medicine. 1989;46(8):559–65. [PMC free article: PMC1009826] [PubMed: 2775675]
  382. International Agency for Research on Cancer. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Some Aromatic Amines, Hydrazine and Related Substances, N-Nitroso Compounds and Miscellaneous Alkylating Agents. Vol. 4. Lyon (France): International Agency for Research on Cancer; 1974. pp. 127–36.
  383. International Agency for Research on Cancer. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Some Monomers, Plastics and Synthetic Elastomers, and Acrolein. Vol. 19. Lyon (France): International Agency for Research on Cancer; 1979. pp. 377–438.
  384. International Agency for Research on Cancer. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Some Industrial Chemicals and Dyestuffs. Vol. 29. Lyon (France): International Agency for Research on Cancer; 1982. pp. 93–148.
  385. International Agency for Research on Cancer. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Polynuclear Aromatic Compounds, Part 1: Chemical, Environmental and Experimental Data. Vol. 32. Lyon (France): International Agency for Research on Cancer; 1983. pp. 33–451.
  386. International Agency for Research on Cancer. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Tobacco Smoking. Vol. 38. Lyon (France): International Agency for Research on Cancer; 1986.
  387. International Agency for Research on Cancer. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Some Naturally Occurring Substances: Food Items and Constituents, Heterocyclic Aromatic Amines and Mycotoxins. Vol. 56. Lyon (France): International Agency for Research on Cancer; 1993.
  388. International Agency for Research on Cancer. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Some Industrial Chemicals. Vol. 60. Lyon (France): International Agency for Research on Cancer; 1994.
  389. International Agency for Research on Cancer. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Dry Cleaning, Some Chlorinated Solvents and Other Industrial Chemicals. Vol. 63. Lyon (France): International Agency for Research on Cancer; 1995a. pp. 393–407. [PMC free article: PMC7681564] [PubMed: 9139128]
  390. International Agency for Research on Cancer. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Human Papillomaviruses. Vol. 64. Lyon (France): International Agency for Research on Cancer; 1995b. pp. 35–378.
  391. International Agency for Research on Cancer. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Wood Dust and Formaldehyde. Vol. 62. Lyon (France): International Agency for Research on Cancer; 1995c. pp. 217–362.
  392. International Agency for Research on Cancer. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Re-evaluation of Some Organic Chemicals, Hydrazine and Hydrogen Peroxide. Vol. 71. Lyon (France): International Agency for Research on Cancer; 1999. [PMC free article: PMC7681305] [PubMed: 10507919]
  393. International Agency for Research on Cancer. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Tobacco Smoke and Involuntary Smoking. Vol. 83. Lyon (France): International Agency for Research on Cancer; 2004. [PMC free article: PMC4781536] [PubMed: 15285078]
  394. International Agency for Research on Cancer. IARC TP53 Mutation Database, October 2006. [accessed: November 8, 2006]. < http://www-p53​.iarc.fr/>.
  395. International Agency for Research on Cancer. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Smokeless Tobacco and Tobacco-Specific Nitrosamines. Vol. 89. Lyon (France): International Agency for Research on Cancer; 2007. [PMC free article: PMC4781254] [PubMed: 18335640]
  396. International Agency for Research on Cancer. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Air Pollution, Part 1, Some Non-heterocyclic Polycyclic Aromatic Hydrocarbons and Some Related Industrial Exposures. Vol. 92. Lyon (France): International Agency for Research on Cancer; in press.
  397. Ishibe N, Wiencke JK, Zuo ZF, McMillan A, Spitz M, Kelsey KT. Susceptibility to lung cancer in light smokers associated with CYP1A1 polymorphisms in Mexican- and African-Americans. Cancer Epidemiology, Bio-markers & Prevention. 1997;6(12):1075–80. [PubMed: 9419406]
  398. Jalas JR, Hecht SS, Murphy SE. Cytochrome P450 enzymes as catalysts of metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, a tobacco-specific carcinogen. Chemical Research in Toxicology. 2005;18(2):95–110. [PubMed: 15720112]
  399. Jänne PA, Johnson BE. The role of MYC, JUN, and FOS oncogenes. Lung Cancer: Principles and Practice. 2nd ed. Pass HI, Mitchell JB, Johnson DH, Turrisi ATM, Minna JD, editors. Philadelphia: Lippincott Williams & Wilkins; 2000. pp. 98–119.
  400. Jaskula-Sztul R, Sokolowski W, Gajecka M, Szyfter K. Association of arylamine N-acetyltransferase (NAT1 and NAT2) genotypes with urinary bladder cancer risk. Journal of Applied Genetics. 2001;42(2):223–31. [PubMed: 14564055]
  401. Jeggo PA, Hafezparast M, Thompson AF, Broughton BC, Kaur GP, Zdzienicka MZ, Athwal RS. Localization of a DNA repair gene (XRCC5) involved in double-strand-break rejoining to human chromosome 2. Proceedings of the National Academy of Sciences of the United States of America. 1992;89(14):6423–7. [PMC free article: PMC49513] [PubMed: 1631138]
  402. Jeon H-S, Kim KM, Park SH, Lee SY, Choi JE, Lee GY, Kam S, Park RW, Kim I-S, Kim CH, et al. Relationship between XPG codon 1104 polymorphism and risk of primary lung cancer. Carcinogenesis. 2003;24(10):1677–81. [PubMed: 12869423]
  403. Jernstrom B, Funk M, Frank H, Mannervik B, Seidel A. Glutathione S-transferase A1-1-catalysed conjugation of bay and fjord region diol epoxides or polycyclic aromatic hydrocarbons with glutathione. Carcinogenesis. 1996;17(7):1491–8. [PubMed: 8706254]
  404. Ji H, Ramsey MR, Hayes DN, Fan C, McNamara K, Kozlowski P, Torrice C, Wu MC, Shimamura T, Perera SA, et al. LKB1 modulates lung cancer differentiation and metastasis. Nature. 2007;448(7155):801–10. [PubMed: 17676035]
  405. Jin X, Wu X, Roth JA, Amos CI, King TM, Branch C, Honn SE, Spitz MR. Higher lung cancer risk for younger African-Americans with the Pro/Pro p53 genotype. Carcinogenesis. 1995;16(9):2205–8. [PubMed: 7554076]
  406. Jin Z, Gao F, Flagg T, Deng X. Nicotine induces multisite phosphorylation of Bad in association with suppression of apoptosis. Journal of Biological Chemistry. 2004a;279(22):23837–44. [PubMed: 15037618]
  407. Jin Z, Gao F, Flagg T, Deng X. Tobacco-specific nitrosa-mine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone promotes functional cooperation of Bcl2 and c-Myc through phosphorylation in regulating cell survival and proliferation. Journal of Biological Chemistry. 2004b;279(38):40209–19. [PubMed: 15210690]
  408. Jin Z, Xin M, Deng X. Survival function of protein kinase Cι as a novel nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-activated Bad kinase. Journal of Biological Chemistry. 2005;280(16):16045–52. [PubMed: 15705582]
  409. Johns LE, Houlston RS. N-acetyl transferase-2 and bladder cancer risk: a meta-analysis. Environmental and Molecular Mutagenesis. 2000;36(3):221–7. [PubMed: 11044903]
  410. Johnson BE, Jänne PA. Epidermal growth factor receptor mutations in patients with non-small cell lung cancer. Cancer Research. 2005;65(17):7525–9. [PubMed: 16140912]
  411. Johnson L, Mercer K, Greenbaum D, Bronson RT, Crowley D, Tuveson DA, Jacks T. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature. 2001a;410(6832):1111–6. [PubMed: 11323676]
  412. Johnson RE, Haracska L, Prakash S, Prakash L. Role of DNA polymerase η in the bypass of a (6-4) TT photoproduct. Molecular and Cellular Biology. 2001b;21(10):3558–63. [PMC free article: PMC100277] [PubMed: 11313481]
  413. Johnson RE, Kondratick CM, Prakash S, Prakash L. hRAD30 Mutations in the variant form of xeroderma pigmentosum. Science. 1999;285(5425):263–5. [PubMed: 10398605]
  414. Johnson RE, Washington MT, Haracska L, Prakash S, Prakash L. Eukaryotic polymerases ι and ζ act sequentially to bypass DNA lesions. Nature. 2000;406(6799):1015–9. [PubMed: 10984059]
  415. Johnston-Early A, Cohen MH, Minna JD, Paxton LM, Fossieck BE Jr, Ihde DC, Bunn PA Jr, Matthews MJ, Makuch R. Smoking abstinence and small cell lung cancer survival. An association. JAMA: the Journal of the American Medical Association. 1980;244(19):2175–9. [PubMed: 6252357]
  416. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nature Reviews Genetics. 2002;3(6):415–28. [PubMed: 12042769]
  417. Jongeneelen FJ. Biological monitoring of environmental exposure to polycyclic aromatic hydrocarbons; 1-hydroxypyrene in urine of people. Toxicology Letters. 1994;72(1–3):205–11. [PubMed: 8202933]
  418. Jongeneelen FJ. Benchmark guideline for urinary 1-hydroxypyrene as biomarker of occupational exposure to polycyclic aromatic hydrocarbons. Annals of Occupational Hygiene. 2001;45(1):3–13. [PubMed: 11137694]
  419. Jongeneelen FJ, Anzion RB, Leijdekkers CM, Bos RP, Henderson PT. 1-Hydroxypyrene in human urine after exposure to coal tar and a coal tar derived product. International Archives of Occupational and Environmental Health. 1985;57(1):47–55. [PubMed: 4077281]
  420. Jull BA, Plummer HK III, Schuller HM. Nicotinic receptor-mediated activation by the tobacco-specific nitro-samine NNK of a Raf-1/MAP kinase pathway, resulting in phosphorylation of c-myc in human small cell lung carcinoma cells and pulmonary neuroendocrine cells. Journal of Cancer Research and Clinical Oncology. 2001;127(12):707–17. [PubMed: 11768610]
  421. Junker K, Stachetzki U, Rademacher D, Linder A, Macha H-N, Heinecke A, Müller K-M, Thomas M. HER2/neu expression and amplification in non-small cell lung cancer prior to and after neoadjuvant therapy. Lung Cancer. 2005;48(1):59–67. [PubMed: 15777971]
  422. Kadlubar FF, Beland FA. Chemical properties of ultimate carcinogenic metabolites of arylamines and arylamides. Polycyclic Hydrocarbons and Carcinogenesis. ACS Symposium Series 283. Harvey RG, editor. Washington: American Chemical Society; 1985. pp. 341–70.
  423. Kaghad M, Bonnet H, Yang A, Creancier L, Biscan J-C, Valent A, Minty A, Chalon P, Lelias J-M, Dumont X, et al. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell. 1997;90(4):809–19. [PubMed: 9288759]
  424. Kaina B, Fritz G, Mitra S, Coquerelle T. Transfection and expression of human O6-methylguanine-DNA methyltransferase (MGMT) cDNA in Chinese hamster cells: the role of MGMT in protection against the genotoxic effects of alkylating agents. Carcinogenesis. 1991;12(10):1857–67. [PubMed: 1657427]
  425. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harsh-man K, Tavtigian SV, Stockert E, Day RS III, Johnson BE, Skolnick MH. A cell cycle regulator potentially involved in genesis of many tumor types. Science. 1994;264(5157):436–40. [PubMed: 8153634]
  426. Kanematsu T, Yano S, Uehara H, Bando Y, Sone S. Phosphorylation, but not overexpression, of epidermal growth factor receptor is associated with poor prognosis of non-small cell lung cancer patients. Oncology Research. 2003;13(5):289–98. [PubMed: 12688680]
  427. Kang MJ, Oh Y-M, Lee JC, Kim DG, Park MJ, Lee MG, Hyun IG, Han SK, Shim Y-S, Jung K-S. Lung matrix metalloproteinase-9 correlates with cigarette smoking and obstruction of airflow. Journal of Korean Medical Science. 2003;18(6):821–7. [PMC free article: PMC3055149] [PubMed: 14676438]
  428. Kangavari S, Matetzky S, Shah PK, Yano J, Chyu K-Y, Fish-bein MC, Cercek B. Smoking increases inflammation and metalloproteinase expression in human carotid atherosclerotic plaques. Journal of Cardiovascular Pharmacology and Therapeutics. 2004;9(4):291–8. [PubMed: 15678248]
  429. Kantarci OH, Lesnick TG, Yang P, Meyer RL, Hebrink DD, McMurray CT, Weinshenker BG. Myeloperoxidase –463 (G → A) polymorphism associated with lower risk of lung cancer. Mayo Clinic Proceedings. 2002;77(1):17–22. [PubMed: 11794452]
  430. Kanuri M, Minko IG, Nechev LV, Harris TM, Harris CM, Lloyd RS. Error prone translesion synthesis past γ-hydroxypropano deoxyguanosine, the primary acrolein-derived adduct in mammalian cells. Journal of Biological Chemistry. 2002;277(21):18257–65. [PubMed: 11889127]
  431. Kari C, Chan TO, Rocha de Quadros M, Rodeck U. Targeting the epidermal growth factor receptor in cancer: apoptosis takes center stage. Cancer Research. 2003;63(1):1–5. [PubMed: 12517767]
  432. Karran P. Mechanisms of tolerance to DNA damaging therapeutic drugs. Carcinogenesis. 2001;22(12):1931–7. [PubMed: 11751422]
  433. Karuman P, Gozani O, Odze RD, Zhou XC, Zhu H, Shaw R, Brien TP, Bozzuto CD, Ooi D, Cantley LC, et al. The Peutz-Jegher gene product LKB1 is a mediator of p53-dependent cell death. Molecular Cell. 2001;7(6):1307–19. [PubMed: 11430832]
  434. Kasai H, Iwamoto-Tanaka N, Miyamoto T, Kawanami K, Kawanami S, Kido R, Ikeda M. Life style and urinary 8-hydroxydeoxyguanosine, a marker of oxidative DNA damage: effects of exercise, working conditions, meat intake, body mass index, and smoking. Japanese Journal of Cancer Research. 2001;92(1):9–15. [PMC free article: PMC5926588] [PubMed: 11173538]
  435. Kato S, Bowman EF, Harrington A, Blomeke B, Shields PG. Human lung carcinogen-DNA adduct levels mediated by genetic polymorphisms in vivo. Journal of the National Cancer Institute. 1995;87(12):902–7. [PubMed: 7666479]
  436. Katoh T, Kaneko S, Taksawa S, Nagata N, Inatomi H, Ikemura K, Itoh H, Matsumoto T, Kawamoto T, Bell DA. Human glutathione-S-transferase P1 polymorphism and susceptibility to smoking related epithelial cancer; oral, lung, gastric, colorectal and urothelial cancer. Pharmacogenetics. 1999;9(2):165–9. [PubMed: 10376763]
  437. Kauffmann-Zeh A, Rodriguez-Viciana P, Ulrich E, Gilbert C, Coffer P, Downward J, Evan G. Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB. Nature. 1997;385(6616):544–8. [PubMed: 9020362]
  438. Kaur TB, Travaline JM, Gaughan JP, Richie JP Jr, Stellman SD, Lazarus P. Role of polymorphisms in codons 143 and 160 of the O6-alkylguanine DNA alkyltransferase gene in lung cancer risk. Cancer Epidemiology, Bio-markers & Prevention. 2000;9(3):339–42. [PubMed: 10750675]
  439. Kawajiri K, Nakachi K, Imai K, Watanabe J, Hayashi S-I. Germ line polymorphisms of p53 and CYP1A1 genes involved in human lung cancer. Carcinogenesis. 1993;14(6):1085–9. [PubMed: 8389669]
  440. Kawajiri K, Nakachi K, Imai K, Yoshii A, Shinoda N, Watanabe J. Identification of genetically high risk individuals to lung cancer by DNA polymorphisms of the cytochrome P450 0IA1 gene. FEBS Letters. 1990;263(1):131–3. [PubMed: 1691986]
  441. Kelley DJ, Mestre JR, Subbaramaiah K, Sacks PG, Schantz SP, Tanabe T, Inoue H, Ramonetti JT, Dannenberg AJ. Benzo[a]pyrene up-regulates cyclooxygenase-2 gene expression in oral epithelial cells. Carcinogenesis. 1997;18(4):795–9. [PubMed: 9111217]
  442. Kennedy SG, Wagner AJ, Conzen SD, Jordan J, Bellacosa A, Tsichlis PN, Hay N. The PI 3-kinase/Akt signaling pathway delivers an anti-apoptotic signal. Genes & Development. 1997;11(6):701–13. [PubMed: 9087425]
  443. Keohavong P, DeMichele MAA, Melacrinos AC, Landreneau RJ, Weyant RJ, Siegfried JM. Detection of K-ras mutations in lung carcinomas: relationship to prognosis. Clinical Cancer Research. 1996;2(2):411–8. [PubMed: 9816185]
  444. Kern JA, Schwartz DA, Nordberg JE, Weiner DB, Greene MI, Torney L, Robinson RA. p185neu Expression in human lung adenocarcinomas predicts shortened survival. Cancer Research. 1990;50(16):5184–7. [PubMed: 1974168]
  445. Kerr JFR, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. British Journal of Cancer. 1972;26(4):239–57. [PMC free article: PMC2008650] [PubMed: 4561027]
  446. Khan QA, Vousden KH, Dipple A. Lack of p53-mediated G1 arrest in response to an environmental carcinogen. Oncology. 1999;57(3):258–64. [PubMed: 10545796]
  447. Khokhlatchev A, Rabizadeh S, Xavier R, Nedwidek M, Chen T, Zhang X, Seed B, Ayruch J. Identification of a novel ras-regulated proapoptotic pathway. Current Biology. 2002;12(4):253–65. [PubMed: 11864565]
  448. Khwaja A. Akt is more than just a Bad kinase. Nature. 1999;401(6748):33–4. [PubMed: 10485701]
  449. Kihara M, Kihara M, Noda K. Lung cancer risk of GSTM1 null genotype is dependent on the extent of tobacco smoke exposure. Carcinogenesis. 1994;15(2):415–8. [PubMed: 8313538]
  450. Kihara M, Kihara M, Noda K. Lung cancer risk of the GSTM1 null genotype is enhanced in the presence of the GSTP1 mutated genotype in male Japanese smokers. Cancer Letters. 1999;137(1):53–60. [PubMed: 10376794]
  451. Kihara M, Kihara M, Noda K, Okamoto N. Increased risk for lung cancer in Japanese smokers with mu class glutathione-S-transferase gene deficiency. Cancer Letters. 1993;71(1–3):151–5. [PubMed: 8364889]
  452. Kim D, Guengerich FP. Cytochrome P450 activation of arylamines and heterocyclic amines. Annual Review of Pharmacology and Toxicology. 2005;45:27–49. [PubMed: 15822170]
  453. Kim D-H, Kim JS, Ji Y-I, Shim YM, Kim H, Han J, Park J. Hypermethylation of RASSF1A promoter is associated with the age at starting smoking and a poor prognosis in primary non-small cell lung cancer. Cancer Research. 2003;63(13):3743–6. [PubMed: 12839968]
  454. Kim D-H, Nelson HH, Wiencke JK, Christiani DC, Wain JC, Mark EJ, Kelsey KT. Promoter methylation of DAP-kinase: association with advanced stage in non-small cell lung cancer. Oncogene. 2001;20(14):1765–70. [PubMed: 11313923]
  455. Kim JH, Sherman ME, Curriero FC, Guengerich FP, Strickland PT, Sutter TR. Expression of cytochromes P450 1A1 and 1B1 in human lung from smokers, non-smokers, and ex-smokers. Toxicology and Applied Pharmacology. 2004a;199(3):210–9. [PubMed: 15364538]
  456. Kim PM, Wells PG. Genoprotection by UDP-glucuro-nosyltransferases in peroxidase-dependent, reactive oxygen species-mediated micronucleus initiation by the carcinogens 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and benzo[a]pyrene. Cancer Research. 1996;56(7):1526–32. [PubMed: 8603397]
  457. Kim SY, Choi JK, Cho YH, Chung EJ, Paek D, Chung HW. Chromosomal aberrations in workers exposed to low levels of benzene: association with genetic polymorphisms. Pharmacogenetics. 2004b;14(7):453–63. [PubMed: 15226677]
  458. Kinzler KW, Zehnbauer BA, Brodeur GM, Seeger RC, Trent JM, Meltzer PS, Vogelstein B. Amplification units containing human N-myc and c-myc genes. Proceedings of the National Academy of Sciences of the United States of America. 1986;83(4):1031–5. [PMC free article: PMC323004] [PubMed: 3006024]
  459. Klungland A, Lindahl T. Second pathway for completion of human DNA base excision-repair: reconstitution with purified proteins and requirement for DNase IV (FEN1). EMBO Journal. 1997;16(11):3341–8. [PMC free article: PMC1169950] [PubMed: 9214649]
  460. Koch KS, Fletcher RG, Grond MP, Inyang AI, Lu XP, Brenner DA, Leffert HL. Inactivation of plasmid reporter gene expression by one benzo(a)pyrene diol-epoxide DNA adduct in adult rat hepatocytes. Cancer Research. 1993;53(10 Suppl):2279–86. [PubMed: 8485714]
  461. Kohno T, Shinmura K, Tosaka M, Tani M, Kim S-R, Sugimura H, Nohmi T, Kasai H, Yokota J. Genetic polymorphisms and alternative splicing of the hOGG1 gene, that is involved in the repair of 8-hydroxyguanine in damaged DNA. Oncogene. 1998;16(25):3219–25. [PubMed: 9681819]
  462. Koi M, Umar A, Chauhan DP, Cherian SP, Carethers JM, Kunkel TA, Boland CR. Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N’-nitro-N-nitroso-guanidine tolerance in colon tumor cells with homozygous hMLH1 mutation. Cancer Research. 1994;54(16):4308–12. [PubMed: 8044777]
  463. Koki A, Khan NK, Woerner BM, Dannenberg AJ, Olson L, Seibert K, Edwards D, Hardy M, Isakson P, Masferrer JL. Cyclooxygenase-2 in human pathological disease. Advances in Experimental Medicine and Biology. 2002;507:177–84. [PubMed: 12664583]
  464. Kopplin A, Eberle-Adamkiewicz G, Glüsenkamp KH, Nehls P, Kirstein U. Urinary excretion of 3-methyladenine and 3-ethyladenine after controlled exposure to tobacco smoke. Carcinogenesis. 1995;16(11):2637–41. [PubMed: 7586179]
  465. Korsmeyer SJ. Regulators of cell death. Trends in Genetics. 1995;11(3):101–5. [PubMed: 7732571]
  466. Korsmeyer SJ. BCL-2 gene family and the regulation of programmed cell death. Cancer Research. 1999;59(7 Suppl):1693s–1700s. [PubMed: 10197582]
  467. Kozack R, Seo K-Y, Jelinsky SA, Loechler EL. Toward an understanding of the role of DNA adduct conformation in defining mutagenic mechanism based on studies of the major adduct (formed at N2-dG) of the potent environmental carcinogen, benzo[a]pyrene. Mutation Research. 2000;450(1–2):41–59. [PubMed: 10838133]
  468. Kozekov ID, Nechev LV, Moseley MS, Harris CM, Rizzo CJ, Stone MP, Harris TM. DNA interchain cross-links formed by acrolein and crotonaldehyde. Journal of the American Chemical Society. 2003;125(1):50–61. [PubMed: 12515506]
  469. Krause RJ, Elfarra AA. Oxidation of butadiene monoxide to meso- and (±)-diepoxybutane by cDNA-expressed human cytochrome P450s and by mouse, rat, and human liver microsomes: evidence for preferential hydration of meso-diepoxybutane in rat and human liver microsomes. Archives of Biochemistry and Biophysics. 1997;337(2):176–84. [PubMed: 9016811]
  470. Kreuzer M, Heinrich J, Kreienbrock L, Rosario AS, Gerken M, Wichmann HE. Risk factors for lung cancer among nonsmoking women. International Journal of Cancer. 2002;100(6):706–13. [PubMed: 12209611]
  471. Kreuzer M, Kreienbrock L, Gerken M, Heinrich J, Bruske-Hohlfeld I, Muller K-M, Wichmann HE. Risk factors for lung cancer in young adults. American Journal of Epidemiology. 1998;147(11):1028–37. [PubMed: 9620046]
  472. Kriek E, Rojas M, Alexandrov K, Bartsch H. Polycyclic aromatic hydrocarbon-DNA adducts in humans: relevance as biomarkers for exposure and cancer risk. Mutation Research. 1998;400(1–2):215–31. [PubMed: 9685648]
  473. Kris MG, Natale RB, Herbst RS, Lynch TJ Jr, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H, Sandler A, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non–small cell lung cancer: a randomized trial. JAMA: The Journal of the American Medical Association. 2003;290(16):2149–58. [PubMed: 14570950]
  474. Kroemer G. Mitochondrial control of apoptosis: an overview. Biochemical Society Symposium. 1999;66:1–15. [PubMed: 10989652]
  475. Krysan K, Merchant FH, Zhu L, Dohadwala M, Luo J, Ling Y, Heuze-Vourc’h N, Põld M, Seligson D, Chia D, et al. COX-2-dependent stabilization of survivin in non-small cell lung cancer. FASEB Journal. 2004;18(1):206–8. [PubMed: 14597555]
  476. Krzesniak M, Butkiewicz D, Samojedny A, Choraży M, Rusin M. Polymorphisms in TDG and MGMT genes–epidemiological and functional study in lung cancer patients from Poland. Annals of Human Genetics. 2004;68(4):300–12. [PubMed: 15225156]
  477. Kubota Y, Nash RA, Klungland A, Schar P, Barnes DE, Lindahl T. Reconstitution of DNA base excision-repair with purified human proteins: interaction between DNA polymerase beta and the XRCC1 protein. EMBO Journal. 1996;15(23):6662–70. [PMC free article: PMC452490] [PubMed: 8978692]
  478. Kurie JM, Shin HJ, Lee JS, Morice RC, Ro JY, Lippman SM, Hittelman WN, Yu R, Lee JJ, Hong WK. Increased epidermal growth factor receptor expression in metaplastic bronchial epithelium. Clinical Cancer Research. 1996;2(10):1787–93. [PubMed: 9816131]
  479. Lackmann GM, Salzberger U, Töllner U, Chen M, Carmella SG, Hecht SS. Metabolites of a tobacco-specific carcinogen in the urine from newborns. Journal of the National Cancer Institute. 1999;91(5):459–65. [PubMed: 10070946]
  480. Lahn M, Su C, Li S, Chedid M, Hanna KR, Graff JR, Sandusky GE, Ma D, Nikikiza C, Sundell KL, et al. Expression levels of protein kinase C-α in non-small-cell lung cancer. Clinical Lung Cancer. 2004;6(3):184–9. [PubMed: 15555220]
  481. Landi S. Mammalian class theta GST and differential susceptibility to carcinogens: a review. Mutation Research. 2000;463(3):247–83. [PubMed: 11018744]
  482. Landi MT, Sinha R, Lang NP, Kadlubar FF. Human cyto-chrome P4501A2. IARC Scientific Publications. 1999;(148):173–95. [PubMed: 10493258]
  483. Landi MT, Zocchetti C, Bernucci I, Kadlubar FF, Tannenbaum S, Skipper P, Bartsch H, Malaveille C, Shields P, Caporaso NE, et al. Cytochrome P4501A2: enzyme induction and genetic control in determining 4-ami-nobiphenyl-hemoglobin adduct levels. Cancer Epidemiology, Biomarkers & Prevention. 1996;5(9):693–8. [PubMed: 8877060]
  484. Lasko DD, Harvey SC, Malaikal SB, Kadlubar FF, Essigmann JM. Specificity of mutagenesis by 4-aminobiphenyl: a possible role for N-(deoxyadenosin-8-yl)-4-aminobi-phenyl as a premutational lesion. Journal of Biological Chemistry. 1988;263(30):15429–35. [PubMed: 3049608]
  485. Latham GJ, Zhou L, Harris CM, Harris TM, Lloyd RS. The replication fate of R- and S-styrene oxide adducts on adenine N6 is dependent on both the chirality of the lesion and the local sequence context. Journal of Biological Chemistry. 1993;268(31):23427–34. [PubMed: 8226868]
  486. LaVoie EJ, Rice JE. Structure-activity relationships among tricyclic polynuclear aromatic hydrocarbons. Polycyclic Aromatic Hydrocarbon Carcinogenesis: Structure-Activity Relationships. Yang SK, Silverman BD, editors. Vol. 1. Boca Raton (FL): CRC Press; 1988. pp. 151–75.
  487. Lawrence CW, Borden A, Banerjee SK, LeClerc JE. Mutation frequency and spectrum resulting from a single abasic site in a single–stranded vector. Nucleic Acids Research. 1990;18(8):2153–7. [PMC free article: PMC330696] [PubMed: 2186377]
  488. Lazarus P, Zheng Y, Runkle EA, Muscat JE, Wiener D. Genotype-phenotype correlation between the polymorphic UGT2B17 gene deletion and NNAL glucuronidation activities in human liver microsomes. Pharmacogenetics and Genomics. 2005;15(11):769–78. [PubMed: 16220109]
  489. Le Calvez F, Mukeria A, Hunt JD, Kelm O, Hung RJ, Tanière P, Brennan P, Boffetta P, Zaridze DG, Hainut P. TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: distinct patterns in never, former, and current smokers. Cancer Research. 2005;65(12):5076–83. [PubMed: 15958551]
  490. Le Marchand L, Derby KS, Murphy SE, Hecht SS, Hatsukami D, Carmella SG, Tiirikainen M, Wang H. Smokers with the CHRNA lung cancer-associated variants are exposed to higher levels of nicotine equivalents and a carcinogenic tobacco-specific nitrosamine. Cancer Research. 2008;68(22):9137–40. [PMC free article: PMC2587068] [PubMed: 19010884]
  491. Le Marchand L, Donlon T, Lum-Jones A, Seifried A, Wilkens LR. Association of the hOGG1 Ser326Cys polymorphism with lung cancer risk. Cancer Epidemiology, Biomarkers & Prevention. 2002;11(4):409–12. [PubMed: 11927502]
  492. Le Marchand L, Seifried A, Lum A, Wilkens LR. Association of the myeloperoxidase −463G→A polymorphism with lung cancer risk. Cancer Epidemiology, Biomarkers & Prevention. 2000;9(2):181–4. [PubMed: 10698479]
  493. Le Marchand L, Sivaraman L, Pierce L, Seifried A, Lum A, Wilkens LR, Lau AF. Associations of CYP1A1, GSTM1, and CYP2E1 polymorphisms with lung cancer suggest cell type specificities to tobacco carcinogens. Cancer Research. 1998;58(21):4858–63. [PubMed: 9809991]
  494. Leach FS, Nicolaides NC, Papadopoulos N, Liu B, Jen J, Parsons R, Peltomaki P, Sistonen P, Aaltonen LA, Nystrom-Lahti M. Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell. 1993;75(6):1215–25. [PubMed: 8261515]
  495. Lechner JF, Fugaro JM. RAS and ERBB 2. Lung Cancer Principles and Practice. 2nd ed. Pass HI, Mitchell JB, Johnson DH, Turrisi AT, Minna JD, editors. Philadelphia: Lippincott Williams & Wilkins; 2000. pp. 89–97.
  496. Lee BL, Ong HY, Ong YB, Ong CN. A sensitive liquid chromatographic method for the spectrophotometric determination of urinary trans, trans-muconic acid. Journal of Chromatography B. 2005;818(2):277–83. [PubMed: 15734170]
  497. Lee D-H, O’Connor TR, Pfeifer GP. Oxidative DNA damage induced by copper and hydrogen peroxide promotes CG→TT tandem mutations at methylated CpG dinu-cleotides in nucleotide excision repair-deficient cells. Nucleic Acids Research. 2002a;30(16):3566–73. [PMC free article: PMC134245] [PubMed: 12177298]
  498. Lee H-C, Lim MLR, Lu C-Y, Liu VWS, Fahn H-J, Zhang C, Nagley P, Wei Y-H. Concurrent increase of oxidative DNA damage and lipid peroxidation together with mitochondrial DNA mutation in human lung tissues during aging—smoking enhances oxidative stress on the aged tissues. Archives of Biochemistry and Biophysics. 1999a;362(2):309–16. [PubMed: 9989940]
  499. Lee J-M, Lee Y-C, Yang S-Y, Yang P-W, Luh S-P, Lee C-J, Chen C-J, Wu M-T. Genetic polymorphisms of XRCC1 and risk of the esophageal cancer. International Journal of Cancer. 2001;95(4):240–6. [PubMed: 11400117]
  500. Lee SH, Kim HS, Park WS, Kim SY, Lee KY, Kim SH, Lee JY, Yoo NJ. Non-small cell lung cancers frequently express phosphorylated Akt; an immunohistochemical study. APMIS. 2002b;110(7–8):587–92. [PubMed: 12390418]
  501. Lee WJ, Brennan P, Boffetta P, London SJ, Benhamou S, Rannug A, To-Figueras J, Ingelman-Sundberg M, Shields P, Gaspari L, et al. Microsomal epoxide hydrolase polymorphisms and lung cancer risk: a quantitative review. Biomarkers. 2002c;7(3):230–41. [PubMed: 12141066]
  502. Lemjabbar H, Li D, Gallup M, Sidhu S, Drori E, Basbaum C. Tobacco smoke-induced lung cell proliferation mediated by tumor necrosis factor α-converting enzyme and amphiregulin. Journal of Biological Chemistry. 2003;278(28):26202–7. [PubMed: 12711607]
  503. Levin JO. First international workshop on hydroxypyrene as a biomarker for PAH exposure in man—summary and conclusions. Science of the Total Environment. 1995;163(1–3):165–8. [PubMed: 7716494]
  504. Levin W, Wood AW, Yagi H, Dansette PM, Jerina DM, Conney AH. Carcinogenicity of benzo[a]pyrene 4,5-, 7,8-, and 9,10-oxides on mouse skin. Proceedings of the National Academy of Sciences of the United States of America. 1976;73(1):243–7. [PMC free article: PMC335877] [PubMed: 1061121]
  505. Levine RL, Miller H, Grollman A, Ohashi E, Ohmori H, Masutani C, Hanaoka F, Moriya M. Translesion DNA synthesis catalyzed by human pol η and pol κ across 1,N6-ethenodeoxyadenosine. Journal of Biological Chemistry. 2001;276(22):18717–21. [PubMed: 11376002]
  506. Lewis SJ, Cherry NM, Niven RM, Barber PV, Povey AC. Associations between smoking, GST genotypes and N7-methylguanine levels in DNA extracted from bronchial lavage cells. Mutation Research. 2004;559(1–2):11–8. [PubMed: 15066569]
  507. Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC, Altieri DC. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature. 1998a;396(6711):580–4. [PubMed: 9859993]
  508. Li G, Sturgis EM, Wang L-E, Chamberlain RM, Amos C, Spitz MR, El-Naggar A, Hong WK, Wei Q. Association of a p73 exon 2 G4C14-to-A4T14 polymorphism with risk of squamous cell carcinoma of the head and neck. Carcinogenesis. 2004a;25(7):1–7. [PubMed: 15180941]
  509. Li G, Wang L-E, Chamberlain RM, Amos CI, Spitz MR, Wei Q. p73 G4C14-to-A4T14 polymorphism and risk of lung cancer. Cancer Research. 2004b;64(19):6863–6. [PubMed: 15466174]
  510. Li GM, Modrich P. Restoration of mismatch repair to nuclear extracts of H6 colorectal tumor cells by a heterodimer of human MutL homologs. Proceedings of the National Academy of Sciences of the United States of America. 1995;92(6):1950–4. [PMC free article: PMC42400] [PubMed: 7892206]
  511. Li GM, Wang H, Romano LJ. Human MutSα specifically binds to DNA containing aminofluorene and acetylami-nofluorene adducts. Journal of Biological Chemistry. 1996;271(39):24084–8. [PubMed: 8798646]
  512. Li H, Yang P, Schwartz AG. Analysis of age of onset data from case–control family studies. Biometrics. 1998b;54(3):1030–9. [PubMed: 9750249]
  513. Li X, Hemminki K. Inherited predisposition to early onset lung cancer according to histological type. International Journal of Cancer. 2004;112(3):451–7. [PubMed: 15382071]
  514. Lijinsky W. Chemistry and Biology of N-Nitroso Compounds. New York: Cambridge University Press; 1992.
  515. Lin D, Lay JO Jr, Bryant MS, Malaveille C, Friesen M, Bartsch H, Lang NP, Kadlubar FF. Analysis of 4-ami-nobiphenyl-DNA adducts in human urinary bladder and lung by alkaline hydrolysis and negative ion gas chromatography-mass spectrometry. Environmental Health Perspectives. 1994;102(Suppl 6):11–6. [PMC free article: PMC1566844] [PubMed: 7889831]
  516. Lin P, Wang S-L, Wang H-J, Chen K-W, Lee H-S, Tsai K-J, Chen C-Y, Lee H. Association of CYP1A1 and microsomal epoxide hydrolase polymorphisms with lung squamous cell carcinoma. British Journal of Cancer. 2000;82(4):852–7. [PMC free article: PMC2374384] [PubMed: 10732758]
  517. Lin X, Böhle AS, Dohrmann P, Leuschner I, Schulz A, Kremer B, Fändrich F. Overexpression of phosphatidylinositol 3-kinase in human lung cancer. Langenbeck’s Archives of Surgery. 2001b;386(4):293–301. [PubMed: 11466572]
  518. Lindstrom J. Nicotinic acetylcholine receptors in health and disease. Molecular Neurobiology. 1997;15(2):193–222. [PubMed: 9396010]
  519. Lindstrom JM. Nicotinic acetylcholine receptors of muscles and nerves: comparison of their structures, functional roles, and vulnerability to pathology. Annals of the New York Academy of Sciences. 2003;998:41–52. [PubMed: 14592862]
  520. Lips J, Kaina B. DNA double-strand breaks trigger apoptosis in p53-deficient fibroblasts. Carcinogenesis. 2001;22(4):579–85. [PubMed: 11285192]
  521. Liu G, Zhou W, Wang LI, Park S, Miller DP, Xu L-L, Wain JC, Lynch TJ, Su L, Christiani DC. MPO and SOD2 polymorphisms, gender, and the risk of non-small cell lung carcinoma. Cancer Letters. 2004;214(1):69–79. [PubMed: 15331175]
  522. Liu L, Qin X, Gerson SL. Reduced lung tumorigenesis in human methylguanine DNA—methyltransferase transgenic mice achieved by expression of transgene within the target cell. Carcinogenesis. 1999;20(2):279–84. [PubMed: 10069465]
  523. Liu Z, Muehlbauer K-R, Schmeiser HH, Hergenhahn M, Belharazem D, Hollstein MC. p53 Mutations in benzo(a)pyrene-exposed human p53 knock-in murine fibroblasts correlate with p53 mutations in human lung tumors. Cancer Research. 2005;65(7):2583–7. [PubMed: 15805253]
  524. Lloyd DR, Hanawalt PC. p53-dependent global genomic repair of benzo[a]pyrene-7,8-diol-9,10-epoxide adducts in human cells. Cancer Research. 2000;60(3):517–21. [PubMed: 10676627]
  525. Lloyd DR, Hanawalt PC. p53 controls global nucleotide excision repair of low levels of structurally diverse benzo(g)chrysene-DNA adducts in human fibroblasts. Cancer Research. 2002;62(18):5288–94. [PubMed: 12234998]
  526. Loechler EL, Green CL, Essigmann JM. In vivo mutagenesis by O6-methylguanine built into a unique site in a viral genome. Proceedings of the National Academy of Sciences of the United States of America. 1984;81(20):6271–5. [PMC free article: PMC391905] [PubMed: 6093094]
  527. Loft S, Poulsen HE. Estimation of oxidative DNA damage in man from urinary excretion of repair products. Acta Biochimica Polonica. 1998;45(1):133–44. [PubMed: 9701506]
  528. Loktionova NA, Pegg AE. Interaction of mammalian O6-alkylguanine-DNA alkyltransferases with O6-benzylgua-nine. Biochemical Pharmacology. 2002;63(8):1431–42. [PubMed: 11996884]
  529. Lonardo F, Dragnev KH, Freemantle SJ, Ma Y, Memoli N, Sekula D, Knauth EA, Beebe JS, Dmitrovsky E. Evidence for the epidermal growth factor receptor as a target for lung cancer prevention. Clinical Cancer Research. 2002;8(1):54–60. [PubMed: 11801540]
  530. London SJ, Daly AK, Cooper J, Navidi WC, Carpenter CL, Idle JR. Polymorphism of glutathione-S-transferase M1 and lung cancer risk among African-Americans and Caucasians in Los Angeles County, California. Journal of the National Cancer Institute. 1995;87(16):1246–53. [PubMed: 7563171]
  531. London SJ, Yuan JM, Chung FL, Gao YT, Coetzee GA, Ross RK, Yu MC. Isothiocyanates, glutathione S-transferase M1 and T1 polymorphisms, and lung-cancer risk: a prospective study of men in Shanghai, China. Lancet. 2000;356(9231):724–9. [PubMed: 11085692]
  532. Longley MJ, Pierce AJ, Modrich P. DNA polymerase δ is required for human mismatch repair in vitro. Journal of Biological Chemistry. 1997;272(16):10917–21. [PubMed: 9099749]
  533. López-Larraza D, De Luca JC, Bianchi NO. The kinetics of DNA damage by bleomycin in mammalian cells. Mutation Research. 1990;232(1):57–61. [PubMed: 1697038]
  534. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE, Jacks T. p53 status and the efficacy of cancer therapy in vivo. Science. 1994;266(5186):807–10. [PubMed: 7973635]
  535. Lu L-M, Zavitz CCJ, Chen B, Kianpour S, Wan Y, Stampfli MR. Cigarette smoke impairs NK cell-dependent tumor immune surveillance. Journal of Immunology. 2007;178(2):936–43. [PubMed: 17202355]
  536. Lu W, Xing D, Qi J, Tan W, Miao X, Lin D. Genetic polymorphism in myeloperoxidase but not GSTM1 is associated with risk of lung squamous cell carcinoma in a Chinese population. International Journal of Cancer. 2002;102(3):275–9. [PubMed: 12397651]
  537. Luch A. Nature and nurture – lessons from chemical car-cinogenesis. Nature Reviews Cancer. 2005;5(2):113–25. [PubMed: 15660110]
  538. Lukas J, Parry D, Aagaard L, Mann DJ, Bartkova J, Strauss M, Peters G, Bartek J. Retinoblastoma-protein-dependent cell-cycle inhibition by the tumor suppressor p16. Nature. 1995;375(6531):503–6. [PubMed: 7777060]
  539. Lunn RM, Helzlsouer KJ, Parshad R, Umbach DM, Harris EL, Sanford KK, Bell DA. XPD polymorphisms: effects on DNA repair proficiency. Carcinogenesis. 2000;21(4):551–5. [PubMed: 10753184]
  540. Lunn RM, Langlois RG, Hsieh LL, Thompson CL, Bell DA. XRCC1 polymorphisms: effects on aflatoxin B1–DNA adducts and glycophorin A variant frequency. Cancer Research. 1999;59(11):2557–61. [PubMed: 10363972]
  541. Lutz RJ. Role of the BH3 (Bcl-2 homology 3) domain in the regulation of apoptosis and Bcl-2-related proteins. Biochemical Society Transactions. 2000;28(2):51–6. [PubMed: 10816098]
  542. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non–small-cell lung cancer to gefitinib. New England Journal of Medicine. 2004;350(21):2129–39. [PubMed: 15118073]
  543. Ma QW, Lin GF, Chen JG, Xiang CQ, Guo WC, Golka K, Shen JH. Polymorphism of N-acetyltransferase 2 (NAT2) gene polymorphism in Shanghai population: occupational and non-occupational bladder cancer patient groups. Biomedical and Environmental Sciences. 2004;17(3):291–8. [PubMed: 15602826]
  544. Ma S, Egyházi S, Ueno T, Lindholm C, Kreklau EL, Stierner U, Ringborg U, Hansson J. O6-methylguanine-DNA-methyltransferase expression and gene polymorphisms in relation to chemotherapeutic response in meta-static melanoma. British Journal of Cancer. 2003;89(8):1517–23. [PMC free article: PMC2394337] [PubMed: 14562026]
  545. Mabrouk I, Baccouche S, El-Abed R, Mokdad-Gargouri R, Mosbah A, Said S, Daoud J, Frikha M, Jlidi R, Gargouri A. No evidence of correlation between p53 codon 72 polymorphism and risk of bladder or breast carcinoma in Tunisian patients. Annals of the New York Academy of Sciences. 2003;1010:764–70. [PubMed: 15033824]
  546. Macklin KD, Maus ADJ, Pereira EFR, Albuquerque EX, Conti-Fine BM. Human vascular endothelial cells express functional nicotinic acetylcholine receptors. Journal of Pharmacology and Experimental Therapeutics. 1998;287(1):435–9. [PubMed: 9765366]
  547. Maclure M, Bryant MS, Skipper PL, Tannenbaum SR. Decline of the hemoglobin adduct of 4-minobiphenyl during withdrawal from smoking. Cancer Research. 1990;50(1):181–4. [PubMed: 2293553]
  548. Maehama T, Taylor GS, Dixon JE. PTEN and myotubularin: novel phosphoinositide phosphatases. Annual Review of Biochemistry. 2001;70:247–79. [PubMed: 11395408]
  549. Mai H, May WS, Gao F, Jin Z, Deng X. A functional role for nicotine in Bcl2 phosphorylation and suppression of apoptosis. Journal of Biological Chemistry. 2003;278(3):1886–91. [PubMed: 12421819]
  550. Mäkelä TP, Kere J, Winqvist R, Alitalo K. Intrachromosomal rearrangements fusing L-myc and rlf in small-cell lung cancer. Molecular and Cellular Biology. 1991;11(8):4015–21. [PMC free article: PMC361204] [PubMed: 1649386]
  551. Malats N, Camus-Radon A-M, Nyberg F, Ahrens W, Constantinescu V, Mukeria A, Benhamou S, Batura-Gabryel H, Bruske-Hohfeld I, Simonato L, et al. Lung cancer risk in nonsmokers and GSTM1 and GSTT1 genetic polymorphism. Cancer Epidemiology, Biomarkers & Prevention. 2000;9(8):827–33. [PubMed: 10952100]
  552. Malaveille C, Vineis P, Esteve J, Ohshima H, Brun G, Hautefeuille A, Gallet P, Ronco G, Terracini B, Bartsch H. Levels of mutagens in the urine of smokers of black and blond tobacco correlate with their risk of bladder cancer. Carcinogenesis. 1989;10(3):577–86. [PubMed: 2924402]
  553. Malkinson AM, You M. The intronic structure of cancer-related genes regulates susceptibility to cancer. Molecular Carcinogenesis. 1994;10(2):61–5. [PubMed: 8031465]
  554. Mancini R, Romano G, Sgambato A, Flamini G, Giovagnoli MR, Boninsegna A, Carraro C, Vecchione A, Cittadini A. Polycyclic aromatic hydrocarbon-DNA adducts in cervical smears of smokers and nonsmokers. Gynecologic Oncology. 1999;75(1):68–71. [PubMed: 10502428]
  555. Maneckjee R, Minna JD. Opioids induce while nicotine suppresses apoptosis in human lung cancer cells. Cell Growth & Differentiation. 1994;5(10):1033–40. [PubMed: 7848904]
  556. Mao H, Schnetz-Boutaud NC, Weisenseel JP, Marnett LJ, Stone MP. Duplex DNA catalyzes the chemical rearrangement of a malondialdehyde deoxyguanosine adduct. Proceedings of the National Academy of Sciences of the United States of America. 1999;96(12):6615–20. [PMC free article: PMC21963] [PubMed: 10359760]
  557. Mao L, Lee JS, Kurie JM, Fan YH, Lippman SM, Lee JJ, Ro JY, Broxson A, Yu R, Morice RC, et al. Clonal genetic alterations in the lungs of current and former smokers. Journal of the National Cancer Institute. 1997;89(12):857–62. [PubMed: 9196251]
  558. Marcus PM, Hayes RB, Vineis P, García-Closas M, Caporaso NE, Autrup H, Branch RA, Brockmöller J, Ishizaki T, Karakaya AE, et al. Cigarette smoking, N-acetyltrans-ferase 2 acetylation status, and bladder cancer risk: a case-series meta-analysis of a gene-environment interaction. Cancer Epidemiology, Biomarkers & Prevention. 2000a;9(5):461–7. [PubMed: 10815690]
  559. Marcus PM, Vineis P, Rothman N. NAT2 slow acetylation and bladder cancer risk: a meta-analysis of 22 case-control studies conducted in the general population. Pharmacogenetics. 2000b;10(2):115–22. [PubMed: 10761999]
  560. Margison GP, Povey AC, Kaina B, Santibáñez Koref MF. Variability and regulation of O6-alkylguanine-DNA alk-yltransferase. Carcinogenesis. 2003;24(4):625–35. [PubMed: 12727789]
  561. Mariatos G, Bothos J, Zacharatos P, Summers MK, Scolnick DM, Kittas C, Halazonetis TD, Gorgou-lis VG. Inactivating mutations targeting the chfr mitotic checkpoint gene in human lung cancer. Cancer Research. 2003;63(21):7185–9. [PubMed: 14612512]
  562. Marintchev A, Mullen MA, Maciejewski MW, Pan B, Gryk MR, Mullen GP. Solution structure of the single-strand break repair protein XRCC1 N-terminal domain. Nature Structural Biology. 1999;6(9):884–93. [PubMed: 10467102]
  563. Marsit CJ, Karagas MR, Danaee H, Liu M, Andrew A, Schned A, Nelson HH, Kelsey KT. Carcinogen exposure and gene promoter hypermethylation in bladder cancer. Carcinogenesis. 2006;27(1):112–6. [PubMed: 15987713]
  564. Martey CA, Pollock SJ, Turner CK, O’Reilly KMA, Baglole CJ, Phipps RP, Sime PJ. Cigarette smoke induces cyclooxygenase-2 and microsomal prostaglan-din E2 synthase in human lung fibroblasts: implications for lung inflammation and cancer. American Journal of Physiology – Lung Cellular and Molecular Physiology. 2004;287(5):L981–L991. [PubMed: 15234907]
  565. Martin SJ. Destabilizing influences in apoptosis: sowing the seeds of IAP destruction. Cell. 2002;109(7):793–6. [PubMed: 12110175]
  566. Martinez C, Agundez JAG, Olivera M, Martin R, Ladero JM, Benitez J. Lung cancer and mutations at the polymorphic NAT2 locus. Pharmacogenetics. 1995;5(4):207–14. [PubMed: 8528267]
  567. Marwick JA, Kirkham P, Gilmour PS, Donaldson K, Mac-Nee W, Rahman I. Cigarette smoke-induced oxidative stress and TGF-β1 increase p21waf1/cip1 expression in alveolar epithelial cells. Annals of the New York Academy of Sciences. 2002;973:278–83. [PubMed: 12485877]
  568. Maser RS, Monsen KJ, Nelms BE, Petrini JH. hMre11 and hRad50 nuclear foci are induced during the normal cellular response to DNA double-strand breaks. Molecular and Cellular Biology. 1997;17(10):6087–96. [PMC free article: PMC232458] [PubMed: 9315668]
  569. Massion PP, Taflan PM, Shyr Y, Rahman SMJ, Yildiz P, Shakthour B, Edgerton ME, Ninan M, Andersen JJ, Gonzalez AL. Early involvement of the phosphati-dylinositol 3-kinase/Akt pathway in lung cancer progression. American Journal of Respiratory and Critical Care Medicine. 2004;170(10):1088–94. [PubMed: 15317667]
  570. Masutani C, Kusumoto R, Iwai S, Hanaoka F. Mechanisms of accurate translesion synthesis by human DNA poly-merase η EMBO Journal. 2000;19(12):3100–9. [PMC free article: PMC203367] [PubMed: 10856253]
  571. Masutani C, Kusumoto R, Yamada A, Dohmae N, Yokio M, Yuasa M, Araki M, Iwai S, Takio K, Hanaoka F. The XPV (xeroderma pigmentosum variant) gene encodes human DNA polymerase η Nature. 1999;399(6737):700–4. [PubMed: 10385124]
  572. Matakidou A, Eisen T, Houlston RS. TP53 polymorphisms and lung cancer risk: a systematic review and meta-analysis. Mutagenesis. 2003;18(4):377–85. [PubMed: 12840112]
  573. Mathur RS, Mathur SP, Young RC. Up-regulation of epidermal growth factor-receptors (EGF-R) by nicotine in cervical cancer cell lines: this effect may be mediated by EGF. American Journal of Reproductive Immunology. 2000;44(2):114–20. [PubMed: 10994639]
  574. Matsumoto S, Iwakawa R, Takahashi K, Kohno T, Nakanishi Y, Matsuno Y, Suzuki K, Nakamoto M, Shimizu E, Minna JD, et al. Prevalence and specificity of LKB1 genetic alterations in lung cancers. Oncogene. 2007;26(40):5911–8. [PMC free article: PMC3457639] [PubMed: 17384680]
  575. Matsumoto Y, Kim K. Excision of deoxyribose phosphate residues by DNA polymerase beta during DNA repair. Science. 1995;269(5224):699–702. [PubMed: 7624801]
  576. Matter B, Wang G, Jones R, Tretyakova N. Formation of diastereomeric benzo[a]pyrene diol epoxide-guanine adducts in p53 gene-derived DNA sequences. Chemical Research in Toxicology. 2004;17(6):731–41. [PubMed: 15206894]
  577. Mattern J, Koomägi R, Volm M. Smoking-related increase in O6-methylguanine-DNA methyltransferase expression in human lung carcinomas. Carcinogenesis. 1998;19(7):1247–50. [PubMed: 9683184]
  578. Matullo G, Guarrera S, Carturan S, Peluso M, Malaveille C, Davico L, Piazza A, Vineis P. DNA repair gene polymorphisms, bulky DNA adducts in white blood cells and bladder cancer in a case-control study. International Journal of Cancer. 2001a;92(4):562–7. [PubMed: 11304692]
  579. Matullo G, Palli D, Peluso M, Guarrera S, Carturan S, Celentano E, Krogh V, Munnia A, Tumino R, Polidoro S, et al. XRCC1, XRCC3, XPD gene polymorphisms, smoking and 32P-DNA adducts in a sample of healthy subjects. Carcinogenesis. 2001b;22(9):1437–45. [PubMed: 11532866]
  580. Mauderly JL, Gigliotti AP, Barr EB, Bechtold WE, Belinsky SA, Hahn FF, Hobbs CA, March TH, Seilkop SK, Finch GL. Chronic inhalation exposure to mainstream cigarette smoke increases lung and nasal tumor incidence in rats. Toxicological Sciences. 2004;81(2):280–92. [PubMed: 15213336]
  581. Maus AD, Pereira EFR, Karachunski PI, Horton RM, Navaneetham D, Macklin K, Cortes WS, Albuquerque EX, Conti-Fine BM. Human and rodent bronchial epithelial cells express functional nicotinic acetylcholine receptors. Molecular Pharmacology. 1998;54(5):779–88. [PubMed: 9804613]
  582. Mayne ST, Buenconsejo J, Janerich DT. Familial cancer history and lung cancer risk in United States nonsmoking men and women. Cancer Epidemiology, Biomarkers & Prevention. 1999;8(12):1065–9. [PubMed: 10613338]
  583. McCormick F. Cancer: survival pathways meet their end. Nature. 2004;428(6980):267–9. [PubMed: 15029179]
  584. McCoy GD, Chen C-H, Hecht SS, McCoy EC. Enhanced metabolism and mutagenesis of nitrosopyrrolidine in liver fractions isolated from chronic ethanol-consuming hamsters. Cancer Research. 1979;39(3):793–6. [PubMed: 570882]
  585. McCoy GD, Hecht SS, Katayama S, Wynder EL. Differential effect of chronic ethanol consumption on the carcinogenicity of N-nitrosopyrrolidine and N’-nitro-sonornicotine in male Syrian golden hamsters. Cancer Research. 1981;41(7):2849–54. [PubMed: 7248945]
  586. McWilliams JE, Sanderson BJS, Harris EL, Richert-Boe KE, Henner WD. Glutathione-S-transferase M1 (GSTM1) deficiency and lung cancer risk. Cancer Epidemiology, Biomarkers & Prevention. 1995;4(6):589–94. [PubMed: 8547824]
  587. Meier P, Finch A, Evan G. Apoptosis in development. Nature. 2000;407(6805):796–801. [PubMed: 11048731]
  588. Melikian AA, Sun P, Prokopczyk B, El-Bayoumy K, Hoff-mann D, Wang X, Waggoner S. Identification of benzo[a]pyrene metabolites in cervical mucus and DNA adducts in cervical tissues in humans by gas chromatography-mass spectrometry. Cancer Letters. 1999;146(2):127–34. [PubMed: 10656617]
  589. Melton DW, Ketchen A-M, Nuñez F, Bonatti-Abbondan-dolo S, Abbondandolo A, Squires S, Johnson RT. Cells from ERCC1-deficient mice show increased genome instability and a reduced frequency of S-phase-dependent illegitimate chromosome exchange but a normal frequency of homologous recombination. Journal of Cell Science. 1998;111(Pt 3):395–404. [PubMed: 9427687]
  590. Merlo A, Gabrielson E, Askin F, Sidransky D. Frequent loss of chromosome 9 in human primary non-small cell lung cancer. Cancer Research. 1994;54(3):640–42. [PubMed: 8306323]
  591. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB, Sidransky D. 5′CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nature Medicine. 1995;1(7):686–92. [PubMed: 7585152]
  592. Mihara M, Erster S, Zaika A, Petrenko O, Chittenden T, Pancoska P, Moll UM. p53 has a direct apoptogenic role at the mitochondria. Molecular Cell. 2003;11(3):577–90. [PubMed: 12667443]
  593. Mijal RS, Thomson NM, Fleischer NL, Pauly GT, Moschel RC, Kanugula S, Fang Q, Pegg AE, Peterson LA. The repair of the tobacco specific nitrosamine derived adduct O6-[4-oxo-4-(3-pyridyl)butyl]guanine by O6-alkylguanine-DNA alkyltransferase variants. Chemical Research in Toxicology. 2004;17(3):424–34. [PubMed: 15025514]
  594. Miller DP, Liu G, De Vivo I, Lynch TJ, Wain JC, Su L, Christiani DC. Combinations of the variant genotypes of GSTP1, GSTM1, and p53 are associated with an increased lung cancer risk. Cancer Research. 2002;62(10):2819–23. [PubMed: 12019159]
  595. Miller DP, Neuberg D, De Vivo I, Wain JC, Lynch TJ, Su L, Christiani DC. Smoking and the risk of lung cancer: susceptibility with GSTP1 polymorphisms. Epidemiology. 2003;14(5):545–51. [PubMed: 14501269]
  596. Mittal RD, Srivastava DS, Mandhani A. NAT2 gene polymorphism in bladder cancer: a study from North India. International Brazilian Journal of Urology. 2004;30(4):279–88. [PubMed: 15679955]
  597. Miyabe I, Zhang Q-M, Kino K, Sugiyama H, Takao M, Yasui A, Yonei S. Identification of 5-formyluracil DNA glyco-sylase activity of human hNTH1 protein. Nucleic Acids Research. 2002;30(15):3443–8. [PMC free article: PMC137084] [PubMed: 12140329]
  598. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell. 1995;80(2):293–9. [PubMed: 7834749]
  599. Miyata M, Kudo G, Lee Y-H, Yang TJ, Gelboin HV, Fernandez-Salguero P, Kimura S, Gonzalez FJ. Targeted disruption of the microsomal epoxide hydrolase gene: microsomal epoxide hydrolase is required for the carcinogenic activity of 7,12-dimethylbenz[a]anthracene. Journal of Biological Chemistry. 1999;274(34):23963–8. [PubMed: 10446164]
  600. Mohrenweiser HW, Carrano AV, Fertitta A, Perry B, Thompson LH, Tucker JD, Weber CA. Refined mapping of the three DNA repair genes, ERCC1, ERCC2, and XRCC1, on human chromosome 19. Cytogenetics and Cell Genetics. 1989;52(1–2):11–14. [PubMed: 2558854]
  601. Mohrenweiser HW, Jones IM. Variation in DNA repair is a factor in cancer susceptibility: a paradigm for the promises and perils of individual and population risk estimation? Mutation Research. 1998;400(1–2):15–24. [PubMed: 9685572]
  602. Møller P, Knudsen LE, Frentz G, Dybdahl M, Wallin H, Nexø BA. Seasonal variation of DNA damage and repair in patients with non-melanoma skin cancer and referents with and without psoriasis. Mutation Research. 1998;407(1):25–34. [PubMed: 9539978]
  603. Moore SM, Rintoul RC, Walker TR, Chilvers ER, Haslett C, Sethi T. The presence of a constitutively active phos-phoinositide 3-kinase in small cell lung cancer cells mediates anchorage-independent proliferation via a protein kinase B and p70s6k-dependent pathway. Cancer Research. 1998;58(22):5239–47. [PubMed: 9823338]
  604. Moraitis D, Du B, De Lorenzo MS, Boyle JO, Weksler BB, Cohen EG, Carew JF, Altorki NK, Lopelovitch L, Sub-baramaiah K, et al. Levels of cyclooxygenase-2 are increased in the oral mucosa of smokers: evidence for the role of epidermal growth factor receptor and its ligands. Cancer Research. 2005;65(2):664–70. [PubMed: 15695412]
  605. Moriya M, Grollman AP. Mutations in the mutY gene of Escherichia coli enhance the frequency of targeted G:C→T:A transversions induced by a single 8-oxogua-nine residue in single-stranded DNA. Molecular and General Genetics. 1993;239(1–2):72–6. [PubMed: 8510665]
  606. Moriya M, Spiegel S, Fernandes A, Amin S, Liu T, Geacintov N, Grollman AP. Fidelity of translesional synthesis past benzo[a]pyrene diol epoxide—2′-deoxyguanosine DNA adducts: marked effects of host cell, sequence context, and chirality. Biochemistry. 1996;35(51):16646–51. [PubMed: 8988000]
  607. Moriya M, Zhang W, Johnson F, Grollman AP. Mutagenic potency of exocyclic DNA adducts: marked differences between Escherichia coli and simian kidney cells. Proceedings of the National Academy of Sciences of the United States of America. 1994;91(25):11899–903. [PMC free article: PMC45343] [PubMed: 7991554]
  608. Morrow JD, Frei B, Longmire AW, Gaziano JM, Lynch SM, Shyr Y, Strauss WE, Oates JA, Roberts LJ II. Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers: smoking as a cause of oxidative damage. New England Journal of Medicine. 1995;332(18):1198–203. [PubMed: 7700313]
  609. Moscatello DK, Holgado-Madruga M, Emlet DR, Mont-gomery RB, Wong AJ. Constitutive activation of phos-phatidylinositol 3-kinase by a naturally occurring mutant epidermal growth factor receptor. Journal of Biological Chemistry. 1998;273(1):200–6. [PubMed: 9417065]
  610. Mu D, Park C-H, Matsunaga T, Hsu DS, Reardon JT, Sancar A. Reconstitution of human DNA repair excision nuclease in a highly defined system. Journal of Biological Chemistry. 1995;270(6):2415–8. [PubMed: 7852297]
  611. Mukherjee S, Palmer LJ, Kim JY, Aeschliman DB, Houk RS, Woodin MA, Christiani DC. Smoking status and occupational exposure affects oxidative DNA injury in boilermakers exposed to metal fume and residual oil fly ash. Cancer Epidemiology, Biomarkers & Prevention. 2004;13(3):454–60. [PubMed: 15006923]
  612. Mukohara T, Kudoh S, Yamauchi S, Kimura T, Yoshimura N, Kanazawa H, Hirata K, Wanibuchi H, Fukushima S, Inoue K, et al. Expression of epidermal growth factor receptor (EGFR) and downstream-activated peptides in surgically excised non-small-cell lung cancer (NSCLC). Lung Cancer. 2003;41(2):123–30. [PubMed: 12871775]
  613. Mulder TPJ, Court DA, Peters WHM. Variability of glutathione S-transferase α in human liver and plasma. Clinical Chemistry. 1999;45(3):355–9. [PubMed: 10053036]
  614. Muller SJ, Caradonna S. Isolation and characterization of a human cDNA encoding uracil-DNA glycosylase. Bio-chimica et Biophysica Acta. 1991;1088(2):197–207. [PubMed: 2001396]
  615. Murakami I, Hiyama K, Ishioka S, Yamakido M, Kasagi F, Yokosaki Y. p53 gene mutations are associated with shortened survival in patients with advanced non-small cell lung cancer: an analysis of medically managed patients. Clinical Cancer Research. 2000;6(2):526–30. [PubMed: 10690534]
  616. Murphy SE, Spina DA, Nunes MG, Pullo DA. Glucuronidation of 4-(hydroxymethyl)nitrosamino)-1-(3-pyridyl)-1-butanone, a metabolically activated form of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, by phenobarbital-treated rats. Chemical Research in Toxicology. 1995;8(5):772–9. [PubMed: 7548761]
  617. Muscat JE, Kleinman W, Colosimo S, Muir A, Lazarus P, Park J, Richie JP Jr. Enhanced protein glutathiolation and oxidative stress in cigarette smokers. Free Radical Biology & Medicine. 2004;36(4):464–70. [PubMed: 14975449]
  618. Mustonen R, Schoket B, Hemminki K. Smoking-related DNA adducts: 32P-postlabeling analysis of 7-methyl-guanine in human bronchial and lymphocyte DNA. Carcinogenesis. 1993;14(1):151–4. [PubMed: 8425264]
  619. Myrnes B, Giercksky KE, Krokan H. Interindividual variation in the activity of O6-methyl-guanine-DNA methyltransferase and uracil-DNA glycosylase in human organs. Carcinogenesis. 1983;4(12):1565–8. [PubMed: 6652869]
  620. Nagar S, Remmel RP. Uridine diphosphoglucuronosyl-transferase pharmacogenetics and cancer. Oncogene. 2006;25(11):1659–72. [PubMed: 16550166]
  621. Nahle Z, Polakoff J, Davuluri RV, McCurrach ME, Jacobson MD, Narita M, Zhang MQ, Lazebnik Y, Bar-Sagi D, Lowe SW. Direct coupling of the cell cycle and cell death machinery by E2F. Nature Cell Biology. 2002;4(11):859–64. [PubMed: 12389032]
  622. Nakachi K, Imai K, Hayashi S, Kawajiri K. Polymorphisms of the CYP1A1 and glutathione-S-transferase genes associated with susceptibility to lung cancer in relation to cigarette dose in a Japanese population. Cancer Research. 1993;53(13):2994–9. [PubMed: 8319207]
  623. Nakachi K, Imai K, Hayashi S, Watanabe J, Kawajiri K. Genetic susceptibility to squamous cell carcinoma of the lung in relation to cigarette smoking dose. Cancer Research. 1991;51(19):5177–80. [PubMed: 1655248]
  624. Nakano K, Vousden KH. PUMA, a novel proapoptotic gene, is induced by p53. Molecular Cell. 2001;7(3):683–94. [PubMed: 11463392]
  625. Nan H-M, Kim H, Lim H-S, Choi JK, Kawamoto T, Kang J-W, Lee C-H, Kim Y-D, Kwon EH. Effects of occupation, lifestyle and genetic polymorphisms of CYP1A1, CYP2E1, GSTM1 and GSTT1 on urinary 1-hydroxypyrene and 2-naphthol concentrations. Carcinogenesis. 2001;22(5):787–93. [PubMed: 11323399]
  626. Naoki K, Chen T-H, Richard WG, Sugarbaker DJ, Meyerson M. Missense mutations of the BRAF gene in human lung adenocarcinomas. Cancer Research. 2002;62(23):7001–3. [PubMed: 12460919]
  627. Nath RG, Ocando JE, Guttenplan JB, Chung FL. 1,N2-pro-panodeoxyguanosine adducts: potential new biomarkers of smoking-induced DNA damage in human oral tissue. Cancer Research. 1998;58(4):581–4. [PubMed: 9485001]
  628. Nazar-Stewart V, Vaughan TL, Stapleton P, Van Loo J, Nicol-Blades B, Eaton DL. A population-based study of glutathione S-transferase M1, T1 and P1 genotypes and risk for lung cancer. Lung Cancer. 2003;40(3):247–58. [PubMed: 12781423]
  629. Nebert DW, Dalton TP, Okey AB, Gonzalez FJ. Role of aryl hydrocarbon receptor-mediated induction of the CYP1 enzymes in environmental toxicity and cancer. Journal of Biological Chemistry. 2004;279(23):23847–50. [PubMed: 15028720]
  630. Neddermann P, Gallinari P, Lettieri T, Schmid D, Truong O, Hsuan JJ, Wiebauer K, Jiricny J. Cloning and expression of human G/T mismatch-specific thymine-DNA glycosylase. Journal of Biological Chemistry. 1996;271(22):12767–74. [PubMed: 8662714]
  631. Neddermann P, Jiricny J. The purification of a mismatch-specific thymine-DNA glycosylase from HeLa cells. Journal of Biological Chemistry. 1993;268(28):21218–24. [PubMed: 8407958]
  632. Neddermann P, Jiricny J. Efficient removal of uracil from G/U mispairs by the mismatch-specific thymine DNA glycosylase from HeLa cells. Proceedings of the National Academy of Sciences of the United States of America. 1994;91(5):1642–6. [PMC free article: PMC43219] [PubMed: 8127859]
  633. Nelms BE, Maser RS, MacKay JF, Lagally MG, Petrini JHJ. In situ visualization of DNA double-strand break repair in human fibroblasts. Science. 1998;280(5363):590–2. [PubMed: 9554850]
  634. Nelson DR. Comparison of P450s from human and fugu: 420 million years of vertebrate P450 evolution. Archives of Biochemistry and Biophysics. 2003;409(1):18–24. [PubMed: 12464240]
  635. Nelson HH, Kelsey KT. The molecular epidemiology of asbestos and tobacco in lung cancer. Oncogene. 2002;21(48):7284–8. [PubMed: 12379872]
  636. Nelson HH, Wilkojmen M, Marsit CJ, Kelsey KT. TP53 mutation, allelism and survival in non-small cell lung cancer. Carcinogenesis. 2005;26(10):1770–3. [PubMed: 15905205]
  637. Nerurkar PV, Okinaka L, Aoki C, Seifried A, Lum-Jones A, Wilkens LR, Le Marchand L. CYP1A1, GSTM1, and GSTP1 genetic polymorphisms and urinary 1-hydroxypyrene excretion in non-occupationally exposed individuals. Cancer Epidemiology, Biomarkers & Prevention. 2000;9(10):1119–22. [PubMed: 11045797]
  638. Nevins JR. E2F: a link between the Rb tumor suppressor protein and viral oncoproteins. Science. 1992;258(5081):424–9. [PubMed: 1411535]
  639. Ng D-P, Tan K-W, Zhao B, Seow A. CYP1A1 polymorphisms and risk of lung cancer in non-smoking Chinese women: influence of environmental tobacco smoke exposure and GSTM1/T1 genetic variation. Cancer Causes & Control. 2005;16(4):399–405. [PubMed: 15953982]
  640. Nia AB, van Schooten FJ, Schilderman PAEL, De Kok TMCM, Haenen GR, Van Herwijnen MHM, van Agen E, Pachen D, Kleinjans JCS. A multi-biomarker approach to study the effects of smoking on oxidative DNA damage and repair and antioxidative defense mechanisms. Carcinogenesis. 2001;22(3):395–401. [PubMed: 11238178]
  641. Nicolaides NC, Papadopoulos N, Liu B, Wei YF, Carter KC, Ruben SM, Rosen CA, Haseltine WA, Fleischmann RD, Fraser CM, et al. Mutations of two PMS homologues in hereditary nonpolyposis colon cancer. Nature. 1994;371(6492):75–80. [PubMed: 8072530]
  642. Nilsen H, Haushalter KA, Robins P, Barnes DE, Verdine GL, Lindahl T. Excision of deaminated cytosine from the vertebrate genome: role of the SMUG1 uracil–DNA glycosylase. EMBO Journal. 2001;20(15):4278–86. [PMC free article: PMC149160] [PubMed: 11483530]
  643. Nishioka M, Kohno T, Tani M, Yanaihara N, Tomizawa Y, Otsuka A, Sasaki S, Kobayashi K, Niki T, Maeshima A, et al. MY018B, a candidate tumor suppressor gene at chromosome 22q12.1, deleted, mutated, and methylated in human lung cancer. Proceedings of the National Academy of Sciences of the United States of America. 2002;99(19):12269–74. [PMC free article: PMC129434] [PubMed: 12209013]
  644. Nomoto S, Haruki N, Kondo M, Konishi H, Takahashi T, Takahashi T, Takahashi T. Search for mutations and examination of allelic expression imbalance of the p73 gene at 1p36.33 in human lung cancers. Cancer Research. 1998;58(7):1380–3. [PubMed: 9537234]
  645. Norppa H, Hirvonen A, Jarventaus H, Uuskula M, Tasa G, Ojajarvi A, Sorsa M. Role of GSTT1 and GSTM1 genotypes in determining individual sensitivity to sister chromatid exchange induction by diepoxybutane in cultured human lymphocytes. Carcinogenesis. 1995;16(6):1261–4. [PubMed: 7788840]
  646. O’Connor TR, Laval J. Human cDNA expressing a functional DNA glycosylase excising 3-methyladenine and 7-methylguanine. Biochemical and Biophysical Research Communications. 1991;176(3):1170–7. [PubMed: 1645538]
  647. Oda Y. Analysis of the involvement of human N-acetyl-transferase 1 in the genotoxic activation of bladder carcinogenic arylamines using a SOS/umu assay system. Mutation Research. 2004;554(1–2):399–406. [PubMed: 15450435]
  648. Oda E, Ohki R, Murasawa H, Nemoto J, Shibue T, Yamashita T, Tokino T, Taniguchi T, Tanaka N. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science. 2000a;288(5468):1053–8. [PubMed: 10807576]
  649. Oda K, Arakawa H, Tanaka T, Matsuda K, Tanikawa C, Mori T, Nishimori H, Tamai K, Tokino T, Nakamura Y, Taya Y. p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell. 2000b;102(6):849–62. [PubMed: 11030628]
  650. O’Donnell RA, Richter A, Ward J, Angco G, Mehta A, Rousseau K, Swallow DM, Holgate ST, Dujukanovic R, Davies DE, et al. Expression of ErbB receptors and mucins in the airways of long term current smokers. Thorax. 2004;59(12):1032–40. [PMC free article: PMC1746902] [PubMed: 15563701]
  651. O’Donovan A, Davies AA, Moggs JG, West SC, Wood RD. XPG endonuclease makes the 3′ incision in human DNA nucleotide excision repair. Nature. 1994;371(6496):432–5. [PubMed: 8090225]
  652. Oesch F, Klein S. Relevance of environmental alkylating agents to repair protein O6-alkylguanine-DNA alkyl-transferase: determination of individual and collective repair capacities of O6-methylguanine. Cancer Research. 1992;52(7):1801–3. [PubMed: 1532345]
  653. Offer H, Wolkowicz R, Matas D, Blumenstein S, Livneh Z, Rotter V. Direct involvement of p53 in the base excision repair pathway of the DNA repair machinery. FEBS Letters. 1999;450(3):197–204. [PubMed: 10359074]
  654. Ogawara Y, Kishishita S, Obata T, Isazawa Y, Suzuki T, Tanaka K, Masuyama N, Gotoh Y. Akt enhances Mdm2-mediated ubiquitination and degradation of p53. Journal of Biological Chemistry. 2002;277(24):21843–50. [PubMed: 11923280]
  655. Ohashi E, Ogi T, Kusumoto R, Iwai S, Masutani C, Hanaoka F, Ohmori H. Error-prone bypass of certain DNA lesions by the human DNA polymerase κ Genes & Development. 2000;14(13):1589–94. [PMC free article: PMC316741] [PubMed: 10887153]
  656. Ohmori H, Friedberg EC, Fuchs RP, Goodman MF, Hana-oka F, Hinkle D, Kunkel TA, Lawrence CW, Livneh Z, Nohmi T, et al. The Y-family of DNA polymerases [letter] Molecular Cell. 2001;8(1):7–8. [PubMed: 11515498]
  657. Okada T, Kawashima K, Fukushi S, Minakuchi T, Nishimura S. Association between a cytochrome P450 CYPIA1 genotype and incidence of lung cancer. Pharmacogenetics. 1994;4(6):333–40. [PubMed: 7704039]
  658. Okamoto I, Kenyon LC, Emlet DR, Mori T, Sasaki J, Hirosako S, Ichikawa Y, Kishi H, Godwin AK, Yoshioka M, et al. Expression of constitutively activated EG-FRvIII in non-small cell lung cancer. Cancer Science. 2003;94(1):50–6. [PubMed: 12708474]
  659. Olsen LC, Aasland R, Wittwer CU, Krokan HE, Helland DE. Molecular cloning of human uracil-DNA glycosylase, a highly conserved DNA repair enzyme. EMBO Journal. 1989;8(10):3121–5. [PMC free article: PMC401392] [PubMed: 2555154]
  660. Ong CN, Kok PW, Lee BL, Shi CY, Ong HY, Chia KS, Lee CS, Luo XW. Evaluation of biomarkers for occupational exposure to benzene. Occupational and Environmental Medicine. 1995;52(8):528–33. [PMC free article: PMC1128288] [PubMed: 7663638]
  661. Ong CN, Kok PW, Ong HY, Shi CY, Lee BL, Phoon WH, Tan KT. Biomarkers of exposure to low concentrations of benzene: a field assessment. Occupational and Environmental Medicine. 1996;53(5):328–33. [PMC free article: PMC1128475] [PubMed: 8673180]
  662. Ooi WL, Elston RC, Chen VW, Bailey-Wilson JE, Rothschild H. Increased familial risk for lung cancer. Journal of the National Cancer Institute. 1986;76(2):217–22. [PubMed: 3456060]
  663. Orzechowski A, Schrenk D, Bock-Hennig BS, Bock KW. Glucuronidation of carcinogenic arylamines and their N-hydroxy derivatives by rat and human phenol UDP-glucuronosyltransferase of the UGT1 gene complex. Carcinogenesis. 1994;15(8):1549–53. [PubMed: 8055632]
  664. Osann KE. Lung cancer in women: the importance of smoking, family history of cancer, and medical history of respiratory diseases. Cancer Research. 1991;51(18):4893–7. [PubMed: 1654203]
  665. Osterman-Golkar S, Ehrenberg L, Segerback D, Hallstrom I. Evaluation of genetic risks of alkylating agents. II: haemoglobin as a dose monitor. Mutation Research. 1976;34(1):1–10. [PubMed: 1250243]
  666. Oyama T, Kawamoto T, Mizoue T, Yasumoto K, Kodama Y, Mitsudomi T. N-acetylation polymorphism in patients with lung cancer and its association with p53 gene mutation. Anticancer Research. 1997;17(1B):577–81. [PubMed: 9066583]
  667. Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, Donner DB. NF-κB activation by tumour necrosis factor requires the Akt serine-threonine kinase [letter] Nature. 1999;401(6748):82–5. [PubMed: 10485710]
  668. Page JE, Pilcher AS, Yagi H, Sayer JM, Jerina DM, Dipple A. Mutational consequences of replication of M13mp7L2 constructs containing cis-opened benzo[a]pyrene 7,8-diol 9,10-epoxide–deoxyadenosine adducts. Chemical Research in Toxicology. 1999;12(3):258–63. [PubMed: 10077488]
  669. Page JE, Zajc B, Oh-hara T, Lakshman MK, Sayer JM, Jerina DM, Dipple A. Sequence context profoundly influences the mutagenic potency of trans-opened benzo[a]pyrene 7,8-diol 9,10-epoxide–purine nucleoside adducts in site-specific mutation studies. Biochemistry. 1998;37(25):9127–37. [PubMed: 9636059]
  670. Palmisano WA, Crume KP, Grimes MJ, Winters SA, Toyota M, Esteller M, Joste N, Baylin SB, Belinsky SA. Aberrant promoter methylation of the transcription factor genes PAX5 α and β in human cancers. Cancer Research. 2003;63(15):4620–5. [PubMed: 12907641]
  671. Palombo F, Gallinari P, Iaccarino I, Lettieri T, Hughes M, D’Arrigo A, Truong O, Hsuan JJ, Jiricny J. GTBP, a 160-kilodalton protein essential for mismatch-binding activity in human cells. Science. 1995;268(5219):1912–4. [PubMed: 7604265]
  672. Palombo F, Iaccarino I, Nakajima E, Ikejima M, Shimada T, Jiricny J. hMutSβ, a heterodimer of hMSH2 and hMSH3, binds to insertion/deletion loops in DNA. Current Biology. 1996;6(9):1181–4. [PubMed: 8805365]
  673. Pandya G, Moriya M. 1,N6-ethenodeoxyadenosine, a DNA adduct highly mutagenic in mammalian cells. Biochemistry. 1996;35(35):11487–92. [PubMed: 8784204]
  674. Pap M, Cooper GM. Role of glycogen synthase kinase-3 in the phosphatidylinositol 3-kinase/Akt cell survival pathway. Journal of Biological Chemistry. 1998;273(32):19929–32. [PubMed: 9685326]
  675. Papadopoulos N, Nicolaides NC, Wei YF, Ruben SM, Carter KC, Rosen CA, Haseltine WA, Fleischmann RD, Fraser CM, Adams MD, et al. Mutation of a mutL homolog in hereditary colon cancer. Science. 1994;263(5153):1625–9. [PubMed: 8128251]
  676. Park JY, Chen L, Elahi A, Lazarus P, Tockman MS. Genetic analysis of microsomal epoxide hydrolase gene and its association with lung cancer risk. European Journal of Cancer Prevention. 2005;14(3):223–30. [PMC free article: PMC3715303] [PubMed: 15901990]
  677. Park JY, Park SH, Choi JE, Lee SY, Jeon H-S, Cha SI, Kim CH, Park J-H, Kam S, Park RW, et al. Polymorphisms of the DNA repair gene Xeroderma pigmentosum group A and risk of primary lung cancer. Cancer Epidemiology, Biomarkers & Prevention. 2002;11(10 Pt 1):993–7. [PubMed: 12376498]
  678. Park S, Tretyakova N. Structural characterization of the major DNA-DNA cross-link of 1,2,3,4-diepoxybutane. Chemical Research in Toxicology. 2004;17(2):129–36. [PubMed: 14966999]
  679. Parker AR, Eshleman JR. Human MutY: gene structure, protein functions and interactions, and role in carcinogenesis. Cellular and Molecular Life Sciences. 2003;60(10):2064–83. [PubMed: 14618256]
  680. Parsons WD, Carmella SG, Akerkar S, Bonilla LE, Hecht SS. A metabolite of the tobacco-specific lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in the urine of hospital workers exposed to environmental tobacco smoke. Cancer Epidemiology, Bio-markers & Prevention. 1998;7(3):257–60. [PubMed: 9521443]
  681. Pauly GT, Hughes SH, Moschel RC. Mutagenesis in Escherichia coli by three O6-substituted guanines in double-stranded or gapped plasmids. Biochemistry. 1995;34(27):8924–30. [PubMed: 7612634]
  682. Pauly GT, Moschel RC. Mutagenesis by O6-methyl-, O6-ethyl- and O6-benzylguanine and O4-methylthymine in human cells: effects of O6-alkylguanine-DNA alkyl-transferase and mismatch repair. Chemical Research in Toxicology. 2001;14(7):894–900. [PubMed: 11453737]
  683. Pauly GT, Peterson LA, Moschel RC. Mutagenesis by O6-[4-oxo-4-(3-pyridyl)butyl]guanine in Escherichia coli and human cells. Chemical Research in Toxicology. 2002;15(2):165–9. [PubMed: 11849042]
  684. Paz-Elizur T, Krupsky M, Blumenstein S, Elinger D, Schechtman E, Livneh Z. DNA repair activity for oxidative damage and risk of lung cancer. Journal of the National Cancer Institute. 2003;95(17):1312–9. [PubMed: 12953085]
  685. Peeper DS, Upton TM, Ladha MH, Neuman E, Zalvide J, Bernards R, DeCaprio JA, Ewen ME. Ras signalling linked to the cell-cycle machinery by the retinoblas-toma protein [letter] Nature. 1997;386(6621):177–81. [PubMed: 9062190]
  686. Pegg AE. Repair of O6-alkylguanine by alkyltransferases. Mutation Research. 2000;462(2–3):83–100. [PubMed: 10767620]
  687. Pekarsky Y, Garrison PN, Palamarchuk A, Zanesi N, Aqeilan RI, Huebner K, Barnes LD, Croce CM. Fhit is a physiological target of the protein kinase Src. Proceedings of the National Academy of Sciences of the United States of America. 2004;101(11):3775–9. [PMC free article: PMC374320] [PubMed: 15007172]
  688. Pelosi G, Del Curto B, Dell’Orto P, Pasini F, Veronesi G, Spaggiari L, Maisonneuve P, Iannucci A, Terzi A, Lonar-doni A, et al. Lack of prognostic implications of HER-2/neu abnormalities in 345 stage I nonsmall cell carcinomas (NSCLC) and 207 stage I-III neuroendocrine tumours (NET) of the lung. International Journal of Cancer. 2005;113(1):101–8. [PubMed: 15386424]
  689. Penning TM, Burczynski ME, Hung C-F, McCoull KD, Palackal NT, Tsuruda LS. Dihydrodiol dehydrogenases and polycyclic aromatic hydrocarbon activation: generation of reactive and redox active o-quinones. Chemical Research in Toxicology. 1999;12(1):1–18. [PubMed: 9894013]
  690. Perbellini L, Princivalle A, Cerpelloni M, Pasini F, Brug-none F. Comparison of breath, blood and urine concentrations in the biomonitoring of environmental exposure to 1,3-butadiene, 2,5-dimethylfuran, and benzene. International Archives of Occupational and Environmental Health. 2003;76(6):461–6. [PubMed: 12687377]
  691. Perera FP, Mooney LA, Stampfer M, Phillips DH, Bell DA, Rundle A, Cho S, Tsai W-Y, Ma J, Blackwood A, et al. Associations between carcinogen–DNA damage, glutathione S-transferase genotypes, and risk of lung cancer in the prospective Physicians’ Health Cohort Study. Carcinogenesis. 2002;23(10):1641–46. [PubMed: 12376472]
  692. Pérez-Soler R, Chachoua A, Hammond LA, Rowinsky EK, Huberman M, Karp D, Rigas J, Clark GM, Santabárbara P, Bonomi P. Determinants of tumor response and survival with erlotinib in patients with non–small-cell lung cancer. Journal of Clinical Oncology. 2004;22(16):3238–47. [PubMed: 15310767]
  693. Petersen I, Langreck H, Wolf G, Schwendel A, Psille R, Vogt P, Reichel MB, Ried T, Dietel M. Small-cell lung cancer is characterized by a high incidence of deletions on chromosomes 3p, 4q, 5q, 10q, 13q and 17p. British Journal of Cancer. 1997;75(1):79–86. [PMC free article: PMC2222682] [PubMed: 9000602]
  694. Peterson LA, Hecht SS. O6-methylguanine is a critical determinant of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone tumorigenesis in A/J mouse lung. Cancer Research. 1991;51(20):5557–64. [PubMed: 1913675]
  695. Peterson LA, Thomson NM, Crankshaw DL, Donaldson EE, Kenney PJ. Interactions between methylating and pyridyloxobutylating agents in A/J mouse lungs: implications for 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced lung tumorigenesis. Cancer Research. 2001;61(15):5757–63. [PubMed: 11479212]
  696. Petit C, Sancar A. Nucleotide excision repair: from E. coli to man. Biochimie. 1999;81(1–2):15–25. [PubMed: 10214906]
  697. Petruzzelli S, Tavanti LM, Celi A, Giuntini C. Detection of N7-methyldeoxyguanosine adducts in human pulmonary alveolar cells. American Journal of Respiratory Cell and Molecular Biology. 1996;15(2):216–23. [PubMed: 8703477]
  698. Pezzagno G, Maestri L, Fiorentino ML. Trans, transmuconic acid, a biological indicator to low levels of environmental benzene: some aspects of its specificity. American Journal of Industrial Medicine. 1999;35(5):511–8. [PubMed: 10212704]
  699. Pfeifer GP, Denissenko MF, Olivier M, Tretyakova N, Hecht SS, Hainaut P. Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene. 2002;21(48):7435–51. [PubMed: 12379884]
  700. Pfeiffer P, Goedecke W, Obe G. Mechanisms of DNA double-strand break repair and their potential to induce chromosomal aberrations. Mutagenesis. 2000;15(4):289–302. [PubMed: 10887207]
  701. Philip PA, Fitzgerald DL, Cartwright RA, Peake MD, Rogers HJ. Polymorphic N-acetylation capacity in lung cancer. Carcinogenesis. 1988;9(3):491–3. [PubMed: 3345587]
  702. Phillips DH. Fifty years of benzo[a]pyrene. Nature. 1983;303(5917):468–72. [PubMed: 6304528]
  703. Phillips DH. Smoking-related DNA and protein adducts in human tissues. Carcinogenesis. 2002;23(12):1979–2004. [PubMed: 12507921]
  704. Pilger A, Germadnik D, Riedel K, Meger-Kossien I, Scherer G, Rudiger HW. Longitudinal study of urinary 8-hydroxy-2′-deoxyguanosine excretion in healthy adults. Free Radical Research. 2001;35(3):273–80. [PubMed: 11697126]
  705. Pinarbasi H, Silig Y, Cetinkaya O, Seyfikli Z, Pinarbasi E. Strong association between the GSTM1-null genotype and lung cancer in a Turkish population. Cancer Genetics and Cytogenetics. 2003;146(2):125–9. [PubMed: 14553946]
  706. Pinsky PF, Kramer BS, Reding D, Buys S. Reported family history of cancer in the prostate, lung, colorectal, and ovarian cancer screening trial. American Journal of Epidemiology. 2003;157(9):792–9. [PubMed: 12727673]
  707. Piyathilake CJ, Frost AR, Manne U, Weiss H, Bell WC, Heimburger DC, Grizzle WE. Differential expression of growth factors in squamous cell carcinoma and precancerous lesions of the lung. Clinical Cancer Research. 2002;8(3):734–44. [PubMed: 11895903]
  708. Poeta ML, Manola J, Goldwasser MA, Forastiere A, Benoit N, Califano JA, Ridge JA, Goodwin J, Kenady D, Saunders J, et al. TP53 mutations and survival in squamous-cell carcinoma of the head and neck. New England Journal of Medicine. 2007;357(25):2552–61. [PMC free article: PMC2263014] [PubMed: 18094376]
  709. Poirier MC, Santella RM, Weston A. Carcinogen macromolecular adducts and their measurement. Carcinogenesis. 2000;21(3):353–9. [PubMed: 10688855]
  710. Popanda O, Schattenberg T, Phong CT, Butkiewicz D, Risch A, Edler L, Kayser K, Dienemann H, Schulz V, Drings P, et al. Specific combinations of DNA repair gene variants and increased risk for non-small cell lung cancer. Carcinogenesis. 2004;25(12):2433–41. [PubMed: 15333465]
  711. Port JL, Yamaguchi K, Du B, De Lorenzo M, Chang M, Heerdt PM, Kopelovich L, Marcus CB, Altorki NK, Sub-baramaiah K, et al. Tobacco smoke induces CYP1B1 in the aerodigestive tract. Carcinogenesis. 2004;25(11):2275–81. [PubMed: 15297370]
  712. Pöschl G, Seitz HK. Alcohol and cancer. Alcohol and Alcoholism. 2004;39(3):155–65. [PubMed: 15082451]
  713. Pourcelot S, Faure H, Firoozi F, Ducros V, Tripier M, Hee J, Cadet J, Favier A. Urinary 8-oxo-7,8-dihydro-2′-deoxyguanosine and 5-(hydroxymethyl)uracil in smokers. Free Radical Research. 1999;30(3):173–80. [PubMed: 10711787]
  714. Povey AC, Hall CN, Cooper DP, O’Connor PJ, Margison GP. Determinants of O6-alkylguanine-DNA alkyltransferase activity in normal and tumour tissue from human colon and rectum. International Journal of Cancer. 2000;85(1):68–72. [PubMed: 10585585]
  715. Prakash S, Prakash L. Translesion DNA synthesis in eukaryotes: a one- or two-polymerase affair. Genes & Development. 2002;16(15):1872–83. [PubMed: 12154119]
  716. Prasad R, Beard WA, Strauss PR, Wilson SH. Human DNA polymeraseβ deoxyribose phosphate lyase: substrate specificity and catalytic mechanism. Journal of Biological Chemistry. 1998;273(24):15263–70. [PubMed: 9614142]
  717. Prasad R, Singhal RK, Srivastava DK, Molina JT, Tom-kinson AE, Wilson SH. Specific interaction of DNA polymeraseβ and DNA ligase I in a multiprotein base excision repair complex from bovine testis. Journal of Biological Chemistry. 1996;271(27):16000–7. [PubMed: 8663274]
  718. Preussmann R, Stewart BW. N-Nitroso carcinogens. Chemical Carcinogens, Second Edition. ACS Monograph 182. Searle CE, editor. Vol. 2. Washington: American Chemical Society; 1984. pp. 643–828.
  719. Prevost V, Shuker DE, Friesen MD, Eberle G, Rajewsky MF, Bartsch H. Immunoaffinity purification and gas chromatography-mass spectrometric quantification of 3-alkyladenines in urine: metabolism studies and basal excretion levels in man. Carcinogenesis. 1993;14(11):199–204. [PubMed: 8435861]
  720. Prevost V, Shuker DEG. Cigarette smoking and urinary 3-alkyladenine excretion in man. Chemical Research in Toxicology. 1996;9(2):439–44. [PubMed: 8839047]
  721. Prieme H, Loft S, Klarlund M, Gronbaek K, Tonnesen P, Poulsen HE. Effect of smoking cessation on oxidative DNA modification estimated by 8-oxo-7,8-dihydro-2′-deoxyguanosine excretion. Carcinogenesis. 1998;19(2):347–51. [PubMed: 9498287]
  722. Probst-Hensch NM, Bell DA, Watson MA, Skipper PL, Tannenbaum SR, Chan KK, Ross RK, Yu MC. N-Ace-tyltransferase 2 phenotype but not NAT1*10 genotype affects aminobiphenyl-hemoglobin adduct levels. Cancer Epidemiology, Biomarkers & Prevention. 2000;9(6):619–23. [PubMed: 10868698]
  723. Proctor RN. Tobacco and the global lung cancer epidemic. Nature Reviews Cancer. 2001;1(1):82–6. [PubMed: 11900255]
  724. Prokopczyk B, Hoffmann D, Bologna M, Cunningham AJ, Trushin N, Akerkar S, Boyiri T, Amin S, Desai D, Colosimo S, et al. Identification of tobacco-derived compounds in human pancreatic juice. Chemical Research in Toxicology. 2002;15(5):677–85. [PubMed: 12018989]
  725. Prokopczyk B, Leder G, Trushin N, Cunningham AJ, Akerkar S, Pittman B, Ramadani M, Straeter J, Beger HG, Henne-Bruns D, et al. 4-Hydroxy-1-(3-pyridyl)-1-butanone, an indicator for 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone–induced DNA damage, is not detected in human pancreatic tissue. Cancer Epidemiology, Biomarkers & Prevention. 2005;14(2):540–1. [PubMed: 15734986]
  726. Prokopczyk B, Trushin N, Leszczynska J, Waggoner SE, El-Bayoumy K. Human cervical tissue metabolizes the tobacco-specificnitrosamine,4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, via α-hydroxylation and carbonyl reduction pathways. Carcinogenesis. 2001;22(1):107–14. [PubMed: 11159748]
  727. Proskocil BJ, Sekhon HS, Jia Y, Savchenko V, Blakely RD, Lindstrom J, Spindel ER. Acetylcholine is an auto-crine or paracrine hormone synthesized and secreted by airway bronchial epithelial cells. Endocrinology. 2004;145(5):2498–506. [PubMed: 14764638]
  728. Pryor WA, Stone K, Zang L-Y, Bermúdez E. Fractionation of aqueous cigarette tar extracts: fractions that contain the tar radical cause DNA damage. Chemical Research in Toxicology. 1998;11(5):441–8. [PubMed: 9585474]
  729. Pulling LC, Divine KK, Klinge DM, Gilliland FD, Kang T, Schwartz AG, Bocklage TJ, Belinsky SA. Promoter hypermethylation of the O6-methylguanine-DNA methyltransferase gene: more common in lung adenocarcinomas from never-smokers than smokers and associated with tumor progression. Cancer Research. 2003;63(16):4842–8. [PubMed: 12941804]
  730. Pulling LC, Vuillemenot BR, Hutt JA, Devereux TR, Belinsky SA. Aberrant promoter hypermethylation of the death-associated protein kinase gene is early and frequent in murine lung tumors induced by cigarette smoke and tobacco carcinogens. Cancer Research. 2004;64(11):3844–8. [PubMed: 15172992]
  731. Qiao Y, Spitz MR, Guo Z, Hadeyati M, Grossman L, Kraemer KH, Wei Q. Rapid assessment of repair of ultraviolet DNA damage with a modified host-cell reactivation assay using a luciferase reporter gene and correlation with polymorphisms of DNA repair genes in normal human lymphocytes. Mutation Research. 2002a;509( 1–2):165–74. [PubMed: 12427537]
  732. Qiao Y, Spitz MR, Shen H, Guo Z, Shete S, Hedayati M, Grossman L, Mohrenweiser H, Wei Q. Modulation of repair of ultraviolet damage in the host-cell reactivation assay by polymorphic XPC and XPD/ERCC2 genotypes. Carcinogenesis. 2002b;23(2):295–9. [PubMed: 11872635]
  733. Qiuling S, Yuxin Z, Suhua Z, Cheng X, Shuguang L, Fengsheng H. Cyclin D1 polymorphism and susceptibility to lung cancer in a Chinese population. Carcinogenesis. 2003;24(9):1499–1503. [PubMed: 12807740]
  734. Qu Q, Cohen BS, Shore R, Chen LC, Li G, Jin X, Melikian AA, Yin S, Yan H, Xu B, et al. Benzene exposure measurement in shoe and glue manufacturing: a study to validate biomarkers. Applied Occupational and Environmental Hygiene. 2003;18(12):988–98. [PubMed: 14612295]
  735. Qu Q, Melikian AA, Li G, Shore R, Chen L, Cohen B, Yin S, Kagan MR, Li H, Meng M, et al. Validation of bio-markers in humans exposed to benzene: urine metabolites. American Journal of Industrial Medicine. 2000;37(5):522–31. [PubMed: 10723046]
  736. Quan T, Reiners JJ Jr, Bell AO, Hong N, States JC. Cytotoxicity and genotoxicity of (+/−)-benzo[a]py-rene-trans-7,8-dihydrodiol in CYP1A1-expressing human fibroblasts quantitatively correlate with CYP1A1 expression level. Carcinogenesis. 1994;15(9):1827–32. [PubMed: 7923575]
  737. Quan T, Reiners JJ Jr, Culp SJ, Richter P, States JC. Differential mutagenicity and cytotoxicity of (+/−)-benzo[a] pyrene-trans-7,8-dihydrodioland(+/−)-anti-benzo[a]py-rene-trans-7,8-dihydrodiol-9,10-epoxide in genetically engineered human fibroblasts. Molecular Carcinogenesis. 1995;12(2):91–102. [PubMed: 7662121]
  738. Radicella JP, Dherin C, Desmaze C, Fox MS, Boiteux S. Cloning and characterization of hOGG1, a human homolog of the OGG1 gene of Saccharomyces cerevisiae. Proceedings of the National Academy of Sciences of the United States of America. 1997;94(15):8010–5. [PMC free article: PMC21547] [PubMed: 9223305]
  739. Radzikowska E, Roszkowski K, Glaz P. Lung cancer in patients under 50 years old. Lung Cancer. 2001;33(2–3):203–11. [PubMed: 11551415]
  740. Rajee-Behbahani N, Schmezer P, Risch A, Rittgen W, Kay-ser KW, Dienemann H, Schulz V, Drings P, Thiel S, Bartsch H. Altered DNA repair capacity and bleomycin sensitivity as risk markers for non-small cell lung cancer. International Journal of Cancer. 2001;95(2):86–91. [PubMed: 11241317]
  741. Rajesh M, Wang G, Jones R, Tretyakova N. Stable isotope labeling-mass spectrometry analysis of methyl- and pyridyloxobutyl-guanine adducts of 4-(methylnitro-samino)-1-(3-pyridyl)-1-butanone in p53-derived DNA sequences. Biochemistry. 2005;44(6):2197–207. [PubMed: 15697245]
  742. Rameh LE, Cantley LC. The role of phosphoinositide 3-kinase lipid products in cell function. Journal of Biological Chemistry. 1999;274(13):8347–50. [PubMed: 10085060]
  743. Ratnasinghe D, Yao S-X, Tangrea JA, Qiao Y-L, Andersen MR, Barrett MJ, Giffen CA, Erozan Y, Tockman MS, Taylor PR. Polymorphisms of the DNA repair gene XRCC1 and lung cancer risk. Cancer Epidemiology, Biomarkers & Prevention. 2001;10(2):119–23. [PubMed: 11219768]
  744. Reardon JT, Bessho T, Kung HC, Bolton PH, Sancar A. In vitro repair of oxidative DNA damage by human nucleotide excision repair system: possible explanation for neurodegeneration in xeroderma pigmentosum patients. Proceedings of the National Academy of Sciences of the United States of America. 1997;94(17):9463–8. [PMC free article: PMC23224] [PubMed: 9256505]
  745. Rebbeck TR. Molecular epidemiology of the human gluta-thione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility. Cancer Epidemiology, Biomarkers & Prevention. 1997;6(9):733–43. [PubMed: 9298582]
  746. Reddell RR, Ke Y, Gerwin BI, McMenamin MG, Lechner JF, Su RT, Brash DE, Park JB, Rhim JS, Harris CC. Transformation of human bronchial epithelial cells by infection with SV40 or adenovirus-12 SV40 hybrid virus, or transfection via strontium phosphate coprecipitation with a plasmid containing the SV40 early region genes. Cancer Research. 1988;48(7):1904–9. [PubMed: 2450641]
  747. Reed JC. Dysregulation of apoptosis in cancer. Journal of Clinical Oncology. 1999;17(9):2941–53. [PubMed: 10561374]
  748. Reed JC. Mechanisms of apoptosis. American Journal of Pathology. 2000;157(5):1415–30. [PMC free article: PMC1885741] [PubMed: 11073801]
  749. Reeves WH, Sthoeger ZM. Molecular cloning of cDNA encoding the p70 (Ku) lupus autoantigen. Journal of Biological Chemistry. 1989;264(9):5047–52. [PubMed: 2466842]
  750. Ren Q, Murphy SE, Zheng Z, Lazarus P. O-Glucuronidation of the lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) by human UDP-glucuro-nosyltransferases 2B7 and 1A9. Drug Metabolism and Disposition. 2000;28(11):1352–60. [PubMed: 11038164]
  751. Renner T, Fechner T, Scherer G. Fast quantification of the urinary marker of oxidative stress 8-hydroxy-2′-deoxyguanosine using solid-phase extraction and high-performance liquid chromatography with triple-stage quadrupole mass detection. Journal of Chromatography B: Biomedical Sciences and Applications. 2000;738(2):311–7. [PubMed: 10718649]
  752. Reznick AZ, Cross CE, Hu ML, Suzuki YJ, Khwaja S, Safadi A, Motchnik PA, Packer L, Halliwell B. Modification of plasma proteins by cigarette smoke as measured by protein carbonyl formation. Biochemical Journal. 1992;286(Pt 2):607–11. [PMC free article: PMC1132941] [PubMed: 1530591]
  753. Rich T, Allen RL, Wyllie AH. Defying death after DNA damage. Nature. 2000;407(6805):777–83. [PubMed: 11048728]
  754. Richie JP Jr, Carmella SG, Muscat JE, Scott DG, Akerkar SA, Hecht SS. Differences in the urinary metabolites of the tobacco-specific lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in black and white smokers. Cancer Epidemiology, Bio-markers & Prevention. 1997;6(10):783–90. [PubMed: 9332760]
  755. Richter A, O’Donnell RA, Powell RM, Sanders MW, Holgate ST, Djukanović R, Davies DE. Autocrine ligands for the epidermal growth factor receptor mediate interleukin-8 release from bronchial epithelial cells in response to cigarette smoke. American Journal of Respiratory Cell and Molecular Biology. 2002;27(1):85–90. [PubMed: 12091250]
  756. Riedl K, Krysan K, Põld M, Dalwadi H, Heuze-Vourc’h N, Dohadwala M, Liu M, Cui X, Figlin R, Mao JT, et al. Multifaceted roles of cyclooxygenase-2 in lung cancer. Drug Resistance Updates. 2004;7(3):169–84. [PubMed: 15296859]
  757. Riedy M, Wang J-Y, Miller AP, Buckler A, Hall J, Guida M. Genomic organization of the UGT2b gene cluster on human chromosome 4q13. Pharmacogenetics. 2000;10(3):251–60. [PubMed: 10803681]
  758. Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, Mariotto A, Feuer EJ, Edwards BK, editors. SEER Cancer Statistics Review, 1975–2001. Bethesda (MD): National Cancer Institute; 2004.
  759. Riffelmann M, Muller G, Schmieding W, Popp W, Norpoth K. Biomonitoring of urinary aromatic amines and arylamine hemoglobin adducts in exposed workers and nonexposed control persons. International Archives of Occupational and Environmental Health. 1995;68(1):36–43. [PubMed: 8847111]
  760. Risinger JI, Umar A, Barrett JC, Kunkel TA. A hPMS2 mutant cell line is defective in strand-specific mismatch repair. Journal of Biological Chemistry. 1995;270(31):18183–6. [PubMed: 7629132]
  761. Rivenson A, Hoffmann D, Prokopczyk B, Amin S, Hecht SS. Induction of lung and exocrine pancreas tumors in F344 rats by tobacco-specific and Areca-derived N-nitrosamines. Cancer Research. 1988;48(23):6912–7. [PubMed: 3180100]
  762. Robles AI, Bemmels NA, Foraker AB, Harris CC. APAF-1 is a transcriptional target of p53 in DNA damage-induced apoptosis. Cancer Research. 2001;61(18):6660–4. [PubMed: 11559530]
  763. Robles AI, Linke SP, Harris CC. The p53 network in lung carcinogenesis. Oncogene. 2002;21(45):6898–907. [PubMed: 12362272]
  764. Rodriguez-Viciana P, Warne PH, Khwaja A, Marte BM, Pappin D, Das P, Waterfield MD, Ridley A, Downward J. Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras. Cell. 1997;89(3):457–67. [PubMed: 9150145]
  765. Rojas M, Alexandrov K, Cascorbi I, Brockmoller J, Likhachev A, Pozharisski K, Bouvier G, Auburtin G, Mayer L, Koop-Schneider A, et al. High benzo[a]pyrene diol-epoxide DNA adduct levels in lung and blood cells from individuals with combined CYP1A1 MspI/Msp-GSTM1*0/*0 genotypes. Pharmacogenetics. 1998;8(2):109–18. [PubMed: 10022748]
  766. Rojas M, Marie B, Vignaud JM, Martinet N, Siat J, Grosdidier G, Cascorbi I, Alexandrov K. High DNA damage by benzo[a]pyrene 7,8-diol-9,10-epoxide in bronchial epithelial cells from patients with lung cancer: comparison with lung parenchyma. Cancer Letters. 2004;207(2):157–63. [PubMed: 15072824]
  767. Romashkova JA, Makarov SS. NF-κB is a target of AKT in anti-apoptotic PDGF signaling [letter] Nature. 1999;401(6748):86–90. [PubMed: 10485711]
  768. Rosas SLB, Koch W, da Costa Carvalho MG, Wu L, Califano J, Westra W, Jen J, Sidransky D. Promoter hypermethylation patterns of p16, O6-methylguanine-DNA-methyltransferase, and death-associated protein kinase in tumors and saliva of head and neck cancer patients. Cancer Research. 2001;61(3):939–42. [PubMed: 11221887]
  769. Rosell R, Li S, Skacel Z, Mate JL, Maestre J, Canela M, Tolosa E, Armengol P, Barnadas A, Ariza A. Prognostic impact of mutated K-ras gene in surgically resected non-small cell lung cancer patients. Oncogene. 1993;8(9):2407–12. [PubMed: 8395679]
  770. Rosenquist TA, Zharkov DO, Grollman AP. Cloning and characterization of a mammalian 8-oxoguanine DNA glycosylase. Proceedings of the National Academy of Sciences of the United States of America. 1997;94(14):7429–34. [PMC free article: PMC23838] [PubMed: 9207108]
  771. Ross GM, McMillan TJ, Wilcox P, Collins AR. The single cell microgel electrophoresis assay (comet assay): technical aspects and applications. Mutation Research. 1995;337(1):57–60. [PubMed: 7596358]
  772. Rowe JD, Nieves E, Listowsky I. Subunit diversity and tissue distribution of human glutathione S-transferases: interpretations based on electrospray ionization-MS and peptide sequence-specific antisera. Biochemical Journal. 1997;325(Pt 2):481–6. [PMC free article: PMC1218585] [PubMed: 9230131]
  773. Roymans D, Slegers H. Phosphatidylinositol 3-kinases in tumor progression. European Journal of Biochemistry. 2001;268(3):487–98. [PubMed: 11168386]
  774. Roz L, Andriana F, Ferreira CG, Giaccone G, Sozzi G. The apoptotic pathway triggered by the Fhit protein in lung cancer cell lines is not affected by Bcl-2 or Bcl-x(L) overexpression. Oncogene. 2004;23(56):9102–10. [PubMed: 15489891]
  775. Ruano-Ravina A, Figueiras A, Loidi L, Barros-Dios JM. GSTM1 and GSTT1 polymorphisms, tobacco and risk of lung cancer: a case-control study from Galicia, Spain. Anticancer Research. 2003;23(56):4333–7. [PubMed: 14666648]
  776. Ruggeri B, DiRado M, Zhang SY, Bauer B, Goodrow T, Klein-Szanto AJP. Benzo[a]pyrene-induced murine skin tumors exhibit frequent and characteristic G to T mutations in the p53 gene. Proceedings of the National Academy of Sciences of the United States of America. 1993;90(3):1013–7. [PMC free article: PMC45801] [PubMed: 8430068]
  777. Rusch V, Baselga J, Cordon-Cardo C, Orazem J, Zaman M, Hoda S, McIntosh J, Kurie J, Dmitrovsky E. Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Research. 1993;53(10 Suppl):2379–85. [PubMed: 7683573]
  778. Rusch V, Klimstra D, Linkov I, Dmitrovsky E. Aberrant expression of p53 or the epidermal growth factor receptor is frequent in early bronchial neoplasia and coexpression precedes squamous cell carcinoma development. Cancer Research. 1995;55(6):1365–72. [PubMed: 7882337]
  779. Ruvolo PP, Deng X, May WS. Phosphorylation of Bcl2 and regulation of apoptosis. Leukemia. 2001;15(4):515–22. [PubMed: 11368354]
  780. Ryan BM, McManus R, Daly JS, Carton E, Keeling PWN, Reynolds JV, Kelleher D. A common p73 polymorphism is associated with a reduced incidence of oesophageal carcinoma. British Journal of Cancer. 2001;85(10):1499–503. [PMC free article: PMC2363958] [PubMed: 11720435]
  781. Ryberg D, Skaug V, Hewer A, Phillips DH, Harries LW, Wolf CR, Ogreid D, Ulvik A, Vu P, Haugen A. Genotypes of glutathione transferase M1 and P1 and their significance for lung DNA adduct levels and cancer risk. Car-cinogenesis. 1997;18(7):1285–9. [PubMed: 9230269]
  782. Saarikoski ST, Reinikainen M, Antilla S, Karjalainen A, Vainio H, Husgafvel-Pursiainen K, Hirvonen A. Role of NAT2 deficiency in susceptibility to lung cancer among asbestos-exposed individuals. Pharmacogenetics. 2000;10(2):183–5. [PubMed: 10762006]
  783. Sakumi K, Tominaga Y, Furuichi M, Xu P, Tsuzuki T, Seki-guchi M, Nakabeppu Y. Ogg1 knockout-associated lung tumorigenesis and its suppression by Mth1 gene disruption. Cancer Research. 2003;63(5):902–5. [PubMed: 12615700]
  784. Samet JM, Humble CG, Pathak DR. Personal and family history of respiratory disease and lung cancer risk. American Review of Respiratory Disease. 1986;134(3):466–70. [PubMed: 3752703]
  785. Samson L, Derfler B, Boosalis M, Call K. Cloning and characterization of a 3-methyladenine DNA glyco-sylase cDNA from human cells whose gene maps to chromosome 16. Proceedings of the National Academy of Sciences of the United States of America. 1991;88(20):9127–31. [PMC free article: PMC52665] [PubMed: 1924375]
  786. Sancar A, Lindsey-Boltz LA, Ünsal-Kaçmaz K, Linn S. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annual Review of Biochemistry. 2004;73:39–85. [PubMed: 15189136]
  787. Sanchez-Cespedes M, Ahrendt SA, Piantadosi S, Rosell R, Monzo M, Wu L, Westra WH, Yang SC, Jen J, Sidransky D. Chromosomal alterations in lung adenocarcinoma from smokers and nonsmokers. Cancer Research. 2001;61(4):1309–13. [PubMed: 11245426]
  788. Sanchez-Cespedes M, Parrella P, Esteller M, Nomoto S, Trink B, Engles JM, Westra WH, Herman JG, Sidransky D. Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. Cancer Research. 2002;62(13):3659–62. [PubMed: 12097271]
  789. Sanyal S, Festa F, Sakano S, Zhang Z, Steineck G, Norming U, Wijström H, Larsson P, Kumar R, Hemminki K. Polymorphisms in DNA repair and metabolic genes in bladder cancer. Carcinogenesis. 2004;25(5):729–34. [PubMed: 14688016]
  790. Sapkota GP, Deak M, Kieloch A, Morrice N, Goodarzi AA, Smythe C, Shiloh Y, Lees-Miller SP, Alessi DR. Ionizing radiation induces ataxia telangiectasia mutated kinase (ATM)-mediated phosphorylation of LKB1/STK11 at Thr-366. Biochemical Journal. 2002;68(Pt 2):507–16. [PMC free article: PMC1223019] [PubMed: 12234250]
  791. Schabath MB, Spitz MR, Grossman HB, Zhang K, Dinney CP, Zheng P-J, Wu X. Genetic instability in bladder cancer assessed by the comet assay. Journal of the National Cancer Institute. 2003;95(7):540–7. [PubMed: 12671022]
  792. Schabath MB, Spitz MR, Hong WK, Delclos GL, Reynolds WF, Gunn GB, Whitehead LW, Wu X. A myeloperoxidase polymorphism associated with reduced risk of lung cancer. Lung Cancer. 2002;37(1):35–40. [PubMed: 12057865]
  793. Scherer G, Meger M, Meger-Kossien I, Pachinger A. Biological monitoring of the tobacco-smoke related exposure to benzene. Proceedings of the American Association for Cancer Research. 2001;42:150.
  794. Scherer G, Renner T, Meger M. Analysis and evaluation of trans,trans-muconic acid as a biomarker for benzene exposure. Journal of Chromatography B: Biomedical Sciences and Applications. 1998;717(1–2):179–99. [PubMed: 9832246]
  795. Schlade-Bartusiak K, Rozik K, Laczmanska I, Ramsey D, Sasiadek M. Influence of GSTT1, mEH, CYP2E1 and RAD51 polymorphisms on diepoxybutane-induced SCE frequency in cultured human lymphocytes. Mutation Research. 2004;558(1–2):121–30. [PubMed: 15036125]
  796. Schmezer P, Rajaee-Behbahani N, Risch A, Thiel S, Rittgen W, Drings P, Dienemann H, Kayser KW, Schulz V, Bartsch H. Rapid screening assay for mutagen sensitivity and DNA repair capacity in human peripheral blood lymphocytes. Mutagenesis. 2001;16(1):25–30. [PubMed: 11139596]
  797. Schmitt CA, Lowe SW. Apoptosis and chemoresistance in transgenic cancer models. Journal of Molecular Medicine. 2002;80(3):137–46. [PubMed: 11894140]
  798. Schofield MJ, Hsieh P. DNA mismatch repair: molecular mechanisms and biological function. Annual Review of Microbiology. 2003;57:579–608. [PubMed: 14527292]
  799. Schott AF, Apel IJ, Nuñez G, Clarke MF. Bcl-XL protects cancer cells from p53-mediated apoptosis. Oncogene. 1995;11(7):1389–94. [PubMed: 7478561]
  800. Schuller HM, Orloff M. Tobacco-specific carcinogenic nitrosamines: ligands for nicotinic acetylcholine receptors in human lung cancer cells. Biochemical Pharmacology. 1998;55(9):1377–84. [PubMed: 10076528]
  801. Schuller HM, Plummer HK III, Bochsler PN, Dudric P, Bell JL, Harris RE. Co-expression of β-adrenergic receptors and cyclooxygenase-2 in pulmonary adenocarcinoma. International Journal of Oncology. 2001;19(3):445–9. [PubMed: 11494020]
  802. Schuller HM, Plummer HK III, Jull BA. Receptor-mediated effects of nicotine and its nitrosated derivative NNK on pulmonary neuroendocrine cells. Anatomical Record Part A, Discoveries in Molecular, Cellular, and Evolutionary Biology. 2003;270(1):51–8. [PubMed: 12494489]
  803. Schuller HM, Tithof PK, Williams M, Plummer H III. The tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone is a β-adrenergic agonist and stimulates DNA synthesis in lung adenocarcinoma via β-adrenergic receptor-mediated release of arachidonic acid. Cancer Research. 1999;59(18):4510–5. [PubMed: 10493497]
  804. Schwartz AG, Prysak GM, Bock CH, Cote ML. The molecular epidemiology of lung cancer. Carcinogenesis. 2007;28(3):507–18. [PubMed: 17183062]
  805. Schwartz AG, Siegfried JM, Weiss L. Familial aggregation of breast cancer with early onset lung cancer. Genetic Epidemiology. 1999;17(1):274–84. [PubMed: 10520210]
  806. Schwartz AG, Yang P, Swanson GM. Familial risk of lung cancer among nonsmokers and their relatives. American Journal of Epidemiology. 1996;144(6):554–62. [PubMed: 8797515]
  807. Seidegard J, Vorachek WR, Pero RW, Pearson WR. Hereditary differences in the expression of the human glutathione transferase active in trans-stilbene oxide are due to a gene deletion. Proceedings of the National Academy of Sciences of the United States of America. 1988;85(19):7293–7. [PMC free article: PMC282172] [PubMed: 3174634]
  808. Sekido Y, Takahashi T, Mäkelä TP, Obata Y, Ueda R, Hida T, Hibi K, Shimokata K, Alitalo K, Takahashi T. Complex intrachromosomal rearrangement in the process of amplification of the L-myc gene in small-cell lung cancer. Molecular and Cellular Biology. 1992;12(4):1747–54. [PMC free article: PMC369618] [PubMed: 1312669]
  809. Sellers TA, Bailey-Wilson JE, Elston RC, Wilson AF, Elston GZ, Ooi WL, Rothschild H. Evidence for mendelian inheritance in the pathogenesis of lung cancer. Journal of the National Cancer Institute. 1990;82(15):1272–9. [PubMed: 2374177]
  810. Sellers TA, Elston RC, Atwood LD, Rothschild H. Lung cancer histologic type and family history of cancer. Cancer. 1992;69(1):86–91. [PubMed: 1727678]
  811. Selvaggi G, Novello S, Torri V, Leonardo E, De Giuli P, Borasio P, Mossetti C, Ardissone F, Lausi P, Scagliotti GV. Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer. Annals of Oncology. 2004;15(1):28–32. [PubMed: 14679115]
  812. Seow A, Zhao B, Poh W-T, Teh M, Eng P, Wang Y-T, Tan W-C, Lee EJD, Lee H-P. NAT2 slow acetylator genotype is associated with increased risk of lung cancer among non-smoking Chinese women in Singapore. Carcino-genesis. 1999;20(9):1877–81. [PubMed: 10469638]
  813. Serdar B, Waidyanatha S, Zheng Y, Rappaport SM. Simultaneous determination of urinary 1- and 2-naphthols, 3- and 9-phenanthrols, and 1-pyrenol in coke oven workers. Biomarkers. 2003;8(2):93–109. [PubMed: 12775495]
  814. Shapiro JA, Jacobs EJ, Thun MJ. Cigar smoking in men and risk of death from tobacco-related cancers. Journal of the National Cancer Institute. 2000;92(4):333–7. [PubMed: 10675383]
  815. Shaw GL, Falk RT, Pickle LW, Mason TJ, Buffler PA. Lung cancer risk associated with cancer in relatives. Journal of Clinical Epidemiology. 1991;44(4–5):429–37. [PubMed: 2010787]
  816. Sheehan D, Meade G, Foley VM, Dowd CA. Structure, function and evolution of glutathione transferases: implications for classification of non-mammalian members of an ancient enzyme superfamily. Biochemical Journal. 2001;360(Pt 1):1–16. [PMC free article: PMC1222196] [PubMed: 11695986]
  817. Shen H, Sturgis EM, Khan SG, Qiao Y, Shahlavi T, Eicher SA, Xu Y, Wang X, Strom SS, Spitz MR, et al. An intronic poly (AT) polymorphism of the DNA repair gene XPC and risk of squamous cell carcinoma of the head and neck: a case-control study. Cancer Research. 2001;61(8):3321–5. [PubMed: 11309287]
  818. Shen MR, Jones IM, Mohrenweiser H. Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans. Cancer Research. 1998;58(4):604–8. [PubMed: 9485007]
  819. Sherratt PJ, Pulford DJ, Harrison DJ, Green T, Hayes JD. Evidence that human class Theta glutathione S-transferase T1-1 can catalyse the activation of dichlo-romethane, a liver and lung carcinogen in the mouse: comparison of the tissue distribution of GST T1-1 with that of classes Alpha, Mu and Pi GST in human. Biochemical Journal. 1997;326(Pt 3):837–46. [PMC free article: PMC1218740] [PubMed: 9307035]
  820. Shi D, He G, Cao S, Pan W, Zhang HZ, Yu D, Hung MC. Overexpression of the c-erbB-2/neu-encoded p185 protein in primary lung cancer. Molecular Carcinogenesis. 1992;5(3):213–8. [PubMed: 1350198]
  821. Shields PG, Harris CG. Cancer risk and low-penetrance susceptibility genes in gene-environment interactions. Journal of Clinical Oncology. 2000;18(11):2309–15. [PubMed: 10829052]
  822. Shih C-M, Lin P-T, Wang H-C, Huang W-C, Wang Y-C. Lack of evidence of association of p21WAF1/CP1 polymorphism with lung cancer susceptibility and prognosis in Taiwan. Japanese Journal of Cancer Research. 2000;91(1):9–15. [PMC free article: PMC5926229] [PubMed: 10744039]
  823. Shimada T, Fujii-Kuriyama Y. Metabolic activation of polycyclic aromatic hydrocarbons to carcinogens by cytochromes P450 1A1 and 1B1. Cancer Science. 2004;95(1):1–6. [PubMed: 14720319]
  824. Shimada T, Gillam EMJ, Oda Y, Tsumura F, Sutter TR, Guengerich FP, Inoue K. Metabolism of benzo[a] pyrene to trans-7,8-dihydroxy-7, 8-dihydrobenzo[a] pyrene by recombinant human cytochrome P450 1B1 and purified liver epoxide hydrolase. Chemical Research in Toxicology. 1999;12(7):623–9. [PubMed: 10409402]
  825. Shimada T, Gillam EMJ, Sutter TR, Strickland PT, Guengerich FP, Yamazaki H. Oxidation of xenobiotics by recombinant human cytochrome P450 1B1. Drug Metabolism and Disposition. 1997;25(5):617–22. [PubMed: 9152602]
  826. Shimada T, Hayes CL, Yamazaki H, Amin S, Hecht SS, Guengerich FP, Sutter TR. Activation of chemically diverse procarcinogens by human cytochrome P450 1B1. Cancer Research. 1996;56(13):2979–84. [PubMed: 8674051]
  827. Shimizu E, Coxon A, Otterson GA, Steinberg SM, Kratzke RA, Kim YW, Fedorko J, Oie H, Johnson BE, Mulshine JL, et al. RB protein status and clinical correlation from 171 cell lines representing lung cancer, extrapulmonary small cell carcinoma, and mesothelioma: a predictive evidence for conformational change to influence mito-chondrial transport and a study of allelic association in Parkinson’s disease. Oncogene. 1994;9(9):2441–8. [PubMed: 8058306]
  828. Shishodia S, Aggarwal BB. Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates activation of cigarette smoke-induced nuclear factor (NF)-κB by suppressing activation of IκBα kinase in human non-small cell lung carcinoma: correlation with suppression of cyclin D1, COX-2, and matrix metalloproteinase-9. Cancer Research. 2004;64(14):5004–12. [PubMed: 15256475]
  829. Shuker DE, Friesen MD, Garren L, Prevost V. A rapid gas chromatography-mass spectrometry method for the determination of urinary 3-methyladenine: application in human subjects. IARC Scientific Publications. 1991;(105):102–6. [PubMed: 1855830]
  830. Sijbers AM, de Laat WL, Ariza RR, Biggerstaff M, Wei Y-F, Moggs JG, Carter KC, Shell BK, Evans E, de Jong MC, et al. Xeroderma pigmentosum group F caused by a defect in a structure-specific DNA repair endonuclease. Cell. 1996;86(5):811–22. [PubMed: 8797827]
  831. Singer B, Grunberger D. New York: Plenum Press; Molecular Biology of Mutagens and Carcinogens. 1983:45–94.
  832. Singh NP, McCoy MT, Tice RR, Schneider EL. A simple technique for quantitation of low levels of DNA damage in individual cells. Experimental Cell Research. 1988;175(1):184–91. [PubMed: 3345800]
  833. Singh R, Kaur B, Farmer PB. Detection of DNA damage derived from a direct acting ethylating agent present in cigarette smoke by use of liquid chromatography-tandem mass spectrometry. Chemical Research in Toxicology. 2005;18(2):249–56. [PubMed: 15720129]
  834. Singhal S, Amin KM, Kruklitis R, DeLong P, Friscia ME, Litzky LA, Putt ME, Kaiser LR, Albelda SM. Alterations in cell cycle genes in early stage lung adenocarcinoma identified by expression profiling. Cancer Biology & Therapy. 2003;2(3):291–8. [PubMed: 12878869]
  835. Själander A, Birgander R, Rannug A, Alexandrie A-K, Torn-ling G, Beckman G. Association between the p21 codon 31 A1 (arg) allele and lung cancer. Human Heredity. 1996;46(4):221–5. [PubMed: 8807325]
  836. Skipper PL, Peng X, Soohoo CK, Tannenbaum SR. Protein adducts as biomarkers of human carcinogen exposure. Drug Metabolism Reviews. 1994;26(1–2):111–24. [PubMed: 8082561]
  837. Skipper PL, Tannenbaum SR. Protein adducts in the molecular dosimetry of chemical carcinogens. Carcinogenesis. 1990;11(4):507–18. [PubMed: 2182215]
  838. Slebos RJ, Kibbelaar RE, Dalesio O, Kooistra A, Stam J, Meijer CJ, Wagenaar SS, Vanderschueren RG, van Zan-dwijk N, Mooi WJ, et al. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. New England Journal of Medicine. 1990;323(9):561–5. [PubMed: 2199829]
  839. Slupphaug G, Lettrem I, Myrnes B, Krokan HE. Expression of O6-methylguanine-DNA methyltransferase and uracil-DNA glycolase in human placentae from smokers and nonsmokers. Carcinogenesis. 1992;13(10):1769–73. [PubMed: 1423836]
  840. Slupska MM, Baikalov C, Luther WM, Chiang JH, Wei YF, Miller JH. Cloning and sequencing a human homolog (hMYH) of the Escherichia coli mutY gene whose function is required for the repair of oxidative DNA damage. Journal of Bacteriology. 1996;178(13):3885–92. [PMC free article: PMC232650] [PubMed: 8682794]
  841. Slupska MM, Luther WM, Chiang JH, Yang H, Miller JH. Functional expression of hMYH, a human homolog of the Escherichia coli MutY protein. Journal of Bacteriology. 1999;181(19):6210–3. [PMC free article: PMC103656] [PubMed: 10498741]
  842. Smith CJ, Huang W, Walcott CJ, Turner W, Grainger J, Patterson DG Jr. Quantification of monohydroxy-PAH metabolites in urine by solid-phase extraction with isotope dilution-GC-MS. Analytical and Bioanalytical Chemistry. 2002a;372(1):216–20. [PubMed: 11939197]
  843. Smith CJ, Walcott CJ, Huang W, Maggio V, Grainger J, Patterson DG Jr. Determination of selected monohy-droxymetabolites of 2-,3- and 4-ringpolycyclicaromatic hydrocarbons in urine by solid-phase microextraction and isotope dilution gas chromatography—mass spectrometry. Journal of Chromatography B. 2002b;778( 1–2):157–64. [PubMed: 12376123]
  844. Smith LE, Denissenko MF, Bennett WP, Li H, Amin S, Tang M-S, Pfeifer GP. Targeting of lung cancer mutational hotspots by polycyclic aromatic hydrocarbons. Journal of the National Cancer Institute. 2000;92(10):803–11. [PubMed: 10814675]
  845. Snyder R, Chepiga T, Yang CS, Thomas H, Platt K, Oesch F. Benzene metabolism by reconstituted cytochromes P450 2B1 and 2E1 and its modulation by cytochrome b5, microsomal epoxide hydrolase, and glutathione transferases: evidence for an important role of microsomal epoxide hydrolase in the formation of hydroquinone. Toxicology and Applied Pharmacology. 1993;122(2):172–81. [PubMed: 8211999]
  846. Snyder R, Hedli CC. An overview of benzene metabolism. Environmental Health Perspectives. 1996;104(Suppl 6):1165–71. [PMC free article: PMC1469747] [PubMed: 9118888]
  847. Sobol RW, Horton JK, Kuhn R, Gu H, Singhal RK, Prasad R, Rajewsky K, Wilson SH. Requirement of mammalian DNA polymerase-β in base-excision repair. Nature. 1996;379(6561):183–6. [PubMed: 8538772]
  848. Soengas MS, Alarcón RM, Yoshida H, Giaccia AJ, Hakem R, Mak TW, Lowe SW. Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition. Science. 1999;284(5411):156–9. [PubMed: 10102818]
  849. Song P, Sekhon HS, Jia Y, Keller JA, Blusztajn JK, Mark GP, Spindel ER. Acetylcholine is synthesized by and acts as an autocrine growth factor for small cell lung carcinoma. Cancer Research. 2003a;63(1):214–21. [PubMed: 12517800]
  850. Song P, Sekhon HS, Proskocil B, Blusztajn JK, Mark GP, Spindel ER. Synthesis of acetylcholine by lung cancer. Life Sciences. 2003b;72(18–19):2159–68. [PubMed: 12628474]
  851. Sopori M. Effects of cigarette smoke on the immune system. Nature Reviews Immunology. 2002;2(5):372–7. [PubMed: 12033743]
  852. Sørensen M, Autrup H, Tjønneland A, Overvad K, Raaschou-Nielsen O. Glutathione S-transferase T1 null-genotype is associated with an increased risk of lung cancer. International Journal of Cancer. 2004a;110(2):219–24. [PubMed: 15069685]
  853. Sørensen M, Autrup H, Tjønneland A, Overvad K, Raaschou-Nielsen O. Genetic polymorphisms in CYP1B1, GSTA1, NQO1 and NAT2 and the risk of lung cancer. Cancer Letters. 2005;221(2):185–90. [PubMed: 15808404]
  854. Sørensen M, Poole J, Autrup H, Muzyka V, Jensen A, Loft S, Knudsen LE. Benzene exposure assessed by metabolite excretion in Estonian oil shale mineworkers: influence of glutathione S-transferase polymorphisms. Cancer Epidemiology, Biomarkers & Prevention. 2004b;13(11):1729–35. [PubMed: 15533900]
  855. Sozzi G, Miozzo M, Donghi R, Pilotti S, Cariani CT, Pastorino U, Della Porta G, Pierotti MA. Deletions of 17p and p53 mutations in preneoplastic lesions of the lung. Cancer Research. 1992;52(21):6079–82. [PubMed: 1394234]
  856. Spitz MR, Duphorne CM, Detry MA, Pillow PC, Amos CI, Lei L, de Andrade M, Gu X, Hong WK, Wu X. Dietary intake of isothiocyanates: evidence of a joint effect with glutathione S-transferase polymorphisms in lung cancer risk. Cancer Epidemiology, Biomarkers & Prevention. 2000;9(10):1017–20. [PubMed: 11045782]
  857. Spitz MR, Hsu TC, Wu X, Fueger JJ, Amos CI, Roth JA. Mutagen sensitivity as a biologic marker of lung cancer risk in African Americans. Cancer Epidemiology, Bio-markers & Prevention. 1995;4(2):99–103. [PubMed: 7537995]
  858. Spitz MR, Wei Q, Dong Q, Amos CI, Wu X. Genetic susceptibility to lung cancer: the role of DNA damage and repair. Cancer Epidemiology, Biomarkers & Prevention. 2003;12(8):689–98. [PubMed: 12917198]
  859. Spitz MR, Wu X, Mills G. Integrative epidemiology: from risk assessment to outcome prediction. Journal of Clinical Oncology. 2005;23(2):267–75. [PubMed: 15637390]
  860. Spitz MR, Wu X, Wang Y, Wang L-E, Shete S, Amos CI, Guo Z, Lei L, Mohrenweiser H, Wei Q. Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. Cancer Research. 2001;61(4):1354–7. [PubMed: 11245433]
  861. Squier CA, Cox P, Hall BK. Enhanced penetration of nitrosonornicotine across oral mucosa in the presence of ethanol. Journal of Oral Pathology. 1986;15(5):276–9. [PubMed: 3091795]
  862. Sridhar SS, Seymour L, Shepherd FA. Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer. Lancet Oncology. 2003;4(7):397–406. [PubMed: 12850190]
  863. Srivastava DK, Vande Berg BJ, Prasad R, Molina JT, Beard WA, Tomkinson AE, Wilson SH. Mammalian abasic site base excision repair: identification of the reaction sequence and rate-determining steps. Journal of Biological Chemistry. 1998;273(33):21203–9. [PubMed: 9694877]
  864. Srivenugopal KS, Yuan X-H, Friedman HS, Ali-Osman F. Ubiquitination-dependent proteolysis of O6-methyl-guanine-DNA methyltransferase in human and murine tumor cells following inactivation with O6-benzylgua-nine or 1,3- bis (2-chloroethyl)-1-nitrosourea. Biochemistry. 1996;35(4):1328–34. [PubMed: 8573590]
  865. Stambolic V, Mak TW, Woodgett JR. Modulation of cellular apoptotic potential: contributions to oncogenesis. Oncogene. 1999;18(45):6094–103. [PubMed: 10557100]
  866. Stasiak AZ, Larquet E, Stasiak A, Müller S, Engel A, Van Dyck E, West SC, Egelman EH. The human Rad52 protein exists as a heptameric ring. Current Biology. 2000;10(6):337–40. [PubMed: 10744977]
  867. Stepanov I, Hecht SS. Tobacco-specific nitrosamines and their pyridine-N-glucuronides in the urine of smokers and smokeless tobacco users. Cancer Epidemiology, Biomarkers & Prevention. 2005;14(4):885–91. [PubMed: 15824160]
  868. Stern MC, Umbach DM, Lunn RM, Taylor JA. DNA repair gene XRCC3 codon 241 polymorphism, its interaction with smoking and XRCC1 polymorphisms, and bladder cancer risk. Cancer Epidemiology, Biomarkers & Prevention. 2002;11(9):939–43. [PubMed: 12223443]
  869. Stern MC, Umbach DM, van Gils CH, Lunn RM, Taylor JA. DNA repair gene XRCC1 polymorphisms, smoking, and bladder cancer risk. Cancer Epidemiology, Biomarkers & Prevention. 2001;10(2):125–31. [PubMed: 11219769]
  870. Stillwell WG, Glogowski J, Xu HX, Wishnok JS, Zavala D, Montes G, Correa P, Tannenbaum SR. Urinary excretion of nitrate, N-nitrosoproline, 3-methylade-nine, and 7-methylguanine in a Colombian population at high risk for stomach cancer. Cancer Research. 1991;51(1):190–4. [PubMed: 1988083]
  871. Stojic L, Brun R, Jiricny J. Mismatch repair and DNA damage signalling. DNA Repair. 2004;3(8–9):1091–101. [PubMed: 15279797]
  872. Stommel P, Müller G, Stücker W, Verkoyen C, Schöbel S, Norpoth K. Determination of S-phenylmercapturic acid in the urine—an improvement in the biological monitoring of benzene exposure. Carcinogenesis. 1989;10(2):279–82. [PubMed: 2912579]
  873. Strauss BS. The ‘A rule’ of mutagen specificity: a consequence of DNA polymerase bypass of non-instructional lesions? BioEssays. 1991;13(2):79–84. [PubMed: 2029269]
  874. Strauss B, Sagher D, Schwartz J, Karrison T, Larson R. Heterogeneity in the O6-alkyl-guanine DNA alkyl-transferase (AGT) activity of human peripheral blood lymphocytes (PBL’s). DNA Repair Mechanisms and Their Biological Implications in Mammalian Cells. Lambert MW, Laval J, editors. New York: Plenum Press; 1989. p. 618.
  875. Strom SS, Wu X, Sigurdson AJ, Hsu TC, Fueger JJ, Lopez J, Tee PG, Spitz MR. Lung cancer, smoking patterns, and mutagen sensitivity in Mexican-Americans. Journal of the National Cancer Institute Monographs. 1995;18:29–33. [PubMed: 8562219]
  876. Stücker I, Hirvonen A, de Waziers I, Cabelguenne A, Mitrunen K, Cénée S, Koun-Besson E, Hémon D, Beaune P, Loriot M-A. Genetic polymorphisms of glutathione-S-transferases as modulators of lung cancer susceptibility. Carcinogenesis. 2002;23(9):1475–81. [PubMed: 12189190]
  877. Stucki M, Pascucci B, Parlanti E, Fortini P, Wilson SH, Hübscher U, Dogliotti E. Mammalian base excision repair by DNA polymerases δ and ɛ Oncogene. 1998;17(7):835–43. [PubMed: 9780000]
  878. Sturgis EM, Castillo EJ, Li L, Zheng R, Eicher SA, Clayman GL, Strom SS, Spitz MR, Wei Q. Polymorphisms of DNA repair gene XRCC1 in squamous cell carcinoma of the head and neck. Carcinogenesis. 1999;20(11):2125–9. [PubMed: 10545415]
  879. Sturgis EM, Dahlstrom KR, Spitz MR, Wei Q. DNA repair gene ERCC1 and ERCC2/XPD polymorphisms and risk of squamous cell carcinoma of the head and neck. Archives of Otolaryngology—Head & Neck Surgery. 2002;128(9):1084–8. [PubMed: 12220217]
  880. Su L, Liu G, Zhou W, Xu LL, Miller DP, Park S, Lynch TJ, Wain JC, Christiani DC. No association between the p21 codon 31 serine-arginine polymorphism and lung cancer risk. Cancer Epidemiology, Biomarkers & Prevention. 2003;12(2):174–5. [PubMed: 12582031]
  881. Su T, Bao Z, Zhang Q-Y, Smith TJ, Hong J-Y, Ding X. Human cytochrome P 450 CYP2A13: predominant expression in the respiratory tract and in high efficiency metabolic activation of a tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Cancer Research. 2000;60(18):5074–9. [PubMed: 11016631]
  882. Sugimura T. History, present and future, of heterocyclic amines, cooked food mutagens. Princess Takamatsu Symposia. 1995;23:214–31. [PubMed: 8844813]
  883. Sugimura H, Kohno T, Wakai K, Nagura K, Genka K, Igarashi H, Morris BJ, Baba S, Ohno Y, Gao CM, et al. hOGG1 Ser326Cys polymorphism and lung cancer susceptibility. Cancer Epidemiology, Biomarkers & Prevention. 1999;8(8):669–74. [PubMed: 10744126]
  884. Sundberg K, Dreij K, Seidel A, Jernström B. Glutathione conjugation and DNA adduct formation of dibenzo[a,l] pyrene and benzo[a]pyrene diol epoxides in V79 cells stably expressing different human glutathione transferases. Chemical Research in Toxicology. 2002;15(2):170–9. [PubMed: 11849043]
  885. Sundberg K, Johansson A-S, Stenberg G, Widersten M, Seidel A, Mannervik B, Jernström B. Differences in the catalytic efficiencies of allelic variants of glutathione transferase P1-1 towards carcinogenic diol epoxides of polycyclic aromatic hydrocarbons. Carcinogenesis. 1998;19(3):433–6. [PubMed: 9525277]
  886. Sundberg K, Widersten M, Seidel A, Mannervik B, Jernström B. Glutathione conjugation of bay- and fjord-region diol epoxides of polycyclic aromatic hydrocarbons by glutathione transferases M1-1 and P1-1. Chemical Research in Toxicology. 1997;10(11):1221–7. [PubMed: 9403173]
  887. Sutter TR, Tang YM, Hayes CL, Wo YY, Jabs EW, Li X, Yin H, Cody CW, Greenlee WF. Complete cDNA sequence of a human dioxin-inducible mRNA identifies a new gene subfamily of cytochrome P450 that maps to chromosome 2. Journal of Biological Chemistry. 1994;269(18):13092–9. [PubMed: 8175734]
  888. Suzuki H, Gabrielson E, Chen W, Anbazhagan R, van Engeland M, Weijenber MP, Herman JG, Baylin SB. A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nature Genetics. 2002;31(2):141–9. [PubMed: 11992124]
  889. Suzuki S, Dobashi Y, Sakurai H, Nishikawa K, Hanawa M, Ooi A. Protein overexpression and gene amplification of epidermal growth factor receptor in non-small cell lung carcinomas: an immunohistochemical and fluorescence in situ hybridization study. Cancer. 2005;103(6):1265–73. [PubMed: 15712203]
  890. Swafford DS, Middleton SK, Palmisano WA, Nikula KJ, Tesfaigzi J, Baylin SB, Herman JG, Belinsky SA. Frequent aberrant methylation of p16INK4a in primary rat lung tumors. Molecular and Cellular Biology. 1997;17(3):1366–74. [PMC free article: PMC231861] [PubMed: 9032263]
  891. Swann PF, Coe AM, Mace R. Ethanol and dimethylnitrosa-mine and diethylnitrosamine metabolism and disposition in the rat: possible relevance to the influence of ethanol on human cancer incidence. Carcinogenesis. 1984;5(10):1337–43. [PubMed: 6435899]
  892. Swenberg JA, Koc H, Upton PB, Georguieva N, Ranasinghe A, Walker VE, Henderson R. Using DNA and hemoglobin adducts to improve the risk assessment of butadiene. Chemico-Biological Interactions. 2001:135–136. 387–403. [PubMed: 11397403]
  893. Szyfter K, Hemminki K, Szyfter W, Szmeja Z, Banaszewski J, Pabiszczak M. Tobacco smoke-associated N7-alkylguanine in DNA of larynx tissue and leucocytes. Carcinogenesis. 1996;17(3):501–6. [PubMed: 8631136]
  894. Takao M, Kanno S, Kobayashi K, Zhang Q-M, Yonei S, van der Horst GTJ, Yasui A. A back-up glycosylase in Nth1 knock-out mice is a functional Nei (endonuclease VIII) homologue. Journal of Biological Chemistry. 2002;277(44):42205–13. [PubMed: 12200441]
  895. Tan D, Deeb G, Wang J, Slocum HK, Winston J, Wiseman S, Beck A, Sait S, Anderson T, Ńwogu C, et al. HER-2/neu protein expression and gene alteration in stage I-IIIA non–small-cell lung cancer: a study of 140 cases using a combination of high throughput tissue microarray, immunohistochemistry, and fluorescent in situ hybridization. Diagnostic Molecular Pathology. 2003;12(4):201–11. [PubMed: 14639106]
  896. Tan T, Chu G. p53 binds and activates the xeroderma pigmentosum DDB2 gene in humans but not mice. Molecular and Cellular Biology. 2002;22(10):3247–54. [PMC free article: PMC133779] [PubMed: 11971958]
  897. Tang CK, Gong X-Q, Moscatello DK, Wong AJ, Lippman ME. Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer. Cancer Research. 2000;60(11):3081–7. [PubMed: 10850460]
  898. Tang M-S, Zheng JB, Denissenko MF, Pfeifer GP, Zheng Y. Use of UvrABC nuclease to quantify benzo[a]pyrene diol epoxide–DNA adduct formation at methylated versus unmethylated CpG sites in the p53 gene. Carcino-genesis. 1999;20(6):1085–9. [PubMed: 10357792]
  899. Tapper AR, McKinney SL, Nashmi R, Schwarz J, Deshpande P, Labarca C, Whiteaker P, Marks MJ, Collins AC, Lester HA. Nicotine activation of α4* receptors: sufficient for reward, tolerance, and sensitization. Science. 2004;306(5698):1029–32. [PubMed: 15528443]
  900. Tarroni P, Rubboli F, Chini B, Zwart R, Oortgiesen M, Sher E, Clementi F. Neuronal-type nicotinic receptors in human neuroblastoma and small-cell lung carcinoma cell lines. FEBS Letters. 1992;312(1):66–70. [PubMed: 1330682]
  901. Tateishi M, Ishida T, Mitsudomi T, Kaneko S, Sugimachi K. Immunohistochemical evidence of autocrine growth factors in adenocarcinoma of the human lung. Cancer Research. 1990;50(21):7077–80. [PubMed: 2208175]
  902. Tefre T, Rybert D, Haugen A, Nebert DW, Skaug V, Brogger A, Borresen AL. Human CYP1A1 gene: lack of association between the Msp I restriction fragment length polymorphism and incidence of lung cancer in a Nor-wegian population. Pharmacogenetics. 1991;1(1):20–5. [PubMed: 1726950]
  903. Terakawa N, Kanamori Y, Yoshida S. Loss of PTEN expression followed by Akt phosphorylation is a poor prognostic factor for patients with endometrial cancer. Endocrine-Related Cancer. 2003;10(2):203–8. [PubMed: 12790783]
  904. Thakker DR, Yagi H, Levin W, Wood AW, Conney AH, Jerina DM. Polycyclic aromatic hydrocarbons: metabolic activation to ultimate carcinogens. Bioactivation of Foreign Compounds. Anders MW, editor. New York: Academic Press; 1985. pp. 177–242.
  905. Thier R, Pemble SE, Kramer H, Taylor JB, Guengerich FP, Ketterer B. Human glutathione S-transferase T1-1 enhances mutagenicity of 1,2-dibromoethane, dibro-momethane and 1,2,3,4-diepoxybutane in Salmonella typhimurium. Carcinogenesis. 1996;17(1):163–6. [PubMed: 8565128]
  906. Thomas M, Kalita A, Labrecque S, Pim D, Banks L, Matla-shewski G. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Molecular and Cellular Biology. 1999;19(2):1092–100. [PMC free article: PMC116039] [PubMed: 9891044]
  907. To-Figueras J, Gené M, Gómez-Catalán J, Galán MC, Fuentes M, Ramón JM, Rodamilans M, Huguet E, Corbella J. Glutathione-S-transferase M1 (GSTM1) and T1 (GSTT1) polymorphism and lung cancer risk among northwestern Mediterraneans. Carcinogenesis. 1997;18(8):1529–33. [PubMed: 9276626]
  908. To-Figueras J, Gené M, Gómez-Catalán J, Piqué E, Borrego N, Carrasco JL, Rámon J, Corbella J. Genetic polymorphism of glutathione-S-transferase P1 gene and lung cancer risk. Cancer Causes & Control. 1999;10(1):65–70. [PubMed: 10334644]
  909. Tokuhata GK, Lilienfeld AM. Familial aggregation of lung cancer in humans. Journal of the National Cancer Institute. 1963;30(2):289–312. [PubMed: 13985327]
  910. Tolias KF, Cantley LC, Carpenter CL. Rho family GTPases bind to phosphoinositide kinases. Journal of Biological Chemistry. 1995;270(30):17656–9. [PubMed: 7629060]
  911. Tomizawa Y, Kohno T, Fujita T, Kiyama M, Saito R, Noguchi M, Matsuno Y, Hirohashi S, Yamaguchi N, Nakajima T, et al. Correlation between the status of the p53 gene and survival in patients with stage I non-small cell lung carcinoma. Oncogene. 1999;18(4):1007–14. [PubMed: 10023676]
  912. Tomizawa Y, Kohno T, Kondo H, Otsuka A, Nishioka M, Niki T, Yamada T, Maeshima A, Yoshimura K, Saito R, et al. Clinicopathological significance of epigenetic inactivation of RASSF1A at 3p21.3 in stage I lung adenocarcinoma. Clinical Cancer Research. 2002;8(7):2362–8. [PubMed: 12114441]
  913. Toorchen D, Topal MD. Mechanisms of chemical mutagenesis and carcinogenesis: effects on DNA replication of methylation at the O6-guanine position of dGTP. Carcinogenesis. 1983;4(12):1591–7. [PubMed: 6360407]
  914. Tornaletti S, Hanawalt PC. Effect of DNA lesions on transcription elongation. Biochimie. 1999;81(1–2):139–46. [PubMed: 10214918]
  915. Tornaletti S, Pfeifer GP. Complete and tissue-independent methylation of CpG sites in the p53 gene: implications for mutations in human cancers. Oncogene. 1995;10(8):1493–9. [PubMed: 7731703]
  916. Törnqvist M, Ehrenberg L. On cancer risk estimation of urban air pollution. Environmental Health Perspectives. 1994;102(Suppl 4):173–82. [PMC free article: PMC1566917] [PubMed: 7821292]
  917. Travis WD, Travis LB, Devesa SS. Lung cancer. Cancer. 1995;75(1 Suppl):191–202. [PubMed: 8000996]
  918. Tretyakova N, Matter B, Jones R, Shallop A. Formation of benzo[a]pyrene diol epoxide–DNA adducts at specific guanines within K-ras and p53 gene sequences: stable isotope-labeling mass spectrometry approach. Biochemistry. 2002;41(30):9535–44. [PubMed: 12135376]
  919. Tricker AR. N-nitroso compounds and man: sources of exposure, endogenous formation and occurrence in body fluids. European Journal of Cancer Prevention. 1997;6(3):226–68. [PubMed: 9306073]
  920. Tricker AR, Scherer G, Conze C, Adlkofer F, Pachinger A, Klus H. Evaluation of 4-(N-methylnitrosamino)-4-(3-pyridyl)butyric acid as a potential monitor of endogenous nitrosation of nicotine and its metabolites. Carcinogenesis. 1993;14(7):1409–14. [PubMed: 8330358]
  921. Trincao J, Johnson RE, Escalante CR, Prakash S, Prakash L, Aggarwal AK. Structure of the catalytic core of S. cerevisiae DNA polymerase η: implications for translesion DNA synthesis. Molecular Cell. 2001;8(2):417–26. [PubMed: 11545743]
  922. Trombino S, Cesario A, Margaritora S, Granone PL, Motta G, Falugi C, Russo P. α7-Nicotinic acetylcholine receptors affect growth regulation of human mesothelioma cells: role of mitogen-activated protein kinase pathway. Cancer Research. 2004;64(1):135–45. [PubMed: 14729617]
  923. Trushin N, Castonguay A, Rivenson A, Hecht SS. Effects of ethanol consumption on the metabolism and carcinogenicity of N’-Nitrosonornicotine in F344 rats. Annals of the New York Academy of Sciences. 1984;435(1):214–8. [PubMed: 6722769]
  924. Tsao AS, McDonnell T, Lam S, Putnam JB, Bekele N, Hong WK, Kurie JM. Increased phospho-AKT (Ser473) expression in bronchial dysplasia: implications for lung cancer prevention studies. Cancer Epidemiology, Bio-markers & Prevention. 2003;12(7):660–4. [PubMed: 12869408]
  925. Tsuda M, Kurashima Y. Tobacco smoking, chewing, and snuff dipping: factors contributing to the endogenous formation of N-nitroso compounds. Critical Reviews in Toxicology. 1991;21(4):243–53. [PubMed: 2069710]
  926. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell. 1995;83(3):493–501. [PubMed: 8521479]
  927. Tsurutani J, Castillo SS, Brognard J, Granville CA, Zhang C, Gills JJ, Sayyah J, Dennis PA. Tobacco components stimulate Akt-dependent proliferation and NFκB-dependent survival in lung cancer cells. Carcinogenesis. 2005;26(7):1182–95. [PubMed: 15790591]
  928. Tukey RH, Strassburg CP. Human UDP-glucuronosyl-transferases: metabolism, expression, and disease. Annual Review of Pharmacology and Toxicology. 2000;40:581–616. [PubMed: 10836148]
  929. Umar A, Boyer JC, Kunkel TA. DNA loop repair by human cell extracts. Science. 1994;266(5186):814–6. [PubMed: 7973637]
  930. Umar A, Koi M, Risinger JI, Glaab WE, Tindall KR, Kolodner RD, Boland CR, Barrett JC, Kunkel TA. Correction of hypermutability, N-methyl-N’-nitro-N-nitrosoguanidine resistance, and defective DNA mismatch repair by introducing chromosome 2 into human tumor cells with mutations in MSH2 and MSH6. Cancer Research. 1997;57(18):3949–55. [PubMed: 9307278]
  931. US Department of Health and Human Services. The Health Consequences of Smoking: A Report of the Surgeon General. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2004.
  932. US Department of Health and Human Services. 11th Report on Carcinogens. Research Triangle Park (NC): U.S. Department of Health and Human Services, Public Health Service, National Toxicology Program; 2005.
  933. University of Louisville School of Medicine. Arylamine N-Acetyltransferase (NAT) Nomenclature. Oct 24, 2006. [accessed: November 3, 2006]. < http://www​.louisville​.edu/medschool/pharmacology/NAT.html>.
  934. Upadhyaya P, Kenney PMJ, Hochalter JB, Wang M, Hecht SS. Tumorigenicity and metabolism of 4-(methyl-nitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) enantiomers and metabolites in the A/J mouse. Carcinogenesis. 1999;20(8):1577–82. [PubMed: 10426810]
  935. Upadhyaya P, McIntee EJ, Hecht SS. Preparation of pyridine-N-glucuronides of tobacco-specific nitrosamines. Chemical Research in Toxicology. 2001;14(5):555–61. [PubMed: 11368554]
  936. Upadhyay S, Liu C, Chatterjee A, Hoque MO, Kim MS, Engles J, Westra W, Trink B, Ratovitski E, Sidransky D. LKB1/STK11 suppresses cyclooxygenase-2 induction and cellular invasion through PEA3 in lung cancer. Cancer Research. 2006;66(16):7870–9. [PubMed: 16912160]
  937. Urban M, Gilch G, Schepers G, van Miert E, Scherer G. Determination of the major mercapturic acids of 1,3-butadiene in human and rat urine using liquid chromatography with tandem mass spectrometry. Journal of Chromatography B. 2003;796(1):131–40. [PubMed: 14552824]
  938. Uusküla M, Järventaus H, Hirvonen A, Sorsa M, Norppa H. Influence of GSTM1 genotype on sister chromatid exchange induction by styrene-7,8-oxide and 1,2- epoxy-3-butene in cultured human lymphocytes. Carcinogenesis. 1995;16(4):947–50. [PubMed: 7728978]
  939. Vähäkangas K, Trivers GE, Plummer S, Hayes RB, Krokan H, Rowe M, Swartz RP, Yeager H Jr, Harris CC. O6-methylguanine-DNA methyltransferase and uracil DNA glycosylase in human broncho-alveolar lavage cells and peripheral blood mononuclear cells from tobaccosmokersandnonsmokers. Carcinogenesis. 1991;12(8):1389–94. [PubMed: 1860159]
  940. Vainio H, Weiderpass E. Smokeless tobacco: harm reduction or nicotine overload? European Journal of Cancer Prevention. 2003;12(2):89–92. [PubMed: 12671531]
  941. van Delft JH, Steenwinkel M-JST, van Asten JG, de Vogel N, Bruijntjes-Rozier TCDM, Schouten T, Cramers P, Maas L, Van Herwijnen MH, van Schooten F-J, et al. Biological monitoring the exposure to polycyclic aromatic hydrocarbons of coke oven workers in relation to smoking and genetic polymorphisms for GSTM1 and GSTT1. Annals of Occupational Hygiene. 2001;45(5):395–408. [PubMed: 11418090]
  942. Van Duuren BL, Goldschmidt BM. Cocarcinogenic and tumor-promoting agents in tobacco carcinogenesis. Journal of the National Cancer Institute. 1976;56(6):1237–42. [PubMed: 994224]
  943. Van Rooij JGM, Veeger MMS, Bodelier-Bade MMJ, Scheepers PTJ, Jongeneelen FJ. Smoking and dietary intake of polycyclic aromatic hydrocarbons as sources of interindividual variability in the baseline excretion of 1- hydroxypyrene in urine. International Archives of Occupational and Environmental Health. 1994;66(1):55–65. [PubMed: 7927844]
  944. Van Schooten FJ, Boots AW, Knaapen AM, Godschalk RWL, Maas LM, Borm PJ, Drent M, Jacobs JA. Myelo-peroxidase (MPO) –463GA reduces MPO activity and DNA adduct levels in bronchoalveolar lavages of smokers. Cancer Epidemiology, Biomarkers & Prevention. 2004;13(5):828–33. [PubMed: 15159316]
  945. van Sittert NJ, Boogaard PJ, Beulink GD. Application of the urinary S-phenylmercapturic acid test as a biomarker for low levels of exposure to benzene in industry. British Journal of Industrial Medicine. 1993;50(5):460–9. [PMC free article: PMC1012165] [PubMed: 8507599]
  946. van Sittert NJ, Megens HJ, Watson WP, Boogaard PJ. Bio-markers of exposure to 1,3-butadiene as a basis for cancer risk assessment. Toxicological Sciences. 2000;56(1):189–202. [PubMed: 10869468]
  947. Vanhaesebroeck B, Leevers SJ, Panayotou G, Waterfield MD. Phosphoinositide 3-kinases: a conserved family of signal transducers. Trends in Biochemical Sciences. 1997;22(7):267–72. [PubMed: 9255069]
  948. Veale D, Ashcroft T, Marsh C, Gibson GJ, Harris AL. Epidermal growth factor receptors in non-small cell lung cancer. British Journal of Cancer. 1987;55(5):513–6. [PMC free article: PMC2001730] [PubMed: 3038157]
  949. Veglia F, Matullo G, Vineis P. Bulky DNA adducts and risk of cancer: a meta-analysis. Cancer Epidemiology, Bio-markers & Prevention. 2003;12(2):157–60. [PubMed: 12582026]
  950. Verdina A, Galati R, Falasca G, Ghittori S, Imbriani M, Tomei F, Marcellini L, Zijno A, Vecchio VD. Metabolic polymorphisms and urinary biomarkers in subjects with low benzene exposure. Journal of Toxicology and Environmental Health A. 2001;64(8):607–18. [PubMed: 11766168]
  951. Verghis SBM, Essigmann JM, Kadlubar FF, Morningstar ML, Lasko DD. Specificity of mutagenesis by 4-ami-nobiphenyl: mutations at G residues in bacteriophage M13 DNA and G→C transversions at a unique dG8-ABP lesion in single-stranded DNA. Carcinogenesis. 1997;18(12):2403–14. [PubMed: 9450488]
  952. Videtic GMM, Stitt LW, Dar AR, Kocha WI, Tomiak AT, Truong PT, Vincent MD, Yu EW. Continued cigarette smoking by patients receiving concurrent chemora-diotherapy for limited-stage small-cell lung cancer is associated with decreased survival. Journal of Clinical Oncology. 2003;21(8):1544–9. [PubMed: 12697879]
  953. Vineis P. Molecular epidemiology: low-dose carcinogens and genetic susceptibility. International Journal of Cancer. 1997;71(1):1–3. [PubMed: 9096656]
  954. Vineis P, Fabrizio V, Benhamou S, Butkiewicz D, Cascorbi I, Clapper ML, Dolzan V, Haugen A, Hirvonen A, Ingelman-Sundberg M, et al. CYP1A1 T3801 C polymorphism and lung cancer: a pooled analysis of 2,451 cases and 3,358 controls. International Journal of Cancer. 2003;104(5):650–7. [PubMed: 12594823]
  955. Vineis P, Marinelli D, Autrup H, Brockmöller J, Cascorbi I, Daly AK, Golka K, Okkels H, Risch A, Rothman N, et al. Current smoking, occupation, N-acetyltransferase-2 and bladder cancer: a pooled analysis of genotype-based studies. Cancer Epidemiology, Biomarkers & Prevention. 2001;10(12):1249–52. [PubMed: 11751441]
  956. Vineis P, Veglia F, Anttila S, Benhamou S, Clapper ML, Dol-zan V, Ryberg D, Hirvonen A, Kremers P, Le Marchand L, et al. CYP1A1, GSTM1 and GSTT1 polymorphisms and lung cancer: a pooled analysis of gene-gene interactions. Biomarkers. 2004;9(3):298–305. [PubMed: 15764294]
  957. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature. 2000;408(6810):307–10. [PubMed: 11099028]
  958. Volker M, Moné MJ, Karmakar P, van Hoffen A, Schul W, Vermeulen W, Hoeijmakers JHJ, van Driel R, van Zee-land AA, Mullenders LHF. Sequential assembly of the nucleotide excision repair factors in vivo. Molecular Cell. 2001;8(1):213–24. [PubMed: 11511374]
  959. Vos MD, Ellis CA, Elam C, Ülkü AS, Taylor BJ. RASSF2 is a novel K-Ras-specific effector and potential tumor suppressor. Journal of Biological Chemistry. 2003;278(30):28045–51. [PubMed: 12732644]
  960. Walczak H, Bouchon A, Stahl H, Krammer PH. Tumor necrosis factor-related apoptosis-inducing ligand retains its apoptosis-inducing capacity on Bcl-2- or Bcl-xL-overexpressing chemotherapy-resistant tumor cells. Cancer Research. 2000;60(11):3051–7. [PubMed: 10850456]
  961. Wan J, Shi J, Hui L, Wu D, Jin X, Zhao N, Huang W, Xia Z, Hu G. Association of genetic polymorphisms in CYP2E1, MPO, NQO1, GSTM1, and GSTT1 genes with benzene poisoning. Environmental Health Perspectives. 2002;110(12):1213–8. [PMC free article: PMC1241108] [PubMed: 12460800]
  962. Wang H, Tan W, Hao B, Miao X, Zhou G, He F, Lin D. Substantial reduction in risk of lung adenocarcinoma associated with genetic polymorphism in CYP2A13, the most active cytochrome P450 for the metabolic activation of tobacco-specific carcinogen NNK. Cancer Research. 2003a;63(22):8057–61. [PubMed: 14633739]
  963. Wang J, Deng Y, Cheng J, Ding J, Tokudome S. GST genetic polymorphisms and lung adenocarcinoma susceptibility in a Chinese population. Cancer Letters. 2003b;201(2):185–93. [PubMed: 14607333]
  964. Wang J, Deng Y, Li L, Kuriki K, Ding J, Pan X, Zhuge X, Jiang J, Luo C, Lin P, Tokudome S. Association of GSTM1, CYP1A1 and CYP2E1 genetic polymorphisms with susceptibility to lung adenocarcinoma: a case-control study in Chinese population. Cancer Science. 2003c;94(5):448–52. [PubMed: 12824892]
  965. Wang J, Lee JJ, Wang L, Liu DD, Lu C, Fan Y-H, Hong WK, Mao L. Value of p16INK4a and RASSF1A promoter hypermethylation in prognosis of patients with resectable non–small cell lung cancer. Clinical Cancer Research. 2004a;10(18 Pt 1):6119–25. [PubMed: 15447998]
  966. Wang L, Habuchi T, Takahashi T, Mitsumori K, Kamato T, Kakehi Y, Kakinuma H, Sato K, Nakamura A, Ogawa O, et al. Cyclin D1 gene polymorphism is associated with an increased risk of urinary bladder cancer. Carcinogenesis. 2002;23(2):257–64. [PubMed: 11872630]
  967. Wang L, Spratt TE, Liu X-K, Hecht SS, Pegg AE, Peterson LA. Pyridyloxobutyl adduct O6-[4-oxo-4-(3-pyridyl) butyl]guanine is present in 4-(acetoxymethylnitrosa-mino)-1-(3-pyridyl)-1-butanone-treated DNA and is a substrate for O6-alkylguanine-DNA alkyltransferase. Chemical Research in Toxicology. 1997;10(5):562–7. [PubMed: 9168254]
  968. Wang LI, Giovannucci EL, Hunter D, Neuberg D, Su L, Christiani DC. Dietary intake of cruciferous vegetables, glutathione S-transferase (GST) polymorphisms and lung cancer risk in a Caucasian population. Cancer Causes & Control. 2004b;15(10):977–85. [PubMed: 15801482]
  969. Wang LI, Miller DP, Sai Y, Liu G, Su L, Wain JC, Lynch TJ, Christiani DC. Manganese superoxide dismutase alanine-to-valine polymorphism at codon 16 and lung cancer risk. Journal of the National Cancer Institute. 2001a;93(23):1818–21. [PubMed: 11734599]
  970. Wang LI, Neuberg D, Christiani DC. Asbestos exposure, manganese superoxide dismutase (MnSOD) genotype, and lung cancer risk. Journal of Occupational and Environmental Medicine. 2004c;46(6):556–64. [PubMed: 15213518]
  971. Wang X, Christiani DC, Wiencke JK, Fischbein M, Xu X, Cheng TJ, Mark E, Wain JC, Kelsey KT. Mutations in the p53 gene in lung cancer are associated with cigarette smoking and asbestos exposure. Cancer Epidemiology, Biomarkers & Prevention. 1995a;4(5):543–8. [PubMed: 7549812]
  972. Wang XW, Yeh H, Schaeffer L, Roy R, Moncollin V, Egly J-M, Wang Z, Freidberg EC, Evans MK, Taffe BG, et al. p53 Modulation of TFIIH–associated nucleotide excision repair activity. Nature Genetics. 1995b;10(2):188–95. [PubMed: 7663514]
  973. Wang Y, Pereira EFR, Maus ADJ, Ostlie NS, Navaneetham D, Lei S, Albuquerque EX, Conti-Fine BM. Human bronchial epithelial and endothelial cells express α7 nicotinic acetylcholine receptors. Molecular Pharmacology. 2001b;60(6):1201–9. [PubMed: 11723227]
  974. Wang Y-C, Lee H-S, Chen S-K, Chang Y-Y, Chen C-Y. Prognostic significance of p53 codon 72 polymorphism in lung carcinomas. European Journal of Cancer. 1999;35(2):226–30. [PubMed: 10448264]
  975. Wani MA, Zhu Q, El-Mahdy M, Venkatachalam S, Wani AA. Enhanced sensitivity to anti-benzo(a)pyrene-diol-epoxide DNA damage correlates with decreased global genomic repair attributable to abrogated p53 function in human cells. Cancer Research. 2000;60(8):2273–80. [PubMed: 10786695]
  976. Warren AJ, Shields PG. Molecular epidemiology: carcinogen-DNA adducts and genetic susceptibility. Proceedings of the Society for Experimental Biology and Medicine. 1997;216(2):172–80. [PubMed: 9349686]
  977. Watson MA, Stewart RK, Smith GB, Massey TE, Bell DA. Human glutathione-S-transferase P1 polymorphisms: relationship to lung tissue enzyme activity and population frequency distribution. Carcinogenesis. 1998;19(2):275–80. [PubMed: 9498276]
  978. Weddle DL, Tithoff P, Williams M, Schuller HM. β-Adrenergic growth regulation of human cancer cell lines derived from pancreatic ductal carcinomas. Carcinogenesis. 2001;22(3):473–9. [PubMed: 11238189]
  979. Wei Q, Cheng L, Amos CI, Wang L-E, Guo Z, Hong WK, Spitz MR. Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: a molecular epidemiological study. Journal of the National Cancer Institute. 2000;92(21):1764–72. [PubMed: 11058619]
  980. Wei Q, Gu J, Cheng L, Bondy ML, Jiang H, Hong WK, Spitz MR. Benzo(a)pyrene diol epoxide-induced chromosomal aberrations and risk of lung cancer. Cancer Research. 1996;56(17):3975–9. [PubMed: 8752166]
  981. Wei Q, Matanoski GM, Farmer ER, Hedayati MA, Gross-man L. DNA repair and aging in basal cell carcinoma: a molecular epidemiology study. Proceedings of the National Academy of Sciences of the United States of America. 1993;90(4):1614–8. [PMC free article: PMC45925] [PubMed: 8434025]
  982. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell. 1995;81(3):323–30. [PubMed: 7736585]
  983. Weisenberger DJ, Romano LJ. Cytosine methylation in a CpG sequence leads to enhanced reactivity with benzo[a]pyrene diol epoxide that correlates with a conformational change. Journal of Biological Chemistry. 1999;274(34):23948–55. [PubMed: 10446162]
  984. Wells PG, Mackenzie PI, Chowdhury JR, Guillemette C, Gregory PA, Ishii Y, Hansen AJ, Kessler FK, Kim PM, Chowdhury NR, et al. Glucuronidation and the UDP-glucuronosyltransferases in health and disease. Drug Metabolism and Disposition. 2004;32(3):281–90. [PubMed: 14977861]
  985. West KA, Brognard J, Clark AS, Linnoila IR, Yang X, Swain SM, Harris C, Belinsky S, Dennis PA. Rapid Akt activation by nicotine and a tobacco carcinogen modulates the phenotype of normal human airway epithelial cells. Journal of Clinical Investigation. 2003;111(1):81–90. [PMC free article: PMC151834] [PubMed: 12511591]
  986. West KA, Castillo SS, Dennis PA. Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resistance Updates. 2002;5(6):234–48. [PubMed: 12531180]
  987. West KA, Linnoila IR, Belinsky SA, Harris CC, Dennis PA. Tobacco carcinogen-induced cellular transformation increases activation of the phosphatidylinositol 3’-kinase/Akt pathway in vitro and in vivo. Cancer Research. 2004a;64(2):446–51. [PubMed: 14744754]
  988. West KA, Linnoila IR, Brognard J, Belinsky S, Harris C, Dennis PA. Tobacco carcinogen-induced cellular transformation increases Akt activation in vitro and in vivo. Chest. 2004b;125(5 Suppl):101S–102S. [PubMed: 15136436]
  989. Weston A, Perrin LS, Forrester K, Hoover RN, Trump BF, Harris CC, Caporaso NE. Allelic frequency of a p53 polymorphism in human lung cancer. Cancer Epidemiology, Biomarkers & Prevention. 1992;1(6):481–3. [PubMed: 1302561]
  990. Westra WH, Baas IO, Hruban RH, Askin FB, Wilson K, Offerhaus GJA, Slebos RJC. K-ras oncogene activation in atypical alveolar hyperplasias of the human lung. Cancer Research. 1996;56(9):2224–8. [PubMed: 8616876]
  991. Wickliffe JK, Ammenheuser MM, Salazar JJ, Abdel-Rah-man SZ, Hastings-Smith DA, Postlethwait EM, Lloyd RS, Ward JB Jr. A model of sensitivity: 1,3-butadiene increases mutant frequencies and genomic damage in mice lacking a functional microsomal epoxide hydrolase gene. Environmental and Molecular Mutagenesis. 2003;42(2):106–10. [PubMed: 12929123]
  992. Wiencke JK. DNA adduct burden and tobacco carcinogenesis. Oncogene. 2002;21(48):7376–91. [PubMed: 12379880]
  993. Wiencke JK, Pemble S, Ketterer B, Kelsey KT. Gene deletion of glutathione S-transferase θ: correlation with induced genetic damage and potential role in endogenous mutagenesis. Cancer Epidemiology, Bio-markers & Prevention. 1995;4(3):253–9. [PubMed: 7606200]
  994. Wiener D, Doerge DR, Fang J-L, Upadhyaya P, Lazarus P. Characterization of N-glucuronidation of the lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) in human liver: importance of UDP-glucuronosyltransferase 1A4. Drug Metabolism and Disposition. 2004a;32(1):72–9. [PubMed: 14709623]
  995. Wiener D, Fang J-L, Dossett N, Lazarus P. Correlation between UDP-glucuronosyltransferase genotypes and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone glucuronidation phenotype in human liver microsomes. Cancer Research. 2004b;64(3):1190–6. [PubMed: 14871856]
  996. Wikman H, Risch A, Klimek F, Schmezer P, Spiegelhalder B, Dienemann H, Kayser K, Schulz V, Drings P, Bartsch H. hOGG1 polymorphism and loss of heterozygosity (LOH): significance for lung cancer susceptibility in a Caucasian population. International Journal of Cancer. 2000;88(6):932–7. [PubMed: 11093817]
  997. Wild CP, Pisani P.